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Abstract 
Objectives:  
Primary care cohort: To determine the rates of undiagnosed psoriatic arthritis (PsA) 
amongst patients with psoriasis using clinical examination and screening questionnaires, 
and test the performance a new PsA screening questionnaire alongside the current 
standard (Psoriasis Epidemiology Screening Tool, PEST). 
Secondary care cohort: To develop novel ultrasound and whole body magnetic 
resonance imaging (WBMRI) protocols to facilitate the comprehensive assessment of 
subclinical abnormalities within the peripheral and axial skeleton of immunomodulatory 
therapy-naïve patients with psoriasis referred to secondary care, and to use these 
protocols to assess the imaging response of abnormalities over 52 weeks of skin-
directed treatment with a licensed IL-12/23p40 inhibitor (ustekinumab). 
Methods:  
Primary care cohort: 932 patients, across five diverse primary care practices, who were 
coded as having a diagnosis of psoriasis, were invited by their General Practitioner to 
attend an evening appointment at their surgery for a consultation with a dermatologist 
and a rheumatologist. Half of patients were sent an educational leaflet regarding PsA 
with their invitation letter. Attendees were examined and asked to complete a PEST 
questionnaire and a new PsA screening questionnaire (CONTEST).  
Secondary care cohort: 73 immunomodulatory therapy-naive patients, without 
musculoskeletal disease or symptoms, who were referred to dermatology for treatment 
of moderate to severe psoriasis were screened using an extensive ultrasound protocol 
to assess for the presence of subclinical enthesitis. Patients who had at least one 
inflammatory abnormality, and in whom biologic therapy was not contraindicated, were 
invited to receive standard-dose skin directed therapy with ustekinumab for 52 weeks. 
Ultrasound examination of 13 entheses and structures within the adjacent synovio-
entheseal complex were performed at weeks 0, 12, 24 and 52. WBMRI was performed 
at week 0, 24 and 52, to assess the axial skeleton and sites in the peripheral skeleton 
inaccessible by ultrasound. 23 healthy volunteers had one ultrasound scan and WBMRI 
using the same protocols, for comparison. 
Results:  
Primary care cohort: 20.5% of patients invited for screening attended. The provision of 
an educational leaflet did not have an impact on attendance for screening, except in the 
most deprived areas. 191 patients were examined, of which 169 had current or previous 
psoriasis (11.5% misdiagnosis rate). 17 patients were newly diagnosed with PsA 
(10.1%). The best sensitivity and specificity of the CONTEST questionnaires were 76.5% 
and 56.5% respectively, without the joint mannequin (cut off ³3), and 70.6% and 63.3% 
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respectively, with the joint mannequin (cut off ³4). The sensitivity and specificity of the 
PEST questionnaire in this cohort, using the validated cut off ³3, was 52.9% and 66.0%. 
Lowering the cut off ³2, the sensitivity improved to 82.4% with a specificity of 44.9%. 
Secondary care cohort: 36 patients (49.3%) had at least inflammatory subclinical 
abnormality on screening ultrasound. 28 of these 36 were eligible for a biologic therapy 
and agreed to undergo a more detailed ultrasound scan and WBMRI. 5 patients 
subsequently chose conventional therapy, and 23 patients consented to treatment with 
ustekinumab and long-term review. 23 patients reached the primary end point of week 
24, and 20 reached week 52. Inflammatory and chronic damage abnormalities were seen 
with greater frequency in the peripheral rather than axial skeleton, mostly involving the 
larger entheses of the knee, foot, ankle and elbows. Healthy volunteers exhibited a 
similar pattern of abnormalities but at a significantly lower frequency (inflammatory 
lesions 4.5% vs. 31.1%, chronic damage lesions 6.0% vs. 27.0%, both p<0.00001). 
Synovitis was seen in 82.1% of patients, while bursitis and tenosynovitis were 
uncommon. Following treatment with ustekinumab, ultrasound inflammation scores 
reduced by 42.2% at the primary end point (week 24, p<0.001), and by 51.5% after 52 
weeks (p=0.01). Chronic damage scores remain unchanged (p=0.082 week 24, p=0.512 
week 52). In the axial skeleton, more patients than volunteers had vertebral unit bone 
marrow oedema (64.3% vs. 30.4%, p<0.00001). Sacroiliac joint inflammation was 
minimal in both groups. Axial structural changes occurred in 14.3% in patients and were 
absent in volunteers. No significant change in spine or SIJ osteitis (p=0.656 week 24, 
p=0.627 week 52), or structural abnormalities were observed after ustekinumab therapy. 
Conclusions:  
A proportion of patients with psoriasis have undiagnosed PsA in primary care, even with 
signs and symptoms of inflammatory arthritis. Screening questionnaires are useful to 
detect some, but not all patients and further measures are required to capture all cases 
of PsA. Early identification and treatment is essential to prevent future pain, functional 
limitation and disability. Treating patients for psoriasis with a therapeutic agent that is 
effective at reducing the development of PsA is one means of addressing the failings of 
clinical examination and screening questionnaires, although the evolution from 
subclinical enthesitis (a common finding in patients with psoriasis) to PsA is not 
understood. This thesis provides preliminary data to suggest that anti-IL-12/23p40 
therapy may reduce the burden of subclinical inflammation at the primary site of lesion 
development in PsA (the enthesis), and further longitudinal studies are now encouraged 
to confirm these observations with ustekinumab and other immunomodulatory therapies.  
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 1 
Chapter 1  
Review of the Literature 
1.1 Psoriasis 
1.1.1 Epidemiology 
Psoriasis is a common, immune-mediated disorder of the skin, affecting around 1.2 
million people in the United Kingdom (Parisi et al., 2013). Rates for psoriasis are equal 
amongst the sexes (Fry, 1988). It can occur at any age, although two peaks in incidence 
are recognised: the first, between twenty and thirty years of age and the second, between 
the ages of fifty and sixty years (Smith et al., 1993). ‘Type I’ psoriasis begins on or before 
the age of forty years and accounts for 75% of all cases; ‘Type II’ psoriasis begins after 
the age of forty. Patients with type I psoriasis are more likely to have greater disease 
severity, a positive family history and a carry the human leucocyte antigen (HLA)-Cw06 
allele when compared to those with type II disease (Henseler and Christophers, 1985). 
At a global level, the epidemiology of psoriasis is diverse and appears to be more 
common in countries more distant from the equator. The prevalence in children ranges 
from 0% in Taiwan to 2.1% in Italy, and in adults from 0.91% in the United States to 8.5% 
in Norway (Parisi et al., 2013). The prevalence of psoriasis is low in certain ethnic groups 
such as the Japanese (Ogawa et al., 2017), and may be absent in aboriginal Australians 
(Green, 1984), Samoans and South American Indians (Gudjonsson and Elder, 2007). 
1.1.2 Pathogenesis  
The pathophysiology of psoriasis is multifaceted and involves a complex interaction 
between genetic, environmental and immunological factors (Lowes et al., 2014). In 
recent years, a number of landmark studies have investigated genetic susceptibility in 
addition to cellular and molecular mechanisms using both human tissue samples and 
animal models of disease. 
Until the early 1980s, psoriasis was considered to be primarily a disease of epidermal 
keratinocyte proliferation, with the cutaneous inflammatory infiltrate a secondary 
consequence (Bos et al., 2005). Histologically, psoriatic lesions are characterised by 
acanthosis (epidermal thickening) arising from rapid keratinocyte proliferation, 
parakeratosis (nuclear retention within corneocytes in the stratum corneum) and 
hypogranulosis (reduced or absent granular layer) from aberrant differentiation of 
keratinocytes with marked dilatation of blood vessels within the papillary dermis (causing 
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lesional erythema). However, with the increasing recognition of the importance of 
immune mechanisms in psoriasis, there has been longstanding historical debate about 
the primacy of these histological changes, as to whether hyperplastic keratinocytes are 
capable of inducing immune activation or whether they are simply responders to a 
primary aberrant immune response. Keratinocytes are equipped with innate immune 
receptors and actively take part in immune responses by producing cytokines and 
chemokines as well as the antimicrobial peptide LL-37 (Nestle et al., 2009a, Pasparakis 
et al., 2014). 
The effective use of therapies designed to inhibit T-cell activation such as ciclosporin 
from the late 1970s (Ellis et al., 1986), and more latterly denileukin diftitox (DAB389 
interleukin (IL)-2 fusion protein) (Gottlieb et al., 1995) and alefacept (a lymphocyte 
function associated antigen 3/immunoglobulin (Ig)G1 fusion protein targeting CD2+ T 
cells) (Abrams et al., 2000, Sano et al., 2005) gave specific indication that the immune 
system could be playing a more integral role in the pathogenesis of psoriasis.The current 
view is of pathological cross-talk between epithelial keratinocytes and the cutaneous 
immune system which sustains the aberrant immunological and epidermal responses 
seen in patients with psoriasis (Di Meglio et al., 2011, Lowes et al., 2013). Evidence from 
mouse models and translational research now strongly indicates that psoriatic plaques 
result from both a primary defect in keratinocytes and inappropriate innate and adaptive 
immune responses, mediated mainly by resident and infiltrating T lymphocytes (Sano et 
al., 2005, Nestle et al., 2005, Lande et al., 2007, Conrad et al., 2007) in genetically 
primed individuals.  
A greater incidence of psoriasis is observed amongst first-degree and second-degree 
relatives of patients than among the general population (Farber and Nall, 1974, Karason 
et al., 2009). Genome wide association studies (GWAS) have confirmed associations 
with numerous polymorphisms within genes involved in: (i) innate immune regulation 
such as nuclear factor NFκB signalling (TRAF31P2, TNIP1, TYK2, TNFAIP3, KFKBIA, 
FBXL19, REL, and CARD14) (Capon et al., 2012, Nair et al., 2009, Jordan et al., 2012a, 
Jordan et al., 2012b) (Prinz, 2017) and interferon signalling (ELM01, TYK2, SOCS1, 
IFIH1/MDA5, RNF114, IRF4, RIG1/DDX58, IFNLR1/IL28RA, IFNGR2) (Prinz, 2017); (ii) 
adaptive immune regulation such as antigen presentation (ERAP1), CD8+ T-call 
maturation, activation and differentiation (ETS1, RUNX3, TNFRSF9, MBD2, IRF4) 
(Prinz, 2017),  and Th17 differentiation, IL-23 and IL-17 signalling (IL-23A, IL-12B, IL-
12RB, IL-23R, TYK2, STAT3, STAT5A/B, SOCS1, ETS1, TRAF3IP2, KLF4, IF3) (Capon 
et al., 2012, Nair et al., 2009, Nair et al., 2008, Cargill et al., 2007) (Prinz, 2017), (iii) 
barrier function (late cornified envelope proteins 3B and 3C) (Capon et al., 2012); and 
(iv) epidermal microbial defence (DEFB4) (Hollox et al., 2008). The precise functional 
effects of these single nucleotide polymorphisms remain to be established, but these 
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analyses add further support to the definition of psoriasis as an immune cell-mediated 
disease of defective keratinocytes (Nograles et al., 2010). 
PSORS1, a major histocompatibility complex (MHC) class 1 region on chromosome 
6p21, is the genetic loci with the largest effect to date (Nestle et al., 2009b), and it is 
within PSORS1 that the human leukocyte antigen (HLA)-Cw06 allele is pinpointed as the 
risk variant that confers the strongest susceptibility to psoriasis (Nair et al., 2006). 
However, only 60–65% of patients with psoriasis carry the HLA-Cw06 gene, compared 
with 15% of individuals without psoriasis (Gudjonsson et al., 2006). Furthermore, a low 
penetrance of approximately 10% points towards other genetic and environmental 
factors being involved (Elder et al., 1994). 
In those with a genetic predisposition, activation of the innate immune system is triggered 
through one or more external stimuli (trauma (Koebner phenomenon), infections, drugs, 
stress and alcohol). Following epidermal damage, ‘stressed’ keratinocytes release both 
LL-37 (cathelicidin) antimicrobial peptide and host DNA/RNA, which together activate 
plasmacytoid dendritic cells to produce large quantities of interferon (IFN)-alpha 
(Marrakchi et al., 2011, Lande et al., 2007, Ganguly et al., 2009). IFN-alpha induces the 
maturation of myeloid (dermal) dendritic cells, which in turn produce cytokines including 
IL-23 and IL-12 (Nestle et al., 2005). IL-23 and IL-12 stimulate the attraction, activation 
and differentiation of T cells within skin draining lymph nodes, thereby bridging the gap 
between the innate and adaptive immune systems (Gilliet et al., 2008) (Figure 1.1). 
Subsequent T-cell expansion and migration into the epidermis (through expression of 
α1β1 integrin) results in characteristic epidermal remodelling (Conrad et al., 2007).  
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Figure 1.1. Pathway for the initiation of psoriasis. Stressed keratinocytes release LL-37 
which bind to nucleic acids to activate plasmacytoid dendritic cells (DCs) to release IFN-
a/b. LL37/RNA complexes also activate resident myeloid DCs to produce IL-12 and IL-
23. 
Differentiated psoriatic T cells are of two distinctly polarised types (Steinman, 2007, 
Trifari et al., 2009): 
• T helper 1 (Th1) cells: Under the influence of IL-12, Th1 cells secrete TNF-a and 
IFN-gamma (Uyemura et al., 1993), which enhances expression of MHC class I 
on keratinocytes. In turn, this may promote the presentation of putative 
autoantigens to intra-epidermal T cells which can lead to further activation of 
pathogenic autoimmune T cells (Lang et al., 2005). 
• T helper 17 (Th17) cells:  When influenced by IL-23 (Lee et al., 2004, Chan et al., 
2006, Tonel et al., 2010), Th17 cells produce IL-17A, IL-17F, IL-21, IL-22 and 
TNF-a (Lowes et al., 2008, Kagami et al., 2010, McGeachy et al., 2009). This is 
supported by experimental IL-23-deficient mouse models, where resistance to 
autoimmune disease correlates with the absence of IL-17 producing T-cells 
(Zheng et al., 2007, Nakae et al., 2002). 
Figure 4. 
Pathways for initiation and maintenance of psoriasis. (a) Early disease: Imiquimod (IMQ), a 
TLR7 agonist, can activate plasmacytoid dendritic cells (pDCs) to produce interferons 
(IFN). LL37, a peptide derived from cathelicidin, may have an important role in the 
initiation of psoriasis lesions via this pathway. LL37 released from keratinocytes (KCs) can 
bind to ucleic acids to activat  pDCs to release IFN-α/β. LL37/RNA complexes can also 
activate resident myeloid DCs to produce IL-12 and IL-23, key psoriatic cytokines. (b) 
Chronic disease: The major pathogenic pathway in psoriasis occurs when (I) mature dermal 
DCs and inflammatory myeloid DCs produce cytokines such as IL-23 and IL-12. (II) These 
cytokines activate T17 (Th17 and Tc17), Th1, and Th22 cells to contribute to the cytokine 
mili u and furt er act o  keratinocytes. (III) As outlined in Figure 1, keratinocytes can 
produce chemokines and antimicrobial peptides (AMPs) to (IV) augment cutaneous immune 
responses.
Lowes et al. Page 30
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Figure 1.2. The chronic pathogenesis of psoriasis occurs when mature dermal dendritic 
cells (DCs) and inflammatory myeloid DCs produce cytokines such as IL-23, and IL-12. 
These cytokines activate Th17 and Th1 cells to contribute to the cytokine milieu and 
further act on keratinocytes. These then produce chemokines and antimicrobial peptides 
(AMPs) to augment cutaneous responses.  
IL-23 is a member of the IL-12 cytokine family, which constitutes a heterodimer formed 
by a p40 chain, which is shared with IL-12, and a unique p19 subunit (Figure 1.3). It is 
produced by dendritic cells, macrophages and other antigen presenting cells and plays 
a pivotal role in the survival and proliferation of Th17 cells after priming with transforming 
growth factor (TGF)-β and IL-6 (Cauli A J Rheumatol Supp 2012).   
 
 
Figure 1.3. IL-23 heterodimer composed of p19 and p40 subunit.  
Figure 4. 
Pathways for initiation and maintenance of psoriasis. (a) Early disease: Imiquimod (IMQ), a 
TLR7 agonist, can activate plasmacytoid dendritic cell  (pDCs) to produce interferons 
(IFN). LL37, a peptide derived from cathelicidin, may have an important role in the 
initiation of psoriasis lesions via this pathway. LL37 released from keratinocytes (KCs) can 
bind to nucleic acids to activate pDCs to release IFN-α/β. LL37/RNA com lexes can also 
activate resident myeloid DCs to produce IL-12 and IL-23, key psoriatic cytokines. (b) 
Chronic disease: The major pathogenic pathway in psoriasis occurs when (I) mature dermal 
DCs and inflammatory myeloid DCs produce cytokines such as IL-23 and IL-12. (II) These 
cytokines activate T17 (Th17 and Tc17), Th1, and Th22 cells to contribute to the cytokine 
milieu and further act on keratinocytes. (III) As outlined in Figure 1, keratinocytes can 
produce chemokines and antimicrobial peptides (AMPs) to (IV) augment cutaneous immune 
responses.
Lowes et al. Page 30
Annu Rev Immunol. Author manuscript; available in PMC 2015 January 01.
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IL-23p19, IL-12p40 (Lee et al., 2004) and IL-23R (Tonel et al., 2010, Wilson et al., 2007) 
have been detected at high level in psoriatic skin lesions, and intradermal injection of IL-
23 in mice is shown to stimulate keratinocyte proliferation and cause epidermal 
acanthosis (Wilson et al., 2007). In xenotransplant mouse models of psoriasis, injection 
of a monoclonal antibody specifically neutralising human IL-23 showed IL-23-dependent 
inhibition of psoriasis development (Tonel et al., 2010). 
IL-17 and IL-22 are key mediators downstream of IL-23 that link the adaptive immune 
response and epithelial dysregulation in psoriasis. Both cooperatively enhance gene 
expression of antimicrobial peptides by keratinocytes including b-defensin 2, 3 and 
S100A7/8/9 (Boniface et al., 2005, Liang et al., 2006). Both IL-17 and IL-22 increase 
production of LL-37 (Liang et al., 2006, Wolk et al., 2004, Peric et al., 2008), leading to 
sustained production of IFN-a and unregulated activation of myeloid dendritic cells, thus 
fuelling the continued activation of the immune system through a positive feedback loop 
(Conrad et al., 2009) (Figure 1.4).  
 
 
Figure 1.4. The critical interplay between keratinocytes, T cells and dendritic cells is 
primarily driven by the pro-inflammatory molecules TNF, IL-23 and IL-17 with other 
mediators such as IFN-α, IFN-γ and IL-22 also contributing to the initiation, amplification 
and maintenance of the psoriatic plaque. 
IL-17 is pro-inflammatory; it induces the expression of chemokines for neutrophils, 
memory T cells and dendritic cells. IL-22 facilitates keratinocyte hyperproliferation and 
IL-22 receptor expression on keratinocytes is upregulated by IFN-alpha (Tohyama et al., 
2012). IL-22 therefore provides an interface between immune activation and epidermal 
acanthosis (Tohyama et al., 2012, Eyerich et al., 2009). These observations are 
supported by experimental mice models - administration of anti-IL-12/IL-23p40 or anti-
IL-23p19 monoclonal antibodies to K5.Stat3C mice markedly lowered transcript levels of 
IL-17 and IL-22, b-defensins and S100A family members in skin lesions, and more so 
than administration of anti-IL-17A antibody therapy supporting the pivotal role of IL-23 in 
psoriasis (Nakajima et al., 2011).  
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In addition to Th17 cells, many innate immune cells respond to IL-23 and are important 
in both resistance to infection and mediating autoimmune pathology. These cells are 
characterized by expression of the transcription factor retinoic-acid-receptor-related 
orphan receptor-γ (RORγt) (Ivanov et al., 2006) and include subsets of γδT cells, natural 
killer T (NKT) cells, ‘natural’ Th17 cells and innate lymphoid cells (ILCs) collectively, and 
are termed ‘Type-17’ (T17) cells (Cua and Tato, 2010, Annunziato et al., 2009, Zuniga 
et al., 2013, Kim et al., 2013, Marks et al., 2009). These innate immune cells are located 
in non-lymphoid tissues where they are poised to respond immediately to tissue injury or 
pathogenic insults. Accumulations of gδT cells have been found in psoriatic plaques (Cai 
et al., 2011), as have Vg9Vδ2 T cells (a novel proinflammatory subset that seems to 
mediate an immediate tissue response upon koebnerization) (Laggner et al., 2011). 
Stimulation of Th17 cells and T17 cells with IL-1β and IL-23 induces local tissue 
inflammation, which is mainly mediated by T17 signature cytokines such as IL-17, IL-22 
and granulocyte–macrophage colony-stimulating factor (GM-CSF) (Langrish et al., 2005, 
Zheng et al., 2007, El-Behi et al., 2011) thus amplifying Th17 responses (Sutton et al., 
2009, Cai et al., 2011, Sumaria et al., 2011). 
1.1.3 Clinical Presentation 
Psoriasis is a papulosquamous dermatosis with a highly variable morphology, 
distribution, severity and course. Chronic, symmetrical, sharply demarcated, 
erythematous plaques with adherent silvery-white scale, ranging in size from one to 
several centimetres are most frequently seen. Removal of scale may reveal many tiny 
bleeding points (Auspitz sign) and a white blanching ring (Woronoff’s ring) may 
occasionally be observed in the skin surrounding a psoriatic plaque. Lesions are typically 
distributed on the extensor surfaces of the limbs, the scalp, trunk, lumbosacral area 
and/or buttocks, although not exclusively. Some patients will develop lesions within the 
body flexures (axillary, infra-mammary, abdominal pannicular, groin and perineal areas) 
and/or genitalia, either with classical plaques at other sites or in isolation. Such lesions 
often lack the classical scale due to a difference in skin  keratinisation patterns. Psoriatic 
plaques may exhibit pathergy at the site of trauma or injury, known as the Koebner 
Phenomenon. 
Several other more uncommon psoriatic phenotypes are recognised; guttate psoriasis 
presents with multiple ‘dew-drop’ lesions distributed in a centripetal pattern, 1-10mm in 
size, often proceeds an acute pharyngeal group B haemolytic streptococcal infection and 
may be self-limiting; generalised pustular psoriasis (vom Zumbusch) presents with 
painful and inflamed areas of skin overlaid with sheets of coalescing monomorphic sterile 
pustules; erythrodermic psoriasis presents as generalised erythema, with or without 
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exfoliation of the skin in an unwell, haemodynamically unstable  individual. Patients with 
any form of psoriasis may experience symptoms of itching, burning or soreness. 
Nail involvement is seen in approximately 12-50% of patients with psoriasis (Mallbris et 
al., 2005, Armesto et al., 2011) and significantly more if psoriatic arthritis (PsA) is present 
(Patrizi et al., 2014). Lesions occur due to disease at the nail matrix (causing irregular 
pitting, leuconychia, red spots in the lunula and crumbling of the nail plate), and at the 
nail bed (causing onycholysis, subungual hyperkeratosis, oil spot dyschromia and 
splinter haemorrhages). The fingernails are more commonly affected than the toenails. 
1.1.4 Impact on Quality of Life 
The chronic and multifaceted nature of psoriasis means that the effects often go deeper, 
beyond the visual signs and physical symptoms (Kimball et al., 2010). Many patients 
report a profound impact on their emotional wellbeing and have a reduction in their 
health-related quality of life similar to, or worse than, patients with other chronic diseases 
including ischaemic heart disease, diabetes, cancer, arthritis (Finlay and Kelly, 1987, 
Rapp et al., 1999). Age and gender are unrelated to the impact on quality of life (de Korte 
et al., 2004). The severity of the emotional impact is also demonstrated not to correlate 
with the severity of skin lesions (Heydendael et al., 2004); in a German study, almost 
one quarter of patients with ‘mild’ disease reported that psoriasis had a ‘very large’ or 
‘extremely large’ effect on their quality of life (Augustin et al., 2008). Patients often feel 
stigmatised (Richards et al., 2001, Armstrong et al., 2012) with 82.9% feeling that they 
need to hide their psoriasis (Weiss et al., 2002). One in five report a sense of rejection 
due to their condition (Ginsburg and Link, 1993) and this contributes to depression and 
suicidal ideation in up to 10% of patients (Kurd et al., 2010, Gupta et al., 1993). Up to 
85% of those affected by psoriasis feel annoyed with their disease (Sampogna et al., 
2012), and 77% describe it as a ‘problem’ or ‘significant problem’ (Dubertret et al., 2006). 
Willingness to pay assessments reveal that patients are willing to pay large sums of 
money for a cure; in one study, 71% stated they could pay £1000 or more for a cure, and 
38% said they would pay in excess of £10,000. When asked if they would prefer to have 
‘a complete cure for their psoriasis’ or be given £1000 in cash but no cure, 98.9% stated 
that they would prefer to have the cure (Finlay and Coles, 1995). Many patients use 
negative health behaviours as a means of coping, and up to 32% of patients with 
moderate to severe psoriasis have been found to have problems with alcohol (McAleer 
et al., 2011).  
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1.1.5 Socioeconomic Burden  
The long-term management of psoriasis is associated with substantial cumulative 
expenses to the patient, the healthcare system and to society as a whole. Costs 
associated with psoriasis are numerous and are classified as direct (treatment and 
healthcare provision), indirect (loss of work productivity and taxation revenue) and 
intangible (impairment of quality of life). In 2013, the annual total cost of psoriasis in the 
United States amounted to approximately $112 billion. Total direct costs ranged from 
$51.7 billion to $63.2 billion and indirect costs from $23.9 billion to $35.4 billion with the 
medical co-morbidities associated with psoriasis estimated to contribute $36.4 billion 
annually (Brezinski et al., 2015). When compared to the general population, the direct 
cost per psoriasis patient in the USA was $350 more per month ($614 vs. $284) (Fowler 
et al., 2008). 
Within the UK, the mean total direct cost of managing a patient with severe psoriasis with 
conventional agents (e.g. methotrexate, ciclosporin) was reported in 2010 to be £4207 
per year, which compares with published figures from several other European countries 
(€2169 to €8831 per annum) (Carrascosa et al., 2006, Schoffski et al., 2007, Colombo 
et al., 2008). With improved treatments comes a higher financial burden to the healthcare 
system, and the introduction of biologic therapy increased drug acquisition costs to 
approximately £9500 per patient per annum (Burden, 2010). However, around £1625 
can be offset per year due to a substantial reduction in hospital admissions courtesy of 
the greater efficacy of these agents, and the direct savings from the prevention of 
psoriatic co-morbidities, although not quantified, are likely to be significant. 
In terms of indirect costs, a survey completed by the Swedish Psoriasis Association 
reported that psoriasis limits employment opportunities and imposes a serious barrier in 
the job market (IFPA, 2007). Unemployment is three times more likely for people affected 
by psoriasis than for those unaffected (Schmitt and Ford, 2006) and approximately one 
third of patients who are not in employment describe being unable to work because of 
their psoriasis (Finlay and Coles, 1995). For those in work, one third of patients report 
missing at least one day per month, and one in ten patients miss three or more days due 
to their psoriatic disease (Schmitt and Ford, 2006). In the USA, it is estimated that 
Americans with psoriasis collectively lose approximately 56 million hours of work per 
year. This in turn has an impact on patient finances, and psoriasis is shown to be 
associated with a reduced household income (Meyer et al., 2010). This is related to 
disease severity; in a survey by the National Psoriasis Foundation, 21% of patients with 
severe psoriasis had a low income (less than US$30,000) compared to 13% for patients 
with mild disease (NPF, 2007). 
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1.1.6 Assessment of Psoriasis 
1.1.6.1 Assessment of Psoriasis Clinical Disease Activity and Severity 
The clinical assessment of psoriasis requires recognition of the phenotype (chronic 
plaque, guttate, inverse, erythrodermic) and the distribution of lesions. The latter is 
relevant not only because of the prognostic implications of lesions in certain areas for 
the development of PsA (Wilson et al., 2009, Patrizi et al., 2014) but also because of the 
higher functional and psychosocial morbidity associated with psoriasis in sites such as 
the face, hands and genitals as compared to lesions elsewhere (Meeuwis et al., 2011). 
In terms of disease activity, at the most basic level, the assessment of psoriasis in clinical 
practice is straightforward. Patient-reported perceptions of severity are combined with 
the physician’s static global assessment (PGA) and the physician is then able to 
determine how severe the psoriasis is and how well the patient is responding to 
treatment. However, patients have a heavy emotional investment in their own skin 
disease with little for comparison, and patient assessed severity and physician assessed 
severity can often be disparate. Any form of clinical assessment should therefore be 
complemented by an assessment of psychological, social, financial and functional 
impact. 
The PGA is an average assessment of all psoriatic lesions based on erythema, scale 
and induration. It does not quantify body surface area (BSA) or evaluate individual lesion 
locations. Different forms of the PGA exist; the static PGA determines psoriasis severity 
at a single time point in time, without taking the baseline condition into account, whereas 
the dynamic PGA relies on the investigator’s memory to evaluate the level of 
improvement of deterioration. The scales used vary widely from four points (Nijsten et 
al., 2007) to ten points (Heydendael et al., 2003), which has the potential to produce non-
standardised assessments. An example of one of the more commonly employed scales 
is the seven point PGA as described in Table 1.1. 
 
 
 
 
 
 
 
 
 11 
Severity Description 
Clear No signs of psoriasis (post-inflammatory pigmentation may be present) 
Almost Clear Very minimal psoriasis, between clear and mild 
Mild Slight plaque elevation, scale and/or erythema 
Mild-to-moderate Intermediate between mild and moderate 
Moderate Moderate plaque elevation, scale and/or erythema 
Moderate-to-severe Intermediate between moderate and severe 
Severe Very marked plaque elevation, scale and erythema 
Table 1.1: Description of the 7-point Physicians Global Assessment (PGA) for Psoriasis 
The PGA should only measure the degree of erythema, scaling and induration. Aside 
from being subjective, it attracts criticism for not providing an overall measure of psoriasis 
severity because it does not account for body surface area (BSA) involvement (Robinson 
et al., 2012, Walsh et al., 2013b). For example, a patient with widespread disease (e.g. 
BSA 40%) could have the same PGA grade as a patient with very limited disease (e.g. 
BSA 1%). As a consequence, the PGA is often misused by clinicians with many taking 
the extent and distribution into account instead of just scoring plaque severity. In addition, 
the static PGA does not take into account the previous disease state, and whilst the 
dynamic PGA attempts to overcome this, it can be difficult for a physician to recall prior 
disease activity for each patient under his/her care, and within one institution, patients 
may be reviewed by multiple different members of the clinical team. Only moderate inter-
rater reliability is found with the PGA (Berth-Jones et al., 2006). 
An assessment of the body surface area (BSA) involvement forms part of many other 
tools for psoriasis activity. The BSA uses the rule of nines, developed for the assessment 
of burns (Wallace, 1951, Ramsay and Lawrence, 1991). Using this method, the head 
and neck contribute approximately 10%, the upper limbs 20%, the trunk (chest, abdomen 
and back) 30% and the lower limbs 40%. It is erroneously suggested that the surface of 
the patient’s own hand (palm and fingers) is approximately equivalent to 1% of the total 
BSA (Jose et al., 2004); however, this method has been shown to overestimate BSA 
(Rossiter et al., 1996), with one outstretched palm and five fingers equating to 0.8% in 
males and 0.7% in females (Long et al., 1992). Several authorities, including the British 
Association of Dermatologists and The National Psoriasis Foundation in the USA define 
severe psoriasis as a BSA of 10% or greater (Smith et al., 2009, Mrowietz et al., 2011, 
Van Voorhees, 2009). 
Over 53 clinometric measures for the assessment of psoriasis activity have been 
described, and aside from the PGA and BSA, the majority combine measures of both 
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surface area involvement and plaque severity (Spuls et al., 2010). These include the 
Psoriasis Area and Severity Index (PASI) (Fredriksson and Pettersson, 1978), Self-
Administered PASI (SAPASI) (Fleischer et al., 1994), Lattice System-PGA (LS-PGA) 
(Langley and Ellis, 2004), Simplified PASI (SPASI) (Louden et al., 2004), Psoriasis Log-
Based Area and Severity Index (PLASI) and Psoriasis Exact Area and Severity Index 
(PEASI) (Jacobson and Kimball, 2004). 
Of these, the PASI is the most commonly used and best validated instrument and is now 
widely accepted as the gold standard assessment tool for psoriasis (Feldman and 
Krueger, 2005, Robinson et al., 2012). In a review of all clinical studies grading the 
severity of psoriasis over a twenty-nine year period, the construct validity, content 
validity, internal consistency, inter-observer variation, sensitivity to change and time 
required to perform the measurement were analysed, and whilst none of the scoring tools 
met all of the validation criteria, the PASI was the most extensively used and most 
thoroughly validated (Puzenat et al., 2010). 
In this method, the sum of the erythema, induration and scaliness of the lesions (graded 
0-4) for each body region (head, upper limbs, trunk, lower limbs) are multiplied by 
weighted area scores, which take into account the relative BSA for each body area 
(Appendix 7) to produce a score that ranges from 0 to 72. With practice, the PASI is 
relatively easy to calculate (Langley and Ellis, 2004), is sensitive to change in chronic 
plaque psoriasis and has shown substantial intra-rater and inter-rater reliability (defined 
as >80% agreement) (Berth-Jones et al., 2006, Chandran et al., 2009a).  
However, the PASI is not without its limitations. It lacks sensitivity for mild disease with 
minimal BSA involvement because changes largely depend on plaque severity score 
(and not surface area) improvement (Jacobson and Kimball, 2004). The PASI score may 
therefore underestimate the general degree of improvement (Spuls et al., 2010) in 
patients with, for example, localised disease affecting the genitals, nails, scalp and/or 
hands (de Korte et al., 2004). Area scores are based on ranges, and areas between 1% 
and 9% are assigned the same area score of 1 (Jacobson and Kimball, 2004). The PASI 
is also not a linear index, which makes the score less meaningful in terms of the impact 
of disease. For example, a small change in the BSA from 9% (area score 1) to 10% (area 
score 2) results in a doubling of the PASI score if the parameters of plaque activity within 
that area remain unchanged (Robinson et al., 2012). 
The PASI was designed to be used in clinical trials, and its widespread uptake within the 
research arena means that, in contrast to the incompatibility of measures used up to the 
1980s, it is now possible to meaningfully compare outcome data from different studies 
(Finlay, 2005). In addition, the PASI score is increasingly used by regulatory bodies, such 
as the National Institute for Health and Care Excellence (NICE) as a means of 
therapeutic rationing, and as such, its use in the clinical setting is now rapidly increasing. 
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In the UK, a PASI score of ten or more is forms part of mandatory eligibility criteria for 
biologic therapy.  
Whilst a PASI score of ten or more is generally accepted to reflect a PGA of ‘severe’, 
there is no consensus on the interpretability (van de Kerkhof, 1992, Krueger et al., 2000, 
Gottlieb et al., 2003a, Jacobson and Kimball, 2004, Langley and Ellis, 2004, Berth-Jones 
et al., 2006). Similarly, there is no consensus on what is a clinically meaningful 
improvement in response to therapy either in the clinical setting or in research trials. For 
patients with severe psoriasis, physicians typically consider at least 75% reduction in 
disease activity (so called a ‘PASI 75’ response) to be an improvement indicative of 
treatment success. However, it is clear that patients with far lower decreases in the PASI 
score can have clinically meaningful improvements in their disease if accompanied by a 
significant rise in quality of life. There is strong evidence that a 50% response (‘PASI 50’) 
can also be clinically significant (Schafer et al., 2010) and that a therapy should not be 
deemed to have failed if a patient does not reach a PASI 75 response (Carlin et al., 
2004). The NICE guidance on the use of biologic therapies in the UK has recognised 
this, and at predetermined time points (usually 12-16 weeks) will allow continuation of 
therapy if a patient achieves either; (i) a 75% reduction in PASI from baseline (in 
isolation) or: (ii) a 50% or greater reduction in baseline PASI and a 5-point or greater 
improvement in the Dermatology Life Quality Index (DLQI), a quality of life measure 
(Smith et al., 2009, Shikiar et al., 2006, Khilji, 2002). However, advances in the 
understanding of the pathogenesis of psoriasis are facilitating an exciting and 
exponential expansion of molecular targets including IL-23p19, IL-17A and IL-17RA, and 
a 90% response (‘PASI 90’) will soon become the new standard in therapeutic efficacy 
(Puig, 2015, Smith et al., 2017). 
1.1.6.2 Assessment of Nail Psoriasis 
Nail psoriasis is a common, burdensome feature of psoriasis that can be severe and 
disfiguring. Nail lesions affect approximately 40% of patients with psoriasis and between 
63% and 83% of patients with PsA (Elkayam et al., 2000, Salomon et al., 2003, Augustin 
et al., 2010, Williamson et al., 2004). One study of 1728 patients with psoriasis found 
that 93% considered nail psoriasis to be a significant cosmetic handicap, 52% reported 
pain and 48% felt that it interfered with their occupation (de Jong et al., 1996).   
Psoriasis can affect any combination of components of the nail, including the nail plate 
and surrounding epithelial structures (proximal nail fold, matrix, nail bed and 
hyponychium). Characteristic features of psoriasis affecting the nail matrix include 
pitting, nail plate crumbling, leukonychia and red spots in the lunula. Pits are sharply 
defined depressions in the nail plate, caused by shedding of nail plate cells, much the 
same as psoriatic scale is shed from the skin. Psoriasis affecting the nail bed produces 
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oil-drop discolouration, onycholysis, nail bed hyperkeratosis and splinter haemorrhages 
(Omura, 1985).  Treatment of nail psoriasis has been largely unsatisfactory, but the 
availability of effective therapies for psoriasis and PsA has raised the possibility of 
treating nail psoriasis in a more effective way.  
While not routinely used in clinical practice, quantitative assessments of response in 
clinical trials have necessitated the development of validated tools for assessing the 
extent and severity of nail involvement. Several instruments have been developed 
including Baran’s nail psoriasis severity Index (Baran, 2004), Cannavo’s Scoring System 
(Cannavo et al., 2003) and Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA) 
tool (Augustin et al., 2014), although the modified Nail Psoriasis Severity Index 
(mNAPSI) (Cassell et al., 2007), and its predecessor, the Nail Psoriasis Severity Index 
(NAPSI) (Rich and Scher, 2003) are the most widely used and validated. The mNAPSI 
involves rating the presence/absence and severity of features of psoriasis in both the 
nail matrix and nail bed of each nail, producing a maximum possible score of 14 per nail 
(140 per patient) (Cassell et al., 2007) (Table 1.2). The mNAPSI has been used as a 
secondary endpoint in several clinical trials of biologic therapies in psoriasis and is shown 
to be sensitive to change (Kavanaugh et al., 2012, Ortonne et al., 2013, Reich et al., 
2005, Rich et al., 2014, Van den Bosch et al., 2010). However the mNAPSI, like all other 
nail psoriasis scoring tools, does not provide an objective measure of patient burden or 
reflect problems such as pain, restrictions on social and working life or the psychological 
impact of nail changes (Augustin and Ogilvie, 2010). 
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Table 1.2. Modified Nail Psoriasis Severity Index (mNAPSI). 
1.1.6.3 Assessment of Psoriasis on Health-Related Quality of Life 
A major component of the assessment of psoriasis is the measurement of health-related 
quality of life (HRQoL) in addition to disease activity. Improvement in a patient’s life and 
wellbeing is the principle goal of any therapy; evaluations of HRQoL are very important 
(Kirby et al., 2001) and should be performed in parallel with measures of visible disease 
severity. Some patients may have widespread psoriatic lesions but not be affected by 
them, whist others may have only a few lesions and be greatly bothered by them, 
especially if they are in very visual sites such as the face, scalp or dorsal hands. Despite 
this lack of direct correlation between HRQoL values and more objective clinical 
measures such as the PASI and PGA (Reich and Griffiths, 2008), significant reductions 
of PASI are likely to correlate with significant improvements of HRQoL. However, the 
correlation is not linear (Mattei et al., 2014, Revicki et al., 2008). 
The effect of psoriasis on HRQoL can be measured using a number of general health, 
dermatology-specific and psoriasis-specific tools. The most widely cited are listed in 
Table 1.3.  
 
Features 
Right Fingernails Left Fingernails 
5 4 3 2 1 1 2 3 4 5 
Onycholysis 
0 = none 0 0 0 0 0 0 0 0 0 0 
1 = 1-10% of nail surface 1 1 1 1 1 1 1 1 1 1 
2 = 11-30% of nail surface 2 2 2 2 2 2 2 2 2 2 
3 = >30% of nail surface 3 3 3 3 3 3 3 3 3 3 
Pitting 
0 = none 0 0 0 0 0 0 0 0 0 0 
1 = 1-10 pits 1 1 1 1 1 1 1 1 1 1 
2 = 11-49 pits 2 2 2 2 2 2 2 2 2 2 
3 = >50 pits 3 3 3 3 3 3 3 3 3 3 
Nail plate 
crumbling 
0 = none 0 0 0 0 0 0 0 0 0 0 
1 = 1-25% of nail 1 1 1 1 1 1 1 1 1 1 
2 = 26-50% of nail 2 2 2 2 2 2 2 2 2 2 
3 = >50% of nail 3 3 3 3 3 3 3 3 3 3 
Features (tick if present) Right Fingernails Left Fingernails 
Leukonychia           
Splinter haemorrhage           
Nail bed hyperkeratosis           
Red spots in lunula           
Oil spot dyschromia           
Total per nail (/14)           
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Category Assessment Tool 
General Health Related 
Medical Outcome Survey Short Form 36 (SF-36)  
(Ware and Sherbourne, 1992) 
EuroQol-5 (EQ-5D) 
(EuroQol, 1990, Brooks et al., 1991) 
Dermatology-Specific 
Dermatology Life Quality Index (DLQI) 
(Finlay and Khan, 1994) 
Skindex 
(Chren et al., 1996) 
Psoriasis-Specific 
Psoriasis Disability Index (PDI) 
(Finlay and Kelly, 1987) 
Psoriasis Index of Quality of Life (PSORIQoL)  
(McKenna et al., 2003) 
Psoriasis Life Stress Inventory (PLSI) 
(Gupta and Gupta, 1995) 
Table 1.3: Quality of life instruments used in the assessment of patients with psoriasis  
The DLQI has been most widely used measure for assessing HRQoL related to psoriasis 
in clinical trials (Finlay and Khan, 1994). This patient-reported outcome measure was 
developed for use in all dermatoses, and comprises ten questions that ask the patient to 
rate how much their skin disease has affected several domains of their life in the past 
seven days from ‘not at all’ to ‘very much’ (scored 0-3). A maximum score of 30 is 
achievable (Appendix 3). The questions concern symptoms and feelings, daily activities, 
work and school, leisure, personal relationships and treatment. Like the PASI, the DLQI 
is the only quality of life assessment tool that forms part of the eligibility criteria for 
biologic therapy in the UK, where a score of ten or more is required.  
Good internal validity, construct validity, content validity and sensitivity to change are 
demonstrated for the DLQI (Bronsard et al., 2010, Safikhani et al., 2013, Mazzotti et al., 
2003, Shikiar et al., 2003). However, while a Rasch analysis found good internal 
reliability, poor responsiveness to change was reported in patients with mild disease 
(Twiss et al., 2012).  
The Psoriasis Disability Index (PDI) was the first HRQoL questionnaire designed 
specifically for use in patients with psoriasis (Finlay and Kelly, 1987). The questionnaire 
is validated (Finlay et al., 1990) and has shown sensitivity to change (Lewis and Finlay, 
2005, Kent and al-Abadie, 1993). However, the PDI is not perfect; it has been shown to 
have a significant floor effect and specific data relating to the least change in the score 
that is of importance to patients have not yet been prospectively identified. The PDI also 
attracts criticism for being more focused on symptoms than quality of life and in more 
recent clinical trials, it has lacked sensitivity (Nijsten et al., 2005, Fernandez-Penas et 
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al., 2012). The Psoriasis Index of Quality of Life (PSORIQoL) (McKenna et al., 2003) and 
the Psoriasis Life Stress Inventory (PSLI) (Gupta and Gupta, 1995) have similarly been 
developed for use specifically in psoriasis, but there has been little uptake of these tools 
in clinical trials in over a decade.  
The difficulty with novel scoring systems such as the PDI, PSORIQoL and PLSI is that 
they are of little or no use in the clinical setting if the clinician is not able to interpret the 
absolute meaning of a score or change in score. This has only been investigated for the 
DLQI where absolute score banding has been proposed (0-1, ‘no effect’ on HRQoL; 2-
5, ‘small effect’; 6-10, ‘moderate effect’; 11-20, ‘very large effect’; 21-30, ‘extremely large 
effect’) (Hongbo et al., 2005). The most critical single concept is that if the DLQI s greater 
than ten, this represents psoriasis that is having a very large effect on a patient’s life, 
meriting intervention, and this is reflected in the NICE guidance for the use of biologic 
therapies (Smith et al., 2009).  
1.2 Management of Psoriasis 
Treatment of psoriasis can be challenging, since a spectrum of clinical presentations, 
different psoriasis phenotypes, comorbidities and patient factors need to be considered. 
In the past decade, a large number of effective treatments have been developed and 
standards regarding management have evolved. These standards include evidence-
based guidelines, implementation tools and the use of valid outcome measures such a 
PASI, mNAPSI and DLQI. 
The successful management of psoriasis must be holistic and can include topical and 
systemic pharmacotherapeutic agents, physical treatments (e.g. phototherapy), 
psychological support and lifestyle modification. The approach to treatment should follow 
a step-wise approach and correlate with the severity of psoriasis (Figure 1.5). 
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Figure 1.5. The stepwise approach to managing psoriasis. FAE; Fumaric acid esters. 
For patients with moderate to severe psoriasis, the landscape has evolved significantly 
and patients can now aim for clear or almost clear skin. Until 2003, phototherapy and 
conventional systemic agents were the mainstay (and top line) of treatment for moderate 
or severe psoriasis that could not be adequately controlled with topical therapies, and 
they remain an integral part of all psoriasis management guidelines as they are effective 
therapy for some patients. However, for others, inadequate response or significant side 
effects (e.g. gastrointestinal upset, organ toxicity or skin cancer) necessitate 
discontinuation and the search for an alternative. Following the first approval of alefacept 
and efalizumab by the FDA in 2003, major advances in the understanding of the 
pathogenesis of psoriasis have facilitated the development of highly selective biological 
agents targeting TNF-a, IL-23 and IL-17, which have revolutionised modern psoriatic 
disease management. 
1.2.1.1 Biologic Therapies 
The recognition that the beneficial effect of ciclosporin in psoriasis is attributable to the 
drug’s impact on T lymphocytes provided a breakthrough in terms of understanding the 
pathogenesis of psoriasis and identified T cells as an important target for psoriasis 
therapy (Griffiths and Voorhees, 1990). The role of the lymphocyte was confirmed when 
Krueger and colleagues successfully treated psoriasis using a lymphocyte-selective 
fusion protein consisting of IL-2 and fragments of diphtheria toxin. This selectively blocks 
activated lymphocytes but has no effect on keratinocytes. Eight out of ten patients treated 
Step 1- Emollients 
and Topical 
Therapies
Mild-to-moderate 
plaque psoriasis
Consider throughout
Step 2 – Systemic 
agent or phototherapy
Moderate-severe 
psoriasis (BSA>10%) 
or inadequate response 
to topicals alone
Phototherapy or 
oral agents (i.e. 
methotrexate, acitretin, 
ciclosporin, FAE)
Step 3 – Biologics
If second line 
treatments ineffective  
or not tolerated           
(as per BAD and 
NICE guidance)
Etanercept, 
Adalimumab, 
Ustekinumab, 
Infliximab, 
Secukinumab, 
Apremilast
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with two doses had a moderate or marked reduction in their psoriasis, confirming the role 
of the lymphocyte (Gottlieb et al., 1995). 
Beyond the cellular components, the concept of a cytokine network in genetically 
predisposed patients leading to abnormal keratinocyte proliferation in response to 
infectious or traumatic skin exposures began to emerge. The importance of Th1 
cytokines and IFN-g in the activation of lymphocytes and T-cell trafficking (Huang et al., 
2001) lead to the development of the first two FDA-approved biologic agents, alefacept 
and efalizumab (both now withdrawn), which blocked T-cell activation (Krueger et al., 
2002, Lebwohl et al., 2003).  
The role of TNF-a was not recognised until anecdotal clinical efficacy had been observed 
in non-psoriatic diseases, where it was noted that TNF-a antagonists rapidly reduced IL-
1 and IL-8, followed by reductions in inflammatory gene expression including IFN-g. The 
reduction in T-lymphocyte activation and decreased production of cytokines, 
chemokines, lymphocytes, neutrophils, dendritic cells and keratinocytes stopped the 
feedback cycle of immune activation leading to keratinocyte proliferation and chronic 
inflammation. By 2004, the FDA approved the first TNF inhibitor, etanercept (a human 
TNF receptor p75 Fc fusion protein), followed by infliximab (a chimeric human-mouse 
IgG monoclonal antibody, 2006) and adalimumab (a recombinant human IgG1 
monoclonal antibody, 2008). These agents are still at the fore of biologic therapy for 
moderate to severe psoriasis and provide PASI 75 responses (by week 10-12) of 30%, 
53% and 80% respectively (Gordon et al., 2006, Gottlieb et al., 2003b, Reich et al., 2005, 
Menter et al., 2008). However, due to the development in some of anti-drug antibodies, 
which can be exacerbated by poor drug compliance, efficacy can be lost and alternative 
agents required to obtain or maintain such PASI responses. TNF inhibitors are also 
associated with worsening of cardiac failure and demyelination.  
Further advances in understanding of the complex cytokine network in psoriasis focused 
attention on the p40 subunit, found on both IL-12 and IL-23, which lead to the 
development of two new anti-p40 monoclonal antibodies, ustekinumab (Lebwohl et al., 
2012) and briakinumab (Reich et al., 2011) (both recombinant human IgG1 kappa 
monoclonal antibodies). Impressive PASI 75 responses were observed (67-76% for 
ustekinumab), and the former was FDA approved for psoriasis in 2009. Briakinumab was 
equally effective but approval was not pursued after a small increase in major adverse 
cardiac events during phase III clinical trials (Langley et al., 2013). Data from the British 
Association of Dermatologists Biologics Intervention Register (BADBIR) (Warren et al., 
2015), the Danish DERMBIO registry (Gniadecki et al., 2015) and PSOriasis Longitudinal 
Assessment and Registry (PSOLAR) have all shown that ustekinumab has a significantly 
longer drug survival than the anti-TNF-a agents, reflecting greater effectiveness, safety 
and tolerability. 
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It has since become apparent that it is inhibition of IL-23 that is the main reason for the 
efficacy of ustekinumab in psoriasis, and the IL-23/IL-17 axis has since come to the fore 
as the key target in psoriasis for the pharmaceutical industry. IL-23 is produced by 
antigen presenting cells and induces and maintains differentiation of Th17 cells, a 
primary cellular source of IL-17, which mediates the epidermal hyperplasia, keratinocyte 
immune activation and tissue inflammation inherent in psoriasis. Selectivity for the other 
subunit of IL-23 (p19) could offer advantages in efficacy over IL-23p40 blockade with 
respect to distal blockade of IL-17A, or its receptor. Two biologic agents, guselkumab 
(CNTO1959, Janssen Biotech, Inc.) and Tildrakizumab (MK-3222, Sun 
Pharmaceuticals) have received FDA approval for psoriasis in 2017, and phase II and III 
trials are currently underway with several other new anti-IL-23p19 biologic drugs 
including Brazikumab (AMG-139, Amgen), Risankizumab (BI 655066, Boehringer-
Ingelheim), Mirikizumab (LY3074828, Eli Lilly). In a head to head comparator study of 
guselkumab versus adalimumab (VOYAGE-1), significantly higher proportions of 
patients receiving the former achieved PASI 90 by week 16 (73.3% vs. 65.9% for 
guselkumab and adalimumab, respectively) (Blauvelt et al., 2017) suggesting a 
therapeutic shift away from TNF-inhibition is highly likely in the near future. The first IL-
23p19 is due to come to market in the UK in early 2018. 
At least four antibodies directly targeting IL-17A, IL-17A/F or its receptor have also been 
studied clinically and have shown dramatic PASI responses in as little as 12 weeks (PASI 
90 59.2-70.9%). Secukinumab (Langley et al., 2014) and Ixekizumab (Leonardi et al., 
2012) both target IL-17A and have received approval by NICE in 2017, and a third, 
Brodalumab (Papp et al., 2012), an antibody to the IL-17 receptor, is expected to receive 
approval imminently. Bimekizumab, which neutralises both IL-17A and IL-17F, has 
completed phase IIb studies with impressive results and has now progressed to a full 
phase III programme (Papp et al., 2018). Class-related adverse effects have been 
observed with IL-17A blockade including mucocutaneous candidiasis and triggering or 
worsening of inflammatory bowel disease, which are absent for other drugs targeting 
cytokines further upstream in the IL-23/Th17 pathway.  
1.2.2 The ‘Psoriatic Disease’ Complex 
Psoriasis should no longer be considered as a distinct disease entity affecting only the 
skin (Lotti et al., 2010). It is believed that up to 73% of patients with psoriasis will have 
at least one comorbidity (Puig-Sanz, 2007), and psoriasis should therefore be considered 
as part of a multisystem psoriatic disease spectrum. This spectrum includes psoriatic 
arthritis, inflammatory bowel disease, non-alcoholic fatty liver disease, uveitis, metabolic 
syndrome (obesity, dyslipidaemia, diabetes mellitus, hypertension), cardiovascular 
disease and psychiatric disorders (Nijsten and Wakkee, 2009). Systemic inflammation is 
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the common denominator for all of these immune-mediated co-morbidities, although 
uncertainty still remains about the factor(s) that either initiate or perpetuate this immune 
reaction and the complex interplay with genetic factors that cause the wide phenotypic 
variation of patients with psoriatic disease. It is not yet known if the presence or severity 
of these comorbid conditions can be attenuated with the early introduction of 
immunomodulatory treatment, and this is the current focus of much research interest.  
1.3 Psoriatic Arthritis 
The association between psoriasis and arthritis was first recognised by Baron Jean Luis 
Aliberti in 1818, and later in the nineteenth century, several French physicians described 
the association between arthritis and psoriasis, including Charles Bourdillon, whose 
1988 doctoral thesis was entitled  ‘Psoriasis et Arthropathies’ (Gladman and Chandran, 
2009). However, many considered the presence of arthritis associated with psoriasis to 
be a variant of rheumatoid arthritis, and it was not until 1956 that Professor Verna Wright 
first described PsA as a specific entity (Wright, 1956). Rheumatoid factor, a test 
discovered in 1948, was found to be positive in 85% of patients with RA and fewer than 
15% of patients with PsA, which cemented the distinction of PsA as a distinct arthropathy 
(Alexander, 1967).  
1.3.1 Epidemiology 
PsA is now recognised as an immune-mediated inflammatory disease that 
predominately affects the musculoskeletal structures as well as the skin, nails and 
mucosa. PsA is considered to be part of the spectrum of seronegative 
spondyloarthropathies, which are unified by their involvement of the axial skeleton and 
entheses and association with human leukocytes antigen (HLA) B27. The prevalence of 
PsA in the general population of Europe, based on studies from the Netherlands, 
England, France, Greece, Norway, Iceland and Denmark, is estimated to be between 
0.05% and 0.195%, in the US, estimates range from 0.101% to 0.25% and in Australia, 
one study revealed a prevalence of 0.47%. Variations are probably due to ethnic 
differences, heterogeneity in study methods and criteria for defining PsA between 
populations. The introduction of the ClASsification criteria for Psoriatic Arthritis 
(CASPAR) has helped to standardise epidemiological assessments for PsA (Figure 1.6) 
(Taylor et al., 2006). Studies outside of Europe and the US are few, but the reported 
prevalence in Japan is strikingly low at 0.00001% (Gladman and Chandran, 2009).  
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Inflammatory articular disease that may involve joint, entheseal or axial manifestations 
 AND  
Current psoriasis 
+ 1 of the following 
Personal or family history of psoriasis 
+ 2 of the following 
No psoriasis 
+ 3 of the following 
 
Dactylitis 
Psoriatic nail 
dystrophy 
Negative 
Rheumatoid Factor 
Radiological evidence of juxta-
articular new bone formation 
Figure 1.6. The ClASsification criteria for Psoriatic ARthritis (CASPAR). 
Amongst patients with psoriasis, clinic-based studies have reported PsA prevalence as 
6 to 48%, again depending on the population measured, diagnostic codes and criteria 
for defining PsA. For example, Alenius et al reported the prevalence at 48%, but included 
a broad reaching definition including peripheral arthritis, axial arthritis, enthesitis and 
undifferentiated spondyloarthritis (Alenius et al., 2002). An international study involving 
clinics from the UK, France, Germany and Spain showed the prevalence increased with 
time since diagnosis of psoriasis, reaching 20.5% after 30 years (Mease et al., 2013). In 
Japan, among a sample of 28,628 cases of psoriasis in 148 dermatology centres, only 
1% had PsA, confirming the very low prevalence of PsA in Japan (Kawada et al., 2003). 
Table 1.4 shows the differences in PsA prevalence from studies of patients with psoriasis 
in the western world. 
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Author (year) Centre Psoriasis Patients (n=) PsA (%) 
Leczinsky (1948) Sweden 534 7 
Vilanova (1951) Barcelona, Spain 214 25 
Little (1975) Toronto, Canada 100 32 
Scarpa (1984) Napoli, Italy 180 34 
Stern (1985) Boston, US 1285 20 
Zaneli (1992) Winston-Salem 459 17 
Barisic-Drusko (1994) Osijek region, Croatia 553 10 
Salvarani (1995) Regio Emilia, Italy 205 36 
Shbeeb (2000) Mayo Clinic, US 1056 6.25 
Brockbank (2001) Toronto, Canada 126 31 
Alenius (2002) Sweden 276 48 
NPF (2002) US 4.4 m 23 
Zachariae (2003) Denmark 5795 30 
Reich (2008) Germany 1511 20.6 
Ogdie (2012) UK 4064 8.6 
Haroon (2013) Dublin, Ireland 100 29 
Walsh (2013) Utah, US 189 30 
Mease (2013) International 1000 30 
Table 1.4. Summary of published studies of the prevalence of psoriatic arthritis (PsA) in 
the western world.  
The incidence of PsA among patients with psoriasis in Europe and the US in the general 
population ranges between 3 and 7.2 cases per 100,000 population (Shbeeb et al., 2000, 
Wilson et al., 2009, Alamanos et al., 2003), although a higher incidence of 23.1 to 27.3 
per 100,000 population is reported in Scandinavia  (Egeberg et al., 2017, Kaipiainen-
Seppanen, 1996).  In a recent prospective cohort study from Canada that involved 
psoriasis patients without PsA at entry, 51 of 464 patients developed PsA over eight 
years of follow up. The annual incidence rate was 2.7 cases per 100 psoriasis patients 
(Eder et al., 2016). This is an increase from 2011, where a previous observational study 
by the same group showed an annual incidence rate of 1.87 cases of PsA per 100 
psoriasis patients (Eder et al., 2011a).  
1.3.2 Pathogenesis 
Investigating the pathology of PsA is complex given the heterogeneity of clinical 
manifestations. As understood in psoriasis, PsA appears to be associated with abnormal 
activation of both the innate and adaptive immune system in genetically primed 
individuals.  The heritability of PsA is much greater than that of psoriasis (recurrence risk 
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ratio estimated at 27 for PsA, and between 4 and 11 for psoriasis) (Gladman et al., 2003, 
Bhalerao and Bowcock, 1998). In those with a first to fourth degree relative with PsA, a 
study from Iceland confirmed significantly increased risk ratios for the development of 
PsA (39, 12, 3.6 and 2.3, respectively, p<0.0001) (Karason et al., 2009). Numerous 
genetic susceptibility loci have been identified for PsA including HLA-B27, B7, DR4, B38 
and DR7, in addition to those shared with psoriasis (HLA-B13, B17, B57 and B39) (Ho 
et al., 2008, Al-Heresh et al., 2002, Chandran et al., 2009b). Assocaition with HLA-Cw06 
remains contentious, with recent cross-phenotype association mapping of the MHC in 
one study finding no association of PsA to HLA-C*06:02 after controlling for the age of 
psoriasis onset. The most significant association was to amino acid at position 97 of 
HLA-B, where the presence of asparagine or serine residue increased PsA risk (Bowes 
et al., 2017). Asparagine at position 97 of HLA-B defines the HLA-B27 alleles. GWAS 
studies have also identified a number of gene polymorphisms including TNF-a promoter, 
IL-23A, IL-23R and IL-12B, and associations within the NFkB pathway (TNF-a induced 
protein 3 (TNFAIP3), and TNFAIP3 interacting protein, TNIP1 (Rahman et al., 2006, 
Cargill et al., 2007, Liu et al., 2008, Nair et al., 2009).  
The presence of susceptibility genes in an individual defines the T-cell repertoire that is 
developed on the individual’s self-peptides and self-MHC, and is poised for auto-
reactivity until triggered. Several environmental factors appear to trigger PsA, with 
multiple studies showing an association with acute trauma, either physical (akin to a 
‘deep koebner’ response) (Thorarensen et al., 2017, Eder et al., 2016, Ogdie and 
Gelfand, 2010, Punzi et al., 1997, Scarpa et al., 1992), or psychological distress (e.g. 
emotional stress) (Pattison et al., 2008). Like psoriasis, infection may also be a significant 
trigger for PsA. Clear associations between human immunodeficiency virus (HIV) 
infection and both psoriasis and psoriatic arthritis have been reported (Njobvu and 
McGill, 2000), and an increased prevalence of hepatitis C infection has been observed 
in patients with PsA compared to patients with psoriasis, RA or the general population 
(Taglione et al., 1999).  Group A streptococcal infections are associated with the 
development of guttate psoriasis, and ribosomal RNA of this bacterium have been 
detected in the peripheral blood and synovial fluid of patients with PsA (Wang et al., 
1999). 
Once triggered, the immune process results in the two main features of PsA; the 
inflammatory infiltrate of T lymphocytes and accessory cells into the entheses and 
synovium, and the response of these tissues to the products and consequences of the 
inflammatory infiltrate. Within the synovium, significant angiogenesis is observed due to 
the upregulation of promoters of angiogenesis, much like in a psoriatic plaque, which 
facilitates an increase in infiltrating immune cells (Gao et al., 2013, Kruithof et al., 2005). 
Synovial tissue in PsA is characterised by expression of proinflammatory cytokines 
including TNF-a, IFN-g, IL-1, IL-6, IL-8 and IL-10 IL-12, IL-15, IL-18 and IL-23 (van Kuijk 
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et al., 2006), with relationships observed between cytokine levels and clinical arthritis 
severity (Szodoray et al., 2007).  Destructive matrix metalloproteinases have been 
associated with synovitis and subsequent bone erosion in PsA, which occurs through 
increased osteoclast activity (Bond et al., 2007). Osteoclasts are derived from TNF-α-
activated peripheral blood mononuclear cells, which migrate to inflamed synovium and 
subchondral bone. Here they are exposed to unopposed receptor activator of NFkB 
ligand (RANKL) and TNF-α, leading to osteoclastogenesis and the formation of bone 
erosions (Ritchlin et al., 2003). Increased osteoclast precursors have been identified in 
the peripheral blood of patients with PsA, which decease with administration of TNF 
inhibitors, which may account for some of their clinical activity (Anandarajah et al., 2008).  
Heterogeneity has been observed in patients with PsA, with some showing 
predominantly synovial disease on MRI (as seen in RA), while others show neighbouring 
inflammation in thickened collateral ligaments and periarticular soft tissue, exhibiting a 
predominantly entheseal driven disease (Jevtic et al., 1995).   Subsequently, enthesitis 
was demonstrated to be a common clinically inconspicuous finding in inflamed synovial 
joints (McGonagle et al., 1998b) and can occur in the absence of synovitis (Frediani et 
al., 2001). Enthesitis is now generally accepted as the primary inflammatory lesion in 
PsA, with secondary dissipation of inflammation to the synovium and extracapsular 
structures. Further detail regarding enthesitis can be found in Chapter 1.3. 
1.3.3 Diagnosis, Classification and Subtypes 
The diagnosis of PsA is principally clinical, based on history and examination findings, 
with support from several imaging modalities. Psoriasis tends to precede the 
development of PsA in 70% of cases, occur simultaneously in 10-15% and develop 
before skin manifestations in 10-15% (Cohen et al., 1999, Leung et al., 2007). Typically, 
in those with precedent psoriasis, PsA symptoms emerge within the first seven to fifteen 
years after psoriasis onset (Tillett et al., 2017a). Patients describe joint stiffness and pain, 
fatigue and decreased physical function, and in those with axial disease, back pain 
and/or buttock pain. Stiffness generally is worse after rising, and improves throughout 
the morning. In the majority, the onset is insidious, but it can be acute in up to one third 
of patients.  
The CASPAR criteria (Figure 1.6) are now widely adopted to help classify patients with 
inflammatory arthritis as PsA if they meet the criteria (Taylor et al., 2006), and have been 
shown to be more sensitive than other classification criteria, even in early PsA (Coates 
et al., 2012). The sensitivity and specificity have been reported in three separate cohorts 
as 98.2-100% and 98.8-99.7%, respectively (Leung et al., 2010, Chandran et al., 2008, 
Tillett et al., 2012a).  
 26 
Five subtypes of PsA have been recognised, although they are seen as a spectrum 
rather than distinct phenotypes (Moll and Wright, 1973): 
- Distal interphalangeal joint predominant arthritis 
- Asymmetrical polyarthritis 
- Symmetrical polyarthritis (similar to rheumatoid arthritis but without a positive 
rheumatoid factor) 
- Arthritis mutilans 
- Axial disease-predominant 
Oligoarthritis is observed most frequently in early PsA, with phenotypic progression to 
polyarthritis described with time (Gladman et al., 1987, Helliwell et al., 1991, Jones and 
McHugh, 1994, Marsal et al., 1999, Khan et al., 2003). Approximately one third of 
patients will also exhibit dactylitis, a uniform swelling of a finger or toe digit or digits 
(Gladman et al., 2013), and/or enthesitis, which may present with tenderness and/or 
swelling over tendon insertion sites (Sakkas et al., 2013). 
1.3.4 Impact on Quality of Life 
PsA places a substantial burden on patients, causing pain and diminishing their capacity 
to carry out daily activities which has an impact on quality of life. Many patients also have 
visible skin involvement, resulting in self-consciousness, embarrassment and anxiety, 
further adding to poor psychosocial function (Mease, 2009). Measures of health-related 
quality of life are lower in patients with PsA than in healthy people and those with other 
inflammatory arthritides (Borman et al., 2007, Husted et al., 2001), and also than in 
patients with psoriasis alone (Rosen et al., 2012).  In the Nottingham Health Profile, PsA 
patients reported greater role limitations caused by emotional problems as well as more 
bodily pain, reduced energy and sleep and social isolation (Borman et al., 2007). 
Depression is also often present; in an observational Canadian study, patients who had 
had PsA for longer than two years were two to five times higher than those of age-
matched controls who had no history of PsA or psoriasis.  
Patients with PsA commonly report fatigue and sleep disturbances, which can contribute 
to reduced quality of life. Approximately 50% complain of moderate-to severe fatigue, 
and 29% complain of severe fatigue (Husted et al., 2009), with the presence of PsA being 
a strong predictor of sleep disturbance (odds ration 3.27, p<0.001) (Callis Duffin et al., 
2009). A pilot test of willingness to pay for cure, most participants were willing to pay a 
median of $10,00 for physical comfort, sleep and work, and $5,000 for emotional health, 
with patients earning higher incomes willing to pay even more (Hu et al., 2010).  
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1.3.5 Socioeconomic Burden 
Approximately 40-60% of patients with PsA may develop erosive and deforming joint 
disease, leading to progressive disability and pain (Liu et al., 2014). PsA is also 
associated with several comorbidities including anxiety and depression, reduced quality 
of life, obesity, hypertension, type II diabetes and cardiovascular disease (Husni and 
Mease, 2010). The proportion of work disabled patients with PsA has been reported to 
be approximately 40% yet few studies to date have focused on the inequities of PsA from 
a social and economic perspective (Kristensen et al., 2013, Tillett et al., 2012b). In a 
recent nationwide population-based cohort study from Denmark based on prospectively 
recorded register data, patients with PsA were found to have significantly more 
comorbidities including cardiovascular disease, respiratory illnesses and infectious 
diseases compared with the general population. Patients had higher total healthcare 
costs and lower income, and incurred on average, a net increased cost to society of 
€10,641 per patient-year than the general population. The relative risk (compared to the 
general population) for being on a disability pension five years prior to the diagnosis of 
PsA was 1.36 (95 C.I. 1.24-1.49), rising to 1.60 (1.49-1.72) at diagnosis and to 2.69 
(2.40-3.02) 10 years after diagnosis, where 21.8% of patients with PsA received a 
disability pension (Kristensen et al., 2017). Given the clinical burden of PsA, it is not 
surprising that patients are significant users of health care resources. In a German study, 
patients made 20.3 visits to a general practitioner every year, and 3.9 visits to a 
rheumatologist, and 12.7% had required at least one hospitalisation in the previous year 
(Zink et al., 2006).  
Disease activity and the need to maintain physical function are the major drivers of cost 
associated with PsA. Mean total healthcare costs in the UK for PsA are reported to range 
from £11 to £20,782 (mean (± s.d.) £1446 ±£1756), with more than one third attributed 
to prescription costs and secondary care attendances (Poole et al., 2010). In another 
study from Germany, mean annual direct costs per patient were €3156, and the mean 
annual indirect cost ranged from €2414 to €7919 per patient, depending on the method 
used to calculate costs (Huscher et al., 2006). Since these studies were performed, the 
expansion of biologic drug prescribing is likely to have significantly added to these costs 
– on analysing the cost in patients with PsA who were treated for six months with or 
without a biologic agent, a greater than 5-fold increase was observed in direct costs, 
estimated at around $7768 per patent year (Olivieri et al., 2008).  However, in studies of 
patients with only severe PsA, markedly elevated per patient year costs are observed in 
terms of direct ($8,808), indirect ($48,834) and total ($57,642) costs, providing further 
motive to provide effective therapeutic intervention early to reduce disability and maintain 
function (Huscher et al., 2006). In a recent study of 229 working age patients with PsA, 
a 30% improvement in work presentism (p<0.001) and a 40% improvement in work 
productivity (p<0.001) was observed among patients treated with a TNF inhibitor for six 
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months, thus to some degree offsetting the high direct pharmaceutical costs for these 
drugs (Tillett et al., 2017b).  
1.3.6 Management of Psoriatic Arthritis  
Much like the management of psoriasis, the approach to the management of PsA also 
follows a ‘step up’ approach to therapy. Data in the literature on treatment strategies for 
PsA are scarce, and therefore a step-wise approach is appropriate to balance safety with 
efficacy. Recommendations for the management of PsA have been published by two 
international organisations: the European League Against Rheumatism (EULAR) and the 
Group for Research in Psoriasis and Psoriatic Arthritis (GRAPPA) (Gossec et al., 2016, 
Coates et al., 2016).  
The first step in both guidelines involves the treatment of symptoms of PsA through the 
use of non-steroidal anti-inflammatory drugs (NSAIDs) and where applicable, local 
glucocorticoid injections. NSAIDS are efficacious for the relief of musculoskeletal 
symptoms, particularly in patients with mild joint disease, although the risks and 
contraindications need to be considered (Ash et al., 2012a). Local glucocorticoid 
injections alleviate pain and inflammation in joints, tendon sheaths and entheses (Eder 
et al., 2010). If ineffective, the next step is to escalate to use of the conventional synthetic 
disease modifying anti-rheumatic drugs (DMARDS) including methotrexate, 
sulphasalazine, leflunomide and ciclosporin, with the exception of patients with 
symptomatic enthesitis or axial disease, in whom, these drugs are ineffective. These 
individuals,  as well as those with peripheral disease in whom conventional DMARDS 
are not adequate at controlling symptoms or progression, should receive biologic agents 
(Coates et al., 2016, Gossec et al., 2016). The clinical response to therapy and the needs 
of the patient should be reviewed periodically in accordance with a treat-to-target 
approach, aiming to achieve minimal disease activity (MDA) as set out in seven criteria 
(Figure 1.7) (Coates et al., 2010, Coates and Helliwell, 2016). 
 
Patients must fulfil five of the following seven criteria: 
• Swollen joint count £1 
• Tender joint count £1 
• PASI £1 or BSA £3% 
• Patient pain (visual analogue score, VAS) £15 
• Patient global disease activity (VAS) £20 
• Health Assessment Questionnaire (HAQ) £0.5 
• Tender entheseal points £1 
Figure 1.7. Minimal Disease Activity (MDA) Criteria for PsA (Coates et al., 2010).   
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The approval for and availability of biologic therapies for PsA is rapidly expanding, 
although little or no data exist to inform treatment order or strategy. TNF inhibitors, 
including adalimumab, etanercept, infliximab, golimumab and certolizumab, have 
demonstrated efficacy in all aspects of PsA treatment (Antoni et al., 2005, Kavanaugh et 
al., 2009, Mease et al., 2014a, Mease et al., 2005, Mease et al., 2004), including the 
inhibition of structural joint damage and are given preference as the first-line biologic 
therapy in the EULAR guidelines, but not the GRAPPA recommendations. In the latter, 
non-anti-TNF biologics can be used first line if the clinician deems it to be appropriate. 
TNF inhibitors were the only available biologic agent licensed for the treatment of PsA 
until 2015, and it is the longer duration of experience and greater quantity of long-term 
efficacy and safety data that lead to them being chosen as first line biologic therapy in 
the EULAR guidelines. However, given the impressive results from trials of IL-23 
inhibition and IL-17A inhibition in psoriasis, dermatologists and rheumatologists working 
in collaboration may wish to consider ustekinumab or secukinumab as first line 
monotherapy for patients with both PsA and moderate to severe skin disease (Kimball 
et al., 2012, Menter et al., 2016). 
ACR20, 50 and 70 rates, amounting to a 20%, 50% or 70% improvement in the American 
College of Rheumatology (ACR) response criteria (Figure 1.8), are shown below for the 
different biologic agents after 24 weeks of therapy (Table 1.5) (Antoni et al., 2005, 
Kavanaugh et al., 2009, Kavanaugh et al., 2014a, McInnes et al., 2013, McInnes et al., 
2015, Mease et al., 2014a, Mease et al., 2005, Mease et al., 2004). Aside from TNF 
inhibitors, the FDA have approved ustekinumab (IL-12/IL-23p40 inhibitor), secukinumab 
(IL-17A inhibitor), ixekizumab (IL-17A inhibitor), brodalumab (IL-17RA antibody), 
guselkumab (IL-23p19 inhibitor), tildrakizumab (IL-23p19 inhibitor) and apremilast 
(phosphodisetersae-4 (PDE-4) inhibitor), and there are many more biologic therapies 
and oral small molecules nearing the end of phase III clinical trials in PsA.  
 
>20/50/70% improvement required in both of the following 
measures of disease activity: 
Tender joint count 
Swollen joint count 
>20/50/70% improvement required in at least three of the 
following measures of disease activity: 
Patient assessment of pain 
Patient global assessment of disease activity 
Physician global assessment of disease activity 
Patient assessment of physical function 
Markers of inflammation 
Figure 1.8. American College of Rheumatology (ACR) Criteria for psoriatic arthritis 
(Felson et al., 1993).  
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ACR20 59 (15) 
57 
(15) 
54 
(16) 
52 
(12) 
64 
(24) 
42 
(23) 
51 
(15) 
59 
(22) 
ACR50 38 (5) 
39 
(6) 
41 
(4) 
30 
(6) 
44 
(13) 
25 
(9) 
35 
(7) 
32 
(7) 
ACR70 11 (1) 
23 
(1) 
27 
(2) 
19 
(2) 
28 
(4) 
12 
(2) 
21 
(1) 
17 
(1) 
Table 1.5. American College of Rheumatology (ACR) 20/50/70 responses (week 24) 
from registry trials for biologic and small molecule therapies approved by the FDA for the 
treatment of psoriatic arthritis. Percentage placebo responses are shown in brackets.  
*denotes EMA and FDA approval for psoriasis.  
The majority of biologic drugs approved for use in PsA also have a license to treat 
psoriasis, with the exception of golimumab and certolizumab. Collaborative working 
between dermatology and rheumatology is therefore imperative to identify the most 
suitable monotherapy for patients with both psoriasis and PsA (Soleymani et al., 2017, 
Okhovat et al., 2017). It is not yet known if skin-directed treatment for psoriasis with a 
biologic therapy that has demonstrated independent efficacy in PsA is able to modify the 
development of future joint disease. 
1.4 Enthesitis 
The term ‘enthesis’ is rooted in the ancient Greek word ‘ἔνθεσις’ or ‘énthesis’, meaning 
‘putting in’ or ‘insertion’.  This refers to the role of the enthesis as the site of attachment 
of tendons, ligaments, joint capsule fibres or fascia into bone (Francois et al., 1995). 
Entheses are numerous in the appendicular and axial skeleton and can be classed as 
fibrous or fibrocartilaginous according to the tissue present at the skeletal attachment 
site (Francois et al., 2001). At fibrous entheses, the collagenous tendon or ligament 
attaches directly to bone and typical examples include the metaphyses and diaphysis of 
long bones. At fibrocartilaginous entheses, cortical bone is extremely thin or absent, and 
tendons and ligaments must therefore connect directly to an underlying bony trabecular 
network and/or bone marrow spaces (Benjamin and McGonagle, 2007). Most entheses 
are fibrocartilaginous and these are the ones that are affected in SpA (Benjamin and 
McGonagle, 2001). 
Fibrous entheses anchor through a network of splayed fibres, tethering to the underlying 
bone like the roots of a tree to provide secure union (Harner et al., 1999). The entheses 
are sites of repeated compression and/or shear during locomotion and mechanical 
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loading, and it is proposed that their splayed and interlocking interface is an evolutionary 
means of attempting dissipating this biomechanical stress to adjacent structures. 
However, the consequence of repeated stress is the accumulation of microtrauma at the 
bony interface, as predicted from estimates of insertion-site deformation that occurs 
during tensile loading of tendon and ligaments (Woo, 1998). Repeated microtrauma 
leads immune activation in an attempt to promote repair, and if this becomes excessive, 
may lead to a clinically significant inflammatory pathology such as SpA (Benjamin et al., 
2007).  
Inflammation at the entheses is termed ‘enthesitis’. If inflammation is sustained, it leads 
to thickening and calcification of the tendon at insertion sites and cystic and erosive 
changes in the bone at insertion sites, followed by periosteal changes, the formation of 
bony spurs (enthesophytes), sub-periosteal new bone and syndesmophytes. Insertional 
disorders in general are referred to as ‘enthesopathies’ and in addition to the widely 
accepted association with SpA, may also be related to degenerative, traumatic, 
metabolic and endocrinological conditions (Resnick and Niwayama, 1983). 
Despite the widespread acceptance of an enthesis being a junction between the tendon 
or ligament and bone, anatomical studies have shown that the enthesis is not restricted 
to just the focal attachment to bone. The enthesis is associated with other adjacent 
structures that are functionally related, giving rise to the concept of the ‘enthesis organ’ 
(Benjamin and McGonagle, 2001, McGonagle et al., 2003). For example, at the Achilles 
tendon, the enthesis organ not only includes the junction point (true enthesis), but also 
the periosteal and sesamoid fibrocartilages, the retrocalcaneal bursa, the tip of Kager’s 
fat pad and the adjacent calcaneal bone. The enthesis is in close proximity to synovium 
with a synovial membrane covering the tip of the fat pad (Rufai et al., 1995, McGonagle 
et al., 2003, McGonagle, 2005). The enthesis itself is avascular, thus enthesis organ 
cartilages rely on adjacent synovium for nourishment and lubrication in a manner 
identical to articular cartilage in synovial joints. These structures, termed the ‘synovio-
entheseal complex’ (SEC), are anatomically, functionally and physiologically related and 
can perform as one entity to protect the enthesis during locomotion (McGonagle et al., 
2007). All of these structures may therefore be involved in entheseal inflammation. This 
concept of the SEC is supported by the pathological changes seen in patients with SpA, 
with diffuse changes in the connective tissue and underlying bone in the immediate 
vicinity of the insertion (McGonagle et al., 1999). The SEC is reported to exist at 82% of 
all entheses (Benjamin and McGonagle, 2007, McGonagle et al., 2007). 
The term ‘functional enthesis’ was coined by Benjamin and McGonagle to refer to sites 
where tendons and ligaments wrap around bony pulleys. Such locations share strong 
anatomical, biomechanical and histological similarities to entheses, however while there 
is contact between hard and soft tissues, there is no anchorage as seen at the traditional 
enthesis. Similar to compressive forces acting at the fibrocartilaginous enthesis insertion, 
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the wraparound nature of these tendons leads to a comparable functional demand for 
fibrocartilage, and this may explain why these regions can also be affected in SpA 
(Benjamin and McGonagle, 2001). Knowledge of these anatomical concepts is important 
as inflammation in enthesitis may be diffuse and not confined to the insertional site 
exclusively. When investigated with imaging such as ultrasound or MRI, abnormalities 
may be seen at sites that are not recognised as true insertions but nevertheless 
represent the same pathological process. 
1.4.1 Histopathological Features of Enthesitis 
It is technically and ethically difficult to obtain suitable tissue from patients with enthesitis, 
and thus most work relating to the pathology of enthesitis stems from cadaveric work 
investigating ‘normal’ entheses. Such studies have shown that the entheses of elderly 
persons sustain a substantial amount of microdamage at the attachment site and at 
adjacent fibrocartilage and synovium through decades of mechanical stress (Benjamin 
et al., 2007). In patients with SpA, it is proposed that there is a perturbation in tissue 
repair or remodelling responses at sites of high mechanical stress leading to a much 
earlier, more pronounced and sustained inflammatory response in genetically primed 
individuals  (McGonagle et al., 2007). 
In patients with SpA, the data for acute enthesitis is limited, but histologically 
inflammatory changes are seen including macrophage infiltration (McGonagle et al., 
2002a). Chronic enthesitis is characterised histologically by bony erosions, inflammatory 
infiltrates (comprising mainly of T lymphocytes) in the bone adjacent to the enthesis and 
oedema in the bone marrow close to fibrocartilage (Maksymowych, 2000, Bollow et al., 
2000). Within the aged enthesis, there are degenerative changes including clusters of 
hypertrophied fibrocartilage cells and matrix fissuring. In later disease, capsular 
ossification, myxoid bone marrow changes, chondroid metaplasia and the formation of 
synchondroses occur.  
1.4.2 Pathogenic Relevance of Enthesitis to Psoriatic Arthritis 
The pathogenesis of PsA is not fully understood, and the cascade of events is subject to 
debate. One model suggests that an adaptive T-cell response to a common skin and 
synovial membrane antigen drives the inflammatory manifestations that occur in PsA 
(Fitzgerald and Winchester, 2009). However, McGonagle and colleagues proposed that 
enthesitis is the primary and unifying event in all types of SpA, and that all other 
manifestations are secondary. The SEC, due to mechanical stress, is prone to 
microdamage (fissuring) and this triggers an innate immune response within the adjacent 
vascular synovium (Benjamin and McGonagle, 2001).  An animal model of spontaneous 
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PsA (aging DBA/1 mice) supports this concept of enthesitis triggering the innate immune 
response (Lories et al., 2004). However, TNF-inhibitor treatment of this animal model 
reduced inflammation but did not affect ankylosis, suggesting the process of entheseal 
ankylosis may be independent of TNF-α.  
A different animal model (type II collagen antibody-induced arthritis in B10.RIII mice) 
demonstrated that enthesitis develops first, in the initial complete absence of synovitis, 
and is induced by IL-23 alone. Blocking IL-23 during the induction of arthritis reduced 
both the clinical disease and the levels of entheseal inflammation in the mice. Over-
expression of IL-23 alone in naïve B10.R111 mice was sufficient to induce enthesitis, 
psoriasis and sacroilitis (Sherlock et al., 2012). 
This mouse model represented a breakthrough in the understanding of how IL-23 can 
promote SpA disease pathogenesis, as previous attempts at producing IL-23 transgenic 
mouse models have been fatal. Sherlock and colleagues developed a new mouse model 
containing a DNA minicircle injection of IL-23. Through IL-23 dose titration, they 
demonstrated that IL-23 promotes a pathology resembling SpA by acting on a previously 
unidentified, very specific subset of (IL-23R+ROR-γt+CD3+CD4−CD8−Sca1+) T cells that 
reside in the enthesis. This resident entheseal population of innate-like T cells express 
the IL-23 receptor and CD3, but not CD4 and CD8. Further characterisation revealed 
they express the transcription factor RAR-related orphan receptor γt (RORγt) and 
produce IL-17 and IL-22 in response to stimulation with IL-23. Mice subsequently treated 
with antibodies that specifically block IL-17 and IL-22 had reduced clinical disease. 
Further adding to the similarity between pathways in skin psoriasis and this mouse model 
of early psoriatic-like SpA, overexpression of IL-22 in these mice promoted bone 
remodelling and foot pad oedema, explained by IL-22 induced STAT3 phosphorylation 
in osteoblasts in vitro (Sherlock et al., 2012).  
Reinhardt et al confirmed these observations in B10.R111 mice, identifying abundant 
activated RORγt+IL-23R+ enthesis-resident lymphocytes in uninflamed entheseal tissue, 
the majority of which were activated Vγ6+CD27- γ/δ T cells capable of producing IL-17A. 
When exposed to mechanical stress, γ/δ T cells increased in number at the Achilles 
tendon enthesis, further supporting the role of γ/δ T cells as key players in the 
pathogenesis of IL-23-induced local inflammation (Reinhardt et al., 2016). 
Collectively, these data, in combination with IL-23 signalling pathway loci in genome-
wide association studies in psoriasis and PsA, provide promising evidence for the key 
role of IL-23 in spondyloarthopathy-based, entheseal-driven pathology as a possible 
forerunner of clinical PsA. However, further studies are necessary to validate these 
findings and replicate them in human tissues to add clinical significance. 
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1.4.3 Clinical manifestations of Enthesitis 
A small number of patients with PsA may have enthesitis alone and/or dactylitis for 
months to years before developing peripheral or axial arthritis (Salvarani et al., 1997). 
Enthesitis is more frequent in the lower than upper limbs, with the Achilles tendon and 
plantar aponeurosis entheses being the most frequently affected entheses. Enthesitis 
may be asymptomatic or cause pain, depending on the site involved, and pain may vary 
from mild to disabling. Pain is most often reported at the heel, with pain experienced on 
weight bearing, after a period of prolonged rest, and which improves gradually with 
movement. Clinically, there may be tenderness on pressure over the enthesis, and 
occasionally soft tissue swelling (McGonagle, 2015). The latter is mostly visible in 
Achilles enthesitis, the humeral lateral epicondyle and the patellar tendon. The frequency 
of clinically detectable enthesitis ranges from 13% to 60%, depending on the type of SpA 
and the entheses involved (Table 1.6) (Braun and Sieper, 1996, Burgos-Vargas and 
Vazquez-Mellado, 1995, Boyer et al., 1999, Collantes et al., 2000, Leirisalo-Repo, 2000).   
 
Spondyloarthopathy Frequency of Enthesitis (%) 
Ankylosing Spondylitis 25-28 
Reactive Arthritis 13-58 
Psoriatic Arthritis 20 
IBD-associated Spondyloarthropathy 7-53 
Undifferentiated Spondyloarthropathy 27 
Table 1.6: Reported frequency of clinically recognisable enthesitis in the various 
spondyloarthropathies 
Clinically recognisable sites include the large tendons and ligaments adjacent to joints 
and superficial spinal insertions. However, many sites of enthesitis, including most of 
those in the spine and in large joints, are clinically inaccessible. This accounts for the 
discrepancy in detection between enthesis identified on clinical examination and that 
detected by imaging such as ultrasound and MRI (Balint et al., 2002, Song et al., 2011a, 
Weckbach et al., 2011, Frediani et al., 2002, Lehtinen et al., 1994).  
1.4.4 Clinical Assessment of Enthesitis 
On clinical examination, enthesitis is detected clinically as tenderness by applying firm 
pressure (approximately 4kg/cm2, or enough to blanch the fingernail) with the pulp of the 
thumb over the enthesis (Mease, 2011). To improve discrimination between true 
tenderness and hyperalgesia (increased sensitivity to pain stimuli), a standard palpation 
 35 
of control sites should be introduced at the beginning of each assessment. For example, 
pressure applied to the anterior-superior aspect of the middle of the medial third of the 
clavicle provides the patient with a reference point for the sensation arising from pressure 
alone (Mander et al., 1987).  
Several clinical methods have been developed to measure enthesitis. The majority of 
these scoring systems were developed primarily for patients with AS, but have since 
been applied to patients with PsA. Table 1.7 lists the most commonly cited scores and 
the entheseal sites assessed in each. 
Site MASES MEI SPARCC SPARCC (8)6/16 Major Gladman LEI 
Nuchal crest  +      
Manubriosternal joint  +      
1st costochondral + +      
2nd-6th costochondral  +      
7th costochondral + +      
Supraspinatus 
insertion   + (+)  +  
Lateral epicondyle 
humerus  + +  +  + 
Medical epicondyle 
humerus  + +  +   
Greater tuberosity 
humerus  +      
5th lumbar spinous 
process (one point) + +      
Cervical, thoracic and 
lumbar spinous 
processes (one point) 
 +      
Posterior-superior 
iliac spine + +      
Anterior-superior iliac 
spine + +      
Iliac crest + +   +   
Sacroiliac joint  +      
Ischial tuberosity  +      
Greater trochanter  + + + +   
Medial femoral 
condyle  +     + 
Lateral femoral 
condyle  +      
Medial tibial condyle  +      
Lateral tibial condyle  +      
Adductor tubercle  +      
Fibula head  +      
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Site MASES MEI SPARCC SPARCC (8)6/16 Major Gladman LEI 
Inferior pole patella   +     
Tibial tubercle  + +   +  
Proximal Achilles + + + + + + + 
Plantar Fascia   + + + + +  
Table 1.7: Enthesitis Indices used in SpA. All assess the enthesis bilaterally unless 
stated. (MEI: Mander Enthesitis Index; MASES: Maastricht Ankylosing Spondylitis 
Enthesitis Score; SPARCC: Spondyloarthritis Research Consortium of Canada; LEI: 
Leeds Enthesitis Index) 
The Mander Enthesitis Index (MEI) was the first reported clinical measure of enthesitis, 
in 1987, in the context of AS. In a development pilot of six patients, sites that were not 
tender at any time point were excluded, leaving 66 sites (Figure 1.9). The patient’s 
response is recorded in a 4-point tenderness scale (0: no pain to 3: severe tenderness 
causing withdrawal). Further validation studies demonstrated correlation between the 
MEI and pain and stiffness VAS scores, and it appears sensitive to change in patients 
treated with a NSAID. Inter-observer variability was not tested. (Mander et al., 1987). 
However, the MEI has attracted criticism for being too time consuming, for having the 
potential to cause the patient distress, for the scale being subjective and for including 
many sites that are tender in fibromyalgia.  
The Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) reduced the number 
of entheseal sites tested to 13 as part of a simplification process of the MEI (Table 1.7, 
Figure 1.9).  The sites with greatest frequency of tenderness were recorded, and then 
excluded if they were difficult to localise or adjacent to other sites already included. A 
dichotomous 0/1 response to tenderness without grading was found to perform with the 
greatest consistency (Heuft-Dorenbosch et al., 2003). The MASES was tested as part of 
the INSPIRE study, which involved the assessment of 19 patients with AS and PsA by 
ten experienced rheumatologists. There was moderate inter-assessor agreement (ICC 
0.56), with superior performance in patients with AS compared to PsA (Gladman et al., 
2007a). Subsequently, a PsA-modified MASES has been designed which includes 15 
sites (plantar fascia included) (Kavanaugh et al., 2012). The MASES has also been 
shown to correlate with ultrasound sonographic scores (both total and acute enthesitis) 
(Hamdi et al., 2011). One limitation of the MASES is that it has a floor effect due to the 
reduced number of entheses tested and therefore may not detect low level enthesitis 
occurring at other insertion sites. 
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Figure 1.9. Schematic representation of entheseal sites assessed by the four principle 
entheseal indices. (MEI: Mander Enthesitis Index; MASES: Maastricht Ankylosing 
Spondylitis Enthesitis Score; SPARCC: Spondyloarthritis Research Consortium of 
Canada; LEI: Leeds Enthesitis Index). Reproduced with permission from Dr. Laura 
Coates (Coates and Helliwell, 2010). 
Around the same time as the MASES, the Major Enthesitis Index was developed in a 
cohort of patients with AS and targeted 12 entheseal sites (Table 1.7) (Braun et al., 
2002). In the INSPIRE cohort, it did not perform as well as the MASES, and it has not 
been validated, widely used, nor studied since (Gladman et al., 2007a). 
The Gladman Index was developed in ten SpA patients using entheseal sites included 
in the MASES. Fair to moderate reliability was found between ten assessors, with 
greatest agreement at the tibial tuberosity of the knee and plantar fascia (Gladman et al., 
2004). A large effect size has been seen with treatment (Healy and Helliwell, 2008). 
The Leeds Enthesitis Index (LEI) is the only clinical measure developed specifically for 
patients with PsA. Following the methodology for the MASES, a dichotomous score was 
used to assess tenderness, followed by a process of data reduction. The most commonly 
involved enthesis was identified and noted, with exclusion of this enthesis in subsequent 
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rounds. This step-wise reduction was performed until 80% of all patients with a positive 
score were identified. This resulted in an index with six sites, which has been well 
received for its brevity and simplicity (Healy and Helliwell, 2008). The LEI was then 
compared with other entheseal indices including the MEI and MASES in an open-label 
longitudinal study. The LEI showed the largest effect size and the closest correlation with 
other disease activity measures. It also had the smallest floor effect size when compared 
to the MEI, meaning that it can identify the majority of patients with enthesitis by testing 
just six sites (Healy and Helliwell, 2008). In the INSPIRE cohort, there was excellent 
inter-rater agreement (ICC 0.81) between rheumatologists (Gladman et al., 2007a). 
However, in a validation study using ultrasound, there was a poor relationship between 
clinical and imaging findings at sites included in the LEI, with 20% of sites exhibiting 
tenderness but no ultrasound changes and 26% having sonographic evidence of 
enthesitis but no tenderness elicited on clinical examination (Ibrahim, 2010). 
Establishing criterion validity for clinical outcome measures has been difficult due to a 
lack of a gold standard. The ideal gold standard would be histological evidence of tissue 
abnormality, but as discussed, biopsy of tendons is invasive and unsafe. Given the 
increasing sensitivity of MRI and ultrasound in detecting enthesitis, it seems imaging is 
the best gold standard available at present. With this in mind, the Spondyloarthritis 
Research Consortium of Canada (SPARCC) adopted a novel approach and created an 
enthesitis index for patients with SpA utilising MRI and ultrasound data to decide which 
sites should be included (Maksymowych et al., 2009b). 16 sites were identified as being 
commonly involved in imaging studies and could be accessed for clinical assessment 
(McQueen et al., 2007b). Good inter-observer reliability and a substantial correlation 
between the enthesitis score and other disease activity measures was found in the 
development cohort, and further validation took place in two Canadian cohorts of AS 
patients. However, the reduction in SPARCC score in patients treated with a TNF 
inhibitor was not significant after 12 weeks of therapy (Maksymowych et al., 2009b). In 
the INSPIRE study, there was excellent agreement between assessors (ICC 0.81) but 
notably the SPARCC performed better in patients with AS rather than PsA (Gladman et 
al., 2007a). Correlation has also been shown between the SPARCC index and total 
sonographic enthesitis score (Hamdi et al., 2011). Reduced versions of the SPARCC 
index targeting the more frequently involved sites (SPARCC 8/16) and only sites that 
discriminate between treatment and placebo (SPARCC 6/16) have shown larger effect 
sizes and standardised response means (Maksymowych et al., 2009b). 
The use of clinical tools for enthesitis has become commonplace in clinical trials of PsA 
but there is debate about which particular measure is optimal. As discussed, validation 
is difficult due to the lack of gold standard to prove or dispute the true presence of 
enthesitis. Imaging techniques can show changes within tendons and tendon sheaths at 
the enthesis, but correlation with clinically appreciable tenderness or swelling is less 
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convincing (D'Agostino et al., 2003). In addition to soft tissue changes, MRI can identify 
the involvement of adjacent bone, but no studies have addressed whether this can be 
identified clinically.  
Clinical measures of enthesitis are also limited in terms of their specificity. Many 
entheseal points are near joints and are accepted fibromyalgia points, thus there is a 
possibility that misdiagnosis may occur. This was investigated by Marchesoni and 
colleagues in a multicentre cross-sectional study of 266 patients with PsA and 120 
patients with fibromyalgia. Univariate analysis showed that patients with fibromyalgia had 
higher mean tender point and MASES [enthesitis] scores. It was the number of affected 
sites (≥8) rather than location that was the discriminating factor, in addition to the number 
of fibromyalgia symptoms such as headache, fatigue and anxiety (≥6) (Marchesoni et 
al., 2012). The key to the reliability of clinical measures of enthesitis is in training of 
assessors to correctly localise the sites and to use any findings within the context of a 
patient’s symptoms. 
1.4.5 Subclinical Enthesitis in Psoriasis 
Subclinical musculoskeletal inflammation, especially osteitis and periostitis, have been 
recognised since the 1970s in patients with psoriasis but no arthritis. Subsequently, 
further understanding of the anatomical basis of enthesitis (and the secondary 
dissipation of inflammation and consequent damage to structures within the surrounding 
synovio-entheseal complex) provides explanation for this osteitis. Asymptomatic 
entheseal inflammation is shown to be common in patients with psoriasis, with ultrasound 
studies showing rates from 39.0% to 59.3% depending on the number of entheses 
assessed and the definition of enthesopathy used (Acquacalda et al., 2015, Ash et al., 
2012b, De Simone et al., 2003, Naredo et al., 2011, Ozcakar et al., 2005). Patients with 
nail psoriasis have been found to have a greater burden of subclinical enthesitis than 
those without nail disease, due to the attachment of the extensor tendon to the terminal 
phalynx enclosing the nail root, which anchors the nail laterally (Ash et al., 2012b, Aydin 
et al., 2012).  
Subclinical inflammation has been demonstrated in psoriasis patients using numerous 
imaging modalities at many peripheral anatomical sites including the large tendon 
insertions of the knee, ankle, the elbow and digits, and using MRI, in the axial skeleton 
within the spine, sacroiliac joints, shoulders, hips and chest wall entheses. Table 1.8 lists 
the many studies using ultrasound and MRI to demonstrate subclinical enthesopathy in 
patients with psoriasis. 
Within these studies and others in spondyloarthropathy, many ‘healthy’ volunteers have 
been imaged and variable proportions are also noted to have similar subclinical 
entheseal changes, albeit at a much smaller magnitude than is seen in psoriasis patients 
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(Ash et al., 2012b, Gisondi et al., 2008, Gutierrez et al., 2011, Naredo et al., 2011, 
Ozcakar et al., 2005, Bandinelli et al., 2013, De Simone et al., 2003). While erosions and 
calcifications tend not to occur in healthy volunteers, thickening of entheses around 
weight bearing joints are reported in up to 8.4% of sites assessed in addition to the 
presence of enthesophytes (Gutierrez et al., 2011). Age, BMI and waist circumference 
have been shown to correlate with the GUESS score, a sonographic scoring system for 
the lower limb entheses, in both patients with psoriasis and healthy volunteers (Gisondi 
et al., 2008). Entheseal abnormalities are attributed to age related degeneration due to 
repeated biomechanical sheer stress on weight bearing joints (Benjamin et al., 2007, 
McGonagle et al., 2002b), but unlike in genetically primed patients with psoriasis, 
inflammation is controlled and structural deformities therefore occur with much lower 
frequency.  
The long-term significance of subclinical enthesitis in patients with psoriasis is not yet 
known, and only one small preliminary cohort study provides data on the predictive value 
of asymptomatic entheseal inflammation. Tinazzi and colleagues performed ultrasound 
of the lower limbs of 30 patients with psoriasis, and of 28 who returned for re-evaluation 
at a mean of 3.5 years, 23% had developed symptomatic inflammatory arthritis that 
satisfied the CASPAR criteria for PsA. Two patients had polyarticular disease, and 5 had 
oligoarticular PsA. These patients had not received systemic immunosuppression 
(Tinazzi et al., 2011).  
1.4.5.1 Management of Subclinical Enthesitis 
The potential evolution of subclinical enthesopathy to frank PsA raises the question as 
to whether skin-directed therapy for psoriasis could prevent the development of PsA.  
Only one small study to date has assessed the response of subclinical enthesitis to 
therapy. 22 patients with psoriasis were treated with methotrexate, with or without 
infliximab (n=1), adalimumab (n=1) or ustekinumab (n=3) for six months. 13 patients that 
returned for a second ultrasound scan, which assessed 5 entheses bilaterally, and the 
number of entheses with morphological abnormalities decreased from 30% to 17.7% 
(p=0.021) (Acquacalda et al., 2015). These data provide an interesting foundation for 
further longitudinal analyses to determine if the early introduction of immunomodulatory 
therapy in patients with psoriasis could impact on the evolution of subclinical enthesitis. 
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2003 
D
e Sim
one 
59 
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H
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U
S 
AT 
3.7- 
34.7 
59.3%
 patients had tendonitis w
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ithout bursitis. 
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A 
56%
 of patients had enthesopathy. M
ean AT thickness significantly 
greater in psoriasis patients. 
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PsA 
U
S 
FFT and 
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33%
 psoriasis patients had enthesopathy, and 25%
 had joint 
effusion. 
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24.7%
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O
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M
ean 
6.7 
11.6%
 entheses w
ith enthesopathy vs 5.3%
 controls. 7.4%
 entheses 
had PD
 vs. 0%
 controls.  3.2%
 joints had synovitis vs 1.3%
 controls. 
2012 
Ash 
46 
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PT, 
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M
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39%
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 patients w
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 erosions. BM
O
 seen in 
10%
 of controls but no enthesitis. 
2015 
Acquacalda 
12 
22  
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S 
D
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M
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 entheses w
ith enthesopathy in psoriasis group, 0%
 w
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44%
 patients w
ith spine BM
O
, 10%
 SIJ BM
O
. 16%
 controls w
ith 
spine BM
O
, 6%
 SIJ BM
O
. 
2016 
Acquitter 
37 
N
il 
U
S 
C
ET, C
FT, 
PPT, D
PT, 
Q
T, AT, PF 
N
A 
20.8%
 entheses w
ith enthesopathy, 0.77%
 w
ith PD
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M
R
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FFT 
M
ean 
6.2 
11%
 patients w
ith BM
O
, 38%
 synovitis, 4%
 tenosynovitis, 29%
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 controls w
ith BM
O
, 7%
 synovitis and 0%
 
tenosynovitis. 
2017 
M
oshrif 
50 
N
il 
U
S 
PPT, D
PT, 
Q
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PASI 
>15 
36%
 of patients had enthesopathy, %
 PD
 not stated. 
Table 1.8. Im
aging assessm
ents of subclinical enthesopathy in asym
ptom
atic patients w
ith psoriasis. (AT: Achilles tendon; BM
O
: Bone m
arrow
 oedem
a; 
C
ET: C
om
m
on extensor tendon; C
FT: C
om
m
on flexor tendon; D
BT: D
istal brachial triceps tendon; D
PT: D
istal patellar tendon; FET: Finger extensor 
tendons; FFT: Finger flexor tendons; LSS: Lum
bosacral spine; N
A: N
ot applicable; PD
: Pow
er D
oppler; PF: Plantar fascia; PPT: Proxim
al patellar 
tendon; Q
T: Q
uadriceps tendon; SIJ: Sacroiliac joints; STI: Soft Tissue Inflam
m
ation).
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1.5 Screening for Psoriatic Arthritis in Patients with Psoriasis 
In six out of every seven patients with psoriatic disease, skin lesions precede the 
development PsA (Chang et al., 2011, Gottlieb et al., 2006), with an average time to 
occurrence of between seven and twelve years (Qureshi et al., 2005). Dermatologists 
and primary care physicians managing patients with psoriasis are therefore at an ideal 
juncture for the early PsA detection. However, knowledge and recognition of PsA within 
such clinical settings remains suboptimal, with an epidemiological study showing that up 
to 29% of patients with psoriasis seen by dermatologists have undiagnosed PsA (Haroon 
et al., 2013). Even when patients are diagnosed with PsA, many are undertreated; 
published results from the population based ‘Multi-national Assessment of Psoriasis and 
Psoriatic Arthritis’ (MAPP) survey revealed that 59% of PsA patients were receiving no 
treatment or only topical therapy for their skin disease (Lebwohl et al., 2014). Whilst this 
survey is limited by the requirement for accurate recall and interpretation of questions by 
the 3426 patients involved, it is still evident that a significant proportion of patients are 
not receiving adequate therapy to prevent the progression of joint damage that may 
ensue. Without early intervention, patients may develop functional limitation, pain and 
disability (Husted et al., 2007, Gladman et al., 2005). Methods of identification of patients 
at greatest risk of developing PsA may therefore provide dermatologists and primary 
care physicians with the ability to screen such patients for early signs or symptoms of 
PsA during their skin follow up and collaborate closely with their colleagues in 
rheumatology to refer early and ultimately improve patient outcomes.  
The impetus for the recognition of early PsA and its effective treatment stems from 
research into rheumatoid arthritis (RA) (Kane et al., 2003, Svensson et al., 2002, 
Chandran et al., 2007) where early disease recognition and prompt therapy initiation 
minimizes joint damage, maintains patients in work and reduces long-term complications 
(Emery, 2002, Cush, 2007, van der Heide et al., 1996). While some patients with RA 
recover spontaneously, most do not; indeed, most sustain erosive damage from 
significant joint inflammation within the first two years of onset (van der Heijde, 1995, 
Mottonen, 1988). The early phase of RA is predominated by inflammation and represents 
a window of opportunity for intervention – it has been hypothesised that immune 
mechanisms involved in the pathogenesis may be more responsive to treatment during 
this phase (Ahmed, 1999). Data from early arthritis clinics show that rheumatological 
assessment in less than twelve weeks is associated with less joint destruction and a 
higher chance of achieving drug-free remission compared with a longer delay in 
assessment (van der Linden et al., 2010). Increasing the proportion of patients treated 
with effective disease modifying drugs within three months of disease onset, from a 
current figure of 10% to 20%, could result in productivity gains for the UK economy of 
£31 million over five years (2009). 
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Collectively, such findings have led to the development of ‘treat-to-target’ guidelines in 
RA, and the concept of achieving tight control of RA early in the disease course is now 
standard practice, with significant numbers of patients achieving low levels of disease 
activity or clinical remission (Ruderman et al., 2012). 
This shift towards early diagnosis and aggressive early arthritis treatment has gradually 
extended to PsA following confirmation that significant inflammation and damage is 
occurring at an early stage in the disease process. One study has shown that patients 
with PsA had similar radiological damage to patients with RA, suggesting that the 
disease may be just as destructive radiologically (Rahman et al., 2001).  
Several studies have now specifically addressed the prognosis of early PsA (Harrison et 
al., 1997, Kane et al., 2003, Lindqvist et al., 2008). Harrison et al evaluated 51 patients 
with early inflammatory polyarthritis and psoriasis in a primary care setting, and found 
that 22% had irreversible joint erosions by one year (Harrison et al., 1997). Kane and 
colleagues prospectively examined a cohort of 129 patients presenting to an early 
inflammatory arthritis clinic; at presentation, 40% had oligoarticular and 60% had 
polyarticular PsA. At baseline, 27% already had radiographic evidence of bony 
erosion(s), increasing to 47% at 2 year follow up (Kane et al., 2003). Similar evidence of 
early disease progression was shown in a Swedish cohort of 183 patients with identical 
frequencies of articular PsA at presentation. 20% had signs of radiographic damage at 
baseline, increasing to 32% after 2 years (Lindqvist et al., 2008).   
More recently, a large retrospective cross-sectional cohort analysed the outcomes of 
PsA patients in relation to lag time from symptom onset to first encounter with a 
rheumatologist. Haroon and colleagues identified that the probability of achieving of 
drug-free remission has a significant negative association with a diagnostic delay of 
greater than one year, and a significant positive association with an early rheumatologist 
encounter within six months of diagnosis. Using univariate model analysis, where this 
six month ‘window of opportunity’ to intervene was missed, patients encountered 
increased radiographic damage (bony erosions: OR 4.58 (95% CI 2.5-8.2) p<0.001; 
osteolysis OR 3.6 (95% CI 1.3-9.5) p=0.01) and joint deformity (OR 2.28 (95% CI 1.35-
3.85) p=0.002), higher functional disability (as measured by HAQ scores) (OR 2.17 (95% 
CI 1.30-3.61) p=0.003) and an increased risk of developing sacroilitis (OR 2.28 (95% CI 
1.17-4.44) p=0.01) (Haroon et al., 2014a). These results suggest that to further improve 
outcomes in PsA patients, an important challenge is to get patients with arthritis to see 
a rheumatologist as early as possible after symptom onset. The early identification of 
PsA among patients with psoriasis assumes considerable importance and this 
strengthens the need for screening within the dermatology setting, supported by close 
collaborative working between dermatologists and rheumatologists. However, the best 
methods for identifying early PsA amongst non-rheumatologists remain unclear.  
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Aside from joint damage, the impetus for early treatment is also driven by the recognition 
of increased mortality in patients with PsA. Patients with PsA are at an increased risk for 
death with a standardised mortality ratio of between 1.36 and 1.62 depending on the age 
of the population studied and duration of disease (Wong et al., 1997, Ali et al., 2007, Mok 
et al., 2011). The causes of death are similar to those within the general population, with 
cardiovascular causes being the most common (Wong et al., 1997, Alamanos et al., 
2003, Ali et al., 2007). PsA is known to be associated with increased subclinical 
atherosclerosis (Eder et al., 2008) and an altered atherogenic lipid profile (Jones et al., 
2000), and many of the immunological factors involved in both atherosclerosis and PsA 
(e.g. TNF-α and IL-1β) are proinflammatory to the vascular endothelium and synovial 
tissue. In PsA, both metabolic syndrome and insulin resistance are also highly prevalent 
and these are shown to be independently associated with the severity of underlying PsA 
(Haroon et al., 2014b). This is supported by the findings in a cohort of patients followed 
prospectively for almost two decades, where the risk for premature mortality in PsA was 
related to previously active and severe joint disease in addition to the presence of erosive 
disease and a high erythrocyte sedimentation rate (ESR) at presentation (Gladman et 
al., 1998).  
1.5.1 Predictors of Psoriatic Arthritis Risk 
While there are similarities between RA and PsA in terms of early progression, PsA lacks 
a reliable serum biomarker such as the anti-citrullinated protein antibody for RA. Efforts 
have been made to identify clinical factors that may help to predict the development of 
PsA in patients with psoriasis, however, there is currently no reliable means of 
determining in an individual psoriasis patient who will develop PsA, nor the pattern, 
severity and time course of the arthritis.  
The risk of developing PsA has been reported to increase with the duration and severity 
of psoriasis, although conflicting data have been published. Yang et al found that an 
older age at psoriasis onset was significantly associated with the development of PsA, 
with 23.3% of patients with type II psoriasis (onset >40 years) developing PsA compared 
to 15.6% of patients with type I disease (p=0.035) (Yang et al., 2011). However, in 
contrast, Reich and colleagues found that patients with PsA had developed psoriasis at 
a younger age (28.4+/-14.8 vs. 34.9+/-18.2 years, p<0.0001) (Reich et al., 2009). 
Christophers et al included a logistic regression model with age of psoriasis onset as a 
continuous variable to control length of time with psoriasis, and found that age at 
psoriasis diagnosis was not associated with an increased risk of developing PsA 
(OR=1.00 for each additional year of age, 95% CI 0.987-1.014, p=0.983) (Christophers 
et al., 2010). A number of other cross-sectional studies have not found any significant 
association between the age of psoriasis onset and PsA risk (Tey et al., 2010, Love et 
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al., 2012a, Gladman and Chandran, 2011, Jamshidi et al., 2008, Salvarani et al., 1995, 
Stern, 1985). 
Three studies have reported psoriasis severity as a risk factor for PsA, with severity 
defined in different ways – three or more sites of psoriasis compared to one site (HR 
2.24, 95% C.I. 1.23-4.08), worst-ever body surface area (HR 1.01 for each unit increase 
in BSA), and >75% BSA of psoriasis at its worst compared to £25% (Soltani-Arabshahi 
et al., 2010, Tey et al., 2010, Wilson et al., 2009). All three case-control studies used 
retrospective data relating to worst-ever BSA rather than a baseline or time-updated 
variable for BSA. While these studies suggest that psoriasis severity may be associated 
with the development of PsA, further adequately powered studies providing information 
on the temporal association between psoriasis severity and the development of PsA are 
needed to confirm this relationship. 
Six cross-sectional studies (Table 1.9) have compared the duration of psoriasis between 
patients with PsA and without; four studies found no significant difference (Gladman and 
Chandran, 2011, Palmou et al., 2011, Soy et al., 2008, Salvarani et al., 1995), and two 
reported an association between a longer duration and an increased risk of developing 
PsA (Yang et al., 2011, Christophers et al., 2010). Christophers and colleagues showed 
that the prevalence of PsA increased progressively with disease duration, reaching 
20.5% in patients with psoriasis for 30 years duration, while the incidence remained 
relatively constant during this period (74 per 1000 person years) (Christophers et al., 
2010).   
 
Author 
(Year) 
Patients 
with 
psoriasis 
(n=) 
Patients 
with 
PsA 
(n=) 
Duration of 
psoriasis - 
WITH PsA 
(years) 
Duration of 
psoriasis -
WITHOUT 
PsA (years) 
Significance 
Yang 
(2011) 
1816 112 14.1+/-11.7 7.8+/-8.9 p<0.001 
Gladman 
(2011) 
438 1066 15.2+/-12.3 16.1+/-14.1 NS 
Palmou 
(2011) 
52 121 23.8+/-19.5 19.6+/-15.2 NS 
Christophers 
(2010) 
1434 126 17.3+/-11.3 11.0+/-11.3 p<0.0005 
Soy 
(2008) 
40 49 19+/-23 17+/-11 NS 
Salvarani 
(1995) 
130 75 17.7+/-14.4 14.2+/-13.8 NS 
Table 1.9. Studies comparing the duration of psoriasis in patients with and without PsA 
(NS: Not Significant) 
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1.5.1.1 Cutaneous Predictors of PsA  
Three studies, including one cohort and two-cross sectional studies, have compared the 
clinical type of psoriasis between patients with and without PsA (Wilson et al., 2009, 
Yang et al., 2011, Jamshidi et al., 2008). No particular psoriatic phenotype was more 
often associated with PsA, although palmoplantar psoriasis was not investigated.  
Conflicting data has been published regarding an association between specific 
anatomical locations of psoriasis and an increased risk of PsA. In multivariate models, 
Eder et al identified a relative risk of 2.5 (p=0.002) for the onset of PsA in patients with 
psoriatic nail pitting in a cohort of 464 patients followed up for 8 years (Eder et al., 2016). 
In a larger prospective cohort study of 1593 psoriasis patients with extended follow up 
(mean (+/-S.D.) 13.1 (+/-8.8) years), a higher risk of developing PsA was found in 
patients with scalp lesions and intergluteal/perianal disease (HR 3.89 (95% CI 2.18-6.94 
and HR 2.35 (95% CI 1.32-4.19) respectively) (Wilson et al., 2009). Scalp disease was 
also identified as a risk factor in two cross-sectional studies (Yang et al., 2011, Zanolli 
and Wikle, 1992), with an increased prevalence of PsA in patients with scalp psoriasis 
compared to those without (90.2% vs. 76.4%, p=0.001 and 87% vs. 72%, p=0.0237 
respectively). Zanolli et al also identified an association between PsA and psoriasis at 
other locations, with PsA occurring more frequently in patients with psoriasis on the 
buttocks and back (68% vs. 45%, p=0.0016 and 68% vs. 49%, p=0.0086 respectively) 
(Zanolli and Wikle, 1992). However, these associations have not been supported in 
several other large scale cross-sectional studies (Love et al., 2012a, Stern, 1985, 
Christophers et al., 2010), making it difficult to draw meaningful conclusions on the 
relationship between anatomical location of psoriasis and PsA risk. 
1.5.1.2 Nail Disease and PsA 
Unlike other body sites where data is conflicting, psoriasis of the nail has repeatedly been 
shown to hold a strong positive association with PsA. Wilson et al reported a higher risk 
of PsA in patients with nail dystrophy compared to those without, with a hazard ratio (HR) 
of 2.93 (95% CI 1.68-5.12) (Wilson et al., 2009). Twelve of thirteen cross-sectional 
studies assessing the association between nail psoriasis and PsA risk have also shown 
an increased risk of PsA in patients with nail disease (Love et al., 2012a, Gladman and 
Chandran, 2011, Yang et al., 2011, Soltani-Arabshahi et al., 2010, Reich et al., 2009, 
Jamshidi et al., 2008, Salvarani et al., 1995, Stern, 1985, Soy et al., 2008, Zanolli and 
Wikle, 1992, Eder et al., 2011b, Maejima et al., 2010, Scarpa et al., 1984), and a recent 
combined meta-analysis of these studies gave an OR of 2.92 (95% CI 2.34-3.64) with a 
significant level of heterogeneity (p=0.00051) (Rouzaud et al., 2014).  
The type of nail changes also appears to be important, with nail bed disease having the 
strongest link to PsA risk. In a small study, Maejima and colleagues found an association 
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with an OR of 4.68 (95% CI 1.29-16.98) for onycholysis and 6.41 (95% CI 1.13-64.91) 
for nail bed hyperkeratosis (Maejima et al., 2010), while Love et al performed multivariate 
analysis and found an OR of 2.05 (95% CI 1.43-2.93) for onycholysis (Love et al., 2012a). 
No association was identified for other nail changes including pitting and subungual 
hyperkeratosis, although this is in contrast to the findings by Eder et al, that found the 
presence of nail pitting to be predictive of the development of PsA (RR 2.5, p=0.002) 
(Eder et al., 2016). Love et al found that overall fingernail involvement was higher in 
those with PsA than those without (mNAPSI score 4.8 +/- 5.3 vs. 2.3 +/- 3.7 respectively, 
p<0.05). In patients with psoriasis but without known PsA, those with nail disease have 
also been found to have a greater magnitude of underlying systemic subclinical 
enthesopathy than those without nail disease, and nail severity (mNAPSI score) 
correlated with both inflammatory entheseal changes (r(2)=0.45, p=0.005) and chronic 
bone damage changes such as erosions (r(2)=0.35, p=0.04) (Love et al., 2012a). 
1.5.1.3 Nail disease and Distal Interphalangeal (DIP) Joint Arthritis 
An association between nail psoriasis and arthritis specifically at the distal 
interphalangeal (DIP) joint has long been reported  (Green, 1968, Jones et al., 1994, 
Cohen et al., 1999, Kane et al., 2003, Williamson et al., 2004, Scarpa et al., 2004, Stern, 
1985). The rationale for this has been extensively investigated by McGonagle and 
colleagues, who have shown that the nail is functionally integrated into the enthesis 
network around the DIP joint. (McGonagle et al., 2009a, Tan et al., 2007, Tan et al., 
2006b). The nail is directly anchored to the underlying bony structures by interdigitating 
fibres from the extensor tendon which envelope the nail root and from the joint collateral 
ligament entheses that merge with the lateral borders of the nail (Tan et al., 2013). It is 
postulated that in genetically primed individuals, frequent microdamage and repair at 
these attachment sites provokes activation of regional innate immunity and persistent 
inflammation, which may then dissipate to the adjacent tissues and cause arthritis of the 
DIP joint (McGonagle, 2009). This has been confirmed by histopathological studies and 
also through use of high resolution MRI scanning. The latter confirmed that the dorsal 
capsular enthesis was the epicentre of the inflammatory reaction in patients with DIP 
joint PsA, with inflammation extending to involve the soft tissues adjacent to the nail. 
Such changes were not seen in patients with OA, who do not exhibit nail disease (Tan 
et al., 2007). 
Using ultrasound, Aydin and colleagues found good agreement between the presence 
and severity of clinically evident nail changes and sonographic nail findings (kappa value 
0.52, p<0.0001).  Entheseal thickening of the extensor tendon on ultrasound occurred 
with greater frequency in patients with psoriatic nail disease compared to those without 
nail disease in patients with and without known PsA (38% vs. 16%, p=0.03 and 47% vs. 
19%, p=0.008, respectively) (Aydin et al., 2012). 
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At the present time, there is strong evidence to support the presence of nail psoriasis as 
predictive for the development of both subclinical and symptomatic PsA, whereas 
cutaneous disease at other anatomical sites remains inconclusive and inadequate as a 
basis for targeted screening for PsA in dermatology clinics. 
1.5.1.4 Obesity and PsA 
Obesity has been identified as a risk factor for psoriasis, and three studies now support 
an increased risk of PsA amongst obese patients with psoriasis, two of which have 
shown a dose effect of BMI on the development of PsA (Li et al., 2012a, Love et al., 
2012b, Soltani-Arabshahi et al., 2010). Possible explanations include increased 
mechanical loading on joints (akin to a deep koebner response), increased systemic 
inflammation induced by adipose tissue and a link with dyslipidaemia, as shown in 
osteoarthritis (Thijssen et al., 2015). A further study has shown the hyperlipidaemia, 
independent of obesity, was associated with the development of PsA (Wu et al., 2014). 
Improvement in disease activity and medication response with weight loss also support 
the concept of high BMI as a driver of inflammation in psoriatic disease. 
1.5.1.5 Smoking and PsA 
Smoking has been shown to be associated with the development of psoriasis and 
rheumatoid arthritis (Setty et al., 2007, Sugiyama et al., 2010), presumably due to 
smoking-induced oxidative stress that may stimulate chronic inflammation. However, 
nicotinic receptor activation inhibits intracellular proinflammatory pathways that are 
thought to be involved in the development of inflammatory arthritis, akin to the ‘protective’ 
role of smoking hypothesised in the development of ulcerative colitis (Eder et al., 2012). 
These contradictory observations may account for the opposing results reported from 
studies examining the relationship between smoking and PsA. Eder and colleagues 
found an inverse association between smoking and the development of PsA, although 
when stratified by HLA-Cw06, the inverse association only held amongst those without 
the gene (Eder et al., 2012). Pattison et al. also observed an inverse association, 
although not statistically significant in a univariate model (OR 0.68, 95% C.I. 0.39-1.17) 
(Pattison et al., 2008). In contrast, Li and colleagues identified a positive association, 
particularly for those who smoked in excess of 15 cigarettes per day, although this study 
only examined women with psoriasis (Li et al., 2012b). Additional studies are therefore 
required to better understand the role of smoking on the development of PsA. 
1.5.1.6 Alcohol and PsA 
Excessive alcohol intake may be a risk factor for psoriasis, but studies examining this 
have produced mixed results. Studies investigating the link between alcohol and PsA 
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have assessed various time points, including at the onset of PsA, and found no 
association (Tey et al., 2010). In one study, women consuming the most alcohol, had a 
substantially elevated risk of PsA compared to those who were tee-total at baseline (HR 
4.45, 95% C.I. 2.07-9.59). However, this association was not significant among patients 
with psoriasis, only the entire study population (Wu et al., 2015). However, a significant 
positive association was observed in excessive drinkers with psoriasis compared to 
those who consumed moderate amounts of alcohol (HR 2.79, 95% C.I. 1.24-6.26).  
1.5.2 Screening Questionnaires for PsA 
In an attempt to improve the diagnostic capabilities of primary care physicians and 
treating dermatologists, a number of screening questionnaires have been developed for 
use in patients with psoriasis. While the gold standard for every psoriasis patient would 
involve an assessment by a rheumatologist combined with imaging, the burden of 
psoriasis in both primary and secondary care renders this unfeasible. Screening tools 
are therefore useful to sub-select a population of patients who have a higher probability 
of PsA for further assessment. The most recent consensus guidelines from both the 
National Institute for Health and Care Excellence (NICE) and the Scottish Intercollegiate 
Guidelines Network (SIGN) for managing psoriasis recommend the use of 
questionnaires for this purpose (Burden et al., 2010, NICE, 2012).  
All of the screening questionnaires that have been developed to date are patient-
completed, although their method of development and purpose are slightly different. One 
of the first to be published (in abstract form) was the Psoriasis and Arthritis Questionnaire 
(PAQ), which was developed in Canada as a twelve-item questionnaire in 1997. This 
predicted PsA with a sensitivity of 0.85 and a specificity of 0.88 for a score of seven or 
higher. In 2002, the PAQ was re-studied and modified in a Swedish cohort of 202 
community and hospital patients, where a receiver operator characteristic (ROC) curve 
analysis determined a best cut off of 4 out of 8, providing a sensitivity of 0.60 and a 
specificity of 0.62 (Alenius et al., 2002). 
In 2007, the Psoriatic Arthritis Screening and Evaluation (PASE) questionnaire was 
developed in Boston, USA. Designed by both dermatologists and rheumatologists using 
a Delphi method, it consists of 15 questions, separated into two subscales: symptoms (7 
questions) and functional impact (8 questions). Each item is scored on a scale from 1 
(strongly disagree) to 5 (strongly agree), giving a maximum possible function score of 40 
and symptom score of 35.  Validation took place in 69 patients in a tertiary care setting, 
against a physician-made diagnosis of psoriasis and psoriatic arthritis, assessed by a 
dermatologist and rheumatologist respectively. Within this cohort, PsA was diagnosed in 
25% and OA in 35%. Patients with PsA had higher scores than those with psoriasis and 
OA, and patients with more severe PsA had higher scores than those with milder 
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disease. PASE scores ranged from 28 to 63, and a cut off of 47 proved optimal for 
differentiating patients with PsA (sensitivity 83%, specificity of 73%) (Husni et al., 2007). 
Further validation was carried out in a further 194 patients with psoriasis and/or PsA. In 
this cohort, the optimal cut off was 44, providing a sensitivity and specificity of 76%. 
Reasonable sensitivity to change in disease state has been shown, and acceptable 
reliability was confirmed with an interclass correlation coefficient of 0.90 for the total 
PASE score (Dominguez et al., 2009).  
The Toronto Psoriasis and Arthritis Screen (ToPAS) was developed and validated by 
Gladman et al in 2008. It was designed by an expert panel of dermatologists and 
rheumatologists as a screening tool for PsA, regardless of whether the patient has 
cutaneous psoriasis. The twelve-item questionnaire differs from other questionnaires in 
that it includes photographs of plaque psoriasis, ‘lifting of the nail’ (onycholysis) and 
pitting in addition to assessing any previous history of (rather than just current) 
symptoms. Following initial development, it was validated on patients with PsA, patients 
in a general rheumatology clinic (with those with PsA excluded), patients in a tertiary 
psoriasis clinic, patients in a general dermatology clinic and patients in a ‘family medicine’ 
(general practice) clinic. Logistic regression and ROC curve analysis were used to 
assess questionnaire responsiveness and in all settings, it was found to be highly 
sensitive and specific, with a sensitivity and specificity of 89-93% and 86-100% 
respectively. While the additional validation in a number of different settings is valuable, 
the ToPAS does not make any assessment of functional impact, instead being designed 
primarily for case identification (Gladman et al., 2009). 
The Psoriasis Epidemiology Screening Tool (PEST) was developed in Leeds by 
rheumatologists with patients from the primary and secondary care settings. Patients 
coded by their General Practitioner as having psoriasis were invited to complete the 
questionnaire by post, and a sample were selected for assessment within the 
rheumatology clinic. A second group of patients with known PsA were also asked to 
complete the questionnaire. 168 questionnaires were returned, of which 89 patients were 
subsequently examined. The questionnaire was based upon the PAQ with some 
additional questions, and unlike previous questionnaires, a mannequin was also included 
to allow patients to easily identify the joints that were causing them symptoms. A logistic 
regression analysis was used to identify the five best performing questions, and in the 
initial cohort a cut off of three or more positive responses provided a sensitivity of 92% 
and specificity of 78% (Ibrahim et al., 2009). 
In 2009, a further self-administered screening questionnaire, the Psoriasis and Arthritis 
Screening Questionnaire (PASQ), was developed in patients with both early and 
established psoriatic arthritis. Like the PEST, it is based on the PAQ, and includes ten 
questions on arthritis and nail signs/symptoms (each scored 0 or 1, to a maximum of ten 
points) and a homunculus with 68 joints on which patients identify painful and swollen 
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sites (either current or historic) (Khraishi, 2010). The diagram is scored 0, 1, 3 or 5 with 
points weighted according to the different presentations of PsA as described by Moll and 
Wright (Moll and Wright, 1973) (Table 1.10). A maximum PASQ score of 15 is 
achievable. 
 
Points Areas marked on the homunculus 
0 Nothing OR non-joint areas 
1 Many symmetric joints (MCP, MTP, wrists, not DIP) 
3 One large joint only OR spine only 
5 
DIPs OR less than five joints OR one large joint (knee, hip or shoulder) 
plus the spine 
Table 1.10. Scoring scheme for the homunculus component of the PASQ. (MCP: 
metacarpophalangeal; MTP: metatarsal-phalangeal; DIP: distal interphalangeal) 
The PASQ was initially developed in a cohort of psoriasis and PsA patients seen at a 
combined dermatology and rheumatology centre in St John’s, Newfoundland, who had 
a mean duration of psoriasis of 20.18 +/- 13.5 years. 58 patients with PsA (that met the 
CASPAR criteria) and 29 patients with psoriasis and no evidence of PsA were included. 
The latter were assessed by a nurse experienced in rheumatological examination, and 
the findings confirmed by a rheumatologist. With a cut off of seven, a sensitivity of 92% 
and a specificity of 78% were achieved. A further study selected patients from a 
prospective cohort of patients with suspected early PsA (with and without psoriasis) who 
were referred for assessment by their general practitioner or dermatologist. The 
objectives were to assess an identical electronic version of the questionnaire (ePASQ), 
which was designed to be self-scoring and require no physician assessment and to 
validate it against the original paper version. ROC curve analysis with a composite 
ePASQ score of 7 provided a sensitivity of 97.6% and a specificity of 75%, and analysis 
of the paper PASQ with a composite score of 7 provided a sensitivity and specificity of 
92.86% and 75% respectively (Khraishi et al., 2011). The ePASQ has yet to be validated 
in patients with psoriasis and no known diagnosis or symptoms of joint disease, and 
neither the paper nor electronic form has been assessed in patients with other 
rheumatological conditions. 
More recently, a screening tool for use in patients with suspected early PsA has been 
developed by Tinazzi and colleagues within the psoriasis clinic in Verona, Italy. The Early 
ARthritis for Psoriatic Patients (EARP) questionnaire initially consisted of 14 questions, 
and after psychometric analysis in a cohort of 228 patients, a simplified questionnaire of 
ten questions was found to have good inter-rater reliability (Cronbach’s α=0.83). An 
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optimal cut off of 3/10 provided a specificity of 91.6% and sensitivity of 90.7%. Patients 
with known PsA, RA, OA and gout were excluded. It has not been validated in any other 
cohorts and its uptake has been limited (Tinazzi et al., 2012). 
Each of the screening tools that have been developed have performed well in their 
development cohorts, and some have been further validated in outside the dermatology 
clinic, such as in the primary care setting or in general rheumatology clinic. They are all 
self-administered and relatively simple to complete and score. However, the optimal 
screening questionnaire for the detection of PsA risk is unknown. Five studies have 
attempted to address this dilemma by comparing several of the tools head-to-head; three 
compare the PASE, PEST and ToPAS (Coates et al., 2013, Haroon et al., 2013, Walsh 
et al., 2013a) one compares the PASQ, PEST and ToPAS (Mease et al., 2014b) and 
one compares the PASE, PEST and EARP. Table 1.11 outlines the comparative 
sensitivity and specificity of each of the questionnaires and the cohorts in which they 
were tested. The number of psoriasis patients diagnosed by a rheumatologist as having 
PsA is displayed in brackets.  
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Coates 
(2013) 
657  
(47 with PsA) 76.6 37.2 76.6 29.7 74.5 38.5     
Haroon 
(2013) 
100   
(29 with PsA)  
+ 100 PsA 
27.5 98 41 90 24 94     
Walsh 
(2013) 
213  
(137 with PsA) 85 45 75 55 68 50     
Mease 
(2014) 
949  
(285 with PsA) 84 75 77 72   67 64   
Karreman 
(2017) 
473 
(53 with PsA) 68 71   66 57   87 34 
Table 1.11: Comparative sensitivity and specificity of different psoriatic arthritis screening 
questionnaires from head-to-head studies. 
Interpreting the findings of these head-to-head trials is problematic owing to substantial 
variation in patient characteristics, including age, duration of psoriasis, severity of 
psoriasis, presence and duration of PsA and therapies used, in addition to recruitment 
methodology. The very low sensitivities found by Haroon and colleagues compared to 
the other investigators may be explained by differences in study population and psoriasis 
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duration, but also high levels of immunosuppressant use (91%), which may be effectively 
treating any symptoms of underlying PsA in the patients with psoriasis. While it is difficult 
to make comparisons however, it is evident that the performance of the screening tools 
is not as optimal as in their development cohorts and that further work is needed to 
produce a screening tool that is reproducible within its intended clinical setting. In order 
to address this, the ‘best performing’ questions from the PEST, PASE and ToPAS have 
been analysed by the investigators of the CONTEST head-to-head study (Coates et al., 
2013) and a new questionnaire (‘CONTEST’) has been developed that incorporates 
these elements (Coates et al., 2014).  
Of four candidate questionnaires combining existing discriminatory items to identify PsA 
in people with psoriasis, three were found to be significant on ROC curve analysis. These 
three were then tested retrospectively in similar PsA screening datasets in Ireland and 
the US, and of these, two questionnaires appeared to perform slightly better than the 
PEST questionnaire – the simple CONTEST questionnaire which included the most 
discriminate items from each of the existing questionnaires and the same questionnaire 
with the addition of a joint mannequin (similar to that seen on the PEST questionnaire) 
(Coates et al., 2014) (Appendix 2). Using a cut-off of 4, the CONTEST without the joint 
mannequin had a sensitivity of 86.0% and a specificity of 35.4%, and with the 
mannequin, using a cut-off of 5, 86.0% and 36.9%, respectively. In the same cohort, the 
PEST questionnaire (using the validated cut-off of 3) had a sensitivity of 76.6% and a 
specificity of 32.0%. Unlike the PEST, these CONTEST questionnaires have only been 
tested in a secondary care dermatology population and remain to be tested in their ability 
to detect PsA in a primary-care population. 
1.6 Imaging in Enthesitis 
The ‘gold standard’ for the diagnosis of enthesitis is histological examination, this is 
neither ethical nor practical in the clinical or research setting. The limitations of clinical 
assessment for entheseal pathology have been previously discussed. Imaging is 
therefore the best option in terms of acceptability, reliability and reproducibility. 
Radiographs, while cheap and readily accessible, can only identify changes arising from 
chronic inflammation that lead to irreversible damage. They provide no information about 
the soft tissues, tendons, entheses or early bone pathology. These limitations can be 
overcome with the use of ultrasound and MRI. Both modalities have advantages and 
disadvantages in enthesitis, and the choice is often largely determined by time 
availability, equipment, economic resources and availability of skilled operators (Table 
1.12).   
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 Advantages Disadvantages 
US 
Comfortable for the patient 
Dynamic assessment 
Multiple sites can be assessed 
Easy to use at follow up 
Time consuming 
Limited by the acoustic window 
Lack of comparison with histology 
MRI 
Ability to detect bone marrow oedema 
Able to demonstrate deep as well as 
superficial enthesis 
Patient discomfort 
Cost 
Lack of comparison with histology 
Table 1.12: Advantages and disadvantages of US and MRI for detecting enthesitis 
1.6.1 Ultrasound 
Ultrasound is easy to use, negates the need for radiation, is low in cost, widely available 
and acceptable to patients. The improved resolution of modern scanners allows for the 
detection of small structures or subtle abnormalities. For these reasons, peripheral joint 
ultrasound is an attractive imaging modality for the detection of disease of the entheses. 
Modern ultrasound also has the capacity to visualize the entheseal fibrocartilage, a 
structure of approximately 0.5mm in thickness, which may become eroded as part of 
disease of the entheseal organ. 
Typical ultrasound abnormalities of enthesopathy include tendon thickening, tendon 
hypoechogenicity, calcifications, enthesophyte formation, erosions, bony irregularities or 
loss of the normal fibrillar tendon structure (Gutierrez et al., 2010, Balint et al., 2002, 
Falsetti et al., 2002). In addition, power Doppler can be applied to signal increased 
vascularity occurring at sites of inflammation, further improving the detection of active 
enthesitis (Iagnocco et al., 2012, D'Agostino et al., 2011). 
1.6.1.1 Ultrasound Definition of Entheseal Disease 
In 2005, the OMERACT group published a consensus definition for the ultrasound 
detection of enthesopathy that includes abnormalities reflective of both active 
inflammation and structural damage: ‘abnormally hypoechoic (loss of normal fibrillar 
architecture) and/or thickened tendon or ligament at its bony attachment (may 
occasionally contain hyperechoic foci consistent with calcification), seen in two 
perpendicular planes that may exhibit Doppler signal and/or bony changes including 
enthesophytes, erosions or irregularity’ (Wakefield et al., 2005). This was recently 
supported by an international Delphi exercise, which found good (>80%) inter-rater 
agreement for a number of core defining features for ultrasound-detected enthesitis: 
hypoechogenicity, increased tendon thickness at the bony insertion, calcification(s), 
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enthesophyte(s), erosion(s) and power Doppler activity (Terslev et al., 2014). Bone 
irregularities are shown to be a less reproducible finding (Filippucci et al., 2009). 
Enthesitis is rarely identified in isolation, with varying degrees of tendon and/or synovial 
inflammation, joint effusion and soft tissue oedema being seen, dependent upon the 
stage of PsA. Ultrasound is superior to radiographic imaging; in one study of early PsA 
patients (symptom duration < 1year), no radiographic abnormalities were seen, but 
ultrasound confirmed an effusion in the target joint in every patient (Bonifati et al., 2012). 
In addition, ultrasound has been shown to have good specificity in PsA, with greater 
sensitivity in detecting erosions than x-rays (Wiell et al., 2007).  
1.6.1.2 Limitations of Ultrasound in Enthesitis 
A key problem of the ultrasound assessment of enthesitis is determining the distinction 
between normal and disease. With increasing age, healthy controls often have thickened 
entheses as a consequence of mechanical frequent use, particularly in the lower limbs. 
Ultrasound is operator dependent, and experience in scanning is a prerequisite for the 
assessment of subtle features such as enthesopathy. Appropriate healthy controls must 
be recruited to trials so as not to over-estimate minor changes that are in fact within the 
normal range for the age of the patient. 
1.6.1.3 Sensitivity to Change of Ultrasound in Enthesitis 
The sensitivity to change of ultrasound in entheseal disease has only been investigated 
in four prospective studies (Genc et al., 2007, Naredo et al., 2010, Aydin et al., 2010, 
Mouterde et al., 2014). There were no significant changes in entheseal abnormalities 
found after sulphasalazine therapy, but this may be due to a lack of treatment efficacy 
(Genc et al., 2007). In contrast, enthesitis scores reduced dramatically in two 
independent studies following TNF inhibition, even after a short treatment term (Naredo 
et al., 2010, Aydin et al., 2010). In a recent trial of patients taking non-steroidal anti-
inflammatory agents, ultrasound scores were seen to rise from baseline after one week 
of stopping the therapy, and subsequently fall again within one week of restarting 
(Mouterde et al., 2014). These data suggest that ultrasound is sensitive enough to 
visualize changes in a timely manner and should be considered as a useful adjunct in 
the assessment of efficacy of novel therapeutic agents for SpA. 
1.6.1.4 Ultrasound Evaluation Vs. Clinical Examination for Enthesitis 
The majority of studies have found that clinical examination underestimates the 
prevalence of enthesitis in PsA, suggesting that subclinical disease is common (Balint et 
al., 2002, Frediani et al., 2002, Lehtinen et al., 1994). Even dedicated entheseal indices 
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(e.g. Leeds Entheseal Index, LEI) designed to detect enthesitis clinically have been 
shown to correlate poorly with ultrasonography (Ibrahim et al., 2011).  
Balint et al found clinical enthesitis in 22% of lower limb sites examined in patients with 
spondyloarthritis (SpA), compared to 56% by ultrasound. Clinical examination had a 
sensitivity and specificity of just 23% and 80% respectively, indicating that further 
modalities are needed for adequate assessment of enthesitis (Balint et al., 2002). Data 
from different studies of the quadriceps tendon and knee tendons also showed an 
underestimation of entheseal disease by clinical examination when compared to 
ultrasonography (Frediani et al., 2002). However, it should be noted that clinical 
assessment of the knee in 14 patients suggested enthesitis, although ultrasound was 
normal. One reason for this may be that the authors excluded enthesophytes from their 
criteria for enthesopathy, deeming them common and non-specific (Li et al., 2010), whilst 
other authors routinely accept enthesophytes as a diagnostic feature on ultrasound 
(Aydin et al., 2010, Gutierrez et al., 2010). 
1.6.1.5 Ultrasound in Subclinical Enthesitis 
The most plausible reason for the discrepancy between the clinical and ultrasound 
assessments of enthesitis is the presence of asymptomatic or ‘subclinical’ enthesitis. 
Estimates of subclinical enthesitis vary considerably, ranging from 4-59.3% (De Filippis 
et al., 2005, Farouk et al., 2010, Gisondi et al., 2008, Gutierrez et al., 2011, Naredo et 
al., 2011, Ash et al., 2012b, Ozcakar et al., 2005, Acquacalda et al., 2015, Acquitter et 
al., 2016, De Simone et al., 2003, Moshrif et al., 2017, Freeston et al., 2012). A cross-
sectional study by D’Agostino et al (D'Agostino et al., 2003) found that 38% of entheses 
in patients with SpA had evidence of subclinical disease using grey-scale (GS) and 
power Doppler (PD) ultrasound, compared with 11% of controls (D'Agostino et al., 2003).  
Naredo et al (Naredo et al., 2011) performed a similar study comparing 162 psoriasis 
patients without arthritis to 60 age matched controls with other skin diseases. 
Ultrasonographic enthesitis was detected in 11.6% of entheses in the psoriasis group 
compared to 5.3% of the entheses of the controls (p<0.0005). Entheseal PD signal was 
detected in 7.4% psoriatic patients, whereas no controls showed this finding (Naredo et 
al., 2011).  In a different study of 30 chronic psoriasis patients without clinical features of 
PsA, mean ultrasound scores (GUESS) of enthesitis were significantly higher (p=0.0001) 
than in healthy age and sex matched controls, and scores correlated with obesity and 
age. In particular, the thickness of all tendons examined was significant higher in cases 
than in controls, as well as the number of enthesophytes in all sites examined (Gisondi 
et al., 2008). More recently, Acquacalda and colleagues found subclinical enthesopathy 
in 46.4% of entheses scanned in the upper and lower limbs of a cohort of 12 psoriasis 
patients (Acquacalda et al., 2015). Moshrif et al identified lower limb enthesitis in 36% of 
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asymptomatic psoriasis patients with severe psoriasis (mean PASI>15.0) (Moshrif et al., 
2017). In the only ultrasound study of psoriasis patients without diagnosed PsA in 
primary care, 45% of 111 patients had at least one inflammatory entheseal lesion, 
although most had clinically tender entheses using MASES and/or LEI, and some had 
musculoskeletal complaints (van der Ven et al., 2016). Further studies are described in 
Table 1.8.  
In contrast, Freeston et al found only 4% of non-tender entheses had GS and/or PD 
ultrasound evidence of subclinical disease in a cohort of patients with early PsA 
(Freeston et al., 2012). However, in this study, the authors permitted a GS score of 1 to 
be classified as normal, as this can occur in healthy individuals as a consequence of 
mechanical stress. GS changes were common in their control group (n=10), although 
only 1% had a positive low-grade PD signal (Freeston et al., 2012); this suggests that 
PD may be a requisite tool for the determination of pathological entheseal disease. 
Data from Aydin and colleagues further supports the use of PD in subclinical enthesitis 
(Aydin et al., 2013a). In their study, psoriasis patients (with or without arthritis) were more 
likely to express an ‘inflammatory’ or vascular phenotype than healthy controls, as 
detected by PD ultrasound. The highest inflammation-related enthesopathy scores were 
found in patients with PsA, even when symptomatic entheses were excluded. Doppler 
positivity in at least one entheseal site was observed more frequently in PsA (36.2%) 
versus psoriasis alone (9.5%) (Aydin et al., 2013a). In other studies of asymptomatic 
patients with psoriasis, PD is reported, albeit at a much lower frequency than in patients 
with established PsA, in 0.7-1% of entheses (Acquitter et al., 2016, Ash et al., 2012b, 
Gutierrez et al., 2011).  
1.6.1.6 Power Doppler Ultrasound in Enthesitis 
The value of PD ultrasound in the diagnosis of early stage SpA has also been evaluated 
in a French cohort (D'Agostino et al., 2011). D’Agostino and colleagues found that the 
presence of at least one vascularized enthesis seen with PD ultrasound gave a sensitivity 
of 76.5% and a specificity of 81.3% for the diagnosis of SpA. In agreement with the 
majority of other studies in this domain, the Achilles and lateral epicondyle tendons were 
more frequently involved in SpA than non-SpA patients (D'Agostino et al., 2011).  
Of the several scoring systems described for the quantification of ultrasound 
abnormalities in SpA, the addition of PD signal has been received favourably both in 
terms of improved sensitivity and specificity of classifying inflammatory arthritis 
(D'Agostino et al., 2011, D'Agostino et al., 2003, Iagnocco et al., 2012), but also in terms 
of responsiveness to treatment (Hammer and Kvien, 2011, Kurosaka et al., 2010, Naredo 
et al., 2008). 
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1.6.1.7 Ultrasound in the Distinction Between Psoriatic Enthesopathy 
and Other Inflammatory Arthritides 
The majority of data relating to the use of ultrasound in inflammatory musculoskeletal 
disease has been obtained through the investigation of RA. Several early studies 
confirmed not only the ability of PD to identify vascular abnormalities known to be 
associated with inflammation in RA, but also the relationship between these features and 
both later damage and response to treatment (Hammer and Kvien, 2011, Kurosaka et 
al., 2010, Naredo et al., 2008).  
Distinguishing between inflammatory arthritides, especially RA and PsA, on the basis of 
entheseal ultrasound can be difficult and several studies have been unable to 
differentiate at a patient level (Iagnocco et al., 2012).  Enthesopathy tends to be more 
severe in PsA when compared to RA, but this is insufficient for diagnosis. Frediani et al 
investigated the ultrasound findings of the quadriceps tendon in patients with RA and 
PsA, and found patients with the latter were more likely to have evidence of enthesitis 
(45% RA vs. 7.5% PsA) (Frediani et al., 2001). Patients with RA were more likely to have 
a joint effusion (95% vs. 60%), and isolated enthesitis without effusion was only seen in 
patients with PsA. RA patients exhibited more inflammatory changes including tendon 
thickening, hypoechogenicity and oedema, whilst features of new bone formation were 
almost exclusively present in those with PsA (Frediani et al., 2001). 
Investigation of the distal upper limb has helped to provide further distinction. In a cohort 
of 25 PsA patients, three had enthesophytes and four had distal phalynx enthesopathy, 
compared to 0/25 patients with RA (Fournie et al., 2006). At the metacarpophalangeal 
joint level, an Italian group found the presence of inflammation around the extensor 
tendon region potentially differentiated PsA and RA patients, with an incidence of 65.8% 
vs. 0% respectively (Gutierrez et al., 2011). When compared to OA, inflammatory 
features were more frequent in the heel entheses of patients with PsA and RA, with 
Achilles enthesitis seen in 8% with PsA and 0% with OA or control subjects. However, it 
is worth noting that in this last cohort, plantar fasciitis was not significantly more common 
in PsA than RA, and the frequency of enthesophytes at the heel was similar in OA and 
PsA (Falsetti et al., 2003).  
In addition to the presence of new bone formation, the presence and shape of bone 
erosions associated with enthesitis may aid diagnosis. McGonagle and colleagues used 
ultrasound to assess the topography of erosions and new bone formation in Achilles 
tendon enthesitis (McGonagle et al., 2008). Erosions were found to occur only in the 
more fibrocartilaginous areas – at the proximal part of the insertion site or the superior 
tuberosity, with none observed in the distal enthesis. In terms of the shape of erosions, 
Finzel et al (Finzel et al., 2011) identified profound differences between the periarticular 
bone changes in PsA and RA. Whilst patients had a similar number of erosions, they 
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tended to be less severe, more evenly distributed and overall smaller in size and depth 
in PsA. Erosions in PsA were mostly Ω-shaped and tubule shaped, whereas U-shaped 
lesions were more typical for RA (Finzel et al., 2011). These data were however derived 
from studies using high resolution μCT scanning, and it remains to be determined if such 
distinction can be made using ultrasound. 
1.6.1.8 Ultrasound in the distinction between Psoriatic Enthesopathy 
and Fibromyalgia 
Clinically, the distinction between PsA and fibromyalgia can be very difficult, especially 
in patients with concomitant psoriasis. Both manifest with tender points, especially on 
palpation during clinical examination. An Italian study aimed to assess the utility of 
ultrasound in this domain, and found that although entheseal changes were significantly 
more common in patients with PsA, patients with fibromyalgia also frequently had 
imaging abnormalities; 80% had enthesopathy, 23% had inflammatory lesions and 23% 
had altered entheseal PD signal. The Achilles and quadriceps tendons were most 
frequently abnormal. Patients with fibromyalgia were more likely to have clinically tender 
but sonographically normal entheses (37% vs. 8% PsA). An ultrasound finding of at least 
three abnormal entheses predicted a diagnosis of PsA with a sensitivity of 72% and a 
specificity of 76% in this cohort (Marchesoni et al., 2012). 
1.6.1.9 Ultrasound Scoring Systems for Enthesitis 
In an attempt to confirm the presence and severity of enthesopathy, several groups have 
attempted the development of ultrasound scoring systems. One of the earliest and most 
widely cited is the Glasgow Ultrasound Enthesitis Scoring System (GUESS), designed 
by Balint and colleagues in 2002. The initial study demonstrated substantial to excellent 
interobserver agreement (Balint et al., 2002), although criticism is levied at the inclusion 
of only the lower limbs, and absence of any PD assessment. In 2003, D’Agostino et al 
aimed to improve on these exclusions by introducing a composite grading system (grade 
0-3b) which included both GS and PD assessments of the common extensor and flexor 
origins at the elbow, the gluteus insertion at the greater trochanter and pubis enthesis as 
well as those of the knee and distal lower limb in patients with SpA (D'Agostino et al., 
2003). The group refined their assessment in 2009 to focus only on those entheses most 
frequently involved (common extensor origin of the elbow, quadriceps tendon insertion, 
superior patella tendon insertion, Achilles tendon and plantar fascia) and to use a more 
simplified scoring system for vascularization and morphological and structural 
abnormalities. Helpfully, both the grading system by Balint and that by D’Agostino 
contain maximum measurements for ‘normal’ entheseal thickness, enabling 
reproducibility in future studies, unlike other published scoring systems. 
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The Madrid Sonographic Entheseal Index (MASEI) was developed in 2009 in a cohort of 
patients with SpA (de Miguel et al., 2009). Again, an enthesis in the upper limb was 
included in order to determine the strength of influence of mechanical factors prone to 
affect the lower limb entheses. GS and PD abnormalities were scored at six sites, with a 
maximum potential score of 136. de Miguel et al reported that with a cut-off point of 20 
more, MASEI correctly classified patients as having SpA with a sensitivity of 53% and a 
specificity of 83.3% among a group of patients with variable probabilities of having some 
form of SpA (de Miguel et al., 2009). 
In psoriatic disease specifically, an independent group in Toronto assessed the 
usefulness of the MASEI in classifying patients as having PsA (Eder et al., 2014). It is 
known that entheseal lesions are commonly found in patients with psoriasis but who do 
not have clinical signs of enthesitis or synovitis (Naredo et al., 2011, Gutierrez et al., 
2011, Gisondi et al., 2008). The significance of such abnormalities is unclear, and other 
factors such as age and high body mass index (BMI) may be contributory. 50 PsA, 66 
psoriasis and 60 healthy controls were scanned and the MASEI scoring system used to 
quantify the extent of entheseal abnormalities in each of these groups. Total, damage 
and inflammatory MASEI scores were, as expected, significantly higher in patients with 
PsA; however, the sensitivity of the MASEI to correctly classify patients as having PsA 
was only 30%, suggesting ultrasound alone is insufficient for diagnosis (Eder et al., 
2014). Specificity ranged from 89% to 95% (for comparison with psoriasis patients and 
healthy controls respectively), confirming a role for GS and PD ultrasound assessment 
in patients where there is clinical suspicion. It was apparent however, that this is 
dependent upon other factors, and most specifically BMI - in this study, no significant 
differences were seen in MASEI scores across the three groups where BMI was in 
excess of 30 (Eder et al., 2014). 
The ultrasound score proposed by Naredo et al in 2010 includes GS and PD assessment 
at seven sites, with two in the upper limb and five in the lower. In addition to 
demonstrating excellent intraobserver reliability, it has also exhibited responsiveness to 
change to treatment. Morphological abnormalities, PD signal and bursitis scores all 
improved with effective anti-inflammatory therapy in the form of TNF inhibition (six 
months), whilst calcific deposits and cortical abnormalities remained unchanged or 
increased, confirming the irreversibility of structural damage (Naredo et al., 2010).  
Other ultrasound scoring systems have been used to assess for enthesopathy and 
treatment responsiveness in cohorts not including patients with PsA. A scoring system 
previously described by Filippucci et al was used to assess only Achilles enthesitis in 
forty-three patients with ankylosing spondylitis (AS) (Filippucci et al., 2009). After two 
months of TNF inhibition, significant improvements in GS and total inflammatory scores 
were seen, although reductions in PD score specifically did not reach statistical 
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significance. Features of chronicity and damage were not assessed as they were 
expected not to change. 
The Sonographic Enthesis Index (SEI) was also developed in patients with AS. A good 
interobserver reliability was found in the initial study, although this did not include PD 
assessment (Alcalde et al., 2007). The SEI was modified in 2011 by Hamdi et al, again 
in patients with AS (Hamdi et al., 2011). The Doppler score correlated well with disease 
activity measures, and the total score correlated well with clinical enthesitis indices; 
however, the validity of the SEI and modified SEI have not been assessed in patients 
with PsA, where peripheral disease tends to be more prominent and where there may 
be associated skin disease associated with entheseal abnormalities. 
Further large-scale validation studies are required to determine which of these published 
scoring systems is the most sensitive and specific scoring system for use in the detection 
and treatment of psoriatic disease. To date, no scoring systems have been published 
that encompass all components of the OMERACT definition of enthesopathy, nor that 
include the full synovio-entheseal complex. 
1.6.2 Magnetic Resonance Imaging in Enthesitis 
Magnetic resonance imaging (MRI) is of primary benefit in the spondyloarthropathies 
(including PsA) for the evaluation of the axial skeleton, principally the sacroiliac (SI) joints 
and spine. However, it can be used as a sensitive imaging modality for any structures 
critical in the evolution of inflammatory arthritis, providing detail of the bone and 
surrounding tissues in three planes. The majority of studies of MRI in PsA have used 
conventional 1.5-Tesla (T) magnets with a surface coil, although 3T magnets are now 
becoming more widely available in the research setting. 
PsA (and SpA in general) are characterised by diverse and anatomically widespread 
disease manifestations and conventional MRI can be inadequate, allowing visualisation 
of a small anatomical area at one examination, limiting its ability to provide an overall 
assessment of disease status. However, with the advent of whole-body MRI (WB-MRI), 
assessment is now possible from ‘head-to-toe’ of all peripheral and axial joints in only 
one examination and in a relative short period of time. Using multi-coil systems and a 
moving table platform, scanning of adjacent anatomical regions is possible without 
repositioning the patient or imaging coils. Fusion of the images allows visualisation of 
lesions in the axial skeleton, anterior chest wall, shoulder and hip girdles, peripheral 
joints and entheses may be visualised within the same image. In axial SpA, reports show 
that reliability of detection is comparable with that of conventional MRI (Weber, 2008b, 
Weber, 2008a). The possible features of SpA that can be assessed with MRI are listed 
in Table 1.13 (Ostergaard et al., 2009, Mager et al., 2009, Maksymowych and Lambert, 
2007). 
  
A
natom
ical 
Location 
Lesion 
Feature 
Sacroiliac 
Joints 
Juxta-articular 
osteitis (active) 
H
igh signal of periarticular bone m
arrow
 on STIR
 im
ages and low
 signal intensity on T1w
 im
ages. C
an be seen 
further aw
ay from
 the joint w
here fatty replacem
ent of bone m
arrow
 is extensive. 
Synovitis (active) 
Seen in the joint space, usually only after contrast enhancem
ent. 
C
apsulitis (active) 
Anterior and posterior high signal intensity, usually only after contrast enhancem
ent. 
Enthesitis (active) 
U
sually affects the interosseous ligam
ents as they course through the retroarticular space (sm
all synovial joint 
com
partm
ent of the SI joints), seen as high intensity signal on STIR
 im
ages. 
Subchondral 
Sclerosis (chronic) 
First arises in the iliac bone as a thin band of low
 signal intensity on all sequences and increases as sclerosis 
progresses. 
Erosions (chronic) 
D
estructive discontinuations of the cortical layer w
ith low
 signal intensity on T1w
 im
ages and high signal intensity on 
STIR
 im
ages. D
iscrete w
hen early – can becom
e confluent to give a ‘string of pearls’ appearance. 
Transarticular 
bridging (chronic) 
R
eflects SI joint ankylosis and represents new
 bone form
ation. C
haracterised by low
 signal intensity on all 
sequences. Progressive ankylosis leads to progressive joint space narrow
ing due to fatty replacem
ent of the bone 
m
arrow
, characterised by increased T1 signal intensity. 
 A
natom
ical 
Location 
Lesion 
Feature 
Spine 
Enthesitis (active) 
Involves the interspinous ligam
ents and is seen as an increase in signal intensity in STIR
 im
ages and fat saturated, 
contrast-enhanced T1w
 sequences. 
Bony irregularities 
(active and 
chronic) 
Acute rom
anus lesions (irregularities of the anterior and posterior edges of the vertebral endplates) are 
characterised by low
 signal intensity on T1w
 im
ages and increased signal intensity on STIR
 im
ages. C
hronic 
rom
anus lesions show
 T1 hyperintensity due to fatty replacem
ent of the bone m
arrow
. Advanced lesions m
ay give 
rise to anterior syndesm
ophytes. 
Peripheral 
Joints 
Enthesitis (active) 
Seen as a non-uniform
 increase in signal intensity in STIR
 im
ages and fat saturated, contrast-enhanced T1w
 
sequences at tendon insertion sites w
ith sw
elling or oedem
a of surrounding soft tissues. 
Synovitis (active) 
H
igh signal intensity in the synovial com
partm
ent on T1w
 sequences, w
ith a thickness greater than the w
idth of 
norm
al synovium
. C
ontrast enhancem
ent is usually needed. 
Tenosynovitis 
(active) 
Increased w
ater content adjacent to a tendon in an area w
ith a tendon sheath, seen as hyperintensity on T2w
 fat-
saturated and STIR
 im
ages, and low
 signal intensity on T1w
 im
ages. C
ontrast enhancem
ent is needed for T1w
 
im
age sequences. 
Periarticular 
inflam
m
ation 
(active) 
Increased w
ater content at extra-articular sites including the periosteum
 and entheses but not the tendon sheaths, 
seen as high signal intensity on T2w
 fat saturated and STIR
 im
ages. C
ontrast enhancem
ent is needs for T1w
 im
age 
sequences. 
Bone m
arrow
 
oedem
a (active) 
A lesion w
ithin trabecular bone w
ith high signal intensity on T2w
 fat-saturated and STIR
 im
age sequences and low
 
signal intensity on T1w
 im
ages. O
ften has ill-defined m
argins and m
ay occur alone or surrounding bony 
abnorm
alities. 
Bony irregularities 
(chronic) 
Enthesophytes and erosions are seen using T1w
 sequences, w
ith a loss of norm
al low
 signal intensity of the 
cortical bone and a loss of norm
al high signal intensity of bone m
arrow
 fat. 
Table 1.13: Potential m
anifestations of PsA identifiable on M
R
I  
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The characteristic features of enthesopathy identifiable by MRI include bone marrow 
oedema, soft tissue oedema, tendon thickening, intra- and extra-osseous erosions and 
enthesophytes, and additional findings such as fluid around tendons or adjacent to bursa 
may also be visualized (Eshed et al., 2007). 
In terms of optimal MRI sequences and acquisitions, spatial resolution and signal-to-
noise ratios need to be considered. T1 weighted (T1w) spin-echo (SE) sequences are 
effective at depicting bone, fat, muscles, ligaments and tendons (Eshed et al., 2007). 
T1w SE sequences with fat suppression after contrast administration are advised for 
depicting bursitis, tendonitis and bony lesions such as osteitis, although experience in 
AS has suggested that axial T1w sequences lack sensitivity for the detection of 
syndesmophytes (Braun et al., 2003), which may apply to the bony lesions of peripheral 
PsA (enthesophytes).  
Short tau inversion recovery (STIR) and T2 weighted (T2w) fast/turbo spin-echo fat 
suppressed sequences are very effective for bone oedema and soft tissue inflammation, 
joint effusion, bursitis and tenosynovitis (Roemer et al., 2005, Eshed et al., 2007) and 
may therefore be preferable in PsA. However, T2w images are more time-consuming to 
acquire and therefore more susceptible to movement artefact (McQueen et al., 2007a). 
Given the superiority of MRI over ultrasound for visualisation of the axial skeleton, many 
of the trials of MRI assessment of enthesitis have been performed in general SpA 
patients, and more specifically those with AS, who have predominantly axial disease. 
However, meaningful conclusions can be drawn from these data for patients with axial 
PsA given the pathological similarities between the seronegative spondyloarthropathies. 
Indeed, the hypothesis that enthesitis is the common primary pathogenic mechanism 
shared in the spondyloarthropathies arose from a MRI-based study of patients with 
inflammatory arthritis, including PsA. McGonagle and colleagues were the first to 
describe characteristic MRI entheseal changes involving the knee joints of ten patients 
with SpA (including three with PsA) and ten with RA with a swollen knee joint of recent 
onset. Three patients with SpA and one with RA had evidence of enthesitis and focal 
bone marrow oedema was seen exclusively in SpA patients (six out of ten). All ten SpA 
patients showed perientheseal high signal outside of the joint compared with four in the 
RA group (McGonagle et al., 1998b). 
1.6.2.1 MRI Definition of Entheseal Disease 
Unlike ultrasound, there is no standardised definition of enthesitis on MRI. The 
Assessment of SpondyloArthritis (ASAS) International Society and OMERACT MRI 
working group describe active enthesitis at the SI joint as ‘a hyperintense signal on STIR 
images and/or contrast enhanced, T1 weighted, fat saturated images at sites where 
ligaments and tendons attach to bone, including the retroarticular space (interosseous 
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ligaments). The signal may extend to bone marrow and soft tissue’ (Rudwaleit et al., 
2009).   
Barozzi et al characterised the MRI features of enthesitis as ‘swelling and deviation from 
the normally uniform low signal intensity of tendons and ligaments, distension of adjacent 
bursae by fluid collection, peritendinous soft tissue swelling and inflammation of bone 
adjacent to the insertion’ (Barozzi, 1988). This was supported by the description from 
Eshed at al (Eshed et al., 2007), in which the group advise that to adequately assess an 
MRI image for enthesitis, the following should be evaluated: 
• ‘Thickness and signal intensity of tendons and ligaments’ 
• ‘Perientheseal soft tissues for swelling or oedema’ 
• ‘Adjacent bone marrow to detect oedema, best appreciated as high signal in fat 
suppressed sequences’ 
• ‘Adjacent bone for erosions (cortical bone defects and contour irregularities)’ and 
enthesophytes (extensions of marrow contents isointense to the medullary bone), 
both best appreciated on T1-weighted sequences’ 
• ‘Additional findings in adjacent structures (joint or bursal fluid for example)’ 
1.6.2.2 Conventional MRI in Enthesitis 
MRI has been used to investigate the presence of enthesitis at several sites in patients 
with PsA and SpA.   Emad and colleagues confirmed the findings in the knee from 
McGonagle et al with enhanced MRI scanning in three groups of patients (SpA, 
established RA and undifferentiated arthritis). Enthesitis was a common feature in the 
SpA group (n=15), completely absent in the RA group (n=15) and observed in three 
patients in the undifferentiated arthritis group (n=25) (Emad et al., 2009). In a second 
study, the group also found enthesitis in the knees of 56 patients with SpA, including 30 
with PsA. The most commonly involved enthesis was the medial collateral ligament 
(40.0%), followed by the patellar tendon insertion (23.3%), lateral collateral ligament 
(16.7%), biceps femoris tendon (10.0%) medial patellofemoral ligament (6.7%) and 
lateral patellofemoral ligament (3.3%) (Emad et al., 2010). 
In the heel, Kamel et al reported on a cohort of 32 patients with SpA. MRI showed tendon 
enlargement (62.5%) with loss of the normal hypointense appearance and focal 
thickening at the insertion site (31.2%), and diminished signals within the pre-Achilles fat 
pad due to inflammatory oedema. 40.6% had associated osteitis. Entheseal 
abnormalities of the heel were also frequently identified on MRI in a different cross-
sectional study of patients with SpA and symptomatic heel pain (81%). However, 
interesting in this study, a surprising proportion of SpA patients without heel pain and 
control subjects (with mechanical back pain) also had abnormalities at the heel (53% 
and 67% respectively, p=0.045). The most common abnormalities in the control subjects 
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were abnormal intertendinous signal (Achilles tendon 20.83%, plantar fascia 41.67%) 
peri-aponeurosis signal (35.42%), enthesophytes (Achilles tendon 16.67%, plantar 
fascia 31.25%) and Achilles tendon thickening (20.83%). Only oedema of the calcaneum 
on MRI was specific enough (94%) to distinguish SpA from control subjects but was not 
sufficiently sensitive for diagnosis (22% of all patients with SpA). 15% of the patients with 
SpA in this study also had psoriasis, but the specific SpA diagnoses were not disclosed 
(Feydy et al., 2012). 
In the upper limb, only the entheses adjacent to the joints of the hands, fingers and wrists 
have been studied with MRI in patients with PsA. Most studies compare MRI changes to 
those in patients with RA; a few reports have shown that inflammation is localised within 
the joint capsule in RA, which is in contrast to PsA, where extra-capsular involvement is 
also present (Jevtic et al., 1995, Schoelnast, 2006, Marzo-Ortega et al., 2009, 
Giovagnoni, 1995, Savnik et al., 2001). In the most recent study, Narvaez and colleagues 
performed MRI scanning on the hands and wrists of patients with both early PsA and 
RA, with duration of clinical symptoms of less than 12 months. Enthesitis was seen 
exclusively in the PsA cohort, with 12 out of 17 patients exhibiting diffuse bone marrow 
oedema and florid inflammatory soft tissue changes adjacent to the insertion site 
(Narvaez et al., 2012). MRI could therefore hold value as a diagnostic tool to differentiate 
between the two conditions, although this concept has not been definitively established 
or validated in patients with early, inflammatory arthritis.  
1.6.2.3 Whole-Body MRI in Enthesitis 
Two studies have assessed the use of WB-MRI for widespread detection of enthesitis in 
patients with PsA (Poggenborg et al., 2014b, Poggenborg et al., 2014a, Weckbach et 
al., 2011) and several more in axial SpA (Karpitschka et al., 2013, Althoff et al., 2013, 
Song et al., 2011a). Reliability analysis of WB-MRI assessments within some of these 
studies has revealed encouragingly high inter-rater correlation coefficients (>0.85) within 
axial SpA (Song et al., 2011a, Karpitschka et al., 2013). Only one study has included 
patients with PsA and found variable inter-reader ICCs, ranging from 0.31-0.85 for 
synovitis, bone marrow oedema and erosions, 0.62-0.68 for bone marrow oedema and 
fat infiltration in the spine, 0.81-1.0 for bone marrow oedema, fat infiltration, erosion and 
ankylosis in the SI joints and 0.58 for enthesitis (Poggenborg et al., 2014a, Poggenborg 
et al., 2014b). It should be noted that this study had a small sample size (only ten 
participants were re-scored after a 12 month interlude) and there was poor readability at 
certain sites, particularly for enthesitis (Poggenborg et al., 2014a).  
In the first ‘proof of concept’ study to assess whether WB-MRI was feasible in PsA, 30 
patients with established PsA were scanned using STIR and T1w gradient echo 
sequences and the images assessed for the presence of bone marrow oedema, 
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effusions, synovitis, enthesitis, bursitis, osseous erosions and osseous destructions. 
Good quality images of the axial skeleton were obtained in 87% of cases and of the 
hands and feet in 53%. Enthesitis was classified as oedema in the attaching tendon and 
in the tendon attachment site of bone, and it was the most common visible finding in the 
hip region. Topographically, enthesitis was closely related to bone marrow oedema like 
signal alterations, extending beyond the joint capsule away from the joint and associated 
with oedema-like alterations in adjacent soft tissues. The areas most frequently affected 
by enthesitis were the hips (66.0%), spine (lumbar, 60.0%; thoracic, 43.3%; cervical 
36.6%) and symphysis pubis (23.3%), followed by the feet (6.7%), SI joints (3.3%) and 
knees (3.3%). Enthesitis within the spine was most commonly seen in the interspinal 
ligaments, adductor tendons and glutei muscle attachment sites. Comparing the number 
of regions of enthesitis detected by clinical examination, WB-MRI was statistically 
superior (p<0.001), with more locations being identified on WB-MRI in 80% of patients. 
However, more sites were scanned than were included in the clinical assessment. 
(Weckbach et al., 2011).  
Poggenborg and colleagues performed WB-MRI on patients with peripheral PsA (n=18), 
axial SpA (n=18) and healthy volunteers (n=12) to assess the presence and pattern of 
inflammatory and structural lesions in axial and peripheral joints, with the aim developing 
a WB-MRI global inflammation and structural damage scoring system (Poggenborg et 
al., 2014b). In a separate publication, the group reported specifically on enthesitis within 
this cohort, and compared the WB-MRI findings to clinical measures of enthesitis 
including the MASES, SPARCC and LEI. WB-MRI allowed adequate visualisation of 53% 
of all entheseal sites investigated, with the pelvic entheses, supraspinate tendons, 
greater femoral trochanters and medial femoral condyles being most easily viewed 
(>94% of patients). The poorest areas were the anterior chest wall and elbows, being in 
the field of view in only 29% and 1% of cases respectively. Within all 888 entheses 
visualised, 17% demonstrated enthesitis, defined as ‘the presence of bone marrow 
oedema, soft tissue oedema, change in tendon thickness, erosions or enthesophytes in 
adjacent bones, and additional findings such as fluid around tendons or adjacent to 
bursa, alone or in combination’. Patients with PsA had enthesitis on WB-MRI in 18% of 
entheses examined, compared to 14% of entheses in healthy subjects. The sites and 
frequencies at which lesions were identified in these groups are described in Table 1.14.  
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Anatomical 
Site Enthesis 
PsA 
(%) 
Healthy 
Subject 
(%) 
Lower Limb 
Greater femoral trochanter 64 58 
Achilles tendon insertion 36 28 
Medical femoral condyle 12 25 
Quadriceps insertion into patella 0 13 
Upper Limb Supraspinate tendon insertion at the humerus 28 13 
Pelvis 
Ischial tuberosity 18 8 
Posterior superior iliac spine 17 0 
Table 1.14. Frequencies of enthesitis found on WB-MRI in patients with PsA (n=18) and 
healthy subjects (n=12). 
The high rates of enthesitis in healthy subjects seen on both clinical examination (8%) 
and WB-MRI (14%) was attributed by the authors to the possible presence of subclinical 
enthesitis (related to other conditions inducing high mechanical stress such as obesity 
or overuse due to physical activity, e.g. long-distance running) (Poggenborg et al., 
2014a). Studies in conventional MRI have shown high levels of enthesitis in the 
shoulders (Lambert et al., 2004) and Achilles tendon (Feydy et al., 2012) in 
asymptomatic patients with axial SpA and healthy subjects. 
1.6.2.4 MRI in Subclinical Enthesitis  
The majority of studies investigating subclinical joint pathology in psoriasis have used 
ultrasound, although one small study has utilised MRI specifically for this purpose. 25 
patients with active psoriasis but no clinical evidence of PsA had a non-contrast MRI 
scan of their hand. 17 patients had one or more signs of arthritis on MRI, including 
capsular distension (n=11), periarticular oedema (n=9) and erosions (n=7) at and around 
the MCP and interphalangeal joints. No articular features of PsA were seen in the healthy 
control group with the exception of a bone cyst in one participant (Offidani et al., 1998). 
Emad and colleagues investigated entheseal related changes shown among patients 
with several forms of spondyloarthropathy. They included six patients with psoriasis 
without clinical signs of synovitis that were not receiving any systemic 
immunosuppressant or biologic therapy. One patient had bone marrow oedema, and 
enthesitis was detected in five patients at the patellar tendon insertion, and one patient 
at the medial patellofemoral ligament (Emad et al., 2010). 
The same group later published data from 48 patients with psoriasis and no clinical 
evidence of peripheral or axial enthesitis or synovitis and 20 age and sex matched 
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controls without arthritis. Amongst the 96 knees scanned in psoriasis patients, 90 
entheseal lesions were identified in addition to soft tissue oedema (n=52), bone marrow 
oedema (n=20), perientheseal bone marrow oedema (n=3), cartilaginous erosions 
(n=42) and bone erosions (n=27). Enthesitis was significantly and positively correlated 
with soft tissue oedema (r=0.304, p=0.036) and cartilaginous erosions (r=0.304, 
p=0.036). The control patients showed no evidence of enthesitis; five had cartilaginous 
erosions and two had bone marrow oedema (Emad et al., 2012). Erdem and colleagues 
performed clinical and MRI examination of the feet of 26 seronegative patients with 
psoriasis (and no signs or symptoms of PsA) and 10 healthy subjects. 24 patients had 
abnormalities on MRI, most commonly Achilles tendonitis (57%), retrocalcaneal bursitis 
(50%), joint effusion/synovitis (46%), soft tissue oedema (46%) and para-articular 
enthesophytes (38%). Enthesopathy, described as ‘abnormalities at ligamentous 
attachments such as enthesitis, enthesophyte and [bone] marrow oedema adjacent to 
the insertion’, was seen in 23% at the Achilles tendon and 15% at the plantar fascia 
attachment. No abnormalities were found in any of their healthy control cases, who were 
aged between 20 and 63 years (mean 42.9 +/- 12.9) (Erdem et al., 2008). 
1.6.2.5 Limitations of MRI in Enthesitis 
In comparison to ultrasound, MRI is considerably more expensive, less widely available, 
and has lower spatial resolution, thus limiting its use in the assessment of enthesitis to 
clinical trials at the present time.  
Conventional MRI can only be used to scan one joint region of interest at a time and this 
is a limitation when assessing a phenotypically heterogeneous disease such as PsA. 
The advent of WB-MRI has largely overcome this problem, however it is less sensitive 
for detecting bone marrow oedema, which in entheseal disease, is a significant limitation. 
‘Readability’ has been a problem in studies using WB-MRI to assess the entheses, with 
a high degree of artefact preventing interpretation. In one study, 16 of 35 sites were 
readable in less than 70% of cases. The Achilles tendon was out of the field of view in 
21% of cases and impossible to evaluate in 8%, and readability was compromised at 
several other sites, including the patellar ligament insertion into the patella and tibia 
(readable in 5% and 2% respectively) and the elbow (readable in 1%) (Poggenborg et 
al., 2014a). In the peripheral skeleton, it is reported that it can be a challenge to image 
the elbow, wrist and finger joints due to the configuration of coils (Mager et al., 2009). 
Nevertheless, despite these problems, much useful data can be obtained from 
conventional and WB-MRI in its current form, and with advances in scanner technology 
coupled with operator experience, such limitations should be overcome in time. 
 
 71 
1.6.2.6 Sensitivity to Change of MRI in Entheseal Disease 
Several trials have used MRI to assess enthesitis before and after treatment. The 
sensitivity to change with TNF inhibitor therapy was first demonstrated in 10 patients 
treated with etanercept, with 86% of MRI-detected lesions improving or resolving after 6 
months of therapy (Marzo-Ortega et al., 2001). Similarly, Karpitschka et al demonstrated 
a 94.3% reduction in MRI enthesitis scores after one year of etanercept (Karpitschka et 
al., 2013), and a significant decrease in bone marrow oedema and synovitis was seen 
on MRI after 20 weeks of infliximab (Marzo-Ortega et al., 2007). Superiority of etanercept 
over sulphasalazine in the treatment of enthesitis has been shown using whole body 
MRI, with no change demonstrated in the latter group after 48 weeks (Song et al., 2011a). 
Only one study has failed to show any resolution in MRI-detected bone marrow oedema 
with etanercept compared with placebo, which was in notable contrast to the patient 
reported outcomes where improvement was significant (Dougados et al., 2010). MRI was 
also used assess the response to a different TNF inhibitor, adalimumab, in a 19-year-old 
male with Achilles enthesitis and plantar fasciitis. Resolution of bone marrow oedema, 
soft tissue oedema and retrocalcaneal bursitis occurred within six months of treatment 
(Mancarella et al., 2010). 
1.6.2.7 MRI Evaluation Vs. Clinical Examination for Enthesitis 
Several investigators have compared the rate of enthesitis found on clinical examination 
with that seen on MRI. None have found a significant correlation between clinical and 
MRI findings, and there is discrepancy between which method detects the most 
enthesitis. Weber et al investigated the involvement of individual entheses of the anterior 
chest wall and found no association between clinical examination and WB-MRI findings 
(Weber, 2012). This was affirmed by Song and colleagues, who found no significant 
correlations between an MRI enthesitis score and clinical parameters of disease activity 
(Song et al., 2011a).  The percentage agreement between WB-MRI and clinical 
enthesitis was 68-100% for all entheseal sites in the cohort studied by Poggenborg et al, 
with the exception of the medial femoral condyle (64%), Achilles tendon (52%) and 
greater trochanter (49%). Frequently in this study, more enthesitis was detected by 
clinical examination than by WB-MRI (22% and 17% respectively). Tenderness was most 
frequently elicited over the first and seventh costochondral joints (in 32%), whereas no 
enthesitis was found on WB-MRI in the anterior chest wall, supporting the observations 
of Weber et al (Poggenborg et al., 2014a, Weber, 2012). This may be partially explained 
by the fact that the first rib is a synchondrosis or a synostosis, with no movement at the 
anterior joint (Maksymowych and Lambert, 2007). To capture the relevant joints, along 
with varying types of motion, selection of the second and seventh anterior joints may 
have produced better correlation. 
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An opposing relationship was found in the cohort studied by Weckbach and colleagues, 
who reported MRI enthesitis at more locations than at clinical examination in 80% of 
patients with PsA. However, clinically they only assessed those entheses included in the 
MASES index, and their WB-MRI scored more entheseal sites which may account for 
the discrepancy (Weckbach et al., 2011). 
1.6.2.8 MRI in the Distinction Between Psoriatic Enthesopathy and Other 
Inflammatory Arthritides 
There is a small body of evidence to support the use of MRI in the differentiation of 
peripheral inflammatory arthritis, especially with regard to PsA and RA at several 
different anatomical locations. Data from MRI in PsA and RA suggest two principle 
imaging patterns; one where inflammatory changes are primarily based in the synovium 
(‘RA phenotype’, where synovitis is the primary process), and another where periarticular 
entheses are inflamed and associated with intense oedema of the adjacent bone (‘SpA 
phenotype’ where enthesitis is the primary process and synovitis occurs a secondary 
event) (Jevtic et al., 1995). Looking beyond the enthesis is therefore necessary for 
differentiation of PsA from other inflammatory arthritides.  
The combination of MRI findings of enthesitis, multifocal bone marrow oedema, 
periostitis and extracapsular enhancement, in association with synovitis and 
tenosynovitis in the hands, is almost diagnostic of PsA (Tan et al., 2006a, Spira, 2011, 
Narvaez et al., 2012). Several reports have demonstrated extracapsular inflammation in 
PsA, in contrast to RA with active synovitis and pannus formation where inflammatory 
changes were always localised within the joint capsule (Jevtic et al., 1995, Schoelnast, 
2006, Marzo-Ortega et al., 2009, Giovagnoni, 1995, Savnik et al., 2001). This 
phenomenon was first described by Jevtic and colleagues, however it was not uniform 
across their series of 16 patients with PsA, with half having only intra-capsular disease 
and no extracapsular inflammation. This could be explained by the proposal that PsA is 
a heterogeneous condition where some patients have a predominantly synovial disease 
(like RA), whilst others who have an extracapsular focus of their inflammation have an 
entheseal driven disease. However, the authors do also raise the possibility that they 
could have included some cases of seronegative RA who also had co-existent psoriasis 
and fulfilled the Moll and Wright criteria for PsA (Jevtic et al., 1995). 
McGonagle et al showed that demonstration of peri-entheseal bone marrow oedema and 
focal soft tissue oedema could distinguish patients with early SpA from those with early 
RA in patients with new onset knee effusion. Entheseal inflammation and bone marrow 
oedema was much more common in the SpA group, which included patients with PsA 
(McGonagle et al., 1998b). Similarly, Emad and colleagues found that enthesitis was a 
common feature on knee MRI in patients with SpA and absent in patients with RA and 
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undifferentiated arthritis. Enthesitis was most frequently seen in the medial collateral 
ligament (46.7%) followed by the patellar tendon (33.3%), posterior cruciate ligament 
(26.7%) and biceps femoris insertion (13.3%) (Emad et al., 2009).  
1.6.2.9 MRI Scoring Systems for Enthesitis 
Enthesitis is not included in the main MRI scoring system designed for use in peripheral 
PsA (the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System, 
PsAMRIS) (Ostergaard et al., 2009) and no other validated scoring systems are available 
for enthesitis. 
In terms of assessment of change, only one measure, the Leeds Scoring System, has 
been developed to quantify the response specifically in entheseal pathology to therapy 
in patients with SpA. Marzo-Ortega and colleagues describe a semi-quantitative 
measure used to score MRI images from ten patients before and after six months of 
etanercept therapy for inflammatory axial and peripheral SpA in a time blinded order 
(Marzo-Ortega et al., 2001). Several areas were systematically analysed per joint: 
• SI Joint: Lesions were assessed in four quadrants (right upper, left upper, right 
lower, left lower), each divided into iliac and sacral aspects 
• Spine: Lesions were assessed as present in the vertebrae or paraspinal soft 
tissues 
• Peripheral joints: Lesions were assessed in bone and soft tissues 
At baseline, the presence or absence of lesions was recorded in addition to the 
cumulative number of lesions per area scanned. Post-treatment scans were assessed 
using a semi-quantitative scale: 
• - 3 Complete resolution 
• - 2 Moderate improvement 
• - 1 Mild improvement 
• 0 No change 
• + 1 Mild deterioration 
• + 2 Moderate deterioration 
• + 3 Severe deterioration 
Although not formally validated, this measure has subsequently been used in other MRI-
based studies assessing the response to treatment in patients with SpA (Marzo-Ortega 
et al., 2005, Bennett et al., 2009). Bennett et al assessed reliability of the Leeds Scoring 
System in the axial skeleton in patients with AS, who found excellent inter-observer 
agreement for the identification (100% exact agreement) and grade of lesions in the SI 
joints (93% exact agreement) with an overall quadratic-weighted kappa of 0.95. In the 
spine, agreement between different grades of different types of lesions was also 
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substantial (prevalence-adjusted bias-adjusted kappa scores: Romanus lesions, 0.68; 
end-plate lesions, 0.90; posterior element lesions, 0.89; spinous process lesions, 0.83; 
diffuse oedema, 0.90) (Bennett et al., 2009). Reliability has not been tested in 
enthesopathy. 
1.6.2.10 Comparison between Ultrasound and MRI in enthesitis 
Several studies have compared the findings of ultrasound and MRI images from the 
same enthesis in an attempt to determine which modality should be the gold standard 
for imaging entheseal pathology. Independent studies of the knee and heel have 
revealed ultrasound to be more sensitive for inflammation at the enthesis and 
calcifications (Kamel et al., 2003, Kamel et al., 2004). Aydin and colleagues (Aydin et al. 
2013b) also found ultrasound to correlate with clinical enthesis, with swollen knee joints 
exhibiting more hypoechogenicity and thickening at the tendon insertion than non-tender 
joints. MRI at the same sites showed only increased signal in the surrounding tissues, 
not the enthesis itself, which was greater at tender sites (Aydin et al. 2013b). Agreement 
on changes between ultrasound and MRI for individual lesions was very low.  
In contrast, in a more recent study of the elbow, perhaps helped by advances in MRI 
technology, inflammation scores between ultrasound and MRI data from patients with 
enthesitis and PsA revealed complete agreement in 60% of comparisons (Groves et al., 
2017). Both modalities clearly have their role in the assessment of PsA, and given that 
ultrasound is only amenable to imaging peripheral structures, MRI remains an essential 
adjunct for the assessment of axial and less accessible peripheral entheses and 
surrounding tissues. 
1.7 Ustekinumab in the Management of Psoriasis and Psoriatic 
Arthritis 
In January 2009, Ustekinumab (CNTO 1275, Stelara®; Janssen Cilag®) was granted 
marketing authorization by the European Commission for the treatment of moderate to 
severe chronic plaque psoriasis in adults who failed to respond to, who have a 
contraindication to or who are intolerant of systemic oral immunosuppressants. This was 
followed in September 2013 by approval for use in active psoriatic arthritis in adult 
patients, where the response to previous non-biological DMARD therapy has been 
inadequate. Unlike all other biologic agents already brought to market, which targeted 
TNF-α, ustekinumab was the first-in-class anti-interleukin therapy for both psoriasis and 
PsA, and has set the benchmark for future rational anti-psoriasis drug design.  
 
 75 
1.7.1 Pharmacodynamics and Phamacokinetics of Ustekinumab 
Ustekinumab is a fully humanised IgG1κ monoclonal antibody that inhibits IL-12 and IL-
23 activity by binding with high affinity and specificity to their shared p40 subunit. IL-12 
and IL-23 bioactivity is therefore inhibited by preventing their binding to IL-12 receptor 
β1 (IL-12Rβ1) on the surface of immune cells (Janssen, 2012) .  
IL-12 and IL-23 are heterodynamic cytokines secreted by activated antigen presenting 
cells such as dendritic cells and activated macrophages in psoriatic lesional skin 
(Yawalkar et al., 2009). Both cytokines participate in immune functions; IL-12 stimulates 
natural killer (NK) cells and drives the differentiation of naïve CD4+ T cells into Th1 cells 
which produce IFN-γ and TNF-α (Murphy and Reiner, 2002), while IL-23 promotes the 
expansion of Th17 cells and the production of IL-17 and IL-22 (Langrish et al., 2005, 
Harrington et al., 2005). Abnormal regulation of IL-12 and IL-23 are highly implicated in 
the pathogenesis of psoriasis and PsA (Di Cesare et al., 2009, Lowes et al., 2008). 
Psoriasis and PsA have considerable genetic overlap and similar susceptibility loci 
(Hebert et al., 2012); IL-12β single nucleotide polymorphisms and variations in the IL-23 
receptor (IL-23R) are associated with susceptibility to both psoriasis and PsA (Filer et 
al., 2008).  
The pharmacokinetic properties of ustekinumab appear to be similar in patients with 
psoriasis and PsA in terms of mean values for apparent volume of distribution, clearance 
and absorption-rate constant (Zhu et al., 2010). The median time to reach the maximum 
serum concentration is 13.5 days and 7 days, after a single subcutaneous injection of 
ustekinumab 45mg or 90mg, respectively. Following multiple subcutaneous doses of 
ustekinumab, steady-state serum concentrations are achieved by week 28 after initial 
subcutaneous doses at weeks 0 and 4, followed by dosing every 12 weeks thereafter. 
There is no apparent accumulation in serum ustekinumab concentration over time when 
given subcutaneously every twelve weeks. The apparent volume of distribution for 
ustekinumab is reported in one psoriasis cohort as 161(+/-65)ml/kg for the 45mg dose 
and 179(+/-85)ml/kg for the 90mg dose. In terms of metabolism, the metabolic pathway 
of ustekinumab has not been characterised, but as a human IgG1k monoclonal antibody, 
it is expected to be degraded into small peptides and amino acids via catabolic pathways 
in the same manner as endogenous IgG. The mean systemic clearance of ustekinumab 
in patients with psoriasis following a single intravenous dose ranges from 1.90(+/-0.28) 
to 2.22(+/-0.63)ml/kg/day. The mean half-life ranges from 14.9(+/-4.6) to 45.6(+/-80.2) 
days across all studies following intravenous or subcutaneous administration (EMA, 
2009). 
Patient body mass and levels of anti-drug antibodies to ustekinumab significantly affect 
the pharmacokinetic properties (Zhu et al., 2010), although the clinical significance of 
such antibodies has yet to be determined (Hsu and Armstrong, 2013). Median systemic 
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clearance in patients with a body mass in excess of 100kg is approximately 55% higher 
compared to patients who weigh less than 100kg. Other variables, such as age, sex, 
race, smoking and alcohol consumption, disease duration and baseline PASI score show 
no significant effects on the volume of distribution or clearance values (Zhu et al., 2010, 
Zhu et al., 2013, EMA, 2009). In patients with PsA, concomitant use of NSAIDs, oral 
corticosteroids, methotrexate or prior TNF inhibitor use does not affect drug clearance 
(Janssen, 2012). 
In the UK, ustekinumab is supplied in pre-filled syringes. Each vial contains 45mg 
ustekinumab in 0.5ml of solution. The recommended posology is an initial dose of 45mg 
administered subcutaneously, followed by 45mg four weeks later, and then every 12 
weeks thereafter. In patients with a body weight in excess of 100kg, 90mg (two pre-filled 
syringes) should be used due to the higher rate of systemic clearance and lower volume 
of distribution (EMA, 2009). 
1.7.2 Ustekinumab in the Management of Psoriasis 
1.7.2.1 Phase I and II Clinical Trials in Psoriasis 
Reductions in lesional gene expression of IL-12p40, IL-23p19 and other inflammatory 
cytokines were observed as early as two weeks post treatment in the initial phase I 
studies, suggesting ustekinumab may have therapeutic potential in psoriasis (Gottlieb et 
al., 2007, Kauffman et al., 2004, Toichi et al., 2006). The drug was well tolerated and 
appeared to have low immunogenic potential. In some patients, a single intravenous or 
subcutaneous dose resulted in a pronounced clinical response that was sustained for 
16–24 weeks (Gottlieb et al., 2007, Kauffman et al., 2004, Toichi et al., 2006). These 
observations were followed by an initial phase II double-blind, placebo-controlled trial to 
assess dose response. 320 patients were randomised to one of five groups: placebo, 
one 45mg dose, one 90mg dose, four weekly 45mg doses or four weekly 90mg doses. 
Patients assigned to received ustekinumab received one additional dose at week 16 if 
their PGA was greater than three. Patients assigned to placebo crossed over at week 20 
to receive one 90mg dose of ustekinumab. The primary endpoint (PASI 75 response at 
week 12) was reached in all four active treatment groups (45 mg once only, 51.5%; 90mg 
once only, 59.4%; four weekly 45 mg doses, 67.2%; four weekly 90 mg doses, 81.3%) 
and reached statistical significance when compared to placebo (1.6%, p<0.001 for each 
comparison). Clinical responses were maintained out to week 24 before deterioration 
and were supported by substantial improvements in the Dermatology Life Quality Index 
(DLQI). Serious adverse events were not statistically higher in any group (Krueger et al., 
2007).  
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1.7.2.2 Phase III Clinical Trials in Psoriasis 
The safety and efficacy of subcutaneous ustekinumab were initially evaluated in three 
large randomised, controlled trials involving 2899 adult patients with moderate to severe 
psoriasis (defined as PASI >12, PGA ≥3 or BSA >10% BSA) of at least six months’ 
duration and who were eligible for treatment with a systemic immunosuppressant or 
phototherapy. Run in parallel, both PHOENIX I (ClinicalTrials.gov #NCT00267969) 
(Leonardi et al., 2008) and PHOENIX II (ClinicalTrials.gov #NCT00307437) (Papp et al., 
2008) were randomized, double-blind, placebo-controlled, multi-center trials with similar 
objectives, methods and outcomes (primary endpoint: PASI 75 at week 12). The third 
trial, ACCEPT (ClinicalTrials.gov #NCT00454584), shared the same primary endpoint 
but differed in that the efficacy of ustekinumab was compared to etanercept rather than 
placebo (Griffiths et al., 2010). The study design and primary outcomes for these trials 
are described in Table 1.15. 
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53% of patients recruited into PHOENIX I were either non-responsive to, intolerant of, or 
had a contraindication to other systemic therapy. Randomisation was stratified by study 
site, weight (≤90mg or ≥90mg) and the number of systemic therapies to which the patient 
had had an inadequate response, intolerance or contraindication (<3 or ≥3). Primary 
endpoint data can be found in Table 1.15. Re-randomisation occurred at week 40 and 
was again stratified according to study site and weight: 
• Participants that had achieved a PASI 75 response at weeks 28 and 40 were 
maintained on the same dose or given placebo until loss of response.  
• Participants that had achieved a partial response (defined as PASI 50-74) had 
their dosing interval shortened from 12 to 8 weeks.  
• Participants randomised to initially receive placebo crossed over to receive 
ustekinumab (45mg or 90mg) at week 12 and 16, followed by 12 weekly 
administration thereafter. 
This study design allowed not only comparison of ustekinumab with placebo, but also 
assessment of long-term efficacy, duration of therapeutic response after withdrawal and 
the effect of dose escalation in partial responders. 
Significant improvement in psoriasis severity was found at both active treatment arms at 
week 12 compared to placebo (p<0.0001). Improvement was rapid, regardless of dose, 
with many achieving PASI 50 by week 2. Efficacy was maximal at week 24 for both 
dosing regimens (76.1% and 85.0% PASI 75 for 45mg and 90mg respectively) and 
similar results were found in those initially treated with placebo after the same period of 
active therapy. 
After the second randomisation at week 40, preservation of PASI 75 response was 
significantly better at week 76 in those continuing on ustekinumab (84.0%) compared to 
those who were switched to placebo (19.0%). In the latter group, PASI scores began to 
deteriorate by week 44 (16 weeks after their last injection), and accelerated after week 
52, demonstrating that continuous therapy is required for sustained suppression of 
psoriatic skin inflammation. In total, 195 participants needed to restart treatment as their 
PASI improvement from baseline fell below 50%. 85.6% of these patients regained a 
PASI 75 response within 12 weeks of reinstating ustekinumab (Leonardi et al., 2008). 
Fingernail psoriasis was assessed in PHOENIX I using the Nail Psoriasis Severity Index 
(NAPSI) on a target fingernail, in addition to a nail PGA and assessment of the mean 
number of fingernails involved (Rich et al., 2014). Of the 766 patients randomised to 
participate, 545 (71.1%) had nail psoriasis at baseline. NAPSI scores were significantly 
improved from baseline as early as week 12 for both doses of ustekinumab compared 
with placebo (45mg, p<0.001 and 90mg, p=0.001). By week 24, the percentage 
improvement from baseline NAPSI score was 46.5% (95% CI 39.5-53.4) and 48.7% 
(95% CI 42.0-55.3) for ustekinumab 45mg and 90mg, respectively. Among patients 
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receiving placebo who crossed over to ustekinumab at week 12, by week 24, percentage 
improvements in NAPSI score were comparable with week 12 results for patients 
randomised to receive the active drug from baseline. Improvements in the less sensitive 
nail PGA scores were generally not observed in the nail psoriasis cohort at week 12; 
however, significant improvements were noted by week 24, with over 75% of participants 
with a PGA ≥3 achieving improvement by at least one point (Rich et al., 2014). 
In an extension arm to the PHOENIX I trial, patients were subsequently followed to week 
244 (5 years) in order to assess longer-term efficacy and safety (Kimball et al., 2013, 
Papp et al., 2013). 517/753 (68.7%) participants from the initial trial (who had received 
at least one dose of ustekinumab) were evaluated. Clinical responses were generally 
maintained through to week 244 (PASI 75: 63.4% and 72.0%; PASI 90: 39.7% and 
49.0%; PASI 100: 21.6% and 26.4% for 45mg and 90mg respectively) (Kimball et al., 
2013). Analysing 8998 patient years of follow up, adverse event rates were comparable 
between the two doses and no increasing trend was seen over time. Rates of overall 
mortality and malignancies were comparable with the general population in the United 
States (Papp et al., 2013). Per 100 patient years, adverse events were as follows (45mg, 
90mg respectively) (Kimball et al., 2013): 
• All adverse events: 220.92, 209.05 
• All serious adverse events: 5.26, 5.43 
• Serious infections: 0.84, 1.21 
• Non-melanoma skin malignancies: 0.65, 0.26 
• Other NMSC malignancies: 0.59, 0.38 
• Major Cardiovascular Adverse Events (MACE): 0.52, 0.13 
In PHOENIX II, 61% of patients were either non-responsive to, intolerant of, or had a 
contraindication to other systemic therapy. Overall, a significant improvement in PASI 
score was achieved by week 12 for both doses of ustekinumab (Table 1.15), although 
maximal efficacy was not reached until week 20 (45mg, 74.9% and 90mg, 83.5%), with 
similar outcomes seen in the placebo group after cross over to active therapy. The 
median response by the end of the study (week 52) was PASI 95 for those receiving 
45mg, and PASI 96 for those receiving 90mg ustekinumab. 
Secondary randomisation occurred earlier than in PHOENIX I, at week 28. Patients were 
categorised as responders (PASI 75 achieved), partial responders (PASI 50-74) or non-
responders (PASI <50). Patients who achieved PASI 75 by week 28 continued on the 
same dose 12-weekly, and maintained their improvement through to week 52.  Non-
responders discontinued therapy and partial responders were randomised to either 
continue their current regimen or reduce their dosing regimen to 8-weekly. Partial 
responders accounted for 22.7% of patients receiving the 45mg dose and 15.8% of those 
receiving 90mg from baseline. Compared to responders, patients in this group were of 
greater body mass, had more severe PGA scores, a longer duration of psoriasis, a 
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greater incidence of PsA, a higher failure rate with previous systemic 
immunosuppressant therapies and lower serum drug levels at week 28. Alteration of the 
dosing regimen in this group permitted analysis of the number of visits between weeks 
28 and 52 where PASI 75 response was achieved for the two different dosing schedules. 
For those receiving 90mg, a reduction in the dosing interval did equate to a greater 
number of visits where a PASI 75 was achieved, but this was not the case for those 
receiving 45mg every 8 weeks (Papp et al., 2008). 
In terms of safety, the PHOENIX I and II trials reported similar outcomes during the 
placebo-controlled phase. Adverse events occurred in 54.5% and 50.5% of patients 
receiving ustekinumab and 48.2% and 49.8% receiving placebo in PHOENIX I and II 
respectively. Serious adverse events occurred with a low frequency across groups in 
both studies (1.2% ustekinumab vs. 0.8% placebo in PHOENIX I; 1.6% ustekinumab vs. 
2.0% placebo in PHOENIX II). Anti-drug antibodies were mostly of low titre and were 
found in 5.1% of patients by week 72 in PHOENIX I and 5.4% of patients by week 52 in 
PHOENIX II (Papp et al., 2008, Leonardi et al., 2008). 
The ACCEPT trial differed from the PHOENIX trials in that efficacy was compared with 
the active biological therapy etanercept rather than placebo (Griffiths et al., 2010). 
Randomisation was again stratified according to study site and patient weight (<90mg or 
≥90mg). Patients in the etanercept group who did not respond (classified as moderate, 
marked or severe on the PGA) by week 12 (primary endpoint) were given a 90mg dose 
of ustekinumab at weeks 16 and 20, and those who did not respond in the ustekinumab 
arm were given one further additional dose of ustekinumab at week 16. No further doses 
were given to responders (classified as mild, minimal or clear) after week 12. Primary 
endpoint data can be found in Table 1.15. The time to improvement was more rapid in 
the ustekinumab treated group and a significantly higher number of patients achieved 
PASI 90 (36.4% ustekinumab 45mg; 44.7% ustekinumab 90mg; 23.1% etanercept) 
(p<0.001).  
Among the non-responders to etanercept, 48.9% achieved PASI 75 and 23.4% achieved 
PASI 90 12 weeks after cross over to ustekinumab. For those who were graded as 
responders to any therapy at week 12 and therefore had therapy withdrawn, the median 
time to recurrence was 14.4 weeks, 18.1 weeks and 7.3 weeks for ustekinumab 45mg, 
ustekinumab 90mg and etanercept, respectively. Of the 633 patients who were retreated 
after re-emergence of moderate to severe psoriasis, 534 (84.4%) were classed as having 
mild, minimal or no psoriasis within 12 weeks. 
In terms of safety, adverse events occurred with similar frequency across all three 
treatment arms. At least one adverse event occurred in 66.0% of patients receiving 
ustekinumab 45mg, 69.2% receiving ustekinumab 90mg and 70.0% receiving 
etanercept: 
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• Most adverse events were minor, with only four patients in each group 
experiencing a serious adverse event. 
• Discontinuation of therapy was necessary in similar proportions (ranging from 
1.2-2.3%). 
• Injection site reactions were noticeably more frequent in patients treated with 
etanercept (24.8%) compared to ustekinumab (4.3%, 45mg; 3.7%, 90mg), 
although the higher number of injections necessitated by the dosing schedule for 
etanercept must be taken into account (twice weekly compared to week 0, 4 and 
every 12 weeks thereafter for ustekinumab). 
• Infections occurred with a similar frequency in all three treatment arms: 
• 30.6% ustekinumab 45mg 
• 29.7% ustekinumab 90mg 
• 29.1% etanercept 
• NMSCs only occurred in patients treated with ustekinumab but with low frequency 
(3 patients by week 12 and a further 9 by week 64) (Griffiths et al., 2010). 
Several other small phase III clinical trials have assessed the efficacy and safety of 
ustekinumab in non-western populations and have reported similar clinical outcomes to 
the PHOENIX and ACCEPT trials. In the 36-week, multicentre, double-blind PEARL trial, 
121 Taiwanese and Korean patients with moderate-to-severe psoriasis were randomised 
to receive ustekinumab 45mg (week 0, 4 and 16) or placebo (week 0 and 4) followed by 
ustekinumab 45mg (week 12 and 16). PASI 75 was achieved by 67.2% in the 
ustekinumab treated group and 5.0% in the placebo arm at the primary end point of 12 
weeks (p<0.001). Efficacy was maintained by week 28 in the group treated with 
ustekinumab from baseline. Adverse events were similar in both groups, with no deaths, 
malignancies or MACE reported (Tsai et al., 2011). 
An identical study design was used in a 72-week, phase II/III clinical trial of 158 Japanese 
patients, but with the addition of third arm (ustekinumab 90mg). At the primary endpoint 
(week 12), 59.4% and 67.7% of patients treated with ustekinumab 45mg and 90mg 
respectively achieved PASI 75, compared with 6.5% of patients receiving placebo 
(p<0.0001). Rates of infections were comparable between groups (20.3%, ustekinumab 
45mg; 24.2%, ustekinumab 90mg; and 18.8% placebo).  Only single, isolated cases of 
serious infections and non-cutaneous malignancies were reported (both in the 
ustekinumab 90mg group), but no deaths, NMSC or MACE (Igarashi et al., 2012). 
1.7.2.3 Factors Influencing Clinical Response to Ustekinumab in 
Psoriasis 
HLA-Cw06 is widely accepted as the psoriasis susceptibility gene with the greatest 
effect. Latterly, observations have now suggested that this genetic polymorphism may 
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also serve as a pharmacogenetic marker to predict clinical response to 
immunomodulatory agents including ustekinumab (Warren and Griffiths, 2005). 
Ustekinumab efficacy has been shown to be superior in HLA-Cw06 patients (PASI 75 
response at week 12: 96.4% compared to 65.2% in HLA-Cw06 negative patients) by 
Talamonti and colleagues. The time to response was also faster, with 89.3% of HLA-
Cw06 positive patients achieving PASI 50 at week 4 (after a single dose) compared to 
60.9% of HAL-Cw06 negative patients. No significant association was found between 
clinical response and other psoriatic genetic markers studied (TNFAIP3rs610604 
polymorphism and LCE3B/3C gene deletion) (Talamonti et al., 2013). Genetic 
susceptibility can vary amongst different racial groups, however this finding has been 
replicated in Chinese patients with psoriasis (Chiu et al., 2014). A more modest 
improvement in PASI 75 repsonse (17.9%) between those who are HLA-Cw06 positive 
and negative was found in a larger retrospective analysis at week 12, with smaller 
differences still noted at later timepoints for PASI 90 (11.8% at week 24) and PASI 100 
(10.2% at week 28). This raises the possibility that the findings by Talamonti may have 
been an overestimation of the true effect (Li et al., 2016).  
Aside from genetic factors, obesity has been recognised as an important factor related 
to both the incidence and severity of psoriasis (Naldi et al., 2005). Obesity can induce 
overproduction of multiple proinflammatory cytokines in adipose tissue, including TNF-
α, IL-6 and IL-8, all of which are implemented in psoriasis pathogenesis (Hamminga et 
al., 2006). In patients enrolled into the PHOENIX I and II trials, those with a body mass 
greater than 100mg had a reduced efficacy to ustekinumab. The proportion of patients 
with a body mass less than or equal to 100kg achieving PASI 75 was 76.9% compared 
to 54.6% in those weighing more than 100kg at the 45mg dose, and 80.8% (≤100kg) 
compared to 74.2% (>100kg) at the 90mg dose. Serum drug concentrations were also 
affected by weight (Lebwohl et al., 2010b). Together these phase III findings provided 
adequate rationale for the higher dose to be subsequently licensed for patients whose 
weight exceeds 100kg. 
1.7.2.4 Quality of Life Studies in Psoriasis 
Quality of life indices were investigated in the PHOENIX I and II trials (Lebwohl et al., 
2010a, Langley et al., 2010) and a phase II/III trial by the Japanese Ustekinumab Study 
Group (Nakagawa et al., 2012), but not recorded in the ACCEPT trial (Griffiths et al., 
2010). 
In PHOENIX I, in excess of 97% of participants had a score of one or more on the DLQI 
at baseline, and the average score was greater than 10, indicating a significant impact 
on patients’ quality of life. A significantly greater proportion of patients treated with 
ustekinumab achieved normalisation of the DLQI (≤1) compared to placebo (53.2% 
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ustekinumab 45mg and 52.4% ustekinumab 90mg vs. 6.0% placebo; p<0.001 for all 
comparisons) by week 12. Similarly, impressive improvements were recorded in the 
Medical Outcomes Study Short Form 36 (SF-36) survey in terms of the mental (25.5% 
ustekinumab 45mg, 31.3% ustekinumab 90mg, 14.8% placebo) and physical (23.1% 
ustekinumab 45mg, 33.7% ustekinumab 90mg, 15.6% placebo) component scores, and 
like the DLQI responses, these improvements were maintained in ustekinumab-treated 
patients at week 52. Greatest normalisation was recorded in the social functioning and 
bodily pain domains (Lebwohl et al., 2010a).  
In PHOENIX II, the Hospital Anxiety and Depression Score (HADS) replaced the SF-36. 
Again, the high psychological impact of psoriasis was evident at baseline with 40.3% 
(45mg dose) and 26.7% (90mg dose) of patients receiving ustekinumab therapy 
reporting symptoms of anxiety and depression. 54.6% of patients scored ten or more on 
the DLQI. By week 12, the absolute mean reduction in DLQI was by 9.3 (+/- 7.1) points 
in the group dosed with ustekinumab 45mg, and by 10.0 (+/-6.7) points in the 90mg 
group compared to a reduction of only 0.5 (+/-5.7) points in the placebo arm. The 
proportion of patients with baseline symptoms of mild to severe anxiety decreased in 
both the ustekinumab 45mg and ustekinumab 90mg groups, from 38.2% to 25.7% and 
41.0% to 27.1% respectively (both p<0.01 vs. placebo). This represented a combined 
relative reduction of 34% from baseline by week 12, compared to a 1.4% increase in the 
placebo group. More impressive results were found in patients with mild to severe 
symptoms of depression at baseline, with a relative reduction of 55% from baseline in 
ustekinumab-treated patients compared to an increase of 10% in the placebo arm 
(Langley et al., 2010). 
In addition to the DLQI and SF-36, the Psoriasis Disability Index (PDI) was assessed in 
a cohort of 156 Japanese patients with psoriasis, treated with either ustekinumab or 
placebo (Nakagawa et al., 2012). The PDI examines the effect of psoriasis on five 
different aspects of patients’ quality of life: (i) daily activities; (ii) performance at work or 
school; (iii) personal relationships; (iv) leisure; and (v) treatment. A maximum score of 
45 indicates the greatest impairment. (Finlay and Kelly, 1987). Significant improvements 
in PDI scores from baseline to week 12 were observed in patients dosed with 
ustekinumab (45mg, 8.6+/-9.6; 90mg, 12.0+/-11.8) compared with placebo (-0.1+/-4.2) 
(p<0.0001 for both comparisons). Improvements in PDI scores were generally 
maintained through to week 64 in ustekinumab-treated patients, and those in the placebo 
arm who crossed over to receive ustekinumab at week 12 achieved improvements 
similar to those observed in the first 12 weeks in patients randomised to receive 
ustekinumab from baseline (Nakagawa et al., 2012). 
Looking more closely at the specific impairments in quality of life in patients with 
psoriasis, sexual difficulties appeared prevalent in patients recruited to the PHOENIX I 
and II trials. Impaired sexual function was recorded if any patient scored ‘very much’ or 
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‘a lot’ for question 9 of the DLQI. 27.1% of women and 20.8% of men reported sexual 
impairment at baseline, and this was significantly associated with psoriasis severity. 
Effective treatment with ustekinumab (at either dose) reduced the proportion of patients 
reporting sexual difficulties from 22.6% to 2.7% within 12 weeks, compared to no change 
in the cohort dosed with placebo (p<0.001 for all comparisons). A greater mean 
improvement in PASI score related to a greater reduction in sexual difficulties caused by 
psoriasis (Guenther et al., 2011). 
1.7.3 Ustekinumab in the Management of Psoriatic Arthritis and 
Enthesitis 
In 2013, marketing approval for ustekinumab was extended by the European 
Commission to include the treatment of PsA, in adults who have had an inadequate 
response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) 
therapies. In 2015, approval was granted by NICE for prescription in PsA in England and 
Wales, when treatment with TNF inhibitors are contraindicated or have failed to achieve 
an adequate response using the PsARC at 24 weeks. Identical to the license for chronic 
plaque psoriasis, ustekinumab was the first non-TNF-inhibitor to be granted marketing 
authority for use in PsA, finally providing an alternative treatment approach in those 
whom TNF inhibition had failed. In recognition of this position within the rheumatologists 
therapeutic armamentarium, the manufacturers undertook two similar phase III, multi-
centre, double-blind, placebo-controlled trials in PsA (McInnes et al., 2013, Ritchlin et 
al., 2014), with the second (PSUMMIT-2) addressing the issue of previous TNF-inhibitor 
exposure (Ritchlin et al., 2014). 
1.7.3.1 Phase I and II Clinical Trials in Psoriatic Arthritis 
The first phase II, double-blind, randomised, placebo-controlled and crossover study of 
ustekinumab in PsA was published in 2009 (Gottlieb et al., 2009). 146 patients with active 
PsA (defined as ≥3 swollen joints and either an elevated C-reactive protein (CRP) or 
morning stiffness lasting ≥45 minutes) and current psoriasis were recruited from the 
dermatology clinic. Random allocation took place into one of three groups: 
• Subcutaneous ustekinumab (63mg) at week 0, 1, 2 and 3 followed by placebo at 
weeks 12 and 16 (n=76). 
• Placebo at weeks 0, 1, 2 and 3, followed by ustekinumab at weeks 12 and 16 
(n=70). 
The primary endpoint was the percentage of patients achieving a 20% or greater 
improvement in the American College of Rheumatology (ACR20) criteria at week 12 
(Figure 1.8).  At week 12, 42.1% of patients treated with ustekinumab from baseline 
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achieved an ACR20 response compared to 14.3% of the placebo-dosed group. By week 
36, despite no further doses of ustekinumab for 33 weeks, three quarters of the former 
group retained their ACR20 response. In the group initially treated with placebo followed 
by ustekinumab at weeks 12 and 16, 45.0% achieved ACR20 by week 24. Median 
percentage improvement in morning stiffness at week 12 was 50% in the ustekinumab-
treated cohort compared to no change (0%) in the placebo group (Gottlieb et al., 2009). 
As patients in this study were recruited from dermatology, not rheumatology clinics, the 
population was not comparable with those of phase II and III trials of other TNF-inhibitors 
(adalimumab, etanercept and infliximab) in PsA. The baseline characteristics of these 
patients differed from those seen in trials conducted through rheumatology clinics largely 
in terms of concomitant medications. The number of patients in this study prescribed 
methotrexate and NSAIDs was low (20% and 50% respectively) compared to those 
recruited to trials involving TNF-inhibitors who were nearly all taking concomitant 
NSAIDs, oral corticosteroids and/or methotrexate. Safety outcomes were not reported. 
However, despite these considerations, this study did show that PsA patients appear to 
respond well to ustekinumab, supporting the progression to larger scale, phase III trials 
to investigate the efficacy and safety of ustekinumab in active PsA. 
1.7.3.2 Phase III Clinical Trials in Psoriatic Arthritis 
The 52-week PSUMMIT-1 trial (Clinicaltrials.gov#NCT01009086) included 615 TNF-
inhibitor naïve patients with active PsA (defined by ≥5 tender and ≥5 swollen joints and 
CRP ≥3.0mg/l) for six or more months (McInnes et al., 2013). Participants were 
randomised 1:1:1 to receive 45mg ustekinumab, 90mg ustekinumab or placebo at week 
0, 4 and every 12 weeks thereafter. Stratification between groups was based on weight 
(≤100 or >100kg) and baseline methotrexate use (yes or no). At week 16, patients with 
less than 5% improvement from baseline in both tender and swollen joint counts could 
escalate (placebo to 45mg ustekinumab, 45mg ustekinumab to 90mg ustekinumab, no 
escalation if already taking 90mg ustekinumab). Patients taking placebo who did not 
escape at week 16 crossed over to receive 45mg ustekinumab at week 24 and week 28, 
and 12-weekly thereafter. Concomitant drug use had to remain stable until week 52. The 
primary outcome measure was the percentage achieving ACR20 response at week 24. 
Significant differences between the groups, in favour of ustekinumab, were seen (22.8%, 
42.4% and 49.5% for placebo, ustekinumab 45mg and ustekinumab 90mg, respectively) 
(Table 1.16). Concomitant use of methotrexate appeared not to impact on efficacy 
(ACR20 rate with methotrexate 44.5%, without methotrexate 47.5%). Maximal efficacy 
was achieved at week 28.   
Of the patients with dactylitis at baseline, significantly lower proportions in the 
ustekinumab groups (45mg ustekinumab, 56.6%; 90mg ustekinumab, 55.8%) compared 
 87 
to placebo (76.1%) had digits with dactylitis at week 24 (p=0.0013, p=0.0050 and 
p=0.0038 respectively). Of patients with spondylitis at baseline, a significantly higher 
proportion in the ustekinumab groups achieved responses in the Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI) than in the placebo group.   
In terms of safety, at week 16, the proportions of patients experiencing adverse events 
were similar in the ustekinumab and placebo groups (41.8% vs. 42.0%). Nasopharyngitis 
(4.6%), upper respiratory tract infections (3.4%) and headache (3.4%) were the most 
common adverse events in ustekinumab treated patients.  The proportion of patients and 
type of adverse events did not differ in relation to concomitant methotrexate therapy. No 
opportunistic infections (including tuberculosis), death or malignancies were reported by 
the end of the trial (week 52), but three MACEs were reported in the ustekinumab groups 
in the first 30 weeks of treatment (McInnes et al., 2013).  
Reduction in the functional impact of PsA was also demonstrated in PSUMMIT-1. 
Improvements in HAQ-DI scores were significantly greater in patients given ustekinumab 
(median change -0.25) compared to those given placebo (no change, 0.00; p<0.001 for 
all comparisons). An improvement of 0.3 or more in HAQ-DI score is deemed clinically 
meaningful (Mease, 2004), and this was achieved by 47.7% and 28.2% of ustekinumab-
treated and placebo-treated patients respectively (p<0.0001). Significant improvements 
were also recorded in the summary scores of the SF-36 survey (both physical and mental 
components) and DLQI at week 24 in the ustekinumab group, with the exception of the 
mental component of the SF-36 for those treated with the 45mg dose which did not reach 
statistical significance (McInnes et al., 2013). 
A similar study design was employed in the PSUMMIT-2 trial, however, just over half of 
the 312 adult participants had prior TNF-inhibitor exposure. Of these, the majority had 
used more than one agent, with 70% having discontinued the drug(s) because of an 
inadequate response. The same primary endpoint as in PSUMMIT-1 (ACR20 rate at 
week 24) was achieved, with ustekinumab showing superior efficacy over placebo 
despite the more challenging population and smaller sample size. 43.7% of ustekinumab 
45mg-treated patients, 43.8% of ustekinumab 90mg-treated patients and 20.2% of 
placebo-treated patients achieved ACR20 at week 24 (p<0.001) (Table 1.16). 
 PSUMMIT-1 PSUMMIT-2 
 Week 12 Week 24 Week 24 (all patients) Week 24* 
 ACR20 ACR20 ACR50 ACR70 ACR20 ACR50 ACR70 ACR20 
Placebo 21 23 9 2 20 7 3 15 
UST 45mg 41 42 25 2 44 18 7 37 
UST 90mg 41 50 28 14 44 23 9 35 
Table 1.16 Percentage primary (ACR 20) and secondary endpoint (ACR 50/70) rates for 
PSUMMIT-1 and PSUMMIT-2 (*TNF experienced patients only) 
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As expected, response rates in patients in TNF-inhibitor experienced patients were 
inferior to TNF-inhibitor naïve patients, but still significantly better than placebo. By week 
24, ACR20 rates of 35.6% in ustekinumab treated patients compared to 14.5% for those 
receiving placebo. Again, outcomes were independent of concomitant methotrexate use, 
but not weight, with patients weighing over 100kg not responding as well in the 
ustekinumab 90mg group.  
In 127 patients with dactylitis at baseline, a greater improvement was noted in patients 
receiving ustekinumab 90mg compared to placebo, although this was not statistically 
significant. By week 52, a 95% median percentage improvement was seen in dactylitis 
scores in patients treated with ustekinumab. Similarly, BASDAI response rates were 
numerically, but not statistically, better in ustekinumab-treated than placebo-treated 
patients at week 24. 
By week 16, adverse events were reported in 61.8% of ustekinumab-treated and 54.8% 
of placebo-treated patients. Serious adverse events occurred in 0.5% and 4.8% of 
ustekinumab-treated and placebo-treated patients, respectively. By week 60, in patients 
treated with ustekinumab, serious infections were reported in two patients, two reported 
malignancies (breast cancer and cutaneous squamous cell carcinoma; both were TNF 
inhibitor experienced) and three patients experienced MACEs. There were no deaths 
and no cases of tuberculosis (Ritchlin et al., 2014). 
In terms of functional impairment, in PSUMMIT-2, improvements in HAQ-DI scores at 
week 24 were significantly greater among ustekinumab-treated than placebo-treated 
patients (p<0.001). A clinically meaningful change of 0.3 or more was reported in 34.0% 
of patients dosed with ustekinumab 45mg, 38.1% dosed with ustekinumab 90mg and 
16.3% dosed with placebo (p<0.01 and 0.001 respectively). Not surprisingly, changes 
from baseline in HAQ-DI were lower in TNF-inhibitor experienced patients compared to 
those who were biologic naïve. Changes in the SF-36 were not significantly different in 
terms of the mental component, but were for the physical component at week 24, with a 
change from baseline of 3.3 for all ustekinumab treated patients compared to 0.0 for 
those receiving placebo (p<0.01). The mean decrease in DLQI was 6 points for those 
treated with ustekinumab, resulting in 35.6% (45mg dose) and 42.6% (90mg dose) 
achieving a score of 0 or 1 at week 24 (compared to 11.1% of placebo-treated patients; 
p<0.001) (Ritchlin et al., 2014). 
To date, the only other available safety data for ustekinumab in PsA is found in meeting 
abstracts. Pooled analyses from trials of psoriasis and PsA were reported at the ACR 
meeting in 2013 (McInnes, 2013) and 2014 (Kalb, 2014). No worrying safety signals were 
raised for serious infections or malignancies. However, MACEs appeared to occur with 
greater frequency in those treated with ustekinumab, although confidence intervals did 
overlap with the placebo rates (rates of events per 100 patient years of exposure (95% 
CI): placebo 0 (0-1.69), ustekinumab 1.23 (1.40-2.87)). In a separate pooled analysis 
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from 2014, data from a two year period contradicts this increase, with no greater MACEs 
occurring at either dose (45mg or 90mg) of ustekinumab (Kavanaugh, 2014). 
Radiographic progression was subsequently reviewed in an integrated data analysis of 
PSUMMIT-1 and PSUMMIT-2 patients, in order to provide an adequate sample size 
(n=927). Using the PsA-modified Sharp van der Heijde (mSvdH) score (maximum score 
528), ustekinumab-treated patients (regardless of dose) showed less radiographic 
progression at week 24 compared to placebo-treated patients (p<0.02), and this was 
maintained out to week 52. However, the mean progression rates (change in mSvdH 
scores) were low across the whole cohort (0.4 for both ustekinumab groups, 1.0 for 
placebo) and the percentage of patients with a radiographic change score that was less 
than the smallest detectable difference was high (91.7%, ustekinumab 45mg; 91.9%, 
ustekinumab 90mg; 83.8% placebo). No data was available on new bone formation, a 
key radiographic change in PsA, as this is not included in the mSvdH score. A further 
limitation of the pooled analyses was the high rate of missing data (approximately 10% 
overall), especially in the group of TNF-inhibitor experienced patients in the placebo arm 
(Kavanaugh et al., 2014b).  
1.7.3.3 Ustekinumab in Psoriatic Enthesitis 
The majority of data for ustekinumab in the treatment of enthesitis is in the form of 
secondary endpoint analyses from clinical trials involving patients with established and 
active PsA. In the PSUMMIT-1 trial, 69.3% of ustekinumab 45mg-treated, 75.5% of 
ustekinumab 90mg-treated and 70.4% of placebo-treated patients had enthesitis at 
baseline. Entheseal tenderness was assessed at 15 body sites as part of the PsA-
modified MASES index, with mean baseline scores of 4 (placebo and ustekinumab 45mg 
groups) or 5 (ustekinumab 90mg group) sites involved. When compared to placebo at 
week 24, patients in the ustekinumab-treated groups had significantly greater 
improvements in enthesitis scores (45mg group p=0.0019, 90mg p<0.0001) (McInnes et 
al., 2013). Further improvements were seen by week 52 and week 100 (McInnes et al., 
2013, Kavanaugh, 2014) (Table 1.17). 
 Week 24 (% change) Week 52 (% change) Week 100 (% change) 
 Placebo 
U
ST 45m
g 
U
ST 90m
g 
Placebo to 
U
ST 45m
g 
U
ST 45m
g 
U
ST 90m
g 
Placebo to 
U
ST 45m
g 
U
ST 45m
g 
U
ST 90m
g 
PSUMMIT-1 0.00 -42.9 -50.0 -87.5 -79.2 -74.2 -87.1 -100 -100 
PSUMMIT-2 0.00 -33.3 -48.3 -33.3 -36.7 -60.0 N/A N/A N/A 
Table 1.17. Median percentage change from baseline in enthesitis score in PSUMMIT-1 
and PSUMMIT-2 clinical trials.  
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Similar proportions of patients had enthesitis at baseline in PSUMMIT-2 (70.2%, 69.9% 
and 72.4% for placebo, ustekinumab 45mg and ustekinumab 90mg, respectively). Again, 
the PsA-modified MASES was used to assess entheseal tenderness at 15 sites, with 
baseline scores of 4 (placebo), 6 (ustekinumab 45mg) and 5 (ustekinumab 90mg) in the 
different groups. Among the 221 patients with enthesitis, significantly lower proportions 
of ustekinumab-dosed, than placebo-dosed patients had residual enthesitis at week 24 
(all p<0.05) (Table 1.17). Patients treated with ustekinumab 90mg exhibited significantly 
greater reductions in their MASES at week 24 versus placebo (p<0.01). By week 52, the 
median percent reduction in enthesitis scores amongst ustekinumab treated patients 
was 50.0%. 
The ECLIPSA study is the only study to investigate enthesitis as a primary endpoint, in 
patients with active PsA.  This prospective, randomised-controlled, open-label study of 
47 patients compared the efficacy of treatment with ustekinumab (n=23) and TNF 
inhibitors (n=24) in completely clearing enthesitis at six months, as measured by the 
SPARCC index.  After six months, 17 out of 24 patients (70.8%) receiving ustekinumab, 
and 10 out of 26 (38.4%) receiving a TNF inhibitor, achieved a SPARCC score of 0. 
Logistic regression predicting enthesitis-free state of disease was significantly related to 
study treatment only, with patients receiving ustekinumab being more likely to show no 
signs of enthesitis at month six (OR=0.037; p=0.005) (Araujo et al., 2017).  
While limited, these data collectively support a role for the use of IL-23/IL-17 pathway 
inhibitors in patients with entheseal driven-disease, although further studies are needed 
with enthesitis as the primary endpoint, ideally with imaging as an outcome to support 
clinical assessment. There are no reported clinical trials or observations of ustekinumab 
efficacy in patients with subclinical enthesitis or very early psoriatic arthritis, although 
these data provide the basis for the hypothesis that early, asymptomatic entheseal 
disease may respond to ustekinumab, and may ultimately be able to limit the progression 
to symptomatic PsA. 
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Thesis Hypotheses and Aims 
Primary Care Cohort 
The detection of psoriatic arthritis among patients with psoriasis in primary care can be 
improved through the provision of educational material detailing the link between arthritis 
and skin disease, and through the use of a novel psoriatic arthritis screening 
questionnaire based on the most discriminate questions of existing tools. 
By inviting patients with psoriasis to attend for an assessment with a rheumatologist and 
dermatologist, this work aims to: 
i. Evaluate the effect of educational material on attendance rates for screening in 
primary care. 
ii. Prospectively test the performance of a novel psoriatic arthritis screening 
questionnaire in the primary care setting, compared against the current standard 
(Psoriasis Epidemiology Screening Tool; PEST). 
 
Secondary Care Cohort 
A significant proportion of patients with moderate-to-severe psoriasis have subclinical 
entheseal disease (compared with the general population), the inflammatory aspect of 
which can be attenuated through the use of skin-directed therapy with an IL-12/IL-23 
inhibitor. Subsequently, demographic and clinical parameters can be used to predict 
response.    
By studying treatment-naïve individuals presenting to secondary care for the 
management of moderate-to-severe psoriasis, this work aims to: 
i. Evaluate the role of grey scale and power Doppler ultrasound in the assessment 
of peripheral subclinical enthesopathy amongst asymptomatic patients and 
develop a comprehensive scoring system incorporating the entire synovio-
entheseal complex to quantify the burden of disease. 
ii. Explore the utility of whole body magnetic resonance imaging in quantifying 
subclinical enthesopathy in both the peripheral and axial skeleton. 
iii. Establish whether skin-directed therapy with ustekinumab impacts on the 
presence and severity of inflammatory and chronic damage abnormalities 
detected by both imaging modalities, and whether any demographic or clinical 
parameters influence therapeutic response within the musculoskeletal system.
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Summary of Thesis Chapters 
Chapter 1 aims to provide a comprehensive review of the literature relating to the 
presentation and pathogenesis of enthesitis and psoriatic disease, and appraise the 
available data regarding the detection and management of subclinical enthesopathy. 
Chapter 2 aims to determine the rates of undiagnosed PsA in a diverse primary care 
population and to test whether educational material explaining the risks of PsA improves 
the attendance of patients with psoriasis for screening. In addition, the two CONTEST 
questionnaires are prospectively tested alongside the PEST in this primary care cohort. 
Chapter 3 aims to assess the prevalence of subclinical enthesitis in new, asymptomatic 
patients presenting to the dermatology clinic for treatment of moderate-to-severe 
psoriasis, and to establish the pattern of inflammatory and chronic damage abnormalities 
to determine the feasibility of an ultrasound screening programme in secondary care. 
Chapter 4 aims to provide reference thresholds for entheseal thickness for those 
tendons where values have not been published, for use in a novel sonographic scoring 
system based on a consensus definition of enthesopathy. This scoring system is used 
to further assess the feasibility of using ultrasound for the detection of subtle 
abnormalities at the synovio-entheseal complex in asymptomatic patients with psoriasis 
compared to healthy volunteers. Finally, this chapter aims to assess the utility of the 
PEST questionnaire in a cohort of psoriasis patients with subclinical enthesitis and 
compares responses with clinical examination and ultrasound findings. 
Chapter 5 aims to assess if subclinical ultrasound abnormalities within the synovio-
entheseal complex alter in response to therapy with anti-interleukin (IL)-12/IL-23 p40 
monoclonal antibody therapy (ustekinumab), assessed at 12, 24 and 52 weeks. It also 
aims to test the feasibility of a large randomised controlled trial comparing ustekinumab 
with other treatment modalities for the management of subclinical psoriatic joint disease 
in patients with psoriasis. Further aims include the analysis of any correlation between 
clinical entheseal assessments, skin and nail outcomes and demographic details and the 
change in sonographic subclinical enthesopathy following ustekinumab therapy. 
Chapter 6 aims to analyse the utilisation of WBMRI to assess the extent, distribution, 
severity and type of inflammatory abnormalities and structural changes in both the 
peripheral and axial skeleton in asymptomatic patients with psoriasis, and compares 
those findings with a cohort of healthy volunteers. 
Chapter 7 aims to investigate the change in active inflammatory lesions and structural 
abnormalities in the axial and peripheral skeleton seen on WBMRI, following skin 
directed treatment with ustekinumab. 
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Chapter 2  
Identification of Undiagnosed Psoriatic Arthritis in Patients with 
Psoriasis in Primary Care 
2.1 Introduction 
In the UK, an estimated 1.82 million people have psoriasis and have consulted with their 
General Practitioner (GP) according to the Clinical Practice Research Datalink (CPRD), 
a large-scale primary care epidemiology database (Springate et al., 2017). Up to 30% 
will develop psoriatic arthritis (PsA), which can be heterogeneous in its clinical 
manifestations, including arthritis, enthesitis, dactylitis and axial disease (Christophers 
et al., 2010, Gelfand et al., 2005, Radtke et al., 2009). The majority of people with PsA 
have antecedent psoriasis (70%) (Gladman, 1998), but many cases of established PsA 
remain unidentified for some time despite presenting to primary care for skin directed 
treatment (Reich et al., 2009). Possible causes of this are patients’ lack of understanding 
of the link between skin and arthritis, the lack of musculoskeletal expertise in primary 
care and the incorrect assumption that symptoms are attributable to mechanical and 
degenerate-related pains and arthritis. It follows that a simple method of screening for 
PsA in people with psoriasis would enable earlier treatment, to prevent the development 
of progressive joint damage and functional limitation which has been shown to occur in 
the first few years of disease onset (McHugh et al., 2003, Kane et al., 2003, Gladman et 
al., 1990). This has been acknowledged in the most recent consensus guidelines for 
psoriasis from both the National Institute for Health and Care Excellence (NICE) and the 
Scottish Intercollegiate Guidelines Network (SIGN), who recommend annual screening 
for PsA including those followed up only in primary care (NICE, 2012, SIGN, 2001).  
Many patient-reported screening questionnaires for PsA have been developed, but they 
have not been widely adopted in clinical practice. NICE acknowledge that the optimal 
screening tool is not yet established, but based on available data, recommend the 
Psoriasis Epidemiology Screening Tool (PEST) (Ibrahim et al., 2009). In the CONTEST 
study, where three of the most frequently used screening tools were compared head-to-
head in a number of UK dermatology clinics, the PEST seemed to perform slightly better 
than the Psoriatic Arthritis Screening and Evaluation (PASE) and Toronto Psoriatic 
Arthritis Screen (ToPAS), but the specificity was much lower than in the development 
cohort (Coates et al., 2013).  Of the patients invited to take part in this study, only 70% 
responded to the questionnaires, and of those contacted for a rheumatological 
assessment, only 61% attended. This was despite a detailed patient information sheet 
explaining about the link between skin and arthritis and the rationale for the study. 
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Recently, a new questionnaire (‘CONTEST’) has been created incorporating the most 
discriminative items from the PEST, PASE and ToPAS questionnaires and tested 
retrospectively in similar secondary care PsA screening datasets in Utah and Dublin 
(Coates et al., 2014). Both the simple CONTEST questionnaire (questions only) and the 
CONTEST questionnaire with the addition of joint mannequin (to reflect that featured in 
the PEST questionnaire) performed better than the PEST questionnaire. It is not known 
how these questionnaires would perform in a primary care setting and if they would offer 
any advantage over the PEST. 
One of the main limitations of screening and identifying PsA is that many patients are 
unaware of the risk of PsA and the consequences of delayed diagnosis and treatment, 
and so do not immediately present to their primary care physician when joint symptoms 
develop. The opportunity to educate patients in secondary care is far more achievable 
than in primary care due to the regularity of follow up. Health promotion campaigns in 
both dermatology and rheumatology that have included the use of patient education 
leaflets have shown improvements in patient awareness and attendance for investigation 
and treatment (Tomlinson et al., 2004, Richard et al., 1999, Geller et al., 2006), but this 
has never been tested in psoriatic patients in the primary care setting. 
The aims of this chapter are to determine the rates of undiagnosed PsA in a 
socioeconomically diverse primary care population and to test whether educational 
material explaining the risks of PsA will improve the attendance of patients with psoriasis 
for screening. In addition, the two CONTEST questionnaires will be prospectively tested 
alongside the PEST in this primary care cohort, where a full spectrum of psoriatic disease 
activity can be found. 
2.2 Methods 
Ethical approval was granted by the National Research Ethics Committee (Reference 
13/NE/0058).   
2.2.1 Participant Recruitment 
Patients with psoriasis were identified from five primary care practices across Yorkshire 
with varied socio-economic backgrounds. The practices varied in size from 2908 to 
19850 patients (Table 2.2), and four of the five practices did not have any GPs with a 
special interest in either dermatology or rheumatology. The fifth practice had two GPs 
with an interest in dermatology.  Each surgery performed a database search to identify 
potential participants, and were eligible if they were aged 18 or over, had a diagnostic 
label of psoriasis (see below) but did not have a coexistent diagnosis of PsA, ankylosing 
spondylitis or rheumatoid arthritis.  A random sample was taken from each practice using 
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random number tables to select participants. Information regarding the study was posted 
by the surgery to those selected. Patients were randomised 1:1 to receive study 
information in isolation, or the study information with an educational leaflet about PsA 
(Figure 2.1).  The education leaflet was a brightly coloured, small folded card with stylised 
graphics depicting the ways in which PsA can present, with sources for further 
information. 
 
Figure 2.1. Psoriatic arthritis education leaflet sent with study information.  
Patients were asked to return a reply slip if they were willing to attend one visit at their 
GP surgery for an assessment by both a dermatologist (the candidate, LJS) and a 
rheumatologist (LC, PH or AM). Clinics were held in the evenings to aid attendance. The 
dermatologist and rheumatologist were blind to whether the patient had received the 
leaflet or not.  
2.2.2 Inclusion/Exclusion Criteria 
2.2.2.1 Inclusion Criteria 
• Age 18 years or older 
• Diagnostic label of psoriasis (Read code M161, x506Y or M16Y) 
• Able to attend the surgery for one evening visit 
Socioeconomic data of the registered patients at each prac-
tice were obtained from National Statistics on deprivation
with each practice given a decile score (range 1–10 where
level 1 represented the most deprived area and level 10 the
least deprived—Public Health England, National General
Practice Profiles). In our study, one practice had a deprivation
score of 3, one had a score of 7 and the rest had a score of 10.
Analysing the impact of the leaflet on response rates by
deprivation showed that there was a significant increase in
response with the leaflet for the practice with a deprivation
decile of 3 (response rate 30.4 vs 3.7%, p < 0.001), but there
was no significant difference identified in the other practices.
In the practice with the deprivation index of 7, there was a
numerical difference between the response rates (18.7 vs
10.7%) but it did not reach significance. Only 150 packs were
sent out at this practice.
Fig. 1 Educational leaflet sent with study information
Table 1 Response rates by leaflet
provision for individual GP
practices
Practice Deprivation
index
Information
given
No. of packs
sent
Response rate
(%)
Pearson chi
squared
p
value
A 10 Leaflet 54 29.6 0.044 0.835
No leaflet 54 31.5
B 3 Leaflet 46 30.4 13.21 <0.001
No leaflet 54 3.7
C 10 Leaflet 150 21.3 0.001 0.976
No leaflet 151 21.2
D 10 Leaflet 136 21.3 0.109 0.741
No leaflet 137 19.7
E 7 Leaflet 75 18.7 1.92 0.166
No leaflet 75 10.7
Clin Rheumatol
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2.2.2.2 Exclusion Criteria 
• Age less than 18 years 
• Diagnostic label of psoriatic arthritis (read code M160), ankylosing spondylitis 
(read code N100) or rheumatoid arthritis (read code N40) 
2.2.3 Data Collection 
Recruitment and data collection took place over twelve months (November 2013 to 
November 2014). Data relating to dermatological assessment was collected by the 
candidate (LJS), and rheumatological assessment by the assessing rheumatologist (LC, 
PH or AM), immediately on to a paper case report form (CRF).  Once written consent 
was obtained, two types of data were collected and recorded for research purposes: 
participant-reported data and clinical data. Participant-recorded data comprised of 
demographics, past medical and surgical history, history of skin and joint disease, family 
history, medications (current prescribed, over-the-counter and psoriasis-
specific/arthritis-specific medications, and any previous therapies), age of psoriasis 
symptom onset, areas ever affected by psoriasis, areas currently affected by psoriasis 
and current or previous musculoskeletal symptoms, diagnoses and treatments. 
Clinical data was collected to assess the type, distribution and severity of psoriasis, the 
severity of psoriatic nail disease and the presence of any clinical signs of psoriatic 
arthritis (joint swelling and/or tenderness, clinical enthesitis, dactylitis or axial disease). 
Data was transcribed from the paper case report forms (CRFs) into an encrypted, 
password-protected database stored on a secure drive within the University of Leeds. 
Paper CRFs are stored in a locked filing cabinet within a locked room within LIRMM, in 
accordance with the University’s Information Security Policy.   
2.2.4 Clinical Assessment 
Following informed written consent, patients were asked to self-complete a questionnaire 
booklet including the PEST questionnaire (Appendix 1) and two CONTEST 
questionnaires (Appendix 2), a Dermatology Life Quality Index (DLQI) (Appendix 3) 
(Finlay and Khan, 1994), a PsA Quality of Life (PsAQoL) questionnaire (Appendix 4)  
(McKenna et al., 2004) and  a Health Assessment Questionnaire (HAQ) (Appendix 5)  
(Fries et al., 1980). Consent was sought to use their clinical and questionnaire data for 
research purposes in addition to data storage.  
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2.2.4.1 Psoriasis Severity 
Patients were reviewed by a dermatologist (the candidate, LJS), and assessment 
included a detailed history regarding the duration of psoriasis symptoms, areas of 
involvement, family history of psoriasis and previous therapies used. Examination 
involved assessment of the type and pattern of psoriasis, calculation of the Psoriasis 
Area and Severity Index (PASI) (Fredriksson and Pettersson, 1978), modified Nail 
Psoriasis Area and Severity Index (mNAPSI) (Cassell et al., 2007) and body surface 
area (BSA).  Patients with moderate to severe skin or nail psoriasis were offered referral 
to secondary care for treatment if they wished. 
2.2.4.2 Psoriatic Arthritis 
Patients were independently assessed by a rheumatologist (LC, PH or AM) and any 
history of musculoskeletal symptoms was recorded in addition to any family history of 
PsA, plus any previous investigations and treatments. Clinical examination included an 
assessment of entheseal tenderness at sites covered by the Leeds Enthesitis Index (LEI) 
(Healy and Helliwell, 2008), Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) 
(Heuft-Dorenbosch et al., 2003) and Spondyloarthritis Research Consortium of Canada 
score (SPARCC) (Maksymowych et al., 2009b), dactylitis digit count and 68 tender and 
66 swollen joint counts. The Classification of PsA (CASPAR) criteria were applied to 
patients with features of inflammatory arthritis (Taylor et al., 2006). Patients with PsA or 
other symptomatic arthritis were offered a referral to secondary care if they wished.  
2.3 Statistical Analysis 
To compare the response rates according to the provision of the educational leaflet, it 
was assumed that a 20% difference in response rate would be of clinical significance 
(50% response without the leaflet, 70% with the leaflet). Using this 20% difference and 
a two-sided test, a sample size calculation was performed using an alpha level of 0.05 
and a beta of 0.9, which provided a sample size of 124 per group (248 in total). This was 
the number of screening invitations sent out to patients. Response rates to the leaflet 
were compared using Pearson’s c2 test.  
To examine the sensitivity and specificity of the CONTEST questionnaire in this new 
primary care cohort, a minimum sample size of 191 patients attending for examination 
was required. This was based on a minimum accuracy of 10% and a confidence interval 
of 95% and assuming a prevalence of 0.3.  This study therefore aimed to recruit a total 
of 191 participants from the minimum number of 248 invitations posted to eligible 
patients.  Receiver operator characteristic (ROC) curve analysis was used to assess the 
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PEST and CONTEST questionnaires using rheumatologist diagnosis as the gold 
standard. The sensitivity and specificity of potential cut points were examined. 
The relationship between specific anatomical sites of psoriasis and the presence of PsA 
were examined using Pearson’s c2 and Fishers exact test. An independent two-sample 
Mann-Whitney U test was used to assess the difference in psoriasis severity between 
those with and without PsA. Missing values were excluded. Analysis was performed 
using IBM© SPSS© version 22.0. 
2.4 Results 
2.4.1 Response to Invitation for Screening for Psoriatic Arthritis 
In total, it was necessary to post out 932 invitations to eligible patients from the five GP 
practices to recruit 191 participants who agreed to attend for assessment. The response 
rate to the study was considerably lower than predicted at 20.5%.  Response rates varied 
widely from 14.7% to 30.6% depending on the practice (Table 2.1). The response rate 
was not significantly higher when patients received the educational leaflet (22.8 vs. 
18.3%, p=0.088). 
Practice Deprivation Index 
Information 
Leaflet Provided 
No. of 
Invitations Sent 
Response 
Rate (%) p value 
A 10 
Yes 54 29.6 
0.835 
No 54 31.5 
B 3 
Yes 46 30.4 
<0.0001 
No 54 3.7 
C 10 
Yes 150 21.3 
0.976 
No 151 21.2 
D 10 
Yes 136 21.3 
0.741 
No 137 19.7 
E 7 
Yes 75 18.7 
0.166 
No 75 10.7 
Table 2.1. Response rates for individual GP practices based on educational leaflet 
provision. 
In terms of demographic and clinical factors, there were no significant differences 
between those who received the leaflet and those who did not. Median (IQR) age (59 
(55,62) vs 58 (55,61) years, p=0.821), duration of psoriasis (27 (23,31 vs. 27 (24,31) 
years, p=0.960), the presence of active psoriasis (58% vs. 55%) and subsequent 
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diagnosis of PsA following clinical examination (9% vs. 9%) were broadly similar in both 
groups. 
Socioeconomic data of the registered patients at each practice were obtained from Public 
Health England (PHE, 2017). National General Practice Profile statistics on deprivation 
were used to allocate each practice a decile score (range 1-10, where 1 represented the 
most deprived area, and level 10 the least deprived).  The deprivation index for surgeries 
included in this study ranged from 3 to 10 (Table 2.1). Analysing the impact of the leaflet 
on response rates by decile score, there was a significant increase in response from 
those who received the leaflet for the practice for the surgery in the most deprived area 
(response rate 30.4% vs. 3.7%, p<0.0001). No significant differences were identified in 
the other practices. In the practice with the deprivation index of 7, a descriptive difference 
was observed between response rates (18.7% vs. 10.7%), but it did not reach statistical 
significance. Only a small proportion of invitations were sent out from this practice (150 
of 932 in total) which may have been too few to detect a small but significant difference. 
2.4.2 Prevalence of Psoriatic Arthritis Amongst Patients in Primary 
Care 
Of the 191 patients attending for assessment, 169 (88.5%) were found to have current 
or previous psoriasis, with the remaining 22 (11.5%) being misdiagnosed or coded 
incorrectly. Other diagnoses include ichthyosis vulgaris, eczema, seborrhoeic dermatitis 
and actinic keratosis. The majority of patients had active psoriasis, but the severity was 
generally mild with a median PASI score of 2.6 (1.1, 5.4). Only twelve patients had a 
PASI score greater than 10, indicating moderate to severe psoriasis, and referrals were 
recommended to made to secondary care where appropriate. The majority of patients 
had chronic plaque psoriasis (79.2%), with the remainder having small plaque disease 
(9.0%), palmoplantar psoriasis (2.8%) and guttate psoriasis (1.4%). In terms of therapies, 
only 49.1% were currently using at least one active topical therapy. Four patients were 
currently under the care of a dermatologist, with two receiving narrowband UVB 
phototherapy, and two receiving oral treatment (acitretin/methotrexate). 
Previously undiagnosed PsA was identified in 17 (10.1%) of patients. 53.3% were found 
to have another musculoskeletal diagnosis, and 36.7% had no musculoskeletal 
problems. Alternative musculoskeletal diagnoses included osteoarthritis and mechanical 
joint pain (74 patients), tendinopathy (seven patients), gout (two patients), fibromyalgia 
(two patients), palindromic arthritis (one patient), Morton metatarsalgia (one patient) and 
joint hypermobility (one patient). Using data from the practices and correcting for the 
misdiagnosis of psoriasis, the estimated prevalence of PsA in the entire primary care 
cohort was 18.1% (95% C.I. 16.2-20.1%) (Table 2.2).  
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Practice A B C D E Total 
List Size (n) 2908 13300 19850 10102 9768 55928 
Patients coded as PsO (n) 118 360 433 450 313 1674 
Patients coded as PsO and PsA (n) 8 12 16 14 18 68 
Patients coded as PsA (n) 2 28 36 2 7 75 
Total coded as PsA (n) 10 40 52 16 25 143 
Patients seen in study (n) 333 16 64 56 22 191 
New PsA diagnosed (n) 3 1 4 7 2 17 
PsO misdiagnosis (n) 4 2 7 6 3 22 
Misdiagnosis rate of PsO (%) 12.1 12.5 10.9 10.7 13.6 11.5 
Correctly likely patients with PsO (n) 105 320 391 404 274 1494 
Corrected prevalence of PsO (%) 3.61 2.41 1.97 3.99 2.80 2.67 
Estimated PsA in Patients with PsO not seen (n) 7 19 20 47 24 117 
Total actual and predicted PsA (n) 20 60 76 70 51 277 
Estimated PsA prevalence in those with PsO (%) 18.9 18.1 19.4 17.4 18.7 18.5 
Table 2.2. The proportion and prevalence of patients in each practice diagnosed with 
psoriasis (PsO) and psoriatic arthritis (PsA) according to read code. 
 
The demographics of the 169 patients diagnosed with psoriasis are shown in Table 2.3. 
Looking at potential clinical predictors of PsA, the incidence of PsA was not significantly 
greater in those with disease of the scalp (p=0.701), retroauricular areas (p=0.359), 
gluteal cleft (p=0.762) or nail (p=0.394), possibly due to the small number of cases of 
PsA. No significant associations were observed between the presence of PsA and 
gender (p=0.872), median age (p=0.234), PASI score (p=0.986), mNAPSI score 
(p=0.987) or duration of psoriasis (p=0.863). 
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Psoriasis 
(n=169) 
Psoriatic 
Arthritis 
(n=17) 
Alternative 
MSK 
diagnosis 
(n=90) 
No MSK 
diagnosis 
(n=62) 
Male gender [n (%)] 83 (49.1) 8 (47.0) 41 (46.0) 34 (55.0) 
Age (years) [median(IQR)] 61.0 (48.0,68.0) 
52.0 
(47.5,62.5) 
61.0 
(50.0,69.0) 
62 
(46.8,68.3) 
PsO duration (years) [median (IQR)] 28.0 (14.0,39.5) 
30.0 
(19.5,43.0) 
30.5 
(13.3,43.0) 
25.0 
(12.5,37.0) 
Active PsO [n (%)] 144 (85.2) 12 (71.0) 75 (83.0) 57 (92.0) 
BSA (%) [median (IQR)] 3 (3,5) 5 (0,5) 3 (2,5) 5 (3,5) 
PASI [median (IQR)] 2.6 (1.1,5.4) 
2.5 
(0.0,5.5) 
1.8 
(1.0,3.6) 
3.6 
(1.3,5.9) 
Active nail disease [n (%)] 39 (23.1) 6 (35.0) 19 (21.0) 14 (23.0) 
mNAPSI score (median {IQR)] 16.0 (8.0,28.0) 
16.0 
(11.0,23.3) 
17.0 
(0.0,35.0) 
12.5 
(8.0,34.3) 
CASPAR criteria met (score ³3) [n (%)] 10 (5.9) 8 (47.0) 2 (2.0) 0 (0.0) 
CASPAR score ³2 [n (%)] 18 (10.6) 14 (82.0) 4 (4.0) 0 (0.0) 
No. of swollen joints (0-66) [median (IQR)] 0 (0.0,0.0)  1 (0.0,2.5) 0 (0.0,0.0) 0 (0.0,0.0) 
No. of tender joints (0-68) [median (IQR)] 0 (0,2.0) 1 (0.5,3.5) 1 (0.0,4.0) 0 (0.0,0.0) 
Active enthesitis [n (%)] 61 (36.1) 7 (41.0) 41 (46.0) 13 (21.0) 
Enthesitis score [median (IQR)] 2.0 (1.0,4.5) 
1.0 
(1.0,6.0) 
3.0 
(1.0,5.0) 
2.0 
(1.0,2.5) 
Active dactylitis [n (%)] 1 (0.6) 1 (6.0) 0 (0.0) 0 (0.0) 
Dactylitis score [median {IQR}] 1 1 0 0 
DLQI score [median (IQR)] 2.0 (1.0,5.0) 
3.0 
(1.0,4.3) 
2.0 
(1.5,5.0) 
2.0 
(1.0,5.0) 
PsAQoL score [median (IQR)]  1.0 (0.0,7.0) 
5.0 
(0.0,12.0) 
2.0 
(0.0,9.0) 
0.0 
(0.0,3.0) 
HAQ score [median (IQR)] 0.0 (0.0,0.4) 
0.4 
(0.0,0.6) 
0.0 
(0.0,0.5) 
0.0 
(0.0,0.0) 
PEST score [median (IQR)] 2.0 (1.0,3.0) 
2.5 
(1.8,4.0) 
2.0 
(1.0,4.0) 
1.0 
(0.0,2.0) 
CONTEST score without mannequin [median (IQR)] 2.0 (1.0,4.0) 
4.0 
(2.8,5.5) 
3.0 
(1.0,4.0) 
1.0 
(0.0,3.0) 
CONTEST score with mannequin [median (IQR)] 2.0 (1.0,5.0) 
4.0 
(3.5,6.5) 
3.0 
(1.0,5.0) 
1.0 
(0.0,3.0) 
Table 2.3. Demographics of the study participants with psoriasis (PsO), psoriatic arthritis 
(PsA), other musculoskeletal (MSK) diagnoses or no MSK problems.  
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Clinical enthesitis was common amongst patients with psoriasis, and did not discriminate 
between those with PsA (41.0%) and those with other musculoskeletal diagnoses 
(46.0%). 13% of patients without any musculoskeletal symptoms also had tender 
entheseal points. In the 17 patients with a diagnosis of PsA, three had a polyarthritis, 
eleven had oligoarthritis, two had pure axial disease, and one had symptomatic and 
clinically inflamed entheseal disease. Three patients with peripheral PsA also had axial 
involvement. 
Scores for quality of life indices were uniformly low, with the exception of the PsAQoL, 
which was noticeably higher in patients with PsA. One patient, who subsequently 
revealed he was unaware of the link between skin and joint disease, scored 12 out of 
20, highlighting the significant impact his symptoms are having on his quality of life and 
the need for urgent secondary care assessment and treatment. 
2.4.3 Performance of CONTEST Questionnaires in Primary Care 
Using ROC curve analysis, all three screening questionnaires showed a significant ability 
to identify PsA. The areas under the curve for the CONTEST questionnaires (with or 
without the mannequin) were marginally higher than that of the PEST, but no statistically 
significant differences were seen between any of the questionnaires (Figure 2.2).  
 
 
Figure 2.2. Receiver operator characteristic (ROC) curve analysis for the Psoriasis 
Epidemiology Screening Tool (PEST) and CONTEST questionnaires (with and without 
a joint mannequin). n=164 (missing data for five patients). 
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Examining the sensitivities and specificities for the different cut points in this cohort, 
optimal scores for the CONTEST questionnaires (with and without the joint mannequin) 
were 3 and 4 respectively.  A score ³3 is advised as the cut off for a diagnosis of PsA 
using the PEST questionnaire (Ibrahim et al., 2009), but a PEST score ³2 performed 
better in this cohort (Table 2.4). Using the validated cut off of 3, eight patients in this 
cohort had false negative results. Seven of eight of these patients answered ‘yes’ to the 
presence of a swollen joint, with the other questions being positive in only one patient 
each, leading to a score of 2 for most of these patients. Five of these participants had 
axial involvement, two of which had pure spinal disease, and the absence of questions 
in the PEST relating to axial symptoms may have accounted for these falsely negative 
questionnaires. However, despite specific questions on spinal pain, only one of these 
patients was identified by the CONTEST questionnaire.  
 
Questionnaire Score Area Under the Curve Sensitivity Specificity 
PEST 
2 0.652 0.824 0.449 
3 0.652 0.529 0.660 
4 0.652 0.235 0.816 
CONTEST 
(without joint 
mannequin) 
2 0.694 0.882 0.388 
3 0.694 0.765 0.565 
4 0.694 0.529 0.680 
5 0.694 0.353 0.816 
CONTEST 
(with joint 
mannequin) 
2 0.704 0.941 0.367 
3 0.704 0.765 0.531 
4 0.704 0.706 0.633 
5 0.704 0.412 0.735 
Table 2.4. Area under the curve, sensitivity and specificity for different cut points for the 
Psoriasis Epidemiology Screening Tool (PEST) and CONTEST questionnaires (with and 
without joint mannequin). n=164 (missing data for five patients). 
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50 patients had falsely positive PEST questionnaires. The majority of these (82.0%) had 
other MSK diagnoses, typically osteoarthritis or mechanical joint pain. Again, most 
patients reported swollen joints (96.0%). 78% reported having previously had a swollen 
and painful digit, 70% reported that they had previously been told they had arthritis, 70% 
reported heel pain, and 56% reported nail psoriasis. Within this group, the HAQ and 
PsAQoL scores were similar to those with PsA (median HAQ 0.25 (0.0,0.75); median 
PsAQoL 5.0 (0.0,12.0)), implying a significant burden of musculoskeletal disease on their 
quality of life. 
2.5 Discussion 
Within this primary care cohort across five diverse GP surgeries, the provision of an 
educational leaflet about PsA did not significantly alter the response rate to an invitation 
for PsA screening with the exception of the practice with the lowest deprivation index. 
There was a numerical suggestion of higher uptake in the second most deprived surgery 
(deprivation index 7) for those sent a leaflet, but the difference did not reach significance. 
Only 150 of a total of 932 invitations were sent from this practice, so this may represent 
a type II error.  
The anticipated response rate was 50/70% (no leaflet/leaflet), but only 18% (without) and 
23% (with leaflet) accepted the invitation for screening. The predicted response rate was 
based on previous study experience in secondary care, however, this was an unsolicited 
postal invitation, albeit from their primary care provider, where the patient may not have 
consulted for some time, or believe their psoriasis to ‘be not that bad’.  Patients in 
secondary care are typically seen on a more frequent basis, have more severe disease, 
are often more informed about their condition and have usually built a relationship with 
their treating dermatologist or rheumatologist, which is likely to improve response rates. 
Basing the sample size calculation on an assumed 50% response rate may have 
therefore underpowered the study and introduced a further type II error. 
The use of an educational leaflet does appear to have played a useful educational role 
in low socioeconomic areas. Traditionally, patients are less engaged in such areas and 
attendance for screening is poor. However, giving this information in an easy to read, 
cartoon format, particularly if given in person by a healthcare practitioner, may be a step 
forward towards identifying PsA in patients with psoriasis.  The response rate without the 
leaflet was only 3%, increasing to 30% with the leaflet, similar to the maximum response 
rate at any of the practices. 
The assumption that screening to identify undiagnosed PsA is worthwhile has not been 
formally assessed, but is based on several observational studies in which earlier 
diagnosis is associated with better disease outcomes (Gladman et al., 2011, Tillett et al., 
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2013). Indeed, in this cohort, a number of patients had significant symptoms that, 
reflected in their PsAQoL and HAQ scores, were clearly having a profound impact on 
their quality of life. Clearly, both patients and GPs need more awareness and education 
about the risks associated with undiagnosed PsA. Around 10% of patients with psoriasis 
had previously been diagnosed (and coded) with PsA, but an additional 10% were found 
to have undiagnosed PsA on examination. This is in keeping with a recent meta-analysis 
which found an overall prevalence of undiagnosed PsA in psoriasis patients of 15.5% 
(Villani et al., 2015). The problem is compounded by the fact that many patients with 
relatively mild psoriasis do not regularly see their GP, and are less likely to connect their 
joint symptoms with a small amount of psoriasis. Further education also appears 
necessary for GPs with regards to the diagnosis of psoriasis, with around 10% of this 
sample being incorrectly diagnosed (or miscoded). Similarly, it is likely that within the 
practices, some patients will have psoriasis but have not been coded as such, perhaps 
because they have not consulted with their doctor or have not had the correct diagnosis 
made, and therefore a limitation of this study is that some patients may have been 
inadvertently excluded.   
For those that have a diagnosis of psoriasis and do engage with their GP, national 
guidelines recommend annual screening for PsA (NICE, 2012, SIGN, 2001), although 
anecdotal evidence suggests this has not been widely adopted. These guidelines 
acknowledge that the optimal screening questionnaire has not yet been established, 
although recommend the PEST questionnaire based on available data. PEST was 
originally developed in a primary-care population and subsequently validated in 
dermatology clinics. The new CONTEST questionnaires (with and without the joint 
mannequin) were developed in two secondary care dermatology populations, and have 
not been previously tested in primary care. In this primary care population, all of these 
questionnaires were able to identify PsA, with no questionnaire significantly out-
performing the others. A much larger study would be required to identify a significant 
difference in the sensitivity and specificity of the questionnaires.   
Interestingly, the optimal cut points of all of the questionnaires seem to be lower in this 
cohort than in their development cohorts. ROC curve analysis identified a PEST score 
³2, rather than the advised cut off of ³3, to be most accurate in identifying PsA, although 
this was at the expense of specificity; given that 50 patients had false positive PEST 
questionnaires using the validated cut off of ³3, even more patients with mechanical joint 
pain, osteoarthritis and other MSK complaints would be incorrectly identified as having 
PsA using a cut off of ³2.  A number of these false positive patients answered ‘yes’ to 
the question relating to dactylitis, a PsA-specific presentation, suggesting that this 
question may need rewording. Of greater concern, the PEST questionnaire failed to 
detect PsA in two patients examined and diagnosed by a rheumatologist. Similarly, the 
CONTEST questionnaires, which contain at least two questions about spinal pain failed 
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to capture either of the only two patients with pure axial disease in the study, even when 
the cut-off was lowered from 4 to 3. 
With the inaccuracies of screening questionnaires for PsA highlighted in this and other 
studies (Coates et al., 2013, Haroon et al., 2013, Walsh et al., 2013a, Mease et al., 
2014b, Mishra et al., 2017), the question arises as to what other methods can be used 
to identify PsA amongst patients with psoriasis. One previous large retrospective 
population-based study identified a number of cutaneous clinical features associated 
with a higher likelihood of PsA including nail dystrophy, scalp lesions and 
intergluteal/perianal psoriasis (Wilson et al., 2009). However, no clinical predictors of 
PsA were identified in this cohort, but this is not surprising given that only 17 patients 
had PsA and the study was powered to assess the performance of the screening 
questionnaires rather than to look at the performance of PsA predictors.   
In terms of musculoskeletal examination, it is recognised that certain clinical features can 
help differentiate PsA from osteoarthritis, rheumatoid and other forms of arthritis 
(Helliwell and Wright, 1998). Included among these distinguishing clinical features is the 
presence of enthesitis. Entheses are widely distributed in the body, but the major 
entheses of the lower limb around the calcaneum provide the hallmark features of 
enthesitis in PsA and other spondyloarthropathies, which accounts for the question 
relating to heel pain in the PEST and CONTEST questionnaires (Ibrahim et al., 2009, 
Coates et al., 2014). Enthesitis is a classification criterion for PsA (CASPAR 
classification) (Taylor et al., 2006) and is now generally accepted as the primary 
pathological lesion in PsA (McGonagle et al., 1998a, McGonagle et al., 2002a). 
Enthesitis has therefore been proposed as an important domain of assessment and 
outcome in PsA (Gladman et al., 2007b), and is the basis of several examination indices, 
including the LEI (Healy and Helliwell, 2008), MASES (Heuft-Dorenbosch et al., 2003) 
and SPARCC (Maksymowych et al., 2009b) which were tested in this cohort. However, 
far from discriminating those patients with PsA from others with different musculoskeletal 
disorders, high levels of tender entheseal points were found in patients with mechanical 
joint pain or osteoarthritis (46%), and also in patients without a musculoskeletal diagnosis 
(13%), suggesting examination alone, especially for early disease, is insufficient. 
Imaging is the gold standard for the assessment of enthesitis, but is not widely available 
in primary care.  
The difficulties of capturing psoriasis patients for PsA screening in primary care, the 
limitations of clinical examination, and the problem of low specificity with screening 
questionnaires, have been highlighted in the findings of this chapter. Even the new 
CONTEST questionnaires, formulated from the best performing questions within existing 
tools, did not improve on the current recommendation of the PEST. PsA is a 
heterogeneous disease, and developing a questionnaire or examination technique to 
identify cases precisely, while excluding other causes of musculoskeletal pain, seems 
 
 
107 
problematic. It may well be the case that existing tools cannot be improved upon and the 
deficiencies should be accepted and acknowledged, and simply by promotion of their 
existence in national guidelines may serve to increase awareness of the link between 
skin and joints amongst GPs. In turn, education of psoriasis patients is also key to the 
earlier recognition and diagnosis of PsA, and the addition of a simple leaflet may be 
beneficial if provided in person by a healthcare provider, especially in lower 
socioeconomic areas. 
2.6 Conclusion  
Health promotion campaigns, including the use of educational leaflets, have previously 
shown improvements in health awareness and attendance for investigation. In this 
cohort, provision of educational material only had an impact in the most deprived 
practices. Low response rates to the invitation for screening made detection of any true 
impact difficult. In hindsight the study was underpowered, with sample size estimates 
incorrectly based on previous response rates in secondary care studies. 10.1% of cases 
of PsA identified among those that did attend were newly diagnosed. All three screening 
questionnaires analysed showed a significant ability to detect PsA, with the two 
CONTEST questionnaires (with and without joint mannequin) being marginally better 
than the PEST, although this difference did not reach statistical significance and 
therefore does not warrant a change in current practice. 
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Chapter 3  
Identification of Early Psoriatic Arthritis in Patients with 
Psoriasis in Secondary Care 
3.1 Introduction 
Psoriasis affects approximately 2% of the western population, and up to 30% will develop 
psoriatic arthritis (PsA) (Gelfand et al., 2005, Reich et al., 2009, Radtke et al., 2009, 
Christophers et al., 2010). The majority of patients will develop the skin manifestations 
of psoriatic disease first, and as such, dermatologists in the secondary care setting are 
often well placed to identify PsA as it develops. The recognition that PsA can lead to 
significant musculoskeletal damage and consequent functional limitation, disability and 
impairment to quality of life has modified the disease management approach and 
treatment paradigm. While outcomes can be variable, patients with psoriasis often 
experience progressive and irreversible joint damage over a relatively short period of 
time. PsA is erosive and deforming in 40-60% of untreated patients where joint damage 
has been seen to occur within the first few years after disease onset (McHugh et al., 
2003, Kane et al., 2003, Gladman et al., 1990). A window of opportunity is said to exist, 
whereby delay in first encounter with a rheumatologist for six months, or a diagnostic 
delay of greater than one year, can contribute to the development of peripheral joint 
erosions and worse long-term physical function (Haroon et al., 2014a). However, as 
discussed in the previous chapter, a lack of both patient and physician awareness of the 
link between the skin and arthritis has a profound negative impact on early diagnosis. 
The concept of ‘early PsA’ remains relatively new, and still lags behind the wealth of 
literature on early rheumatoid arthritis (RA) and the “window of opportunity” that exists to 
treat RA early in order to minimise disability (Quinn and Emery, 2003).  
Though the potential advantages of early diagnosis and effective management of PsA 
have been highlighted, in the absence of a predictive/diagnostic serological biomarker 
such as anti-citrullinated antibody in RA, identifying such patients early in the disease 
course remains a challenge. No association between the severity of skin disease and 
the likelihood of developing PsA has been found, making screening of this prevalent 
disease difficult at the population level. Another key problem is the wide clinical spectrum 
of PsA, which can include the synovial joints, entheses, dactylitis, axial skeleton and nails 
either concomitantly or in isolation. Furthermore, there are erratic temporal associations 
between the skin and joint disease, with psoriasis predating joint disease in 70%, 
occurring prior to skin disease in 15% and occurring concurrently in 15% of cases (Jones 
et al., 1994, McGonagle et al., 2011, Gladman et al., 1987). 
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Several screening questionnaires have been developed to assist dermatologists to 
identify patients with PsA amongst their psoriasis cohorts. However, the most widely 
used have been shown to have suboptimal sensitivity and specificity in head to head 
studies, identifying many cases of musculoskeletal disease rather than PsA specifically 
(Coates et al., 2013, Haroon et al., 2013, Mishra et al., 2017, Mease et al., 2014b, Walsh 
et al., 2013a). Where they do identify PsA, patients have often had symptoms for several 
years and the ‘window of opportunity’ is often missed.  
Despite the introduction of these questionnaires, the prevalence of undiagnosed PsA 
remains high in secondary care, estimated at 15.5% in one recent meta-analysis of 
published studies of newly diagnosed PsA in patients with psoriasis (Villani et al., 2015), 
although on review of dermatology patients within secondary care by a rheumatologist, 
some centres have reported finding up to 85% of cases of PsA within their psoriasis 
cohort were undiagnosed (Reich et al., 2009). Additional approaches are therefore 
desperately needed to try identify PsA much earlier in patients with psoriasis in order to 
target effective treatment strategies and prevent progressive joint damage. 
Identification of subclinical musculoskeletal disease, very early in the disease course, 
could play a vital role in the patients’ management. Histological analysis remains the gold 
standard, although is invasive and impractical outside of the research setting. Ultrasound 
has shown to be an effective means of detecting asymptomatic inflammation at the 
entheses and in surrounding structures, in addition to osseous destructions and new 
bone formation at various sites in patients with psoriasis (Naredo et al., 2011, Gutierrez 
et al., 2011, Gisondi et al., 2008, Balint et al., 2002, De Simone et al., 2011, Ozcakar et 
al., 2005, Moshrif et al., 2017, Acquacalda et al., 2015). However, given the wide clinical 
spectrum of joint involvement in PsA, very few studies have looked beyond more than a 
handful of sites. There are no published studies providing a comprehensive assessment 
of accessible entheses in the upper and lower limbs that could be used to guide a 
screening protocol for patients with psoriasis. This chapter aims to assess the prevalence 
of subclinical enthesitis in new, asymptomatic patients presenting to the dermatology 
clinic for treatment of moderate-to-severe psoriasis, and establish the pattern of 
inflammatory and chronic damage abnormalities to determine the feasibility of an 
ultrasound screening programme in secondary care. 
3.2 Methods 
This study was conducted in one centre (Chapel Allerton Hospital, part of Leeds 
Teaching Hospitals NHS Trust). Ethical approval was obtained from the National 
Research Ethics Committee (Reference 12/YH/0483) and the Medicines and Healthcare 
Products Regulatory Authority (Reference 16767/0264/001-0001).   
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3.2.1 Participant Recruitment 
Recruitment of patients was undertaken within the Leeds Centre for Dermatology at 
Chapel Allerton Hospital (Leeds Teaching Hospitals Trust). All new routine referrals from 
Primary Care to the Department of Dermatology were screened for a diagnosis of 
psoriasis as made by the patients’ General Practitioner. Referrals were excluded if the 
letter made reference to previous treatment with any systemic immunosuppressant, 
PUVA phototherapy or biologic agent. Similarly, any patients with a confirmed diagnosis 
of psoriatic arthritis were excluded. 
Adult patients (aged 18 and over) identified from the screening of referrals were booked 
into a dedicated psoriasis clinic. Within Leeds Teaching Hospitals NHS Trust, patients 
are routinely advised of their initial clinic appointment by standard NHS letter. Patients 
were booked under the named consultant (MDG) who is the Lead Clinician for the 
psoriasis service within the Trust, but the candidate (LJS) conducted all of the 
consultations. 
No modification was made to the initial clinical consultation, except for the addition of 
questionnaires and an invitation to participate in ultrasound screening of the peripheral 
joints. Questionnaires to screen for co-morbidities such as psoriatic arthritis and 
depression are recommended by the National Institute for Health and Care Excellence 
(NICE) and their use within these psoriasis clinics served as a pilot for guideline 
implementation and service improvement.  During the consultation, patients were 
informed about the link between psoriasis and psoriatic arthritis, asked about any joint 
symptoms and briefly examined for any clinical signs of the disease, as recommended 
by NICE. All patients completed a Dermatology Life Quality Index (DLQI) questionnaire 
in line with the current standard of the psoriasis clinic.  
Patients who were clinically eligible were offered the opportunity to undergo a brief (20-
30 minute) ultrasound scan of their peripheral joints. Whilst this is not routine practice, it 
did form part of a service development plan within the Trust. Findings from this study will 
form part of a pilot to see if there are any trends that may identify who should be targeted 
for ultrasound screening in future psoriasis clinics. Ideally, all psoriasis patients would 
undergo ultrasound screening of their joints, but the prevalence of psoriasis is such that 
this is not economically or logistically possible. To develop the service, a targeted 
approach is needed. 
Patients indicating a willingness to undergo an ultrasound scan of their peripheral joints 
were given a verbal explanation about the procedure and the potential findings. They 
were also provided with a generic leaflet about musculoskeletal ultrasound produced by 
the Department of Rheumatology within Leeds Teaching Hospitals NHS Trust. If they 
decided they would like to have the ultrasound, they were booked into the next mutually 
convenient appointment, usually within a week. Patients were reassured that if any 
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pathology was seen at ultrasound, a referral would be made to a Consultant 
Rheumatologist at Chapel Allerton Hospital.  
Written consent was obtained from all patients undergoing a screening ultrasound prior 
to the investigation. Consent was sought to use their clinical, questionnaire, serological 
and imaging data for research purposes in addition to data storage.  
3.2.2 Inclusion/Exclusion Criteria 
Male and female patients over the age of 18 with moderate to severe chronic plaque 
psoriasis (Psoriasis Area and Severity Index (PASI) ≥10) were included. They must have 
had psoriasis for a minimum of 12 months and not previously received treatment with 
any systemic immunosuppressant, PUVA phototherapy or biologic agent, which could 
have potentially had an impact on the musculoskeletal system. Patients with symptoms 
consistent with inflammatory arthritis, or who fulfilled the CASPAR criteria for psoriatic 
arthritis were excluded, as were patients with a diagnosis or symptoms of any other 
rheumatological disorder (Taylor et al., 2006). 
3.2.3 Data Collection 
Recruitment and data collection took place over two years (May 2013 – May 2015), 
through all four seasons to allow for natural variation in psoriasis severity related to 
outdoor ultraviolet levels. Data collection was solely carried out by the candidate (LJS) 
onto paper case record forms (CRF) and then transposed into encrypted password-
protected databases on the University of Leeds server for analysis within seven days. 
Paper record forms are stored in a locked filing cabinet within a locked room within 
LIRMM, in accordance with the University’s Information Security Policy.  All clinical data 
collection took place within the first visit, and imaging data collection within the 
subsequent visit. Two experienced musculoskeletal sonographers (LH and AJ) 
performed ultrasound scans within the Leeds Musculoskeletal Biomedical Research Unit 
(LMBRU) at Chapel Allerton Hospital. 
Once written consent was obtained, three types of data were collected and recorded for 
research purposes: participant-reported data, clinical data and imaging data. Participant-
recorded data comprised of demographics, skin type, social history (smoking, alcohol 
and employment), past medical and surgical history, history of skin and joint disease, 
family history, medications (current prescribed, over-the-counter and psoriasis-specific 
medications, and any previous psoriasis therapies), age of psoriasis symptom onset, 
areas ever affected by psoriasis, areas currently affected by psoriasis and current or 
previous musculoskeletal symptoms. 
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Clinical data was collected to assess the severity of psoriasis, the severity of any 
psoriatic nail disease, baseline observations (height, weight, blood pressure and heart 
rate) and the presence of any clinical signs of psoriatic arthritis (joint swelling and/or 
tenderness, clinical enthesitis or dactylitis). 
3.2.4 Clinical Assessment 
3.2.4.1 Psoriasis Severity 
Following on from a detailed history (see Data Collection above), patients were fully 
undressed (down to their underwear) and a full clinical examination conducted as would 
occur in a standard dermatology consultation. Clinical assessment included 
documentation of the anatomical location of psoriatic plaques, body surface area (BSA) 
involvement, PASI score and modified NAPSI score. Impact of psoriasis on quality of life 
was assessed using the patient-completed Dermatology Life Quality Index (DLQI) 
questionnaire. 
3.2.4.2 Psoriatic Arthritis 
While the patient was undressed for their skin examination, several entheseal sites were 
examined for tenderness. Direct pressure was applied with sufficient force to just blanche 
the examiners fingernail. Clinical examination was performed prior to ultrasound to 
prevent bias. The following sites were evaluated:  
• 1st and 7th costochondral joints 
• Supraspinatus insertion 
• Medial and lateral epicondyles of the humerus 
• Anterior and posterior superior iliac spines 
• Iliac crest 
• 5th lumbar process 
• Greater trochanter 
• Medial condyle of the femur 
• Quadriceps insertion at the patella 
• Inferior pole of the patella 
• Tibial tubercle 
• Proximal Achilles 
• Plantar fascia insertion 
These sites were chosen as they form part of commonly used clinical entheseal scores. 
The fingers and toes were assessed for any fusiform swelling or tenderness consistent 
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with dactylitis. All peripheral joints were examined for gross evidence of joint disease. All 
clinical assessments were performed by the candidate (LS).  
3.2.5 Laboratory Assessment 
To ensure that patients did not have rheumatoid arthritis or any other rheumatological 
disorder, a number of serological assessments were performed. 
• C-reactive protein (CRP) was measured by the standard nephelometry (mg/l). 
• Rheumatoid Factor was measured by nephelometry (IU/ml) 
• Anti-citrullinated peptide (Anti-CCP) antibody was measured by multiplex bead 
technology (bioplex) (U/ml) 
• Anti-nuclear antibody (ANA) was measured by indirect immunofluorescence 
using Hep-2 substrate and results were expressed in titres of 1/40 or higher. 
All of the tests above were measured using commercial kits in the hospital diagnostic 
laboratory. 
3.2.6 Ultrasonography 
Grey scale ultrasound and power Doppler (PD) examinations were performed by two 
dedicated research sonographers (AJ and LH) fully trained in musculoskeletal ultrasound 
using a Logiq E9 machine (General Electric, Wauwatosa, Wisconsin USA). The 
ultrasound equipment is maintained and optimised through regular servicing, routine 
calibration and quality assurance testing. This is in accordance with the Society of Motion 
Picture and Television Engineers (SMPTE), the manufacturers’ (General Electric) 
directions and the Leeds Teaching Hospitals NHS Trust Medical Physics department 
procedures. Adherence to these measures should result in a reduction of random error 
in the measurements. 
The sonographers were aware of the patients’ diagnosis of psoriasis but not aware of 
the findings from their history and clinical examination. Patients were asked not to 
communicate with the sonographer about their medical history during the examination. 
All joints and tendon insertions were examined using a multi-frequency linear probe at 
6-15MHz with a B-mode frequency of 12-15MHz. A multiplanar scanning technique was 
performed according to the indications provided by the EULAR guidelines for 
musculoskeletal ultrasound in rheumatology (Backhaus et al., 2001). The PD settings 
were standardised with a pulse repetition frequency of 0.5-0.8KHz, a colour mode 
frequency of 7.5-10MHz, a gain of 15dB and low wall filters. The colour gain was 
increased to the maximum level that did not generate PD signals under the bony cortex.  
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A broad range of anatomical sites were included with the aim of capturing very early 
psoriatic arthritis that may only affect one or two entheses, in addition to investigating 
which entheses are most commonly involved. The majority of published studies looking 
at subclinical enthesitis in patients with psoriasis have concentrated only on the large 
entheses in the lower limbs. Several peripheral upper and lower limb sites were scanned 
to look for entheseal pathology and associated bursitis in addition to synovitis of 
associated peripheral joints. Table 3.1. summarises the tendon entheses and 
corresponding bone insertion sites scanned and Table 3.2 lists the joints examined for 
synovitis.  
 
Anatomical Site Tendon Enthesis Bone Insertion Point 
Thumb 
Flexor pollicis longus Base of distal phalynx 
Extensor pollicis longus Base of distal phalynx 
Index Finger 
Flexor digitorum profundus Base of distal phalynx 
Extensor digitorum Base of distal phalynx 
Middle Finger 
Flexor digitorum profundus Base of distal phalynx 
Extensor digitorum Base of distal phalynx 
Ring Finger 
Flexor digitorum profundus Base of distal phalynx 
Extensor digitorum Base of distal phalynx 
Little Finger 
Flexor digitorum profundus Base of distal phalynx 
Extensor digitorum Base of distal phalynx 
Elbow 
Common extensor  Lateral epicondyle of humerus 
Common flexor Medial epicondyle of humerus 
Distal brachial triceps Olecranon process of ulna 
Knee 
Quadriceps  Superior pole of patella 
Proximal patellar Inferior pole of patella 
Distal patellar Anterior tibial tuberosity 
Foot and Ankle 
Peroneal brevis 5th metatarsal base lateral tuberosity 
Achilles Superior pole of calcaneus 
Plantar fascia Inferior pole of calcaneus 
Table 3.1. Tendon entheses and bone insertion sites scanned (grey scale and power 
Doppler assessments). 
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Limb Joint 
Upper Limb 
Wrist 
Elbow 
Thumb interphalangeal 
Thumb carpometacarpal 
Index finger distal interphalangeal 
Index finger proximal interphalangeal 
Index finger metacarpophalangeal 
Middle finger distal interphalangeal 
Middle finger proximal interphalangeal 
Middle finger metacarpophalangeal 
Ring finger distal interphalangeal 
Ring finger proximal interphalangeal 
Ring finger metacarpophalangeal 
Little finger distal interphalangeal 
Little finger proximal interphalangeal 
Little finger metacarpophalangeal 
Lower Limb 
Knee 
Ankle 
Table 3.2. Joints scanned for grey scale hypertrophy and power Doppler signal. 
All structures were examined in at least two perpendicular planes and care taken to 
obtain comparable contralateral views. Patients were positioned prone with the legs 
extended and feet over the end of the examination couch, with the ankle dorsiflexed to 
90 degrees to facilitate assessment of the Achilles tendon and plantar aponeurosis 
insertions (superior and inferior calcaneal poles, respectively). Examinations of the 
perineal brevis insertion at the fifth metatarsal base and associated functional entheses 
in the foot and ankle were performed in the supine position with the knee semi-flexed to 
30 degrees and the foot flat on the couch, as were assessments of the quadriceps tendon 
insertion (superior pole of the patella), patellar ligament origin (inferior pole of the patella) 
and the distal patellar tendon insertion (tibial tuberosity). The knee was then extended to 
a neutral position (in order to reduce vascular compression) to confirm the presence of 
any power Doppler signal seen in the semi-flexed position.  Assessment of the elbow 
tendon insertions occurred with patients seated sideways on the examination couch 
facing the sonographer. With their arms resting on a pillow, palms together in a prayer 
position and with the elbow flexed to 90 degrees, the common extensor tendon insertion 
was examined at the lateral epicondyle. Each arm was then fully extended and the 
forearm supinated to allow access to the medial epicondyle to assess the common flexor 
tendon enthesis. Finally, the palms were placed on the pillow with the fingers touching, 
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the arms were abducted to raise the elbows and the elbows brought forward to permit 
scanning of the distal brachial triceps tendon insertion at the radial tuberosity. With the 
elbows relaxed, the hands separated and the lateral border of the hand resting on the 
pillow, compartment 1 of the posterior wrist was scanned over the lateral wrist crease. 
The forearm was then pronated and the remaining compartments (2-6) were scanned 
with the palms resting on the pillow. This position was maintained for examination of the 
thumb extensor pollicis longus and finger extensor digitorum tendons, and then the 
hands turned to permit scanning of the thumb flexor pollicis longus and finger flexor 
digitorum profundus tendons with the palms facing upwards.   
3.2.6.1 Ultrasound Image Interpretation 
Ultrasound images were interpreted at the time of scanning for changes included in the 
OMERACT definition of enthesopathy (see Figure 3.1 below). The following entheseal 
parameters were assessed: 
• Tendon thickness at its bony attachment site 
• Hypoechoic change within the tendon at the bony attachment site 
• Power Doppler signal within the tendon at the bony attachment site 
• Calcification within the tendon at the bony attachment site 
• Enthesophytes arising around the tendon attachment site 
• Erosions arising within the bone around the tendon attachment site 
• Irregularities within the usually smooth bony cortex around the tendon attachment 
site  
 
Figure 3.1. OMERACT definition of enthesopathy (Wakefield et al., 2005). 
Synovitis was assessed using the OMERACT definition of synovial hypertrophy (see 
Figure 3.2 below). The following parameters were assessed: 
• Hypoechoic change within the intraarticular tissue 
• Power Doppler signal within the synovial intraarticular tissue 
OMERACT definition of enthesopathy: ‘Abnormally hypoechoic 
(loss of normal fibrillar architecture) and/or thickened tendon or 
ligament at its bony attachment (may occasionally contain 
hyperechoic foci consistent with calcification), seen in two 
perpendicular planes that may exhibit Doppler signal and/or bony 
changes including enthesophytes, erosions, or irregularity.’  
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Figure 3.2. OMERACT definition of synovial hypertrophy (Wakefield et al., 2005). 
All parameters were scored as 1 for present and 0 for absent. Abnormalities must be 
seen in two perpendicular planes (longitudinal and transverse) to be deemed present. A 
maximum score of 266 was possible for entheseal changes (7 parameters assessed in 
38 entheses – 19 per side), and a maximum score of 72 was possible for synovial 
changes (2 parameters assessed in 36 joints – 18 per side). The total entheseal score 
was composed of two sub scores – an inflammation score (maximum possible 114) and 
a chronic damage score (maximum possible 152). Scores were expected to be low as 
patients were included on the basis of no known rheumatological disease and no 
persistent symptoms in keeping with a diagnosis of psoriatic arthritis. 
3.3 Statistical Analysis 
Categorical data are expressed as frequencies, and continuous variables are given as 
means (standard deviation, s.d.) or medians (interquartile range, IQR), depending on the 
distribution. Correlations between demographic (age, skin type, BMI, smoking history, 
alcohol consumption) and clinical parameters (age of psoriasis onset, duration of 
psoriasis, PASI, BSA, mNAPSI, DLQI) were analysed by Spearman rank correlation or 
rank biserial rb (Somers D) depending on the type of data analysed; absolute rho values 
>0.3 and d values >0.4 are considered to indicate substantive correlation. For categorical 
variables (gender, family history of psoriasis, anatomical location of psoriasis plaques, 
presence/absence of ultrasound inflammation), associations were explored using 
Student’s t-tests, Mann-Whitney U tests or Pearson’s c2 tests according to whether the 
associating variable was normally-distributed interval-scaled data, skewed interval or 
ordinal data, or categorical data respectively. p values <0.05 were regarded as 
statistically significant. Statistical analysis was performed using IBM© SPSS© version 
24.0. 
 
 
 
OMERACT definition of synovial hypertrophy: ‘Abnormal 
hypoechoic (relative to subdermal fat, but sometimes may be 
isoechoic or hyperechoic) intraarticular tissue that is non-
displaceable and poorly compressible and which may exhibit 
Doppler signal.’  
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3.4 Results 
3.4.1 Patient Characteristics 
75 patients with moderate to severe psoriasis were approached, of which 73 agreed to 
undergo a brief ultrasound of their peripheral joints and consented for their data to be 
used for research purposes. Two declined due to holiday commitments within the two 
weeks following their consultation. 
Of the 73, 45 were male and 28 were female. The age of participants ranged from 18 to 
74 years, with a median of 40 years. Mean BMI was 28.7(5.70)kg/m2. The majority of 
patients were Caucasian (skin type I, n=8; skin type II, n=40, skin type III, n=22), with 
three patients being of Asian or Afro-Caribbean ethnicity (skin type IV=0, skin type V=2, 
skin type VI=1). The age of onset of psoriasis symptoms varied greatly from 4 years to 
60 years, with a median of 18 years. 60 patients had type I psoriasis (i.e. onset prior to 
the age of 40 years) and 13 had type II psoriasis (i.e. onset from 40 years or older). 
Participants had had psoriasis symptoms for an average [median(range)] of 14 (1-55) 
years. 43 participants had a family history of psoriasis, and 9 had a family history of 
psoriatic arthritis. Median PASI score was 17.6 (10.0-56.3) and BSA 20% (10-80%). 46 
patients (63%) had nail involvement with a median mNAPSI score of 16 (2-89) out of a 
possible maximum of 140. Every participant had a positive DLQI questionnaire, with a 
mean total of 15 (7.65) out of a possible maximum of 30.  
Despite not reporting any musculoskeletal symptoms, and all having a PEST score of 
two or less, 11 (15.1%) of 73 patients examined had tender entheseal points clinically. 
All 11 had evidence of entheseal inflammation on ultrasound at the corresponding site. 
No patient with a negative ultrasound had tender entheseal sites on clinical examination. 
The number of sites found to be tender on clinical examination was 1 in six patients, 2 in 
three patients, 4 in one patient and 12 in one patient.  These scores were too low to 
warrant calculation of formal entheseal indices such as the Maastricht Ankylosing 
Spondylitis Enthesitis Score (MASES) for comparison. 
Patient characteristics in all 73 cases were further studied dependant on whether the 
patient had a ‘positive’ or ‘negative’ ultrasound. As these chronic changes can occur as 
a result of trauma, repeated stress from heavy exercise or load bearing (e.g. through 
occupation) and as part of the ageing process, only those with abnormally hypoechoic 
or thickened entheses (with or without power Doppler signal) were classified as having 
a positive ultrasound scan and active subclinical enthesitis.  
44 (60.3%) of 73 patients scanned had at least one abnormality on ultrasound, although 
of these 44, only 36 (49.3%) had changes in keeping with inflammatory enthesopathy 
(i.e. abnormally hypoechoic and/or thickened tendon at its bony attachment, with or 
without power Doppler signal). The remaining 8 patients had evidence of chronic damage 
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(entheseal calcification, enthesophytes, bone erosions and/or bone cortex irregularities) 
but no changes in keeping with active entheseal inflammation.  
Patients with a positive ultrasound (i.e, abnormally hypoechoic and/or thickened tendon 
at its bony attachment, with or without power Doppler signal) were older than patients 
without subclinical enthesitis (p<0.001), and also are likely to have never smoked 
(p=0.005). No differences were seen in terms of gender, skin type or amount smoked if 
ever a smoker or alcohol consumption. Patients with inflammatory abnormalities on 
ultrasound were slightly heavier, although this difference did not reach statistical 
significance (Table 3.3.).   
Characteristic Positive US (n=36) 
Negative 
US (n=37) Difference 
Gender [n (%)] 
Male 20 (55.6%) 25 (67.6%) p=0.291 
Female 16 (44.4%) 12 (32.4%) NA 
Age (years) [Median (IQR)] 50 (37-58) 31 (23-42) p<0.001 
Skin Type [n (%)] 
I 4 (11.1%) 4 (10.8%) p=0.715 
II 18 (50.0%) 22 (59.5%) NA 
III 13 (36.1%) 9 (24.3%) NA 
IV 0 (0%) 0 (0%) NA 
V 1 (2.8%) 1 (2.7%) NA 
VI 0 (0%) 1 (2.7%) NA 
BMI (kg/m2) [Mean (s.d.)] 30.0 (5.6) 27.5 (5.6) p=0.059 
Smoking Status [n (%)] 
Never 17 (47.2%) 10 (27.0%) p=0.005 
Current 8 (22.2%) 22 (59.5%) NA 
Previous 11 (30.6%) 5 (13.5%) NA 
Ever 19 (52.8%) 27 (73.0%) p=0.074 
Cigarette pack years (years) [Median (IQR)] 1.75 (0-21) 4 (0-19) p=0.587 
Alcohol consumption (units per week) [Median (IQR)] 10 (10-20) 10 (5-33) p=0.945 
Table 3.3. Comparison of demographic characteristics between psoriasis patients 
categorised according to ultrasound outcome. p<0.05 denotes significance. (US: 
ultrasound; NA: not applicable; IQR: interquartile range; s.d.: standard deviation). 
3.4.2 Skin and Nail Disease Characteristics 
Table 3.4 summaries the differences in psoriasis duration and severity, lesion distribution 
and impact on quality of life between patients with and without evidence of inflammatory 
subclinical enthesitis on ultrasound. No statistically significant differences were found 
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between the two groups. The duration of psoriasis symptoms was marginally longer in 
patients with inflammatory abnormalities on ultrasound (17 years vs. 13 years), but did 
not reach statistical significance (p=0.149).  This was despite patients with an abnormal 
(positive) ultrasound being of older age at symptom onset (28.5 years vs, 19.4 years, 
p=0.05).  
Characteristic 
Positive US  
(with inflammatory 
changes)  
(n=36) 
Negative US 
(normal/chronic 
changes only)  
(n=37) 
Difference 
Age at psoriasis onset (years) 
[Mean (s.d.)]  28.5 (15.86) 19.4 (10.55) p=0.050 
Duration of psoriasis symptoms (years) 
[Median (IQR)] 17 (7.25-29.25) 13 (4.5-22.0) p=0.149 
Positive family history of psoriasis 
[n (%)] 20 (55.6%) 23 (62.2%) p=0.566 
Positive family history of PsA 
[n (%)] 5 (13.9%) 4 (10.8%) p=0.689 
PASI Score 
[Median (IQR)] 17.1 (11.9-25.4) 18.5 (11.8-25.5) p=0.903 
BSA (%) 
[Mean (s.d.)] 28.6 (19.24) 27.5 (16.19) p=0.784 
mNAPSI Score 
Median (IQR) 8 (0-29.5) 6 (0-23) p=0.575 
DLQI Score 
Median (IQR) 15.5 (10.3-22.0) 15.0 (10.5-21.0) p=0.916 
Nail involvement 
[n (%)] 
Current 23 (63.9%) 23 (62.2%) p=0.879 
Ever 23 (63.9%) 24 (64.9%) p=0.931 
Scalp involvement  
[n (%)] 
Current 30 (83.3%) 33 (89.2%) p=0.467 
Ever 36 (100%) 36 (97.3%) p=0.572 
Retroauricular involvement  
[n (%)] 
Current 25 (69.4%) 30 (81.1%) p=0.249 
Ever 31 (86.1%) 33 (89.2%) p=0.689 
Gluteal cleft involvement 
[n (%)] 
Current 22 (61.1%) 21 (56.8%) p=0.705 
Ever 27 (75.0%) 29 (78.4%) p=0.733 
Umbilical involvement 
[n (%)] 
Current 13 (36.1%) 17 (45.9%) p=0.393 
Ever 23 (63.9%) 23 (62.2%) p=0.879 
Facial involvement 
[n (%)] 
Current 15 (41.7%) 15 (40.5%) p=0.922 
Ever 22 (61.1%) 19 (51.4%) p=0.401 
 121 
Characteristic 
Positive US  
(with inflammatory 
changes)  
(n=36) 
Negative US 
(normal/chronic 
changes only)  
(n=37) 
Difference 
Upper limb involvement 
[n (%)] 
Current 35 (97.2%) 37 (100%) p=0.539 
Ever 36 (100%) 37 (100%) p=0.984 
Dorsal hand involvement 
[n (%)] 
Current 19 (52.8%) 23 (62.2%) p=0.417 
Ever 23 (63.9%) 27 (73.0%) p=0.404 
Trunk involvement 
[n (%)] 
Current 35 (97.2%) 35 (94.6%) p=0.572 
Ever 35 (97.2%) 36 (97.3%) p=0.984 
Lower limb involvement 
[n (%)] 
Current 35 (97.2%) 37 (100%) p=0.539 
Ever 36 (100%) 37 (100%) p=0.984 
Flexural involvement 
[n (%)] 
Current 18 (50.0%) 17 (45.9%) p=0.729 
Ever 23 (63.9%) 20 (54.1%) p=0.393 
Genital involvement 
[n (%)] 
Current 11 (30.6%) 14 (37.8%) p=0.512 
Ever 16 (44.4%) 20 (54.1%) p=0.411 
Perianal involvement 
[n (%)] 
Current 5 (13.9%) 9 (24.3%) p=0.258 
Ever 10 (27.8%) 16 (43.2%) p=0.168 
Involvement of the palms 
[n (%)] 
Current 6 (16.7%) 3 (8.1%) p=0.266 
Ever 7 (19.4%) 6 (16.2%) p=0.719 
Involvement of the soles 
[n (%)] 
Current 6 (16.7%) 5 (13.5%) p=0.782 
Ever 9 (25.0%) 4 (10.8%) p=0.113 
Table 3.4. Comparison of skin and nail disease characteristics between psoriasis 
patients categorised according to ultrasound outcome. p<0.05 denotes significance. 
(BSA: Body Surface Area; PASI: Psoriasis Area and Severity Index; mNAPSI: modified 
nail psoriasis area and severity score; DLQI: Dermatology Life Quality Index; US: 
ultrasound; IQR: interquartile range; s.d.: standard deviation). 
3.4.3 Serological Characteristics 
There were very few serological abnormalities in all 73 patients, and no significant 
differences were identified between the group with and the group without positive 
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ultrasound findings. CRP was elevated above the standard cut off of <10.0mg/l in 5 
patients, three of which were within the group with no sonographic abnormalities. The 
highest measurement in all patients was marginally elevated at 15.4mg/l, indicative of a 
very low level of inflammation. All patients with a slightly elevated CRP reported 
symptoms consistent with an acute, self-limiting viral or bacterial illness such as an upper 
respiratory tract infection in the preceding month. 
ANA was positive at low titre in only one patient (positive ultrasound group) as was 
Rheumatoid Factor (27iu/ml – upper limit of normal <20iu/ml) (negative ultrasound 
group). Anti-CCP antibody was normal in all patients. Little difference was found in the 
number of patients with elevated plasma viscosity (PV) levels, with six in the positive 
ultrasound group, and five in the negative ultrasound group. 
3.4.4 Ultrasound Characteristics 
3.4.4.1 Entheseal Changes 
In total, 2774 entheses were scanned in 73 patients (38 per patient) with moderate to 
severe psoriasis. 44 patients had at least one entheseal change (either inflammatory, 
chronic or both) on ultrasound and in these, a total of 640 abnormalities were seen, 
equating to 23.1% of entheses scanned being abnormal (Table 3.5). Frequencies of 
these abnormalities are as follows (in descending order):   
• Entheseal thickening in 264 entheses (9.5%) 
• Enthesophytes in 97 entheses (3.5%) 
• Hypoechogenicity in 92 entheses (3.3%) 
• Calcifications in 72 entheses (2.6%) 
• Bone cortex irregularities in 61 entheses (2.2%) 
• Power Doppler signal in 5 entheses (0.2%) 
• Bone erosions in 5 entheses (0.2%) 
In total, inflammatory lesions (thickening, hypoechogenicity and power Doppler signal) 
were identified in 13.0% of all entheses scanned, whereas chronic entheseal 
abnormalities (enthesophytes, calcifications, bone erosions and bone cortex 
irregularities) occurred in 8.5%. Figure 3.3 and Figure 3.4 demonstrate these 
abnormalities within participants.  
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Figure 3.3. Entheseal thickening (, grade 2), hypoechogenity (Õ, grade 2), calcification 
(, grade 2), bone cortex irregularities and enthesophytes (, grade 1) in the right 
proximal patellar tendon enthesis of an asymptomatic patient with moderate-to-severe 
psoriasis. PT: Patellar tendon; Pat: Patella; Tib: Tibia. 
 
Figure 3.4. Entheseal thickening (, grade 2), hypoechogenity (Õ, grade 1) and power 
Doppler signal (red) in the left common extensor tendon enthesis of an asymptomatic 
patient with moderate-to-severe psoriasis. CET: Common extensor tendon; LE: Lateral 
epicondyle. 
Burseal hypertrophy occurred in 3 of 730 (0.4%) bursae scanned (in 5 sites bilaterally 
per patient) (Figure 3.5). 
 
Figure 3.5. Right deep infrapatellar burseal hypertrophy (B) associated with proximal 
patellar tendon entheseal thickening (, grade 2), hypoechogenicity (Õ, grade 2), 
calcification (, grade 1) and bone cortex irregularities (grade 1) in an asymptomatic 
patient with moderate to severe psoriasis. PT: Patellar tendon; Pat: Patella. 
Pat Tib
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In the 36 patients with a positive ultrasound, inflammatory enthesopathy scores ranged 
from 1 to 19, with a median (interquartile range, IQR) of 6 (2-11) out of a possible 114. 
Chronic damage changes were rarely seen without accompanying signs of active 
inflammation. 8 (11.0%) of the 44 patients with at least one lesion on ultrasound had 
signs of chronic damage only, with the remaining 36 of 44 (81.8%) having at least one 
potentially modifiable inflammatory entheseal abnormality.  
In all patients scanned, chronic damage enthesopathy scores ranged from 0-24, with a 
median of 1 (0-5) out of a possible 182.  In those with a at least one inflammatory lesion 
on ultrasound, the median was 5 (1.25-8.75). 
Total enthesopathy scores ranged from 0 to 37 in all participants, with a median of 2 (0-
11.5) out of a possible total of 266. In the 36 patients with a positive ultrasound, the 
median was 11.5 (4.0-20.25).  
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Enthesophytes 31 21.1 15 20.5 5 6.8 
Bony erosions 0 0.0 0 0.0 0 0.0 
Bone cortex irregularities 5 3.4 3 4.1 0 0.0 
Pr
ox
im
al
 P
at
el
la
r 
Thickening 14 9.6 9 12.3 0 0.0 
Hypoechogenicity 14 9.6 9 12.3 0 0.0 
Power Doppler signal 2 1.4 1 1.4 0 0.0 
Calcifications 5 3.4 3 4.1 0 0.0 
Enthesophytes 6 4.1 4 5.5 0 0.0 
Bony erosions 0 0.0 0 0.0 0 0.0 
Bone cortex irregularities 3 2.1 2 2.7 0 0.0 
D
is
ta
l P
at
el
la
r T
en
do
n 
Thickening 26 17.8 16 22.0 0 0.0 
Hypoechogenicity 10 6.8 8 11.0 0 0.0 
Power Doppler signal 0 0.0 0 0.0 0 0.0 
Calcifications 15 10.3 10 13.7 0 0.0 
Enthesophytes 4 2.7 4 5.5 0 0.0 
Bony erosions 1 0.7 1 1.4 0 0.0 
Bone cortex irregularities 3 2.1 3 4.1 0 0.0 
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Fo
ot
 a
nd
 A
nk
le
 
Pe
ro
ne
al
 B
re
vi
s 
Thickening 6 4.1 4 5.5 0 0.0 
Hypoechogenicity 0 0.0 0 0.0 0 0.0 
Power Doppler signal 0 0.0 0 0.0 0 0.0 
Calcifications 1 0.7 1 1.4 0 0.0 
Enthesophytes 2 1.4 2 2.7 0 0.0 
Bony erosions 0 0.0 0 0.0 0 0.0 
Bone cortex irregularities 3 2.1 3 4.1 0 0.0 
A
ch
ill
es
 
Thickening 7 4.8 6 8.2 0 0.0 
Hypoechogenicity 10 6.8 9 12.3 0 0.0 
Power Doppler signal 1 0.7 1 1.4 0 0.0 
Calcifications 11 7.5 9 12.3 1 1.4 
Enthesophytes 23 15.8 11 15.1 6 8.2 
Bony erosions 1 0.7 1 1.4 0 0.0 
Bone cortex irregularities 3 2.1 2 2.7 0 0.0 
Pl
an
ta
r F
as
ci
a 
Thickening 11 7.5 9 12.3 0 0.0 
Hypoechogenicity 14 9.6 12 16.4 0 0.0 
Power Doppler signal 0 0.0 0 0.0 0 0.0 
Calcifications 4 2.7 4 5.5 0 0.0 
Enthesophytes 2 1.4 2 2.7 0 0.0 
Bony erosions 0 0.0 0 0.0 0 0.0 
Bone cortex irregularities 0 0.0 0 0.0 0 0.0 
Table 3.5. Number of entheseal abnormalities by anatomical site and lesion at the 
entheseal and patient level. 
In terms of the location of subclinical enthesitis, by far the majority of all abnormalities 
occurred in the larger tendon entheses, especially the three knee tendons (quadriceps, 
proximal patellar and distal patellar), Achilles tendon, plantar aponeurosis and elbow 
common extensor and flexor tendons. With the exception of bone cortex abnormalities, 
very few changes were seen in the small tendons of the finger and thumb or the perineal 
brevis tendon in the foot.  Inflammatory lesions (thickening, hypoechogenicity and/or 
power Doppler signal) occurred with the greatest frequency at knee tendon insertion 
sites, followed by the elbows and foot and ankle tendon entheses. Figure 3.6 and Table 
3.6 describe the total number of inflammatory lesions in all patients by tendon enthesis 
type. 
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Figure 3.6. Percentage number of inflammatory entheseal lesions by anatomical location 
(FPL: Flexor Pollicis Longus; EPL: Extensor Pollicis Longus; ED: Extensor Digitorum; 
FDP: Flexor Digitorum Profundus). 
Tendon Enthesis Total number of lesions in all patients (max =146) 
Quadriceps 38 (26.0%) 
Distal patellar 36 (24.7%) 
Proximal patellar 30 (20.5%) 
Common extensor 28 (19.2%) 
Plantar fascia 25 (17.1%) 
Common flexor 21 (14.4%) 
Achilles 18 (12.3%) 
Thumb flexor pollicis longus 9 (6.2%) 
Peroneal brevis 6 (4.1%) 
Distal brachial triceps 6 (4.1%) 
Thumb extensor pollicis longus 5 (3.2%) 
Index finger flexor digitorum profundus 5 (3.2%) 
Index finger extensor digitorum 5 (3.2%) 
Middle finger flexor digitorum profundus 1 (0.7%) 
Middle finger extensor digitorum 0 (0%) 
Ring finger flexor digitorum profundus 0 (0%) 
Ring finger extensor digitorum 0 (0%) 
Little finger flexor digitorum profundus 0 (0%) 
Little finger extensor digitorum 0 (0%) 
Table 3.6. Total number and percentage of inflammatory entheseal lesions by anatomical 
location. 
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Lesions in keeping with chronic damage (entheseal calcification, enthesophytes, bone 
erosions and/or bone cortex irregularities) again occurred with high frequency in the 
larger entheses, although signs of damage were seen in the thumb and index finger 
insertion sites with a noticeably higher incidence than inflammatory lesions. Figure 3.7 
and Table 3.7 describe the total number of chronic damage lesions in all patients by 
tendon enthesis type. 
 
Figure 3.7. Percentage number of entheseal chronic damage lesions by anatomical 
location (FPL: Flexor Pollicis Longus; EPL: Extensor Pollicis Longus; ED: Extensor 
Digitorum; FDP: Flexor Digitorum Profundus). 
Tendon Enthesis Total number of lesions in all patients (max.=146) 
Quadriceps 62 (42.5%) 
Achilles 38 (26.0%) 
Distal patellar 23 (15.8%) 
Thumb flexor pollicis longus 19 (13.0%) 
Distal brachial triceps 16 (11.0%) 
Proximal patellar 14 (9.5%) 
Thumb extensor pollicis longus 13 (8.9%) 
Index finger extensor digitorum 11 (7.5%) 
Common extensor 9 (6.2%) 
Index finger flexor digitorum profundus 9 (6.2%) 
Common flexor 8 (5.5%) 
Plantar fascia 6 (4.1%) 
Peroneal brevis 6 (4.1%) 
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Tendon Enthesis Total number of lesions in all patients (max.=146) 
Middle finger flexor digitorum profundus 0 (0%) 
Middle finger extensor digitorum 0 (0%) 
Ring finger flexor digitorum profundus 0 (0%) 
Ring finger extensor digitorum 0 (0%) 
Little finger flexor digitorum profundus 0 (0%) 
Little finger extensor digitorum 0 (0%) 
Table 3.7. Total number and percentage of chronic damage lesions by anatomical 
location. 
3.4.4.2 Synovial Changes 
Synovial hypertrophy only occurred in patients with inflammatory entheseal lesions. 
Cases were most commonly seen in the wrists (26 joints, 17.8%) and carpometacarpal 
joints of the thumb (22 joints, 15.1%) followed by the metacarpophalangeal joints of the 
index finger (12 joints, 8.2%) and the knee joints (10 joints, 6.8%) (Figure 3.8).  
 
Figure 3.8. Percentage frequency of joints with grey scale synovial hypertrophy (DIP: 
Distal Interphalangeal; PIP: Proximal Interphalangeal; MCP: Metacarpophalangeal; 
CMC: carpometacarpal). 
Like at the enthesis, the incidence of power Doppler signal was low, only affecting the 
wrist joints in four patients (one bilateral and three unilateral) and index 
metacarpophalangeal joints in three patients (one bilateral and two unilateral) (Figure 
3.9). 
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Figure 3.9. Percentage frequency of joints with synovial power Doppler signal (DIP: 
Distal Interphalangeal; PIP: Proximal Interphalangeal; MCP: Metacarpophalangeal; 
CMC: carpometacarpal). 
Table 3.8 displays the frequencies of grey scale and power Doppler synovial changes 
by joint. 
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Th
um
b Interphalangeal 
GS 6 4.1 5 6.8 0 0.0 
PD 0 0.0 0 0.0 0 0.0 
Carpometacarpal 
GS 22 15.1 11 15.1 0 0.0 
PD 0 0.0 0 0.0 0 0.0 
In
de
x 
Fi
ng
er
 Distal Interphalangeal 
GS 8 5.5 8 11.0 0 0.0 
PD 0 0.0 0 0.0 0 0.0 
Proximal Interphalangeal 
GS 8 5.5 5 6.8 0 0.0 
PD 0 0.0 0 0.0 0 0.0 
Metacarpophalangeal 
GS 12 8.2 8 11.0 0 0.0 
PD 4 2.7 3 4.1 0 0.0 
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M
id
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e 
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ng
er
 Distal Interphalangeal  
GS 0 0.0 0 0.0 0 0.0 
PD 0 0.0 0 0.0 0 0.0 
Proximal Interphalangeal 
GS 0 0.0 0 0.0 0 0.0 
PD 0 0.0 0 0.0 0 0.0 
Metacarpophalangeal  
GS 1 0.7 1 1.4 0 0.0 
PD 0 0.0 0 0.0 0 0.0 
R
in
g 
Fi
ng
er
 
Distal Interphalangeal  
GS 0 0.0 0 0.0 0 0.0 
PD 0 0.0 0 0.0 0 0.0 
Proximal Interphalangeal  
GS 0 0.0 0 0.0 0 0.0 
PD 0 0.0 0 0.0 0 0.0 
Metacarpophalangeal  
GS 0 0.0 0 0.0 0 0.0 
PD 0 0.0 0 0.0 0 0.0 
Li
ttl
e 
Fi
ng
er
 Distal Interphalangeal  
GS 0 0.0 0 0.0 0 0.0 
PD 0 0.0 0 0.0 0 0.0 
Proximal Interphalangeal  
GS 0 0.0 0 0.0 0 0.0 
PD 0 0.0 0 0.0 0 0.0 
Metacarpophalangeal 
GS 0 0.0 0 0.0 0 0.0 
PD 0 0.0 0 0.0 0 0.0 
Wrist 
GS 26 17.8 14 19.2 0 0.0 
PD 5 3.4 4 5.5 0 0.0 
Elbow 
GS 0 0.0 0 0.0 0 0.0 
PD 0 0.0 0 0.0 0 0.0 
Knee 
GS 10 6.8 8 11.0 0 0.0 
PD 0 0.0 0 0.0 0 0.0 
Ankle 
GS 1 0.7 1 1.4 0 0.0 
PD 0 0.0 0 0.0 0 0.0 
Table 3.8. Frequency of grey scale synovial hypertrophy and synovial power Doppler 
signal by joint. 
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Synovitis scores ranged from 0-11 in all participants, with a median of 0 (0-2.5) out of a 
possible maximum total of 72. In the 36 patients with at least one inflammatory entheseal 
lesion, the median was 2.5 (0-4.75). 
3.4.5 Associations Between Patient, Clinical and Ultrasound 
Characteristics  
Associations between ultrasound enthesopathy and synovitis scores, and a number of 
demographic and clinical parameters were analysed using Spearman rank correlation 
between ordinal (ranked) data or rank biserial rb (Somers D) for ordinal (ranked) and 
nominal (dichotomous) data correlations. Absolute rho values >0.3 and d values >0.4 
were considered to indicate substantive correlation (Table 3.9). Positive correlations 
were found between enthesopathy scores (inflammation, chronic damage and total), 
synovitis scores and patient age (all p<0.05). Similarly, heavier patients (as assessed 
using BMI) were more likely to have greater enthesopathy and synovitis scores. 
Correlations Inflammation Score 
Chronic 
Damage 
Score 
Total 
Enthesopathy 
Score 
Total 
Synovitis 
Score 
Age rho=0.40* rho=0.41* rho=0.45* rho=0.34* 
Gender d=0.13 d=0.12 d=0.11 d=0.28 
BMI rho=0.32* rho=0.32* rho=0.35* rho=0.30* 
PASI rho=0.00 rho=-0.15 rho=-0.11 rho=-0.01 
mNAPSI rho=0.20 rho=0.21 rho=0.19 rho=0.29 
BSA rho=0.03 rho=-0.09 rho=-0.05 rho=0.04 
Duration of Psoriasis rho=0.13 rho=0.27 rho=0.23 rho=0.14 
Age of Psoriasis Onset rho=0.23 rho=0.16 rho=0.23 rho=0.16 
Smoker (ever) d=-0.09 d=0.03 d=-0.04 d=0.05 
Pack years rho=0.03 rho=0.21 rho=0.13 rho=0.21 
No. of PsO sites (current) rho=0.01 rho=-0.05 rho=-0.04 rho=0.09 
No. of PsO sites (ever) rho=0.05 rho=0.02 rho=0.03 rho=0.14 
Table 3.9. Associations between demographic and clinical parameters, and 
enthesopathy and synovitis scores. rho=Spearman rank correlation coefficient. d=Rank 
biserial correlation coefficient (Somers D). Values in bold represent rho>0.3 and are 
considered to represent a substantive correlation (PsO: psoriasis). *denotes significance 
at p<0.05 level. 
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3.5 Discussion 
Enthesitis has been indicated as a distinctive pathological condition affecting patients 
with psoriatic arthritis, and is best identified using grey scale and power Doppler 
ultrasound where histological analysis is not feasible. These data add further 
confirmation that entheseal abnormalities can be also be documented in patients with 
psoriasis, prior to the development of musculoskeletal symptoms. Previous studies have 
shown asymptomatic inflammatory entheseal abnormalities in 46.4% (Acquacalda et al., 
2015), 39.0% (Ash et al., 2012b), 56.0% (Ozcakar et al., 2005), 39.1% (Naredo et al., 
2011) and 59.3% (De Simone et al., 2003) of patients with psoriasis, which is comparable 
with the 49.3% of patients in this cohort. Power Doppler signal was found in 0.2% of 
entheses, and published data show, where assessed, that either PD signal was absent 
(Acquacalda et al., 2015) or rates were similarly low with 0.77% (Acquitter et al., 2016), 
1.0% (Ash et al., 2012b)  and 0.9% of entheses demonstrating PD signal (Gutierrez et 
al., 2011).  
The majority of previous studies in psoriasis patients have concentrated on imaging the 
larger entheses of the lower limb, studying either the Achilles tendon in isolation 
(Ozcakar et al., 2005, De Simone et al., 2003) or the five entheses included in the 
Glasgow Ultrasound Enthesitis Scoring System (quadriceps, proximal patellar, distal 
patellar, Achilles and plantar fascia tendon insertions) (Gisondi et al., 2008, Bandinelli et 
al., 2013, Ash et al., 2012b, Moshrif et al., 2017, Gutierrez et al., 2011). Few studies 
have looked at sites in the upper limb, with only one study including the brachial triceps 
tendon insertion (Acquacalda et al., 2015), one study including the common extensor 
and flexor tendon insertions into the medial and lateral epicondyles of the elbow 
(Acquitter et al., 2016) and two studies including the flexor/extensor tendons of the 
fingers (Naredo et al., 2011, De Filippis et al., 2005). In all published studies, regardless 
of anatomical site, entheseal abnormalities were identified in asymptomatic patients with 
psoriasis, suggesting their inclusion is paramount if a comprehensive assessment of the 
distribution of entheseal lesions is to be achieved. This is the first study to systematically 
assess all of these sites with grey scale and power Doppler ultrasound in the upper and 
lower limbs in addition to the peroneal brevis tendon insertion of the ankle, using agreed 
definitions for ultrasound pathology in a large population of psoriatic patients without 
musculoskeletal disease.  
Enthesitis is different from enthesopathy, although the two terms, incorrectly, are often 
used interchangeably in the literature (D'Agostino M et al., 2009). Enthesitis is defined 
as the presence of inflammation in tendons, ligaments and capsule insertions into the 
bone, whereas enthesopathy is a term reserved to describe a spectrum of inflammatory 
and structural damage abnormalities within the enthesis, including calcifications, 
enthesophytes, bone erosions and cortical irregularities (D'Agostino, 2010). 
Gandjbakhch showed that many different authors published about enthesitis definition 
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and consensus was needed, which may account for some of the differences seen 
between the data in this thesis and that in previously published studies (Gandjbakhch et 
al., 2011). However, Terslev and colleagues dismissed this observation, demonstrating 
a high agreement concerning different components of the definition of enthesitis such as 
hypoechogenicity, thickness of tendon insertion, enthesophytes, calcifications, erosions 
and power Doppler signal at the entheses £2mm near the bony cortex (Terslev et al., 
2014). For the purposes of this analysis, where ‘enthesitis’ has been reported, this has 
been interpreted to denote only the presence of inflammatory abnormalities, and 
‘enthesopathy’ has been understood to represent the presence of inflammatory lesions 
and/or structural damage abnormalities. 
Using these terms, similar rates of subclinical enthesitis were identified by Naredo et al 
in their study of 162 asymptomatic patients with psoriasis (11.6% of entheses vs. 13.0%), 
as were the frequencies of patients with enthesopathy (62.5% vs. 60.3%), and power 
Doppler signal (7.4% of patients vs. 6.8%) (Naredo et al., 2011). Theirs is the most 
comprehensive assessment published to date, analysing a total of 9 entheses, 18 joints 
and 11 tendons bilaterally. A number of entheses included in this investigation were not 
included (finger extensor tendons, quadriceps tendons, distal brachial triceps tendons, 
common extensor and flexor tendons of the elbow and peroneal brevis tendons). Both 
cohorts had a similar mean participant age (42.6 years vs. 40.1 years) and mean duration 
of psoriasis (13.4 years vs. 16.9 years), although patients in their study had a lower mean 
PASI score (6.7 vs. 20.0), perhaps reflecting their inclusion of patients recently 
discontinuing drugs such as methotrexate, ciclosporin and oral retinoids. This is likely to 
not be of relevance, as this study and several others have found no association between 
the presence of subclinical enthesopathy on ultrasound and PASI score (Bandinelli et 
al., 2013, De Simone et al., 2003, Gisondi et al., 2008, Gutierrez et al., 2011, Naredo et 
al., 2011). 
Naredo and colleagues actively chose to exclude the palmar aspect of the finger joints 
and the metacarpophalangeal joints from the ultrasound examination because, although 
very sensitive to ultrasound imaging in arthritis, a high frequency of synovitis has been 
reported in normal subjects (Wiell et al., 2007, Scheel et al., 2005). This was not the 
experience in this study, where adequate visualisation of the flexor and extensor tendons 
allowed a clear assessment of these entheses, and relatively low rates of synovitis (<9%) 
were observed in the distal interphalangeal, proximal interphalangeal and 
metacarpophalangeal joints, with the exception of the thumb carpometacarpal joint 
(15.1% had synovitis). No synovitis was seen in the ring and little fingers. Naredo and 
colleagues observed low rates of enthesopathy in the deep flexor tendons of the fingers 
(2.4%), with no distinction made between the different digits. In this cohort, no 
enthesopathy was observed in the middle, ring and index fingers, however 6.2% of 
thumb and 3.2% of index finger flexor tendons had inflammatory entheseal 
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abnormalities, alongside 3.2% of thumb and 3.2% of index finger extensor tendons. The 
difference between fingers is most probably attributable to the difference in function of 
the index finger and thumb, through which they sustain the most use and frequent 
microtrauma of all of the digits, which as demonstrated by Benjamin et al, can lead to 
sustained inflammation and structural damage in genetically primed individuals with 
psoriatic disease (Benjamin et al., 2007, Benjamin and McGonagle, 2001). 
Few other data are available for comparison of entheses of the upper limb, with the 
majority of previous studies concentrating on the weight-bearing entheses of the lower 
limbs. Acquacalda and colleagues identified abnormal hypoechogenicity and/or 
thickening of the tendon/ligament at its bony attachment in a proportion of 22 patients at 
the distal brachial triceps tendon, although the frequency is not disclosed (Acquacalda 
et al., 2015). Acquitter et al examined 37 patients with nail, inverse and scalp psoriasis 
and also identified inflammatory abnormalities in the entheseal attachments at the lateral 
and medial epicondyles of the elbows, although again, the frequency of abnormalities is 
not published to facilitate comparison (Acquitter et al., 2016).  
The results in this chapter for the lower limb entheses are in accordance with those of 
previous studies that assessed entheseal abnormalities using (or based on) the Glasgow 
Enthesitis Ultrasound Scoring System (GUESS) in smaller populations of psoriatic 
patients (Ash et al., 2012b, Gutierrez et al., 2011, Gisondi et al., 2008, Bandinelli et al., 
2013, Moshrif et al., 2017, Acquacalda et al., 2015). Quadriceps enthesitis was the most 
common site in this study, closely followed by the other knee tendon entheses. Thickness 
of the quadriceps tendon has been shown to be an independent predictor of the 
development of PsA in the only published longitudinal study of patients with psoriasis 
and psoriatic arthritis, where 7 of 28 patients developed inflammatory arthritis (which 
fulfilled the CASPAR criteria for a diagnosis of PsA) after a mean of 3.5 years (Tinazzi 
et al., 2011).  
Gisondi et al identified similarly high rates to this study of enthesitis at the quadriceps 
and other knee tendon entheses in an older population with mean age 55.8 years 
(quadriceps tendon insertion 30.0% vs. 26.0%; proximal patellar tendon 36.6% vs. 
20.5%; distal patellar tendon insertion 35.0% vs. 24.7%). Lower rates of enthesitis were 
observed in the foot and ankle entheses in both studies (Achilles tendon insertion 16.6% 
vs. 12.3%; plantar fascia insertion into the calcaneus 5.0% vs. 17.1%) (Gisondi et al., 
2008). Achilles tendon enthesitis also occurred with comparable frequency (13.2% vs. 
12.3% of entheses) in a study of 34 psoriasis patients with a similar mean age (43.5 
years vs 40.1 years) and disease duration (16.7 years vs. 16.9 years) (Acquacalda et 
al., 2015).  
Two different authors, Gutierrez and Bandinelli, have also demonstrated a lower 
incidence of foot and ankle enthesitis compared to the knee. 6.7% and 14.1% of patients, 
respectively, had thickening of the plantar aponeurosis insertion, and 20.0% and 38% of 
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patients, respectively, of the Achilles tendon enthesis. At the knee, striking numbers of 
psoriasis patients were found to have entheseal thickening (distal patellar 68.9% and 
59.8% of patients, respectively, compared with 21.9% in this study; proximal patellar 
46.7% and 85.8% of patients, respectively, compared with 12.3% in this study; 
quadriceps tendon 20.0% and 41.3% of patients, respectively, compared with 19.2% in 
this study) (Gutierrez et al., 2011, Bandinelli et al., 2013). The former study included 45 
asymptomatic patients with psoriasis, but no data is published regarding demographic 
factors such as mean age, PASI score or duration of psoriasis for comparison (Gutierrez 
et al., 2011). In the latter, Bandinelli studied older patients (mean age 51.6 years) with 
psoriasis and ‘early PsA’, defined as musculoskeletal symptom duration of less than one 
year, which may account for the higher number of patients with entheseal thickening 
compared with the cohort in this thesis (Bandinelli et al., 2013).  Age is likely to be 
important, with this study and several others reporting a significant correlation between 
age and the presence of inflammatory enthesitis on ultrasound (Gisondi et al., 2008, 
Moshrif et al., 2017, Naredo et al., 2011, Ozcakar et al., 2005). 
Moshrif et al studied a younger cohort of 50 patients with psoriasis (mean age 33.8 years) 
with a shorter duration of skin disease (mean 7.7 years), and found much lower rates of 
asymptomatic ultrasound enthesitis at the knee than Gisondi, Gutierrez and Bandinelli, 
but similar rates of enthesitis to this study (distal patellar tendon 22.2% vs. 21.9%; 
proximal patellar tendon 16.7% vs 12.3%; quadriceps tendon 16.7% vs. 19.2% of 
entheses). However, they observed much higher rates in the Achilles tendon (33.3% vs. 
12.3% of entheses) (Moshrif et al., 2017). Most patients within this study had a high BMI, 
with more than three quarters being overweight and 44% being clinically obese 
(BMI>30kg/m2), compared to a mean BMI in this thesis of 28.7kg/m2. This could translate 
to a greater burden of microtrauma at these key weight-bearing sites and therefore more 
enthesitis, although histopathological analysis would have been required to confirm this. 
Like previous studies, this study found a significant correlation between the presence of 
ultrasound enthesopathy and BMI (Gisondi et al., 2008, Moshrif et al., 2017). However 
no association with BMI has been found by others with the presence of ultrasound 
enthesopathy (Naredo et al., 2011) or mean GUESS score (Gutierrez et al., 2011), 
although it is observed that mean BMI was notably lower within the latter two studies.  
Two other studies have also observed high rates of Achilles tendon enthesopathy 
(described as either tendon thickening and/or hypoechogenicity), in 56.6% (Ozcakar et 
al., 2005) and 59.3% (De Simone et al., 2003) of psoriasis patients examined. However, 
each of these studies included patients with a formal diagnosis of PsA (36.0% and 24.1% 
respectively) and patients with musculoskeletal signs and symptoms (44.0% and 30.5%, 
respectively), which is likely to account for the discrepancy between their cohort and 
those patients in this chapter. 
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Aside from age and BMI, in terms of other risk factors for subclinical entheseal 
inflammation, significantly higher rates were observed in this chapter in psoriasis patients 
who had never smoked (47.2% vs 27.0%, p=0.005). The prevalence of smoking has 
previously been reported to be less among patients with PsA compared with psoriasis 
patients without arthritis (Eder et al., 2011b, Pattison et al., 2008). Several potential 
biological mechanisms have been proposed for this observation including the activation 
of a7 nicotinic acetylcholine receptor by nicotine, which inhibits intracellular pro-
inflammatory pathways that are associated with the development of arthritis. Eder et al 
also demonstrated a protective effect of smoking in the development of PsA, but only in 
patients who were HLA-Cw06 negative (Eder et al., 2012).  
Aside from inflammatory abnormalities, most other studies included assessments of 
chronic damage lesions such as erosions, enthesophytes and entheseal calcifications. 
Bone erosions, seen adjacent to 0.2% of entheses in this cohort, were comparably low, 
reported as 0% (Moshrif et al., 2017, Gisondi et al., 2008, Naredo et al., 2011), 1.1% 
(Gutierrez et al., 2011), 1.7% (Acquitter et al., 2016) and 3.0% in previous studies (Ash 
et al., 2012b). Erosions were seen with much greater frequency in those studies which 
included patients with symptomatic PsA, ranging from 11.8% (Acquacalda et al., 2015) 
to 21.7% (Bandinelli et al., 2013). In asymptomatic psoriasis patients, enthesophytes are 
reported with much greater variation, from 0% (Naredo et al., 2011) to 68.3% (Gisondi 
et al., 2008), but as in this cohort, are reported with the greatest frequency in all studies 
at the Achilles tendon insertion into the calcaneus (Gisondi et al., 2008, Bandinelli et al., 
2013, Ash et al., 2012b). 2.6% of entheses in this cohort demonstrated calcification at 
the enthesis, which is slightly lower than that identified in other studies of asymptomatic 
patients with psoriasis by Acquitter et al (4.6%) (Acquitter et al., 2016) and Ash et al 
(5.0%) (Ash et al., 2012b), and significantly less than that in a study including patients 
with PsA (25.9%) (Acquacalda et al., 2015), which supports the belief of the progressive 
nature of structural damage abnormalities between subclinical enthesopathy and 
symptomatic PsA. No published studies have included the assessment of bony cortex 
irregularities, seen in 2.2% of entheses in this cohort. No correlations were found 
between the total chronic damage score and any demographic or clinical parameters.   
Beyond the enthesis, sustained inflammation is thought to dissipate to adjacent 
structures, although few studies have published data in this domain in patients with 
psoriasis. Only one previous study has included assessments of synovitis, and found 
more at the knee (23.5% of joints) than the ankle (1.1% of joints) (Naredo et al., 2011). 
This is mirrored in this cohort, with synovitis identified in 6.8% of knee joints and 1.4% of 
ankle joints, accompanying adjacent inflammatory entheseal abnormalities. No studies 
have assessed synovitis in the wrist, elbow and finger joints of asymptomatic patients 
with psoriasis, but scanning of these joints is warranted given the high frequency of 
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synovitis seen at the wrist (17.8%) and joints at the base of the thumb and index finger 
(thumb carpometacarpal joint 15.1%, index finger metacarpophalangeal joint 8.2%).  
In terms of feasibility, this study has demonstrated that subclinical enthesopathy, like 
established PsA, can be very diverse in its presentation and distribution, and requires a 
broad-reaching sonographic assessment in order to capture the true prevalence of 
disease. Ultrasound is not able to assess the axial skeleton, and so even with a 
comprehensive peripheral protocol, there will be patients who are missed unless 
complementary imaging is performed using MRI or PET scanning. However, it would not 
be feasible to perform such screening investigations in all patients due to the population 
prevalence of psoriasis. As shown in previous studies, no associations between the 
duration of psoriasis (Gisondi et al., 2008, Gutierrez et al., 2011, Naredo et al., 2011) or 
PASI score (Bandinelli et al., 2013, De Simone et al., 2003, Gisondi et al., 2008, 
Gutierrez et al., 2011, Naredo et al., 2011), have been found which could help stratify 
patients for screening.  
In the research setting, or in patients where it is desirable to know if there is subclinical 
enthesopathy, these data show is that it is not adequate to limit the assessment of 
subclinical arthritis to just the larger entheses of the lower limbs. A high proportion of 
patients had disease at the elbows (19.2%) and small joints of the hands, particularly the 
thumbs (6.2%), with a proportion of these patients having no disease at the knee 
entheses, Achilles tendon and plantar fascia insertions. The inclusion of the small 
entheses of all fingers meant that the protocol used was lengthy (30-35 minutes). Little 
useful information was yielded from the middle, ring and index fingers, with only one 
enthesis showing any inflammatory abnormality and so if removed, could save 15 
minutes of scanning time. The thumb and index finger, as discussed, showed 
significantly higher rates of enthesitis as a consequence of greater use and frequent 
microtrauma and should therefore continue to be included, but the middle, ring and little 
finger could be removed from the protocol.  
The frequency of power Doppler was low as in previous studies, but should be 
maintained in the protocol. It requires very little additional time to do, and where seen at 
entheseal sites, is confirmatory of the presence of abnormal vascularisation which is 
considered a phenotypical sign of PsA (Aydin et al., 2013a).  The assessment of joints 
for synovitis has rarely been included in previous ultrasound protocols, but as data in this 
cohort have shown, high rates of synovitis accompany enthesitis, especially in the upper 
limbs. To further understanding of subclinical arthropathy in patients with psoriasis, future 
studies should include assessment of joint synovium in addition exploration of other 
structures within the synovio-entheseal complex, especially those investigating the 
natural evolution of subclinical enthesopathy or the musculoskeletal response to 
therapeutic intervention.   
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3.6 Conclusion 
Published prevalence estimates for subclinical enthesitis among patients with psoriasis 
vary greatly, with low rates influenced by limited parameters used to define enthesopathy 
and a restriction in the number and distribution of entheses scanned.  Using a novel, 
comprehensive protocol of 19 entheses and 18 joints bilaterally, data in this chapter 
demonstrate that subclinical enthesitis is very diverse in terms of presentation and 
distribution, and therefore requires a broad-reaching sonographic assessment including 
both the upper and lower limb entheses in order to fully capture the true prevalence of 
disease.  
60.3% of patients were found to have an abnormal ultrasound, and 49.3% had at least 
one potentially modifiable inflammatory abnormality.  Older age and higher body mass 
index demonstrated weak association with the burden of entheseal and synovial 
inflammation. The larger, weight bearing entheses were most frequently involved 
especially at the knee, Achilles tendon, plantar fascia and elbows, although up to 6% of 
digital tendon insertions showed inflammatory changes (thumb and index fingers only). 
Entheseal thickening was the most prevalent abnormality overall, followed by 
enthesophyte formation and hypoechogenicity. Power Doppler signal was an uncommon 
finding (0.2% of entheses/6.8% of patients), reflecting the early stage of musculoskeletal 
disease in these asymptomatic patients.  
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Chapter 4  
Comparison of the Ultrasound Appearances of Subclinical 
Enthesitis, Bursitis, Tenosynovitis and Synovitis in Patients 
with Psoriasis at First Presentation to Secondary Care and 
Healthy Controls 
4.1 Introduction 
Enthesitis as the primary lesion in psoriatic arthritis has gained further credibility in recent 
years from animal models showing the importance of tumour necrosis factor (TNF) and 
the interleukin (IL)-23/Th17 axis in the development of enthesopathy (Sherlock et al., 
2012). Mirroring the mouse model data, it appears that therapies designed to treat 
psoriasis by antagonising TNF and/or IL-23 in man are effective for entheseal pathology, 
although available data are only secondary outcomes (McInnes et al., 2013, Kavanaugh 
et al., 2014b, Kavanaugh et al., 2015). Historically, enthesitis was described as an 
isolated disorder at the precise point where tendons anchor onto bone, however this 
notion has been discarded with the introduction of the concept of the synovio-entheseal 
complex (SEC) (McGonagle et al., 2007). The enthesis is now understood to form an 
integral part of an ‘enthesis organ’, whereby normal enthesis-related fibrocartilages are 
functionally integrated with the adjacent soft tissues, and are dependent on immediately 
adjacent synovium (Benjamin and McGonagle, 2001, Benjamin et al., 2004). The 
fibrocartilages adjacent to bones are often located inside joints, which form synovial-
lined bursa. Synovium provides lubrication and nutrition to aid the function of the 
enthesis, and filters debris that occurs as a result of biomechanical stress, which is 
subsequently removed by resident macrophages. This close functional integration is 
thought to explain the progression from primary enthesitis to arthritis, whereby there is 
dissipation of inflammation to adjacent structures over time. This would account for the 
presence of synovial hypertrophy seen on ultrasound in some of the 73 psoriasis patients 
with subclinical enthesitis examined in the previous chapter. To obtain a more 
comprehensive picture of the early subclinical changes that may develop within the entire 
SEC in patients with moderate to severe psoriasis, it would therefore appear logical to 
carefully assess the adjacent bursa and joints in patients with enthesopathy and make 
comparisons with the non-psoriatic population.  
SECs can be found at multiple sites around the body, and although they typically arise 
within the immediate vicinity of insertions and within the joint capsule, may also occur at 
sites distant to insertion points. In a human TNF transgenic mouse model of inflammatory 
arthritis akin to spondyloarthritis, serial sacrifice of animals to ascertain the origins of 
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disease demonstrated infiltration by inflammatory cells in the peritendinous regions that 
equated with tenosynovitis (Hayer et al., 2007). There was no actual tendon insertion at 
this location, but inflammation occurred at the site at which the tendon traversed bony 
prominences. Fibrocartilage was present on the bony surface and adjacent tendon at the 
point of contact, creating what has been termed a ‘function enthesis’. Such regions share 
an identical insult of mechanical shearing forces and stress, which have been shown to 
produce entheseal type pathology on magnetic resonance imaging (MRI) (McGonagle 
et al., 2012). It is therefore postulated that tenosynovitis may also occur in patients with 
psoriasis and subclinical enthesopathy. Some degree of abnormality in the SEC would 
also be expected in ‘healthy’ individuals (without known musculoskeletal disease) as a 
consequence of high body mass and age-related degeneration, although to what extent 
is unknown.  
Using a refined ultrasound protocol based on the findings of that used in Chapter 3, this 
chapter aims to determine the full spectrum (lesion type, anatomical location and 
severity) and frequency of imaging abnormalities within the full synovio-entheseal 
complex (entheses and adjacent bursa, tendon sheaths and joints) in patients with 
moderate to severe psoriasis and subclinical enthesitis and compare those imaging 
abnormalities with a healthy control group of volunteers, to try differentiate between 
those abnormalities that are likely to be pathological and those that are physiological 
(due to age and weight-related degeneration).  
This chapter also aims to provide reference thresholds for entheseal thickness for those 
tendons where values have not been published in the literature, to be used in a novel 
sonographic scoring system based on a consensus definition of enthesopathy. This 
scoring system will be used to further assess the feasibility of using ultrasound for the 
detection of subtle abnormalities at the synovio-entheseal complex in asymptomatic 
patients with psoriasis compared to healthy volunteers, for use in a subsequent research 
trial of an investigational medicinal product, described in the next chapter. Finally, this 
chapter aims to assess the utility of the PEST questionnaire in a cohort of patients with 
psoriasis and subclinical enthesitis and compare the patient-reported responses with 
clinical examination and ultrasound findings.  
4.2 Methods 
4.2.1 Participant Identification and Recruitment 
4.2.1.1 Patients with Psoriasis 
Twenty-eight adult patients (aged 18 and over) with moderate to severe chronic plaque 
psoriasis, without clinical psoriatic arthritis (PsA) but with ultrasound evidence of active 
subclinical enthesitis and 23 healthy controls were recruited.  
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Patients with psoriasis were approached for participation from a pilot study of 73 adult 
patients with moderate to severe psoriasis (defined as a Psoriasis Area and Severity 
Index (PASI) score of 10 or more), who consented to undergo a short, non-invasive 
ultrasound of their peripheral joints and tendons following their first ‘new patient’ 
consultation within the Leeds Centre for Dermatology at Chapel Allerton Hospital (Leeds 
Teaching Hospitals Trust) (Chapter 3). These patients were included in the pilot cohort 
as they had a diagnosis of chronic plaque psoriasis (confirmed by a dermatologist, the 
candidate LS), with symptoms for more than twelve months and had not previously 
received any systemic immunosuppression, PUVA phototherapy or biologic agent that 
could potentially have had an impact on the evolution of any subclinical musculoskeletal 
pathology. Patients were excluded if they had any symptoms suggestive of PsA, defined 
clinically as early morning stiffness (lasting 15 minutes or more in duration) and joint 
swelling, or if they fulfilled the CASPAR criteria (Taylor et al., 2006).   
Of the 73 patients who underwent a short ultrasound, 44 (60.3%) had abnormalities; 8 
of these had changes in keeping with chronic damage only (entheseal calcification, 
enthesophytes, bone erosions and/or bone cortex irregularities), while the remaining 36 
had at least one inflammatory lesion (entheseal thickening, hypoechogenic change and 
or entheseal power Doppler signal). Only those patients with potentially modifiable 
inflammatory lesions were approached for this study. Psoriasis patients who entered this 
study were also to be considered for participation in a clinical trial of an investigational 
biological drug (ustekinumab), and so needed to meet the strict criteria for receiving this 
therapy (Appendix 6) and not have any contraindications to magnetic resonance imaging 
(MRI), e.g. a pacemaker or aneurysm coil in situ.  
On identification of active subclinical enthesitis at ultrasound, patients were invited back 
for a longer, more detailed ultrasound scan to assess for bursitis, tenosynovitis and 
synovitis in addition to enthesopathy, with lesion severity scoring and tendon insertion 
thickness measurements. Patients were given a written information sheet to take home 
which provided details of the scan and also about the potential for inclusion in the drug 
trial. Scans took place within one to three weeks of the initial scan, and a full clinical 
assessment was performed again immediately beforehand to confirm eligibility, given 
the fluctuant and unpredictable nature of psoriasis. Written consent was obtained prior 
to this assessment for any clinical, questionnaire, serological and imaging data to be 
used in an anonymised format for research purposes, in addition to data storage. 
4.2.1.2 Healthy Control Group Volunteers 
Healthy controls were recruited from staff members and their family and friends in the 
Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM) and Leeds Institute 
of Cancer and Pathology (LICAP) at the University of Leeds. Recruitment was by direct 
approach or by invitational email to research groups. Volunteers were excluded if they 
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had a history of psoriasis, PsA or any other rheumatological disorder. Attempts were 
made to identify healthy controls with similar demographics to patients (age, sex, BMI), 
although no specific case matching was performed. A detailed information sheet was 
provided to interested volunteers at least 24 hours prior to participation, and written 
consent was obtained to use and store any data collected for research purposes.  
Participants in both groups were asked to complete the Psoriasis Epidemiology 
Screening Tool (PEST) (Appendix 1). In addition, patients with psoriasis completed a 
Dermatology Life Quality Index (DLQI) questionnaire (Appendix 3).  
4.2.2 Inclusion/Exclusion Criteria 
4.2.2.1 Patients with psoriasis 
Male and female patients over the age of 18 with moderate to severe chronic plaque 
psoriasis (Psoriasis Area and Severity Index (PASI) ≥10) with evidence of active 
subclinical enthesitis on ultrasound were included. Findings at ultrasound must have 
included thickening, hypoechogenic change or power Doppler signal in at least one 
peripheral tendon insertion site. Participants must also not have any contraindications to 
biologic therapy (Appendix 6) or MRI scanning (Appendix 10). Further detail regarding 
the inclusion and exclusion criteria can be found in Chapter 3.2.2. 
4.2.2.2 Healthy Control Group Volunteers 
Males and females over the age of 18 without a personal history of psoriasis, psoriatic 
arthritis or other rheumatological condition, or history of use of any immunosuppressant 
or long-term non-steroidal anti-inflammatory therapy (for any indication) were eligible. 
Volunteers must not have had any contraindications to MRI as they may also have been 
asked to undergo a scan of their axial skeleton using MRI. 
4.2.3 Data Collection 
Data collection was solely carried out by the candidate (LS). Recruitment and data 
collection took place over two years (May 2013 – May 2015), through all four seasons to 
allow for natural variation in psoriasis severity related to outdoor ultraviolet levels. Two 
experienced musculoskeletal sonographers (LH and AJ) performed ultrasound scans 
within the Leeds Musculoskeletal Biomedical Research Unit (LMBRU) at Chapel Allerton 
Hospital. 
Once written consent was obtained, three types of data were collected from psoriasis 
patients and recorded for research purposes: participant-reported data, clinical 
examination data and imaging data. Participant-reported data comprised of 
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demographics, skin type, social history (smoking, alcohol and employment), past 
medical and surgical history, history of skin and joint disease, family history, medications 
(current prescribed, over-the-counter, alternative and psoriasis-specific medications, 
and any previous psoriasis therapies), age of psoriasis symptom onset, areas ever 
affected by psoriasis, areas currently affected by psoriasis and current or previous 
musculoskeletal symptoms. Participants also self-completed two questionnaires (DLQI 
(psoriasis patient group only) and PEST).  
Clinical examination data was collected to assess the severity of psoriasis, the severity 
of any psoriatic nail disease, baseline observations (height, weight, blood pressure and 
heart rate) and the presence of any clinical signs of psoriatic arthritis (joint swelling and/or 
tenderness, clinical enthesitis or dactylitis). 
Data was collected onto paper case record forms (CRF) and then transcribed into an 
encrypted, password-protected database held on a secure drive within the University of 
Leeds. Paper record forms are stored in a locked filing cabinet within a locked room 
within LIRMM, in accordance with the University’s Information Security Policy.   
Healthy volunteers provided written consent for the collection of participant-reported and 
imaging data and for its use for research purposes. Participant reported data included 
demographics, skin type, social history (smoking, alcohol and employment), past 
medical and surgical history, history of skin and joint disease, family history and 
medication history (current prescribed, over-the-counter and homeopathic). Clinical 
observations were recorded (height, weight, blood pressure and heart rate). 
4.2.4 Clinical Assessment 
4.2.4.1 Psoriasis Patients 
4.2.4.1.1 Psoriasis Severity and Impact 
Patients were fully exposed down to their underwear and a detailed assessment made 
of the distribution, extent, thickness, degree of scaling and redness of psoriatic plaques. 
BSA and PASI (Appendix 7) were calculated. The nails were assessed for pitting, 
onycholysis, plate crumbling, leukonychia, red spots in the lunula, oil spot dyschromia 
and nail bed hyperkeratosis, and a modified Nail Area and Severity (mNAPSI) score 
calculated (Appendix 8). Impact of psoriasis on quality of life was assessed using the 
patient-completed Dermatology Life Quality Index (DLQI) questionnaire. 
4.2.4.1.2 Psoriatic Arthritis 
While the patient was exposed, several entheseal sites were examined for clinical signs 
of enthesitis. Direct pressure was applied with sufficient force to just blanche the 
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examiners fingernail to elicit tenderness if present. Clinical examination was performed 
prior to ultrasound to prevent bias. The following sites were evaluated:  
• 1st and 7th costochondral joints 
• Supraspinatus insertion 
• Medial and lateral epicondyles of the humerus 
• Anterior and posterior superior iliac spines 
• Iliac crest 
• 5th lumbar process 
• Greater trochanter 
• Medial condyle of the femur 
• Quadriceps insertion at the patella 
• Inferior pole of the patella 
• Tibial tubercle 
• Proximal Achilles 
• Plantar fascia insertion 
 
From these, three of the most widely published clinical entheseal scores were calculated 
– the Maastricht Ankylosing Spondylitis Enthesitis Score (MASES), the Spondyloarthritis 
Research Consortium of Canada (SPARCC) score and the Leeds Enthesitis Index (LEI). 
Table 4.1 details which sites are included in these scores. 
 
Site MASES SPARCC LEI 
1st costochondral +   
7th costochondral +   
Supraspinatus insertion  +  
Lateral epicondyle humerus  + + 
Medical epicondyle humerus  +  
5th lumbar spinous process (one point) +   
Posterior-superior iliac spine +   
Anterior-superior iliac spine +   
Iliac crest +   
Greater trochanter  +  
Medial femoral condyle   + 
Inferior pole patella  +  
Tibial tubercle  +  
Proximal Achilles + + + 
Plantar Fascia Insertion  +  
Table 4.1. Published enthesitis indices. All assess the enthesis bilaterally unless stated. 
(MASES: Maastricht Ankylosing Spondylitis Enthesitis Score; SPARCC: 
Spondyloarthritis Research Consortium of Canada; LEI: Leeds Enthesitis Index). 
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Fingers and toes were assessed for any fusiform swelling or tenderness consistent with 
dactylitis. All peripheral joints were examined for tenderness or swelling. The clinical 
assessments were performed by the candidate (LS).  Patients were also asked to self-
complete a validated PsA screening questionnaire (PEST) for comparison with clinical 
and ultrasound outcomes, which was assessed only after the participants had undergone 
their ultrasound scan.  
4.2.4.1.3 Healthy Controls 
No clinical examination took place unless the volunteer requested a medical opinion to 
clarify their eligibility in terms of skin or joint signs, or a participant reported pain or 
swelling at a particular site on their screening questionnaires. 
4.2.5 Laboratory Assessment 
To ensure that patients and healthy control group volunteers did not have rheumatoid 
arthritis or any other rheumatological disorder, a number of serological assessments 
were performed and are described in Chapter 3.2.5. 
In addition, two risk alleles (class I surface antigens) for psoriatic arthritis amongst 
patients with psoriasis were measured; HLA-B27 and HLA-Cw06:  
• HLA-Cw06 and HLA-B27 were measured by single antigen bead testing (median 
fluorescent intensity, MFI) 
All of the tests above were measured using commercial kits in the hospital diagnostic 
laboratory. 
4.2.6 Ultrasonography 
4.2.6.1 Ultrasound Equipment and Protocol 
All participants were examined with the same ultrasound protocol. Ultrasound was 
performed using a pulse-echo approach with a brightness-mode (B-mode) display. Grey 
scale ultrasound and power Doppler (PD) examinations were performed by the same 
two dedicated research musculoskeletal sonographers (AJ and LH) who performed the 
initial shorter ultrasound in the patients with psoriasis. It was therefore impossible to blind 
the sonographers to which participants were in the psoriasis group and which were 
healthy volunteers as they had often met the psoriasis patients previously. The 
sonographers were asked not to refer back to the images and results from the previous, 
shorter ultrasound scan in the psoriasis patient group so as not to influence their findings 
on the second scan. Further detail regarding the ultrasound equipment and settings can 
be found in Chapter 3.1.6.  
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Using the results from the scans of the pilot cohort of 73 patients, it was deemed 
unnecessary to scan all fingers as there were such negligible rates of subclinical 
enthesitis and synovitis in the middle, ring and little fingers. In addition, scanning the 
hands was time consuming, even when just having a ‘quick look’ without scoring and 
thickness measurements. The protocol in the pilot study included 20 entheses and 28 
joints for both hands, which took as long to scan as the feet, ankles, knees and elbows 
combined, and yielded only one patient with thickening of the middle finger flexor 
digitorum profundus enthesis and another with synovitis unilaterally in the middle finger 
metacarpophalangeal joint. In contrast, at least one thumb tendon enthesis was involved 
in 9.6% of patients and index finger tendon enthesis in 6.8%. As these two digits are the 
ones that are likely to sustain the most microtrauma from daily use, it was decided to 
keep these in the ultrasound protocol to compare with the healthy control group 
volunteers (Figure 4.1). 
 
 
 
 
 
 
 
 
Figure 4.1. Left index finger extensor digitorum tendon enthesis demonstrating entheseal 
thickening (, grade 1), hypoechogenicity (Õ, grade 2), calcification (, grade 1), bone 
cortex irregularities and enthesophytes (, grade 2) in an asymptomatic patient with 
moderate to severe psoriasis. ED: Extensor digitorum; MP: Middle phalynx; DP: distal 
phalynx. 
Given the rates of synovitis seen in the pilot cohort, the ultrasound protocol was extended 
to include bursal hypertrophy/power Doppler signal at several sites, and tenosynovitis 
(hypoechoic and/or thickened tissue within the tendon sheath), which all form part of the 
synovio-entheseal complex (McGonagle et al., 2007). The full ultrasound clinical record 
form (CRF) can be found in Appendix 9. 
Table 4.2, Table 4.3, Table 4.4 and Table 4.5 summarise the tendon entheses and 
corresponding bone insertion sites, the bursa, the sites for tenosynovitis and the synovial 
joints scanned. 
 
ED
ED * 
●
Nail
Nail
DP
DP
MP
MP
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Anatomical Site Tendon Enthesis Bone Insertion Point 
Thumb 
Flexor pollicis longus Base of distal phalynx 
Extensor pollicis longus Base of distal phalynx 
Index Finger 
Flexor digitorum profundus Base of distal phalynx 
Extensor digitorum Base of distal phalynx 
Elbow 
Common extensor  Lateral epicondyle of humerus 
Common flexor Medial epicondyle of humerus 
Distal brachial triceps Olecranon process of ulna 
Knee 
Quadriceps  Superior pole of patella 
Proximal patella Inferior pole of patella 
Distal patella Anterior tibial tuberosity 
Foot and Ankle 
Peroneal brevis 5th metatarsal base lateral tuberosity 
Achilles Superior pole of calcaneus 
Plantar fascia Inferior pole of calcaneus 
Table 4.2. Tendon entheses and bone insertion sites scanned (grey scale and power 
Doppler assessments) 
Anatomical Site Bursa 
Upper Limb Elbow Olecranon bursa 
Lower Limb 
Knee 
Suprapatellar bursa 
Superficial infrapatellar bursa 
Deep infrapatellar bursa 
Ankle Retrocalcaneal bursa 
Table 4.3. Bursa scanned for grey scale hypertrophy and power Doppler signal. 
Anatomical Site Tendon Sheath 
Upper Limb 
Thumb 
Flexor pollicis longus 
Extensor pollicis longus overlying interphalangeal joint 
Extensor pollicis longus overlying carpometacarpal joint 
Index Finger 
Flexor digitorum profundus 
Extensor digitorum 
Wrist 
Extensor compartment 1 - Abductor Pollicis Longus and 
Extensor Pollicis Brevis 
Extensor compartment 2 - Extensor Carpi Radialis, Longus 
and Brevis 
Extensor compartment 3 - Extensor Pollicis Longus 
Extensor compartment 4 - Extensor Digitorum 
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Anatomical Site Tendon Sheath 
Extensor compartment 5 - Extensor Digiti Minimi 
Extensor compartment 6 - Extensor Carpi Ulnaris 
Lower Limb 
Knee 
Quadriceps  
Proximal patella 
Distal patella 
Foot and 
Ankle 
Posterior tibialis 
Flexor digitorum longus 
Flexor hallucis longus 
Anterior tibialis 
Extensor hallucis longus 
Extensor digitorum longus 
Peroneal longus 
Peroneal brevis 
Table 4.4. Tendon sheaths scanned for tenosynovitis (grey scale and power Doppler 
assessments) 
Limb Joint 
Upper Limb 
Thumb interphalangeal 
Thumb carpometacarpal 
Index finger distal interphalangeal 
Index finger proximal interphalangeal 
Index finger metacarpophalangeal 
Wrist  
Elbow 
Lower Limb 
Knee 
Ankle 
Table 4.5. Joints scanned for synovitis (grey scale and power Doppler assessments) 
All structures were examined in at least two perpendicular planes, and care was taken 
to obtain comparable views of the contralateral side. Joints were continually assessed 
during the scanning of the tendon insertions and bursae. The positioning of participants 
is described in Chapter 3.1.6. The retrocalcaneal bursa around the heel was assessed 
during scanning of the Achilles tendon and plantar aponeurosis insertions while the 
participant lay prone. Examinations of the medial and lateral tendon sheaths of the foot 
occurred with the patient sat supine and with the knee flexed to 30 degrees, following 
assessment of the peroneal brevis tendons. Knee bursae (suprapatellar, superficial 
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infrapatellar and deep infrapatellar) were also scanned in this position during imaging of 
the knee tendon entheses. The olecranon bursa was assessed at the time of scanning 
the distal brachial triceps tendon.  
4.2.6.2 Ultrasound Image Interpretation 
Ultrasound images were interpreted at the time of scanning. Enthesopathy, bone 
erosion, tenosynovitis and synovial hypertrophy were identified according to the 
definitions provided by the Outcome Measures in Rheumatoid Arthritis Clinical Trials 
(OMERACT) Special Interest Group for Musculoskeletal Ultrasound in Rheumatology 
(Figure 4.2, Figure 4.3, Figure 4.4 and Figure 4.5) (Wakefield et al., 2005). Bursitis was 
defined as a well circumscribed, localised anechoic or hypoechoic area at the site of an 
anatomical bursa which was compressible by the transducer with bursal wall thickening, 
with or without periburseal or intraburseal power Doppler signal (Schmidt et al., 2004). 
 
Figure 4.2. OMERACT definition of enthesopathy (Wakefield et al., 2005). 
 
Figure 4.3. OMERACT definition of enthesopathy (Wakefield et al., 2005). 
 
Figure 4.4. OMERACT definition of tenosynovitis (Wakefield et al., 2005). 
OMERACT definition of enthesopathy: ‘Abnormally hypoechoic (loss of 
normal fibrillar architecture) and/or thickened tendon or ligament at its 
bony attachment (may occasionally contain hyperechoic foci consistent 
with calcification), seen in two perpendicular planes that may exhibit 
Doppler signal and/or bony changes including enthesophytes, erosions, 
or irregularity.’  
OMERACT definition of bone erosion: ‘An intraarticular discontinuity of 
the bone surface that is visible in two perpendicular planes’. 
OMERACT definition of tenosynovitis: ‘Hypoechoic or anechoic 
thickened tissue with or without fluid within the tendon sheath, which is 
seen in two perpendicular planes and which may exhibit Doppler signal’.   
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Figure 4.5. OMERACT definition of synovial hypertrophy (Wakefield et al., 2005). 
The following parameters were assessed for enthesopathy: 
• Tendon thickness at its bony attachment site 
• Hypoechoic change within the tendon at the bony attachment site 
• Power Doppler signal within the tendon at the bony attachment site 
• Calcification within the tendon at the bony attachment site 
• Enthesophytes arising around the tendon attachment site 
• Erosions arising within the bone around the tendon attachment site 
• Irregularities within the usually smooth bony cortex around the tendon attachment 
site  
The following parameters were assessed for tenosynovitis: 
• Hypoechoic tendinous sheath thickening 
• Power Doppler signal within the tendon sheath 
The following parameters were assessed for synovitis: 
• Synovial hypertrophy (non-compressible hypoechoic intracapsular area) 
• Power Doppler signal within the synovial intraarticular tissue 
The following parameters were assessed for bursitis: 
• Bursal wall hypertrophy and/or synovial proliferation with a well circumscribed 
hypoechoic area 
• Periburseal or intraburseal Power Doppler signal  
4.2.6.3  Ultrasound Scoring 
Ultrasound parameters were scored either quantitatively or semi-quantitatively. 
Thickness measurements and bone erosions were scored quantitatively, while 
hypoechogenicity, power Doppler signal, calcifications, enthesophytes, bone cortex 
irregularities, bursal hypertrophy, tenosynovitis and synovitis were score semi-
quantitatively. 
 
OMERACT definition of synovial hypertrophy: ‘Abnormal hypoechoic 
(relative to subdermal fat, but sometimes may be isoechoic or 
hyperechoic) intraarticular tissue that is non-displaceable and poorly 
compressible and which may exhibit Doppler signal.’  
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4.2.6.3.1 Entheseal Thickness 
The thickness of each enthesis was measured at its widest point at the insertion point 
on longitudinal scans. Three measurements were taken per enthesis in an attempt to 
avoid error due to transducer obliquity and the average of the three recorded. 
Where available, normal values for the thickness of each insertion were accepted as 
reported in the literature and are listed in Table 4.6 (Balint et al., 2002, Gibbon and Long, 
1999, de Miguel et al., 2009, Roberts et al., 1999, van Holsbeeck and Introcaso, 1991). 
Tendon 
Thickness 
threshold 
Reference 
Achilles ≥ 5.29mm 
van Holsbeeck M, Introcaso J. In: van Holsbeeck 
M, Introcaso J, eds. Musculoskeletal Ultrasound. 
St. Louis: Mosby Year Book, 1991:318. 
Cited by Balint P, Kane D, Wilson H et al. Ann 
Rheum Dis 2002;61:905-10. 
Plantar Aponeurosis ≥ 4.4mm 
Gibbon W, Long G. Skeletal Radiol 1999;28:21-6. 
Cited by Balint P, Kane D, Wilson H et al. Ann 
Rheum Dis 2002;61:905-10. 
Quadriceps ≥ 6.1mm 
van Holsbeeck M, Introcaso J. In: van Holsbeeck 
M, Introcaso J, eds. Musculoskeletal Ultrasound. 
St. Louis: Mosby Year Book, 1991:318. 
Cited by Balint P, Kane D, Wilson H et al. Ann 
Rheum Dis 2002;61:905-10. 
Proximal Patellar ≥ 4.0mm 
van Holsbeeck M, Introcaso J. In: van Holsbeeck 
M, Introcaso J, eds. Musculoskeletal Ultrasound. 
St. Louis: Mosby Year Book, 1991:318. 
Cited by Balint P, Kane D, Wilson H et al. Ann 
Rheum Dis 2002;61:905-10. 
Distal Patellar ≥ 4.0mm 
van Holsbeeck M, Introcaso J. In: van Holsbeeck 
M, Introcaso J, eds. Musculoskeletal Ultrasound. 
St. Louis: Mosby Year Book, 1991:318. 
Cited by Balint P, Kane D, Wilson H et al. Ann 
Rheum Dis 2002;61:905-10. 
Distal Brachial Triceps ≥ 4.3mm 
de Miguel E, Cobo T, Munoz-Fernandez S et al. 
Ann Rheum Dis 2009;68:169-74. 
Table 4.6. Published tendon insertion measurement thresholds, above which entheses 
are deemed thickened. 
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Normal thickness measurements are not published for the other tendons examined. 
While several studies have used ultrasound to look at entheseal thickening in patients 
with psoriasis and included upper limb sites such as the common flexor tendon, no 
measurement values are provided, with thickening being assessed subjectively by the 
sonographer. One of the objectives of this pilot study was to determine thresholds for 
entheseal thickness for those tendons where measurements have not been published 
be used as a more objective measure in a feasibility study of an investigational medicinal 
product, by allowing grading of severity and a more comprehensive assessment of 
change (Chapter 5).  
Within the literature providing measurements, only two deliver any methodology as to 
how the thresholds were reached. de Miguel and colleagues (de Miguel et al., 2009) 
assessed a number of different entheses during the development of an ultrasound 
enthesitis score and used those cited by Balint et al (Balint et al., 2002), with the 
exception of the distal brachial triceps tendon for which no published measurement 
exists. The value used was based on their own control group mean plus one standard 
deviation, to which 0.1mm was then added ‘to reduce subjectivity’.  An alternative method 
was used by Gibbon and Long (Gibbon and Long, 1999), who measured the plantar 
fascia in 48 asymptomatic control subjects (96 heels) and used the upper limit of the 
range as the cut off when examining a cohort of patients with inferior heel pain. Both 
methods were applied to the data from the 23 volunteers in the healthy control group and 
comparisons were made for those tendons where a measurement had been published 
to determine which was more suited to this data. The results can be found in Chapter 
4.4.5.1.  
Once determined from the healthy control group, the reference entheseal thickness 
thresholds were applied to the data from the patients with psoriasis. The published 
values were used where available, i.e. for the Achilles tendon, plantar aponeurosis, three 
knee tendons and distal brachial triceps tendon. 
The extent of thickening was assessed quantitatively in line with that used in a previous 
imaging study of peripheral subclinical enthesitis by Ash et al (Ash et al., 2012b).  
0 = Less than threshold 
1 = Greater than threshold but by less than1mm 
2 = ≥1mm above threshold but <2mm 
3 = ≥2mm above threshold 
4.2.6.3.2 Bone Erosions 
Erosions were scored quantitatively based on the diameter of lesions. The largest 
erosion at any one site was selected for scoring: 
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0 = absence of erosions               
1 = present and <2mm in diameter               
2 = present and 2-3mm in diameter             
3 = present and ≥ 3mm in diameter 
4.2.6.3.3 Other Grey Scale Assessments 
The presence and severity of all other grey scale assessments (entheseal 
hypoechogenicity, calcifications, enthesophytes, bone cortex irregularities, bursal 
hypertrophy, tenosynovitis and synovial hypertrophy) were scored semi-quantitatively: 
0 = absence                
1 = mild                
2 = moderate                 
3 = marked/severe 
4.2.6.3.4 Power Doppler Assessments 
The presence and severity of power Doppler signal at the entheses, tendon sheaths and 
joint synovium were scored semi-quantitatively: 
0 = absence 
1 = mild (£3 isolated signals) 
2 = moderate (>3 isolated signals or confluent signal in <50% of the area under 
examination) 
3 = marked (signals in >50% of the area under examination) 
4.2.6.3.5 Scoring Systems 
Similar to the widely published Glasgow Ultrasound Enthesitis Score (GUESS) score 
(Balint et al., 2002) and Sonographic Enthesitis Index (SEI) (Alcalde et al., 2007), 
summative scores were calculated to allow group comparisons of the extent of 
enthesopathy, although expanded here to include more entheseal sites and parameters 
(e.g. hypoechogenicity, power Doppler signal, bone cortex irregularities) which are now 
accepted as relevant since the publication of the GUESS and SEI scores in 2002 and 
2007 respectively (D'Agostino et al., 2003, Ash et al., 2012b, Wakefield et al., 2005, de 
Miguel et al., 2009). The GUESS score involves the calculation of one total score, 
whereas the SEI is composed of two summative scores; the SEI-A, including those signs 
of acute injury (thickening, hypoechogenicity, peritendinous oedema and bursitis (where 
appropriate)), and the SEI-C, which includes chronic changes (tendon tear, loss of 
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thickness, calcification and bone erosion). Using this as a template, the following scores 
were calculated: 
• Enthesopathy Inflammation Score: The sum of scores from the assessment of 
entheseal thickness, hypoechogenicity and power Doppler signal in all tendons, 
plus any bursal hypertrophy and power Doppler signal where appropriate, at all 
entheseal sites. 
Maximum score: 294 
 
• Enthesopathy Chronicity Score: The sum of scores from the assessment of 
entheseal calcification(s), enthesophytes, bone erosions and bone cortex 
irregularity, at all entheseal sites. 
Maximum Score: 312 
 
• Total Enthesopathy Score: The sum of the inflammation and chronicity scores.  
Maximum Score: 606 
 
In addition, scores were calculated for tenosynovitis and synovitis: 
 
• Tenosynovitis Score: The sum of scores from the grey scale assessment of 
tendon sheath thickening/hypoechogenicity and power Doppler signal at all 
examined sites. 
Maximum Score: 264 
 
• Synovitis score: The sum of the scores from the grey scale assessment of 
synovial hypertrophy/proliferation and power Doppler signal from all examined 
joints. 
Maximum Score: 144 
 
Scores were expected to be low as patients were included on the basis of no known 
rheumatological disease and no persistent symptoms in keeping with a diagnosis of 
psoriatic arthritis. The full scoring systems used (with parameters and anatomical sites) 
were as follows: 
4.2.6.3.6 Enthesopathy Scoring System 
The full enthesopathy scoring system is described in Chapter 4.4.5.1. using the results 
of the different methods to calculate entheseal thickness. 
4.2.6.3.7 Tenosynovitis Scoring System 
All scored 0-3, maximum possible 264. 
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THUMB: 
• Flexor pollicis longus tendon 
1. GS Tenosynovitis 
2. PD Tenosynovitis 
• Extensor pollicis longus tendon overlying the interphalangeal joint  
1. GS Tenosynovitis 
2. PD Tenosynovitis 
• Extensor pollicis longus tendon overlying the carpometacarpal joint  
1. GS Tenosynovitis 
2. PD Tenosynovitis 
INDEX FINGER: 
• Flexor digitorum profundus tendon 
1. GS Tenosynovitis 
2. PD Tenosynovitis 
• Extensor digitorum tendon 
1. GS Tenosynovitis 
2. PD Tenosynovitis 
WRIST: 
• Extensor compartment 1 – Abductor pollicis longus and extensor pollicis brevis 
tendons 
1. GS Tenosynovitis 
2. PD Tenosynovitis 
• Extensor compartment 2 – Extensor carpi radialis, longus and brevis tendons 
1. GS Tenosynovitis 
2. PD Tenosynovitis 
• Extensor compartment 3 – Extensor pollicis longus tendon 
1. GS Tenosynovitis 
2. PD Tenosynovitis 
• Extensor compartment 4 – Extensor digitorum tendon 
1. GS Tenosynovitis 
2. PD Tenosynovitis 
• Extensor compartment 5 – Extensor digiti minimi tendon 
1. GS Tenosynovitis 
2. PD Tenosynovitis 
• Extensor compartment 6 – Extensor carpi ulnaris tendon 
1. GS Tenosynovitis 
2. PD Tenosynovitis 
KNEE: 
• Quadriceps tendon  
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1. GS Tenosynovitis 
2. PD Tenosynovitis 
• Proximal patellar tendon 
1. GS Tenosynovitis 
2. PD Tenosynovitis 
• Distal patellar tendon 
1. GS Tenosynovitis 
2. PD Tenosynovitis 
FOOT AND ANKLE: 
• Posterior tibialis tendon 
1. GS Tenosynovitis 
2. PD Tenosynovitis 
• Flexor digitorum longus tendon 
1. GS Tenosynovitis 
2. PD Tenosynovitis 
• Flexor hallucis longus tendon 
1. GS Tenosynovitis 
2. PD Tenosynovitis 
• Anterior tibialis tendon 
1. GS Tenosynovitis 
2. PD Tenosynovitis 
• Extensor hallucis longus tendon 
1. GS Tenosynovitis 
2. PD Tenosynovitis 
• Extensor digitorum tendon 
1. GS Tenosynovitis 
2. PD Tenosynovitis 
• Peroneal longus tendon 
1. GS Tenosynovitis 
2. PD Tenosynovitis 
• Peroneal brevis tendon 
1. GS Tenosynovitis 
2. PD Tenosynovitis 
4.2.6.3.8 Synovitis Scoring System 
All scored 0-3, maximum possible 144. 
THUMB: 
• Interphalangeal joint  
1. GS Synovitis 
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2. PD Synovitis 
• Carpometacarpal joint  
1. GS Synovitis 
2. PD Synovitis 
INDEX FINGER: 
• Distal interphalangeal joint  
1. GS Synovitis 
2. PD Synovitis 
• Proximal interphalangeal joint 
3. GS Synovitis 
4. PD Synovitis 
• Metacarpophalangeal joint  
5. GS Synovitis 
6. PD Synovitis 
WRIST: 
• Wrist joint 
1. GS Synovitis 
2. PD Synovitis 
ELBOW: 
• Lateral elbow joint  
1. GS Synovitis 
2. PD Synovitis 
• Medial elbow joint 
1. GS Synovitis 
2. PD Synovitis 
• Posterior elbow joint  
1. GS Synovitis 
2. PD Synovitis 
KNEE: 
• Knee joint 
1. GS Synovitis 
2. PD Synovitis 
ANKLE: 
• Midline ankle joint 
1. GS Synovitis 
2. PD Synovitis 
FOOT: 
• Tarsometatarsal joint (between the base of 5th metatarsal and cuboid bone) 
1. GS Synovitis 
2. PD Synovitis 
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4.3 Statistical Analysis 
Categorical data are expressed as frequencies, and continuous variables are given as 
means (standard deviation, s.d.) or medians (interquartile range, IQR), depending on the 
distribution. Pearson’s c2 test was used to compare the frequencies of sonographic 
abnormalities between participant groups, and the Mann-Whitney U test was used to 
compare ultrasound scores, in addition to categorical variables (gender, skin type, 
smoking history). Comparisons between independent means were analysed using 
Student’s t test for continuous variables (age, BMI, alcohol consumption). Linear 
correlation between ultrasound scores (inflammation, chronic damage, total 
enthesopathy, tenosynovitis and synovitis) and demographic (gender, age, BMI, 
smoking history) and clinical covariates (age of psoriasis onset, duration of psoriasis, 
PASI, BSA, mNAPSI, number of psoriatic sites) were analysed by Spearman rank 
correlation or rank biserial rb (Somers D) depending on the type of data analysed; 
absolute rho values >0.3 and d values >0.4 are considered to indicate substantive 
correlation. p values are all two-sided and <0.05 were considered statistically significant. 
Statistical analysis was performed using IBM© SPSS© version 24.0. 
4.4 Results 
4.4.1 Participant Characteristics 
4.4.1.1 Patients with Psoriasis 
36 patients with moderate to severe psoriasis had abnormalities on their initial ultrasound 
scan consistent with inflammatory subclinical enthesitis. As part of their first clinical 
assessment (and standard NHS care within Leeds Teaching Hospitals NHS Trust), all 
patients with moderate to severe psoriasis have a series of serological investigations to 
ascertain their eligibility for immunosuppressive therapy, including a full blood count 
(FBC), urea and electrolytes (U&E), liver function tests (LFTs), C-reactive protein (CRP) 
level, cholesterol and triglycerides, anti-nuclear antibody (ANA) titre, hepatitis B and C 
serology and a QuantiFERON®-TB Gold test to detect mycobacterium tuberculosis (the 
cause of tuberculosis). Of these 36 patients, three were found to have abnormalities that 
precluded them from receiving a biologic drug without further investigation and 
treatment. One had a positive QuantiFERON-TB Gold test suggestive of latent 
tuberculosis, another had deranged LFTs secondary to alcohol excess and the third had 
a high ANA titre (anti-La antibody), requiring further investigation. These patients were 
therefore ineligible for this study, as recruits to this study were also asked to consider 
participation in a pilot drug trial investigating the use of a biological medicinal product 
(Chapter 5), for which an MRI scan was also required.  One patient declined participation 
based on the request to undergo an MRI scan (due to claustrophobia), while another 
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was ineligible as he was going on prolonged overseas travel and one chose, after careful 
consideration, to decline any systemic immunosuppressant therapy and requested a 
prescription for topical therapy only. Another patient was ineligible for inclusion, as when 
he returned for his clinical assessment and second ultrasound scan three weeks after 
his first, his psoriasis had virtually cleared (PASI 2.3). He attributed this to the use of oral 
ginseng from a Chinese Herbalist. Finally, a further patient expressed interest but failed 
to turn up for the assessment and ultrasound scan, and did not attend any further 
appointments made for her outside the study within the Department of Dermatology. 
28 patients consented to participate in the study after a period of at least seven days to 
consider the information supplied in the Patient Information Sheet. 15 male and 13 
female patients, aged between 20 and 74 years (mean 46.5 years) underwent a more 
detailed ultrasound scan of their peripheral joints following on from a detailed clinical 
examination and confirmation of eligibility. One patient was Asian (skin type V), and the 
remainder were Caucasian (skin types I, II and III). Body mass index (BMI) ranged from 
19.6kg/m2 to 46.0kg/m2, with a median of 29.6kg/m2. More than half of the patients (15 
out of 28) had a family history of psoriasis, and four had a family member with psoriatic 
arthritis. Eight had a family history of other rheumatological disorders (six with 
osteoarthritis, two with rheumatoid arthritis), and two had a family history of autoimmune 
disease (one with hypothyroidism, one with type I diabetes mellitus). 7 patients were 
current smokers, smoking between 10 and 20 cigarettes per day (with a median pack 
year history of 20.5 pack years), 10 patients were ex-smokers and 11 had never smoked. 
Of the ex-smokers, pack year history ranged from 1-80 pack years (median 26 pack 
years), and the time since stopped ranged from 1 year to 34 years (median 12 years). 
Four patients did not drink alcohol, and in the remaining 24, weekly consumption ranged 
from 2-76 units (median 17.5 units per week).  Table 4.7 compares these parameters 
with those from the healthy volunteer control group. 
4.4.1.2 Healthy Control Group Volunteers 
25 volunteers were enlisted, from which 23 volunteers (12 male and 11 female) were 
recruited. Two declined on the basis of the need to undergo an MRI scan (one was 
claustrophobic, the other had a history of a metal fragment in the eye). The 23 
participants were health professionals and researchers within the University of Leeds 
and their friends and family members. Volunteers ranged in age from 22 to 59 years, 
with a mean of 39.9 years. BMI ranged from 19.3kg/m2 to 49.1kg/m2, with a median of 
26.8kg/m2. All control group participants were Caucasian (skin type I, II or III) with the 
exception of one volunteer (skin type IV). Ten had a current or previous dermatological 
diagnosis (Acne vulgaris: 4; infantile eczema: 3; seborrhoeic dermatitis: 1; varicose 
eczema: 1; plantar eczema: 1), of which four had previously consulted with a 
dermatologist (three for acne, one for varicose eczema). None of the participants had 
 164 
ever consulted with a rheumatologist. Two had a family history of psoriasis but no 
psoriatic arthritis. Eight had a family history of osteoarthritis, one rheumatoid arthritis and 
one ankylosing spondylitis (the latter in a paternal great uncle). Autoimmune diseases 
occurred in the family members of six participants (coeliac disease: 2; hypothyroidism: 3 
(in one case combined with vitiligo and type I diabetes); Addisons disease: 1). One 
participant was a current smoker (7.5 pack year history), and four were ex-smokers 
(mean 8 pack years). Alcohol consumption averaged 12 units per week and two 
volunteers were tee-total. Table 4.7 compares these parameters with the participants 
with psoriasis and subclinical enthesitis.  
Characteristic 
Healthy 
Controls 
(n=23) 
Psoriasis 
Patients 
(n=28) 
Difference 
Gender [n (%)] 
Male 12 (52.2%) 15 (53.6%) 
p=0.920 
Female 11 (47.8%) 13 (46.4%) 
Age (years) [Mean (s.d.)] 39.9 (8.34) 46.5 (14.05) p=0.053 
Skin Type [n (%)] 
I 4 (17.4%) 5 (17.9%) 
p=0.665 
II 14 (60.9%) 12 (42.9%) 
III 4 (17.4%) 10 (35.7%) 
IV 1 (4.3%) 0 (0%) 
V 0 (0%) 1 (3.6%) 
VI 0 (0%) 0 (0%) 
BMI (kg/m2) [Median (IQR)] 26.8 (24.6, 31.5) 29.6 (28.2, 33.9) p=0.118 
Smoking Status [n (%)] 
Never 18 (78.3%) 11 (39.3%) 
p=0.007 
Current 1 (4.3%) 7 (25.0%) 
Previous 4 (17.4%) 10 (35.7%) 
Ever 5 (21.7%) 17 (60.7%) 
Cigarette pack years in current/ex-smokers 
[Median (IQR)] 7.9 (0,19.8) 7.0 (0, 22.8) p=0.809 
Alcohol consumption in drinkers (units/week) 
[Median (IQR)] 12.0 (5.0,25.5) 10.0 (6.25,20.0) p=0.519 
Family history of psoriasis [n (%)] 2 (8.7%) 15 (53.6%) p=0.0007 
Family history of psoriatic arthritis [n (%)] 0 (0%) 4 (14.3%) p=0.136 
Family history of other rheumatological disorder 
[n (%)] 10 (43.5%) 8 (28.6%) p=0.268 
Family history of autoimmune disease [n (%)] 6 (26.1%) 2 (7.1%) p=0.064 
Table 4.7. Comparison of demographic characteristics between healthy control group 
volunteers and psoriasis patients  
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No significant differences were observed between the groups in terms of gender, age, 
skin type and BMI. In keeping with previous studies, the patients with psoriasis appeared 
to lead an unhealthier lifestyle, with more participants smoking, and smoking more 
heavily than their counterparts in the control group, although these observations failed 
to meet statistical significance (Naldi et al., 2005). Alcohol consumption was similar in 
both groups. A family history of psoriasis was found significantly more frequently in those 
with psoriasis (p=0.0007), although this was not surprising given that 17 patients were 
positive for HLA-Cw06, a genetic risk allele for the development of psoriasis compared 
to just three in the healthy control group (p=0.0005). 
4.4.2 Clinical Characteristics (psoriasis patients only) 
Amongst the 28 patients with moderate to severe psoriasis, median PASI score was 17.1 
(range 10-60), and body surface area (BSA) 20% (range 10-50%). Patients had psoriasis 
symptoms for a median of 18 years, with onset anywhere from age 9 to 54 years (median 
22 years of age). 7 patients had type II psoriasis (with onset at the age of 40 or older), 
the remainder (75.0%) being type I. 
20 patients (71.4%) had current nail involvement with a median modified NAPSI score 
of 9.5 out of possible maximum of 140 (range 0-89). The frequencies of lesions (current 
and ever present) by anatomical site are listed in Table 4.8. Every patient had a positive 
DLQI questionnaire, with scores ranging between 3 and 30 out of possible maximum of 
30 (median 17.5), suggesting a high impact of psoriasis on quality of life.  
Anatomical 
location 
No. of Patients (%) 
Anatomical 
location 
No. of Patients (%) 
Nail 
n (%) 
Current 21 (75.0%) Trunk 
n (%) 
Current 27 (96.4%) 
Ever 21 (75.0%) Ever 27 (96.4%) 
Scalp 
n (%) 
Current 24 (85.7%) Lower limb 
n (%) 
Current 27 (96.4%) 
Ever 28 (100%) Ever 28 (100%) 
Retroauricular 
n (%) 
Current 19 (67.9%) Flexures 
n (%) 
Current 14 (50.0%) 
Ever 24 (85.7%) Ever 18 (64.3%) 
Gluteal cleft 
n (%) 
Current 17 (60.7%) Genitals 
n (%) 
Current 10 (35.7%) 
Ever 21 (75.0%) Ever 13 (46.4%) 
Umbilicus 
n (%) 
Current 11 (39.3%) Perianal 
n (%) 
Current 5 (17.9%) 
Ever 20 (71.4%) Ever 8 (28.6%) 
Face Current 12 (42.9%) Palms Current 5 (17.9%) 
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Anatomical 
location 
No. of Patients (%) 
Anatomical 
location 
No. of Patients (%) 
n (%) Ever 18 (64.3%) n (%) Ever 6 (21.4%) 
Upper limb 
n (%) 
Current 27 (96.4%) Soles 
n (%) 
Current 5 (17.9%) 
Ever 28 (100%) Ever 8 (28.6%) 
Dorsal hand(s) 
n (%) 
Current 14 (50.0%)    
Ever 18 (64.3)    
Table 4.8. Frequency of psoriatic lesions (present on current examination and ever 
present) by anatomical location. 
12 (42.9%) of 28 patients had tender entheseal points clinically despite reporting no 
clinical symptoms of joint pain, tenderness, stiffness or swelling. The number of sites 
found to be tender on examination was one in seven patients, two in three patients, four 
in one patient and twelve in one patient. No healthy volunteers had any significant tender 
entheseal sites. The presence of clinically detectable entheseal tenderness in the 
psoriasis group was so low that calculation of clinical entheseal indices was deemed of 
little value and insufficient for comparison with overall ultrasound scores. 
4.4.3 Serological Characteristics 
There were very few serological abnormalities in all participants. CRP was normal 
amongst the healthy control group but elevated above the standard cut off of <5.0mg/l 
in four psoriasis patients, all of which were most probably attributable to an acute, self-
limiting viral or bacterial illness such as an upper respiratory tract infection given the 
coryzal symptoms described. The highest measurement was marginally elevated at 
15.4mg/l, indicative of a very low level of systemic inflammation, as has been previously 
reported in psoriasis (Rocha-Pereira et al., 2004, Vanizor Kural et al., 2003a, Vanizor 
Kural et al., 2003b). ANA was negative in all participants, as was rheumatoid factor and 
anti-CCP antibody. Significantly more patients were positive for the HLA-Cw06 allele in 
the psoriasis patient group (17 versus 3, p=0.0005). Only one patient was positive for 
the HLA-B27 allele compared to no volunteers. 
4.4.4 Screening Questionnaires 
Despite providing a negative history of current or previous joint pain, stiffness and/or 
swelling to the candidate (LJS) during the initial assessment, only five of 28 patients with 
psoriasis submitted a negative PEST questionnaire. Using the advised cut off of a score 
of three or more, 11 of 28 patients screened positive, with eight achieving a score of 
 167 
three, and three having a score of four. All participants answered ‘no’ to the question 
‘Has a doctor ever told you that you have arthritis?’. 18 patients marked that they had 
previously had a swollen joint or joints, 12 reported heel pain and 8 stated that they had 
had a swollen toe or finger for no reason. On further questioning, no patient provided a 
convincing history consistent with inflammatory arthritis or dactylitis (most instances of 
joint swelling were traumatic and brief) and clinical examination did not identify any 
current joint swelling or tenderness, or dactylitis. Entheseal tenderness was minimal and 
found in just over one third of patients at very few sites (Chapter 4.4.2).  
Of the 12 psoriasis patients who answered ‘yes’ to the question ‘have you had pain in 
your heel?’, eight had sonographic evidence of enthesopathy at the Achilles tendon or 
plantar fascia insertion, and in all, this was inflammatory (hypoechoic change in eight 
and thickening in five). Tenderness was elicited clinically at the Achilles and/or plantar 
fascia in four patients, all of which reported heel pain on the PEST questionnaire. Three 
had corresponding inflammatory entheseal changes at ultrasound whilst the fourth was 
reported as normal. 
15 patients answered ‘yes’ to the question ‘do your fingernails or toenails have holes or 
pits?’. All of these patients had a mNAPSI score greater than 0 (range 3-89), with the 
majority (12/15) having a score greater than 10. Six further patients had also had a 
positive mNAPSI score, although nail changes were mild (mNAPSI score 2-11), and two 
of these patients had changes other than nail pitting (e.g. onycholysis and/or nail plate 
crumbling). 
All healthy volunteers had a PEST score below three, with seven participants scoring 1 
(all answering ‘yes’ to the question ‘have you ever had a swollen joint or joints?’) and 
one participant scoring 2 (answering ‘yes’ to the same question and ‘yes’ to the question 
relating to heel pain). On further questioning, all episodes of joint swelling were reported 
as short lived with a preceding history of acute trauma. No acute inflammatory or chronic 
sonographic abnormalities were found at either the Achilles tendon or plantar fascia in 
the participant who reported heel pain. 
4.4.5 Ultrasound Characteristics 
4.4.5.1 Entheseal Thickness Thresholds 
The methods published by de Miguel et al and Gibbon and Long were applied to the data 
from the healthy control group in this study, and it was found that the first method 
significantly over estimated the number of psoriasis patients with thickened entheses 
(Table 4.9). When comparing the values in this cohort (obtained by calculating the mean 
thickness + one standard deviation + 0.1mm) for a tendon where a published threshold 
existed, there was a notable difference, with the majority of published values being 
significantly higher (by up to 0.9mm). For example, this method produced a threshold of 
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≥3.5mm for the distal brachial triceps tendon entheses, compared with ≥4.3mm in the 
literature. Similarly, the Achilles tendon and plantar fascia insertion thresholds in this 
cohort were ≥4.4mm and ≥3.9mm respectively, compared with published thresholds of 
≥5.29mm and ≥4.4mm.  The same applied to the quadriceps (≥5.6mm versus ≥6.1mm) 
and distal patellar (≥3.8mm versus ≥4.0mm) tendon insertions, although the values for 
the proximal patellar tendon insertion were comparable (≥4.0mm in both cohorts).  
Using the method published by Gibbon and Long, the thresholds calculated using the 
upper limit of the range within the control group were more comparable to those in the 
published literature. For example, here the upper limit of the range for the Achilles tendon 
insertion thickness was ≥5.1mm, compared to ≥5.29mm, and for the plantar fascia, was 
≥4.7mm compared to the published ≥4.4mm. The distal brachial triceps tendon enthesis 
threshold in this cohort was ≥4.1mm compared with ≥4.3mm, and the knee tendon 
insertion thicknesses were all within 0.4mm of the published values (quadriceps tendon 
≥6.4mm versus ≥6.1mm; proximal patellar tendon ≥4.4mm versus ≥4.0mm; distal patella 
tendon ≥4.3mm versus ≥4.0mm). Although some of the thresholds in this healthy control 
cohort are up to 0.4mm higher than the published measurements, they are still closer 
than those obtained by using the method published by de Miguel and colleagues and it 
was therefore felt it was better to apply thresholds to the patient data that may 
underestimate the number of psoriasis patients with entheseal thickening rather than 
overestimate the incidence of subclinical enthesitis. 
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Right Thumb FPL 0.9 0.845 
≥0.8 ≥1.0 N/A Left Thumb FPL 0.9 0.799 
Mean 0.9 0.800 
Right Thumb EPL 0.7 0.762 
≥0.7 ≥1.0 N/A Left Thumb EPL 0.9 0.726 
Mean 0.8 0.700 
Right Index Finger FDP 0.9 0.809 
≥0.8 ≥1.0 N/A Left Index Finger FDP 0.9 0.766 
Mean 0.9 0.800 
Right Index Finger ED 0.6 0.589 
≥0.6 ≥0.9 N/A Left Index Finger ED 0.8 0.629 
Mean 0.7 0.600 
Right Elbow Common Extensor 4.8 4.509 ≥4.5 ≥4.9 N/A 
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Left Elbow Common Extensor 4.6 4.474 
Mean 4.7 4.500 
Right Elbow Common Flexor 4.4 3.940 
≥4.0 ≥4.7 N/A Left Elbow Common Flexor 4.6 4.062 
Mean 4.5 4.000 
Right Distal Brachial Triceps 4.0 3.619 
≥3.5 ≥4.1 ≥4.3 Left Distal Brachial Triceps 3.6 3.472 
Mean 3.8 3.500 
Right Quadriceps 6.3 5.678 
≥5.6 ≥6.4 ≥6.1 Left Quadriceps 6.0 5.452 
Mean 6.15 5.600 
Right Proximal Patellar 4.3 4.079 
≥4.0 ≥4.4 ≥4.0 Left Proximal Patellar 4.1 3.825 
Mean 4.2 4.000 
Right Distal Patellar 4.2 3.944 
≥3.8 ≥4.3 ≥4.0 Left Distal Patellar 4.1 3.746 
Mean 4.15 3.800 
Right Peroneal Brevis 1.8 1.658 
≥1.6 ≥1.9 N/A Left Peroneal Brevis 1.6 1.486 
Mean 1.7 1.600 
Right Achilles 4.5 4.321 
≥4.4 ≥5.1 ≥5.29 Left Achilles 5.0 4.472 
Mean 4.75 4.400 
Right Plantar Fascia 4.6 3.873 
≥3.8 ≥4.7 ≥4.4 Left Plantar Fascia 4.3 3.684 
Mean 4.45 3.800 
Table 4.9. Comparison of the different published methods for calculating tendon 
thickness thresholds and with published thresholds where available (FPL: Flexor pollicis 
longus; EPL: Extensor pollicis longus; FDP: Flexor digitorum profundus; ED: Extensor 
digitorum).   
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Using these thresholds, the following entheseal scoring system was applied to the data, 
based on the original GUESS score by Balint et al. (Balint et al., 2002). All lesions were 
scored 0-3, with a maximum possible total of 606: 
• THUMB: Base of distal phalynx - flexor pollicis longus tendon enthesis 
1. Flexor pollicis longus enthesis thickness ≥ 1.0mm 
2. Flexor pollicis longus enthesis hypoechogenicity 
3. Flexor pollicis longus enthesis power Doppler signal 
4. Base of distal phalynx calcification 
5. Base of distal phalynx enthesophyte(s) 
6. Base of distal phalynx bony erosion(s) 
7. Base of distal phalynx bony cortex irregularity 
 
• THUMB: Dorsal base of distal phalynx – extensor pollicis longus tendon enthesis 
1. Extensor pollicis longus enthesis thickness ≥ 1.0mm 
2. Extensor pollicis longus enthesis hypoechogenicity 
3. Extensor pollicis longus enthesis power Doppler signal 
4. Dorsal base of distal phalynx calcification 
5. Dorsal base of distal phalynx enthesophyte(s) 
6. Dorsal base of distal phalynx bony erosion(s) 
7. Dorsal base of distal phalynx bony cortex irregularity 
 
• INDEX FINGER: Distal phalynx base - flexor digitorum profundus 
1. Flexor digitorum profundus/superficialis enthesis thickness ≥ 1.0mm 
2. Flexor digitorum profundus/superficialis enthesis hypoechogenicity 
3. Flexor digitorum profundus/superficialis enthesis power Doppler signal 
4. Middle/distal phalynx base calcification 
5. Middle/distal phalynx base enthesophyte(s) 
6. Middle/distal phalynx base bony erosion(s) 
7. Middle/distal phalynx base bony cortex irregularity 
 
• INDEX FINGER: Distal phalynx base - extensor digitorum tendon enthesis 
1. Extensor digitorum enthesis thickness ≥ 0.9mm 
2. Extensor digitorum enthesis hypoechogenicity 
3. Extensor digitorum enthesis power Doppler signal 
4. Distal phalynx base calcification 
5. Distal phalynx base enthesophyte(s) 
6. Distal phalynx base bony erosion(s) 
7. Distal phalynx base bony cortex irregularity 
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• ELBOW: Lateral epicondyle of humerus - common extensor tendon enthesis 
1. Elbow common extensor enthesis thickness ≥ 4.9mm 
2. Elbow common extensor enthesis hypoechogenicity 
3. Elbow common extensor enthesis power Doppler signal 
4. Lateral epicondyle of humerus calcification 
5. Lateral epicondyle of humerus enthesophyte(s) 
6. Lateral epicondyle of humerus bony erosion(s) 
7. Lateral epicondyle of humerus bony cortex irregularity 
 
• ELBOW: Medial epicondyle of humerus - common flexor tendon enthesis  
1. Common flexor enthesis thickness ≥ 4.7mm 
2. Common flexor enthesis hypoechogenicity 
3. Common flexor enthesis power Doppler signal 
4. Medial epicondyle of humerus calcification 
5. Medial epicondyle of humerus enthesophyte(s) 
6. Medial epicondyle of humerus bony erosion(s) 
7. Medial epicondyle of humerus bony cortex irregularity 
 
• ELBOW: Olecranon process of the ulna - distal brachial triceps tendon enthesis 
1. Elbow distal brachial triceps enthesis thickness ≥ 4.3mm 
2. Elbow distal brachial triceps enthesis hypoechogenicity 
3. Elbow distal brachial triceps enthesis power Doppler signal 
4. Olecranon process of ulna calcification 
5. Olecranon process of ulna enthesophyte(s) 
6. Olecranon process of ulna bony erosion(s) 
7. Olecranon process of ulna bony cortex irregularity 
8. Olecranon bursitis (GS hypertrophy) 
9. Olecranon burseal power Doppler signal 
 
• KNEE: Superior pole of the patella - quadriceps tendon enthesis 
1. Quadriceps enthesis thickness ≥ 6.1mm 
2. Quadriceps enthesis hypoechogenicity 
3. Quadriceps enthesis power Doppler signal 
4. Superior pole of patella calcification 
5. Superior pole of patella enthesophyte(s) 
6. Superior pole of patella bony erosion(s) 
7. Superior pole of patella bony cortex irregularity 
8. Suprapatellar bursitis (GS hypertrophy) 
9. Suprapatellar burseal power Doppler signal 
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• KNEE: Inferior pole of the patella - proximal patellar tendon enthesis 
1. Proximal patellar enthesis thickness ≥ 4.0mm 
2. Proximal patellar enthesis hypoechogenicity 
3. Proximal patellar enthesis power Doppler signal 
4. Inferior pole of patella calcification 
5. Inferior pole of patella enthesophyte(s) 
6. Inferior pole of patella bony erosion(s) 
7. Inferior pole of patella bony cortex irregularity 
8. Superficial Infrapatellar bursitis (GS hypertrophy) 
9. Superficial Infrapatellar burseal power Doppler signal 
 
• KNEE: Tibial tuberosity - distal patellar tendon enthesis 
1. Distal patellar enthesis thickness ≥ 4.0mm 
2. Distal patellar enthesis hypoechogenicity 
3. Distal patellar enthesis power Doppler signal 
4. Tibial tuberosity calcification 
5. Tibial tuberosity enthesophyte(s) 
6. Tibial tuberosity bony erosion(s) 
7. Tibial tuberosity bony cortex irregularity 
8. Deep Infrapatellar bursitis (GS hypertrophy)  
9. Deep Infrapatellar burseal power Doppler signal  
 
• FOOT: 5th metatarsal base lateral tuberosity - peroneal brevis tendon enthesis 
1. Peroneal brevis enthesis thickness ≥ 1.9mm 
2. Peroneal brevis enthesis hypoechogenicity 
3. Peroneal brevis enthesis power Doppler signal 
4. 5th metatarsal base lateral tuberosity calcification 
5. 5th metatarsal base lateral tuberosity enthesophyte(s) 
6. 5th metatarsal base lateral tuberosity bony erosion(s) 
7. 5th metatarsal base lateral tuberosity bony cortex irregularity 
 
• ANKLE: Superior pole of calcaneus - Achilles tendon enthesis 
1. Achilles enthesis thickness ≥ 5.29mm 
2. Achilles enthesis hypoechogenicity 
3. Achilles enthesis power Doppler signal 
4. Posterior pole of calcaneus calcification 
5. Posterior pole of calcaneus enthesophyte(s) 
6. Posterior pole of calcaneus bony erosion(s) 
7. Posterior pole of calcaneus bony cortex irregularity 
8. Retrocalcaneal bursitis (GS hypertrophy) 
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9. Retrocalcaneal bursae power Doppler signal 
 
• FOOT: Inferior pole of calcaneus - plantar aponeurosis (fascia) enthesis 
1. Plantar aponeurosis thickness ≥ 4.4mm 
2. Plantar aponeurosis hypoechogenicity 
3. Plantar aponeurosis power Doppler signal 
4. Inferior pole of calcaneus calcification 
5. Inferior pole of calcaneus enthesophyte(s) 
6. Inferior pole of calcaneus bony erosion(s) 
7. Inferior pole of calcaneus bony cortex irregularity 
4.4.5.2 Enthesopathy and Bursal Changes 
26 entheseal sites (13 per side) were scanned in each participant, totalling 728 entheses 
in 28 patients with moderate to severe psoriasis and known sonographic evidence of 
enthesitis and 598 entheses in 23 healthy volunteers.  A total of 425 entheseal 
abnormalities were identified in the psoriasis group, compared with 63 in the healthy 
control group. Four healthy volunteers had no enthesopathy.  Table 4.10 describes these 
abnormalities at the entheseal and patient level.  
Te
nd
on
 
Parameter 
Healthy Control  
Group 
Patients with 
Psoriasis 
Enthesis 
(max 
n=46) 
Patient 
(max 
n=23) 
Enthesis 
(max 
n=56) 
Patient 
(max 
n=28) 
n % n % n % n % 
Th
um
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Thickening 0 0.0 0 0.0 9 16.1 7 25.0 
Hypoechogenicity 0 0.0 0 0.0 0 0.0 0 0.0 
Power Doppler signal 0 0.0 0 0.0 0 0.0 0 0.0 
Calcifications 0 0.0 0 0.0 0 0.0 0 0.0 
Enthesophytes 0 0.0 0 0.0 4 7.1 3 10.7 
Bony erosions 0 0.0 0 0.0 0 0.0 0 0.0 
Bone cortex irregularities 1 2.2 1 4.3 15 26.8 11 39.2 
Ex
te
ns
or
 p
ol
lic
is
 lo
ng
us
 Thickening 0 0.0 0 0.0 4 7.1 4 14.3 
Hypoechogenicity 0 0.0 0 0.0 1 1.8 1 3.6 
Power Doppler signal 0 0.0 0 0.0 0 0.0 0 0.0 
Calcifications 1 2.2 1 4.3 0 0.0 0 0.0 
Enthesophytes 0 0.0 0 0.0 6 10.7 4 14.3 
Bony erosions 0 0.0 0 0.0 0 0.0 0 0.0 
Bone cortex irregularities 0 0.0 0 0.0 8 14.3 6 21.4 
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Parameter 
Healthy Control  
Group 
Patients with 
Psoriasis 
Enthesis 
(max 
n=46) 
Patient 
(max 
n=23) 
Enthesis 
(max 
n=56) 
Patient 
(max 
n=28) 
n % n % n % n % 
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 Thickening 0 0.0 0 0.0 5 8.9 5 17.9 
Hypoechogenicity 0 0.0 0 0.0 0 0.0 0 0.0 
Power Doppler signal 0 0.0 0 0.0 0 0.0 0 0.0 
Calcifications 0 0.0 0 0.0 2 3.6 2 7.1 
Enthesophytes 0 0.0 0 0.0 0 0.0 0 0.0 
Bony erosions 0 0.0 0 0.0 0 0.0 0 0.0 
Bone cortex irregularities 1 2.2 1 4.3 5 8.9 4 14.3 
Ex
te
ns
or
 d
ig
ito
ru
m
 
Thickening 0 0.0 0 0.0 1 1.8 1 3.6 
Hypoechogenicity 0 0.0 0 0.0 2 3.6 1 3.6 
Power Doppler signal 0 0.0 0 0.0 0 0.0 0 0.0 
Calcifications 0 0.0 0 0.0 1 1.8 1 3.6 
Enthesophytes 0 0.0 0 0.0 3 5.4 3 10.7 
Bony erosions 0 0.0 0 0.0 0 0.0 0 0.0 
Bone cortex irregularities 1 2.2 1 4.3 7 12.5 4 14.3 
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w
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r 
Thickening 0 0.0 0 0.0 16 28.6 10 35.7 
Hypoechogenicity 2 4.3 2 8.7 15 26.8 11 39.2 
Power Doppler signal 0 0.0 0 0.0 2 3.6 2 7.1 
Calcifications 0 0.0 0 0.0 0 0.0 0 0.0 
Enthesophytes 0 0.0 0 0.0 3 5.4 2 7.1 
Bony erosions 0 0.0 0 0.0 0 0.0 0 0.0 
Bone cortex irregularities 0 0.0 0 0.0 6 10.7 4 14.3 
C
om
m
on
 F
le
xo
r 
Thickening 0 0.0 0 0.0 15 26.8 8 28.6 
Hypoechogenicity 1 2.2 1 4.3 8 14.3 5 17.9 
Power Doppler signal 0 0.0 0 0.0 0 0.0 0 0.0 
Calcifications 0 0.0 0 0.0 1 1.8 1 3.6 
Enthesophytes 0 0.0 0 0.0 4 7.1 3 10.7 
Bony erosions 0 0.0 0 0.0 0 0.0 0 0.0 
Bone cortex irregularities 0 0.0 0 0.0 4 7.1 3 10.7 
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Parameter 
Healthy Control  
Group 
Patients with 
Psoriasis 
Enthesis 
(max 
n=46) 
Patient 
(max 
n=23) 
Enthesis 
(max 
n=56) 
Patient 
(max 
n=28) 
n % n % n % n % 
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Thickening 0 0.0 0 0.0 4 7.1 4 14.3 
Hypoechogenicity 1 2.2 1 4.3 0 0.0 0 0.0 
Power Doppler signal 0 0.0 0 0.0 0 0.0 0 0.0 
Calcifications 1 2.2 1 4.3 5 8.9 4 14.3 
Enthesophytes 0 0.0 0 0.0 6 10.7 4 14.3 
Bony erosions 0 0.0 0 0.0 1 1.8 1 3.6 
Bone cortex irregularities 0 0.0 0 0.0 0 0.0 0 0.0 
Olecranon bursal hypertrophy 0 0.0 0 0.0 0 0.0 0 0.0 
PD within olecranon bursa  0 0.0 0 0.0 0 0.0 0 0.0 
K
ne
e 
Q
ua
dr
ic
ep
s 
Thickening 1 2.2 1 4.3 17 30.4 11 39.2 
Hypoechogenicity 2 4.3 2 8.7 18 32.1 13 46.4 
Power Doppler signal 0 0.0 0 0.0 0 0.0 0 0.0 
Calcifications 4 8.7 4 17.4 21 37.5 15 53.6 
Enthesophytes 7 15.2 5 21.7 22 39.3 13 46.4 
Bony erosions 0 0.0 0 0.0 0 0.0 0 0.0 
Bone cortex irregularities 2 4.3 2 8.7 5 8.9 3 10.7 
Suprapatellar bursal hypertrophy 0 0.0 0 0.0 0 0.0 0 0.0 
PD within suprapatellar bursa 0 0.0 0 0.0 0 0.0 0 0.0 
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al
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Thickening 10 21.7 5 21.7 20 35.7 13 46.4 
Hypoechogenicity 1 2.2 1 4.3 12 21.4 8 28.6 
Power Doppler signal 0 0.0 0 0.0 1 1.8 1 3.6 
Calcifications 0 0.0 0 0.0 5 8.9 3 10.7 
Enthesophytes 1 2.2 1 4.3 6 10.7 4 14.3 
Bony erosions 0 0.0 0 0.0 0 0.0 0 0.0 
Bone cortex irregularities 0 0.0 0 0.0 3 5.4 2 7.1 
D
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l P
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Thickening 3 7.5 2 8.7 28 50.0 18 67.9 
Hypoechogenicity 2 4.3 2 8.7 7 12.5 7 25.0 
Power Doppler signal 0 0.0 0 0.0 0 0.0 0 0.0 
Calcifications 2 4.3 2 8.7 11 19.6 7 25.0 
Enthesophytes 0 0.0 0 0.0 4 7.1 3 10.7 
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Parameter 
Healthy Control  
Group 
Patients with 
Psoriasis 
Enthesis 
(max 
n=46) 
Patient 
(max 
n=23) 
Enthesis 
(max 
n=56) 
Patient 
(max 
n=28) 
n % n % n % n % 
Bony erosions 0 0.0 0 0.0 1 1.8 1 3.6 
Bone cortex irregularities 1 2.2 1 4.3 3 5.4 3 10.7 
Superficial infrapatellar bursal hypertrophy 0 0.0 0 0.0 2 3.6 2 7.1 
PD within superficial infrapatellar bursa 0 0.0 0 0.0 1 1.8 1 3.6 
Deep infrapatellar bursal hypertrophy 0 0.0 0 0.0 1 1.8 1 3.6 
PD within deep infrapatellar bursa 0 0.0 0 0.0 0 0.0 0 0.0 
Fo
ot
 a
nd
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nk
le
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al
 B
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s 
Thickening 0 0.0 0 0.0 7 12.5 5 17.9 
Hypoechogenicity 0 0.0 0 0.0 0 0.0 0 0.0 
Power Doppler signal 0 0.0 0 0.0 0 0.0 0 0.0 
Calcifications 0 0.0 0 0.0 1 1.8 1 3.6 
Enthesophytes 0 0.0 0 0.0 2 3.6 2 7.1 
Bony erosions 0 0.0 0 0.0 0 0.0 0 0.0 
Bone cortex irregularities 0 0.0 0 0.0 3 5.4 3 10.7 
A
ch
ill
es
 
Thickening 0 0.0 0 0.0 7 12.5 6 21.4 
Hypoechogenicity 2 4.3 2 8.7 6 10.7 5 17.9 
Power Doppler signal 0 0.0 0 0.0 0 0.0 0 0.0 
Calcifications 4 8.7 3 13.0 5 8.9 5 17.9 
Enthesophytes 9 19.6 6 26.1 14 25.0 9 32.1 
Bony erosions 0 0.0 0 0.0 1 1.8 1 3.6 
Bone cortex irregularities 1 2.2 1 4.3 3 5.4 2 7.1 
Retrocalcaneal bursal hypertrophy 1 2.2 1 4.3 0 0.0 0 0.0 
PD within retrocalcaneal bursa 0 0.0 0 0.0 0 0.0 0 0.0 
Pl
an
ta
r F
as
ci
a 
Thickening 2 4.3 2 8.7 12 21.4 9 32.1 
Hypoechogenicity 0 0.0 0 0.0 11 19.6 9 32.1 
Power Doppler signal 0 0.0 0 0.0 0 0.0 0 0.0 
Calcifications 0 0.0 0 0.0 4 7.1 4 14.3 
Enthesophytes 0 0.0 0 0.0 2 3.6 2 7.1 
Bony erosions 0 0.0 0 0.0 0 0.0 0 0.0 
Bone cortex irregularities 0 0.0 0 0.0 0 0.0 0 0.0 
Table 4.10. Comparison between patients with psoriasis and healthy volunteers of the 
number of entheseal and bursal abnormalities by anatomical site and lesion at the 
entheseal/bursal and patient level  
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Significantly higher rates of entheseal thickening (p<0.000001), hypoechogenicity 
(p<0.00001), enthesophytes (p<0.00001), calcifications (p=0.00003) and bone cortex 
irregularities (p<0.00001) were observed in the group of patients with moderate to severe 
psoriasis. Bone erosions and power Doppler signal were not found in any healthy 
volunteers, and only in very low frequencies among patients with psoriasis (both 
p=0.258). 
In patients with psoriasis, the following abnormalities were observed: 
• Entheseal thickening in 145 entheses (19.9%) 
• Hypoechogenicity in 80 entheses (11.0%) 
• Power Doppler signal in 3 entheses (0.4%) 
• Enthesophytes in 76 entheses (10.4%) 
• Calcifications in 56 entheses (7.7%) 
• Bone cortex irregularities in 62 entheses (8.5%) 
• Bone erosions in 3 entheses (0.4%) 
 
Among volunteers in the healthy control group, the following abnormalities were 
observed: 
• Entheseal thickening in 16 entheses (2.7%) 
• Hypoechogenicity in 11 entheses (1.8%) 
• Power Doppler signal in 0 entheses (0%) 
• Enthesophytes in 17 entheses (2.8%) 
• Calcifications in 12 entheses (2.0%) 
• Bone cortex irregularities in 7 entheses (1.2%) 
• Bone erosions in 0 entheses (0%) 
 
Inflammatory lesions (thickening, hypoechogenicity and/or power Doppler signal) were 
identified in 31.3% of entheses scanned in the psoriasis group compared to 4.5% in the 
healthy control group (p<0.00001). Chronic lesions (enthesophytes, calcifications, bone 
erosions and/or bone cortex irregularities) were seen in 27.0% of entheses in the disease 
group compared to 6.0% of healthy volunteers (p<0.00001). 
In terms of the location of all lesions, the larger tendons were most frequently involved 
in both groups, especially the three knee tendons (quadriceps, proximal patellar and 
distal patellar) and the common extensor and flexor tendons of the elbow (Figure 4.6). 
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Figure 4.6. Percentages of entheses by location demonstrating inflammatory 
abnormalities (thickening, hypoechogenicity and/or power Doppler signal) – comparison 
between psoriasis patients and healthy control group participants. (FPL: Flexor Pollicis 
Longus; EPL: Extensor Pollicis Longus; ED: Extensor Digitorum; FDP: Flexor Digitorum 
Profundus). *denotes a significant difference between groups (p<0.05). 
Rates of inflammatory lesions were significantly greater in those with psoriasis, with over 
40% of entheses being involved (quadriceps 62.5% vs. 6.5%, p<0.00001; distal patellar 
62.5% vs. 10.9%, p<0.00001) (Figure 4.7); proximal patellar 58.9% vs. 23.9%, 
p=0.00038; common extensor 58.9% vs. 4.3%, p<0.00001; common flexor 41.1% vs. 
2.2%, p=0.00004; plantar fascia 41.1% vs. 4.3%, p=0.00002). Very few inflammatory 
lesions were found in the smaller tendons of the digits and ankle (Figure 4.8) in healthy 
control group participants (Table 4.11).   
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Figure 4.7. Right distal patellar tendon insertion in (a) an asymptomatic patient with 
moderate to severe psoriasis, demonstrating entheseal thickening (, grade 2), 
hypoechogenicity (Õ, grade 2), calcification (, grade 1) and bone cortex irregularities 
(, grade 1) and (b) a healthy volunteer (no abnormalities). PT: Patellar tendon; Tib: 
Tibia.  
 
Figure 4.8.  Right peroneal brevis tendon insertion in (a) an asymptomatic patient with 
moderate to severe psoriasis, demonstrating entheseal thickening (, grade 1), 
calcification (, grade 1) and bone cortex irregularities (, grade 1) and (b) a healthy 
volunteer (no abnormalities). PB: Peroneal brevis; MT: Fifth metatarsal. 
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Of the inflammatory lesions in the non-disease group, the changes were a mixture of 
thickening (2.7%) and hypoechogenicity (1.8%) (no power Doppler signal), which are 
most probably attributable to age-related degeneration and/or localised injury. For 
example, one participant, on further detailed questioning, reported an injury relating to 
recreational running around the time of the ultrasound scan, which was evident 
sonographically as unilateral Achilles tendonitis (hypoechoic change). No patients in the 
psoriasis group reported any sporting injuries or trauma. 
Tendon Enthesis 
Percentage frequency of entheses with                               
inflammatory abnormalities 
Psoriasis 
Patient 
Group 
Healthy 
Control 
Group 
Difference 
Distal patella 62.5 10.9 p<0.00001 
Quadriceps 62.5 6.5 p<0.00001 
Proximal patella 58.9 23.9 p=0.00038 
Common extensor 58.9 4.3 p<0.00001 
Plantar fascia 41.1 4.3 p=0.00002 
Common flexor 41.1 2.2 p=0.00004 
Achilles 23.2 4.3 p=0.0074 
Thumb flexor pollicis longus 16.1 0.0 p=0.0111 
Peroneal brevis 12.5 0.0 p=0.0319 
Thumb extensor pollicis longus 8.9 0.0 p=0.0896 
Index finger flexor digitorum profundus 8.9 0.0 p=0.0896 
Distal brachial triceps 7.1 2.2 p=0.247 
Index finger extensor digitorum 5.4 0.0 p=0.247 
Table 4.11. Comparison of the percentage of inflammatory lesions by enthesis type 
between patients with psoriasis and healthy control group participants. Bold denotes 
significance p<0.05. 
Inflammatory burseal lesions were observed infrequently, with no hypertrophy or power 
Doppler signal seen in the olecranon and suprapatellar bursae in either group.  Two 
psoriasis patients had unilateral grey scale superficial infrapatellar bursal hypertrophy, 
one with additional power Doppler signal, and one patient had unilateral deep 
infrapatellar bursal hypertrophy (Figure 4.9). Unilateral grey scale retrocalcaneal bursal 
hypertrophy was seen in only one healthy volunteer, without power Doppler signal.  
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Figure 4.9. Right deep infrapatellar burseal hypertrophy (B) associated with adjacent 
entheseal thickening (, grade 2), hypoechogenicity (Õ, grade 2), calcification (, grade 
1) and bone cortex irregularities (, grade 1) in a patient with moderate to severe 
psoriasis. B: Bursa; PT: Patella tendon; Pat: Patella. 
Lesions indicative of chronic damage and degeneration were again significantly more 
common in all tendon entheses when compared to healthy control participants (Figure 
4.10 and Table 4.12), with the exception of the foot entheses (Achilles tendon p=0.266, 
plantar fascia insertion p=0.0536, peroneal brevis enthesis p=0.0536), and the flexor 
digitorum profundus tendon of the index finger (p=0.0536)  The majority of chronic 
lesions identified at the Achilles were enthesophytes, followed by entheseal calcification. 
The Achilles is perhaps the enthesis that sustains the most amount of microtrauma of all 
through walking and everyday activity, and it is proposed that the continued damage-
repair cycle that takes place may account for the new bone formation resulting in the 
development of enthesophytes.  
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*
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B
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Figure 4.10. Percentages of entheses by location demonstrating chronic damage 
abnormalities (enthesophytes, calcifications, bone cortex irregularities and bone 
erosions) – comparison between psoriasis patients and healthy control group 
participants. (FPL: Flexor Pollicis Longus; EPL: Extensor Pollicis Longus; ED: Extensor 
Digitorum; FDP: Flexor Digitorum Profundus). *denotes a significant difference between 
groups (p<0.05). 
Tendon Enthesis 
Percentage frequency of entheses with                               
chronic damage abnormalities 
Psoriasis 
Patient 
Group 
Healthy 
Control 
Group 
Difference 
Quadriceps 85.7 28.3 p<0.0.0001 
Achilles 41.1 30.4 p=0.266 
Distal patellar 33.9 6.5 p=0.0008 
Thumb flexor pollicis longus 33.9 2.2 p=0.00006 
Proximal patella 25.0 2.2 p=0.0012 
Thumb extensor pollicis longus 25.0 2.2 p=0.0014 
Distal brachial triceps 21.4 2.2 p=0.0037 
Index finger extensor digitorum 19.6 2.2 p=0.0064 
Common extensor 16.1 0.0 p=0.0111 
Common flexor 16.1 0.0 p=0.0111 
Index finger flexor digitorum profundus 12.5 2.2 p=0.0536 
Plantar fascia 10.7 0.0 p=0.0536 
Peroneal brevis 10.7 0.0 p=0.0536 
Table 4.12. Comparison of the total number and percentage of chronic damage lesions 
by enthesis type between patients with psoriasis and healthy control group participants. 
Bold denotes significance p<0.05. 
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The quadriceps tendon enthesis demonstrated a disproportionately high degree of 
chronic damage in both groups (85.7% in the psoriasis group vs. 28.3% in the healthy 
control group), which again may be accountable to a high degree of stress and 
microdamage caused at this major enthesis, which is then further attenuated by the pro-
inflammatory cascade in those with a genetic predisposition to psoriatic disease. 
Inflammatory lesions were seen in 62.5% of quadriceps entheses in the psoriasis group 
compared to 6.5% of healthy control group participants (Figure 4.11).  
 
 
 
 
Figure 4.11. Left quadriceps tendon enthesis demonstrating entheseal thickening (, 
grade 2), hypoechogenicity (Õ, grade 2), bone cortex irregularities and enthesophytes 
(, grade 1) in a patient with moderate to severe psoriasis. QT: Quadriceps tendon; Pat: 
Patella. 
Chronic damage lesions were seen to a lesser degree in the other entheses, which 
sustain a lesser amount of daily stress and microdamage. However, these lesions were 
always at a significantly greater frequency than healthy controls, again suggesting that 
the genetic aberrations in patients with psoriasis leads to an additional inflammatory 
insult at the enthesis that in turn attenuates the consequences of microdamage and 
repair. 
4.4.5.2.1 Enthesopathy Scores 
In terms of the severity of enthesopathy, the majority (81.1%) of abnormalities (both 
chronic and inflammatory) were mild and scored only as grade 1. 28 (12.1%) of 232 
inflammatory lesions observed were of moderate severity (grade 2) and seven (3.0%) 
were severe (grade 3). 43 (21.8%) of 197 chronic damage lesions were grade 2, and 
three (1.5%) were grade 3.   
Overall mean enthesopathy scores were low, but were still significantly greater in those 
with psoriasis than healthy volunteers (p<0.0001 for all scores): 
• Enthesopathy Inflammation Score (out of a maximum of 294): 
o Psoriasis group participants = 10.04 ±7.08 
o Healthy control group participants = 1.09 ±1.38  
• Enthesopathy Chronic Score (out of a maximum of 312): 
QT
QT
Pat
Pat
 *
*
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o Psoriasis group participants = 9.25 ±7.18 
o Healthy control group participants = 1.96 ±1.92  
• Enthesopathy Total Score (out of a maximum of 606): 
o Psoriasis group participants = 19.29 ±12.68 
o Healthy control group participants = 3.04 ±2.59  
4.4.5.2.2 Correlation of Ultrasound Enthesopathy Scores with Clinical Entheseal 
Tenderness and Screening Questionnaires 
In each participant, 14 entheses could be examined both clinically and sonographically 
(medial and lateral epicondyles of the humerus corresponding to the common flexor and 
extensor tendon insertions at the elbow, quadriceps insertion at the patella, inferior pole 
of the patella corresponding to the insertion of the proximal patellar tendon, tibial tubercle 
corresponding to the distal patellar tendon enthesis, proximal Achilles tendon and plantar 
fascia insertion at the calcaneus). 
12 patients with psoriasis had at least one tender enthesis on clinical examination, 
involving a total of 30 entheses at 19 different sites. Of these, seven entheses at six sites 
could not be easily visualised sonographically or were not included in the ultrasound 
protocol (posterior superior iliac spines bilaterally, left anterior superior iliac spine, left 
iliac crest, medial femoral condyles bilaterally).  Of the remaining 23 clinically tender 
entheses, 12 had evidence of inflammatory enthesopathy (thickening and/or 
hypoechogenicity) on ultrasound, one of which also had chronic damage changes 
(calcifications) and a further site had evidence of chronic damage (enthesophytes) 
without any inflammation. 47.8% of clinically tender entheses were showed no signs of 
inflammation on ultrasound. There was no significant difference in overall mean 
inflammation scores between those patients with clinical enthesitis (9.98 ±7.68, n=12) 
and those without (10.12 ±7.02, n=16) (p=0.960). 
11 of 28 psoriasis patients had a positive PEST screening questionnaire (score of 3 or 
more). No significant differences were observed between patients with a positive and 
negative PEST in terms of mean overall ultrasound inflammation score (10.1 ±4.91 vs. 
6.88 ±4.72, p=0.095), mean chronic damage scores (8.00 ±4.47 vs. 7.00 ±6.95, p=0.676) 
and mean total enthesopathy scores (18.09 ±6.72 vs.13.88 ±9.69, p=0.221). 
4.4.5.3 Tenosynovitis 
Rates of tenosynovitis or peritendonitis were very low in both groups, as demonstrated 
in Figure 4.12. Only three healthy volunteers (13%) had sonographic evidence of 
tenosynovitis, two in a single tendon (both posterior tibialis), and one in two adjacent 
tendons (peroneal longus and brevis). Tenosynovitis was mild (grade 1), unilateral and 
with no associated power Doppler signal.  
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Figure 4.12. Comparison of percentage number of tendons with grey scale synovitis 
between patients with psoriasis and healthy volunteers (EPL: Extensor pollicis longus; 
FDP: Flexor digitorum profundus; FPL: Flexor pollicis longus; EPL: Extensor pollicis 
longus; ED: Extensor digitorum). 
Tenosynovitis or peritendonitis was detected in a greater number of tendons in patients 
with psoriasis than healthy volunteers, although due to the low frequency of tenosynovitis 
in both groups, no significant differences were observed (p=0.199). 11 of 28 patients 
(39.3%) had tenosynovitis, in either one (n=6), two (n=2) or three (n=2) tendons, affecting 
both large and small tendons (Figure 4.13). Knee tendons had the most abnormalities, 
although rates overall were still low – grey scale peritendonitis of the proximal patellar 
tendon occurred in 8.9% of tendons (Table 4.13).  
 
Figure 4.13. Longitudinal view of right peroneus longus tendon demonstrating grey scale 
tenosynovitis with thickening (, grade 2) and hypoechogenicity (Õ, grade 2) in a patient 
with moderate to severe psoriasis. SP: Styloid process at base of 5th metatarsal head; 
Cub: Cuboid. 
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Peritendoneal power Doppler signal was seen in three psoriasis patients, two unilaterally 
in a single tendon (thumb extensor pollicis longus tendon/distal patellar tendon) (Figure 
4.14) and one bilaterally in the proximal patellar tendons.  
 
Figure 4.14. Left distal patella tendon demonstrating grey scale and power Doppler 
peritendonitis (circled, grade 1) in association with adjacent entheseal thickening (, 
grade 2), hypoechogenicity (Õ, grade 2), power Doppler signal (circled, grade 1), bone 
cortex irregularities and enthesophytes (, grade 2) in a patient with moderate to severe 
psoriasis. PT: Patellar tendon; Tib: Tibia. 
Overall mean tenosynovitis scores were not significantly greater in the psoriasis group 
(1.04 ±1.774) compared with healthy volunteers (0.26 ±0.619) volunteers (p=0.052). 
*
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Tib
Tendon 
M
od
e 
Healthy Control 
Group 
Patients with 
Psoriasis 
Tendon 
(max n=46) 
Patient 
(max n=23) 
Tendon 
(max n=56) 
Patient 
(max n=28) 
n % n % n % n % 
Th
um
b 
Flexor pollicis longus 
GS 0 0.0 0 0.0 0 0.0 0 0.0 
PD 0 0.0 0 0.0 0 0.0 0 0.0 
EPL overlying the 
interphalangeal joint 
GS 0 0.0 0 0.0 0 0.0 0 0.0 
PD 0 0.0 0 0.0 0 0.0 0 0.0 
EPL overlying the 
carpometacarpal joint 
GS 0 0.0 0 0.0 1 1.8 1 3.5 
PD 0 0.0 0 0.0 1 1.8 1 3.5 
In
de
x 
Fi
ng
er
 
Flexor digitorum profundus 
GS 0 0.0 0 0.0 1 1.8 1 3.5 
PD 0 0.0 0 0.0 0 0.0 0 0.0 
Extensor digitorum 
GS 0 0.0 0 0.0 0 0.0 0 0.0 
PD 0 0.0 0 0.0 0 0.0 0 0.0 
W
ris
t 
Extensor Compartment 1 
(APL and EPB) 
GS 0 0.0 0 0.0 0 0.0 0 0.0 
PD 0 0.0 0 0.0 0 0.0 0 0.0 
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Table 4.13. Comparison of the frequencies of grey scale and power Doppler 
tenosynovitis/peritendonitis at the patient and tendon level between patients with 
psoriasis and healthy controls (EPL: Extensor pollicis longus; APL: Abductor pollicis 
longus; EPB: Extensor pollicis brevis; ECR: Extensor carpi radialis; ECL: Extensor carpi 
longus; ECB: Extensor carpi brevis). 
Extensor Compartment 2 
(ECR, ECL, ECB) 
GS 0 0.0 0 0.0 0 0.0 0 0.0 
PD 0 0.0 0 0.0 0 0.0 0 0.0 
Extensor Compartment 3 
(Extensor pollicis longus) 
GS 0 0.0 0 0.0 0 0.0 0 0.0 
PD 0 0.0 0 0.0 0 0.0 0 0.0 
Extensor Compartment 4 
(Extensor digitorum) 
GS 0 0.0 0 0.0 0 0.0 0 0.0 
PD 0 0.0 0 0.0 0 0.0 0 0.0 
Extensor Compartment 5 
(Extensor digiti minimi) 
GS 0 0.0 0 0.0 0 0.0 0 0.0 
PD 0 0.0 0 0.0 0 0.0 0 0.0 
Extensor Compartment 6 
(Extensor carpi ulnaris) 
GS 0 0.0 0 0.0 0 0.0 0 0.0 
PD 0 0.0 0 0.0 0 0.0 0 0.0 
K
ne
e 
Quadriceps 
GS 0 0.0 0 0.0 1 1.8 1 3.5 
PD 0 0.0 0 0.0 0 0.0 0 0.0 
Proximal Patellar 
GS 0 0.0 0 0.0 5 8.9 3 10.7 
PD 0 0.0 0 0.0 3 5.4 2 7.1 
Distal Patellar 
GS 0 0.0 0 0.0 1 1.8 1 3.5 
PD 0 0.0 0 0.0 0 0.0 0 0.0 
Fo
ot
 a
nd
 A
nk
le
 
Posterior Tibialis 
GS 3 6.5 2 8.7 2 3.6 2 7.1 
PD 0 0.0 0 0.0 0 0.0 0 0.0 
Flexor Digitorum Longus 
GS 0 0.0 0 0.0 1 1.8 1 3.5 
PD 0 0.0 0 0.0 0 0.0 0 0.0 
Flexor Hallucis Longus 
GS 0 0.0 0 0.0 0 0.0 0 0.0 
PD 0 0.0 0 0.0 0 0.0 0 0.0 
Anterior Tibialis 
GS 0 0.0 0 0.0 0 0.0 0 0.0 
PD 0 0.0 0 0.0 0 0.0 0 0.0 
Extensor Hallucis Longus 
GS 0 0.0 0 0.0 0 0.0 0 0.0 
PD 0 0.0 0 0.0 0 0.0 0 0.0 
Extensor Digitorum 
Longus 
GS 0 0.0 0 0.0 0 0.0 0 0.0 
PD 0 0.0 0 0.0 0 0.0 0 0.0 
Peroneal Longus 
GS 1 2.2 1 4.3 2 3.6 2 7.1 
PD 0 0.0 0 0.0 0 0.0 0 0.0 
Peroneal Brevis 
GS 1 2.2 1 4.3 1 1.8 1 3.5 
PD 0 0.0 0 0.0 0 0.0 0 0.0 
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In terms of correlation with other abnormalities within the synovio-entheseal complex, of 
the 16 tendons with tenosynovitis identified in patients with psoriasis, only nine had 
corresponding entheses included in the ultrasound protocol. While the body of a tendon 
can be easily visualised, not all tendon insertion sites are readily seen on ultrasound, for 
example, the flexor digitorum longus tendon in the foot. However, a corresponding 
enthesis organ can be visualised, where then tendon runs over a bony prominence, and 
is subject to the same mechanical shearing forces during movement as a true enthesis. 
Of the nine sites with corresponding true entheses examined by ultrasound, seven had 
associated enthesopathy, all of which had inflammatory thickening and/or hypoechoic 
changes (five of which also had calcification, enthesophytes and cortical irregularities) 
(Figure 4.14). 
4.4.5.4 Synovitis 
Synovitis was common among patients with psoriasis, with 23 of 28 (82.1%) patients 
having at least one joint affected. Table 4.14 displays the frequencies of grey scale and 
power Doppler synovial changes by joint. Grey scale abnormalities were most frequently 
seen in the wrists (46.4% of wrist joints scanned), followed by the thumb 
carpometacarpal joint (39.3%) and the index metacarpophalangeal joint (21.4%).  
Joint 
M
od
e 
Healthy Control Group Patients with Psoriasis 
Joint 
(max n=46) 
Patient 
(max n=23) 
Joint  
(max n=56) 
Patient   
(max n=28) 
n % n % n % n % 
Th
um
b Interphalangeal 
GS 0 0.0 0 0.0 7 12.5 6 21.4 
PD 0 0.0 0 0.0 0 0.0 0 0.0 
Carpometacarpal 
GS 3 6.5 3 13.0 22 39.3 14 50.0 
PD 0 0.0 0 0.0 1 1.8 1 3.6 
In
de
x 
Fi
ng
er
 
Distal    
Interphalangeal 
GS 0 0.0 0 0.0 8 14.3 8 28.6 
PD 0 0.0 0 0.0 0 0.0 0 0.0 
Proximal 
Interphalangeal 
GS 0 0.0 0 0.0 8 14.3 5 17.9 
PD 0 0.0 0 0.0 0 0.0 0 0.0 
Metacarpophalangeal 
GS 0 0.0 0 0.0 12 21.4 8 28.6 
PD 0 0.0 0 0.0 3 5.4 2 7.1 
Wrist 
GS 12 26.1 8 34.8 26 46.4 17 60.7 
PD 0 0.0 0 0.0 4 7.1 4 14.3 
El
bo
w
 Lateral Elbow 
GS 0 0.0 0 0.0 26 46.4 17 60.7 
PD 0 0.0 0 0.0 4 7.1 4 14.3 
Medial Elbow 
GS 0 0.0 0 0.0 0 0.0 0 0.0 
PD 0 0.0 0 0.0 0 0.0 0 0.0 
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Posterior Elbow 
GS 0 0.0 0 0.0 0 0.0 0 0.0 
PD 0 0.0 0 0.0 0 0.0 0 0.0 
Knee 
GS 3 6.5 2 8.7 0.0 0 0.0 0 
PD 0 0.0 0 0.0 0.0 0 0.0 0 
Ankle 
GS 2 4.3 1 4.3 1 1.8 1 3.6 
PD 0 0.0 0 0.0 0 0.0 0 0.0 
Tarsometatarsal 
GS 0 0.0 0 0.0 0 0.0 0 0.0 
PD 0 0.0 0 0.0 0 0.0 0 0.0 
Table 4.14. Comparison of the frequency of grey scale synovial hypertrophy and synovial 
power Doppler signal by joint between patients with psoriasis and healthy volunteers. 
Grey scale synovitis, while present in healthy volunteers, occurred at significantly lower 
rates than in patients with psoriasis (wrist joint 46.4% vs. 26.1% in healthy controls, 
p=0.0345; thumb carpometacarpal joint 39.3% vs. 6.5%, p=0.0001; index 
metacarpophalangeal joint 21.4% vs. 0%, p=0.0021; knee joint 17.9% vs. 6.5%, 
p=0.0876; index finger distal interphalangeal joint 14.3% vs 0%, p=0.0188; index finger 
proximal interphalangeal joint 14.3% vs. 0%, p=0.0188; thumb interphalangeal joint 
12.5% vs. 0%, p=0.0319), with the exception of the ankle joint (1.8% vs. 4.3% in healthy 
controls, p=0.446) (Figure 4.15).  
 
Figure 4.15. Comparison of the frequency of joints with grey scale synovial hypertrophy 
between patients with psoriasis and healthy volunteers (CMC: Carpometacarpal; MCP: 
Metacarpophalangeal; DIP: Distal interphalangeal; PIP: Proximal interphalangeal; IP: 
Interphalangeal; TMT: Tarsometatarsal). *denotes a significant difference between 
groups (p<0.05). 
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Power Doppler was identified in a total of eight joints (1.2% of all joins scanned) in the 
psoriasis patient group and not in any healthy volunteers (Figure 4.16). No significant 
differences were seen between the groups at any site. No synovitis (grey scale or PD) 
was seen at the elbow in either group.  
 
Figure 4.16. Comparison of the frequency of joints with synovial power Doppler signal 
between patients with psoriasis and healthy volunteers (CMC: Carpometacarpal; MCP: 
Metacarpophalangeal; DIP: Distal interphalangeal; PIP: Proximal interphalangeal; IP: 
Interphalangeal; TMT: Tarsometatarsal). 
Overall mean synovitis scores were significantly higher in patients with psoriasis (4.46 
±3.97) than healthy volunteers (0.96 ±1.15) (p<0.0001). In the psoriasis group, no 
significant differences were observed between patients with a positive PEST (score >3) 
or negative PEST questionnaire and mean overall synovitis score (4.55 ±3.53 vs. 3.18 
±2.96, p=0.278).  
4.4.5.5 Associations between clinical assessments and ultrasound 
findings 
Associations between ultrasound scores and a number of clinical and demographic 
parameters were analysed using Spearman rank correlation, with the exception for 
ordinal and nominal data correlations, where rank biserial rb (Somers D) was used. 
Absolute rho values >0.3 and d>0.4 were considered to indicate substantive correlation.  
In the previous chapter, patients with a positive ultrasound (i.e. at least one inflammatory 
abnormality at screening) were found to be older than those who had a negative 
ultrasound (p<0.001), and using dichotomous scoring (present/absent) for entheseal 
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abnormalities, a positive association was found between age and all enthesopathy 
scores. In this group of 28 patients, this association was further explored taking into 
account the severity of individual lesions, and increasing age was found to correlate only 
with greater chronic damage scores (rho=0.66), and therefore total enthesopathy scores 
(rho=0.51) (Table 4.15). In the healthy volunteer group, age correlated with chronic 
damage score (rho=0.33) but not inflammation score (rho=0.07), total enthesopathy 
score (rho=0.28), synovitis score (rho=0.26) or tenosynovitis score (rho=0.05). 
BMI was found in the previous chapter to correlate with all enthesopathy scores, but in 
this cohort a positive association was only found with inflammation score (rho=0.39) and 
total enthesopathy score (rho=0.33). In the healthy volunteer group, BMI also correlated 
with the inflammation score (rho=0.41) and total enthesopathy score (rho=0.36), but not 
chronic damage, synovitis or tenosynovitis scores.  
The link between the presence and severity of nail disease in patients with psoriasis 
(using the mNAPSI score) and severity of subclinical enthesitis has previously been 
reported (Ash et al., 2012b). In the cohort in this thesis, the mNAPSI score positively 
correlated with inflammation scores for the entheses (rho=0.32) and synovial joints 
(rho=0.49). Higher chronic damage scores were seen in those who had had psoriasis for 
longer (rho=0.44), and who had smoked for longer. No associations were seen in relation 
to the burden of psoriasis, as assessed by PASI score, BSA involvement and the number 
of sites involved (currently or ever), PEST score or the number of entheseal points tender 
on clinical examination and any ultrasound scores.   
Correlations Inflammation Score 
Chronic 
Damage 
Score 
Total 
Enthesopathy 
Score 
Total 
Synovitis 
Score 
Total 
Tenosynovitis 
Score 
Age rho=0.08 rho=0.66* rho=0.51* rho=0.30 rho=0.16 
Gender d=0.14 d=0.16 d=0.14 d=0.25 d=-0.11 
BMI rho=0.39* rho=0.21 rho=0.33* rho=0.25 rho=-0.14 
PASI score rho=-0.26 rho=-0.07 rho=-0.19 rho=0.03 rho=0.30 
mNAPSI score rho=0.32* rho=0.17 rho=0.26 rho=0.29 rho=-0.02 
BSA rho=-0.16 rho=-0.07 rho=-0.12 rho=0.05 rho=0.26 
Duration of 
Psoriasis rho=-0.16 rho=0.44* rho=0.22 rho=015 rho=0.30 
Age of Psoriasis 
Onset rho=0.17 rho=0.10 rho=0.18 rho=0.00 rho=-0.16 
Smoker (ever) d=0.14 d=0.25 d=0.27 d=0.16 d=-0.10 
Smoking pack 
years rho=0.21 rho=0.50* rho=0.49* rho=0.29 rho=-0.15 
No. of PsO sites 
(current) rho=-0.006 rho=-0.05 rho=-0.06 rho=0.29 rho=0.05 
No. of PsO sites 
(ever) rho=-0.001 rho=0.02 rho=-0.008 rho=0.32 rho=-0.07 
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Correlations Inflammation Score 
Chronic 
Damage 
Score 
Total 
Enthesopathy 
Score 
Total 
Synovitis 
Score 
Total 
Tenosynovitis 
Score 
No. of clinically 
tender entheses rho=0.28 rho=-0.17 rho=0.18 rho=0.11 rho=0.07 
PEST Score rho=0.26 rho=0.19 rho=0.29 rho=0.13 rho=0.02 
(Table 4.15. Associations between demographic and clinical parameters, and 
enthesopathy, tenosynovitis and synovitis scores. rho=Spearman rank correlation 
coefficient. d=Rank biserial correlation coefficient (Somers D). Values in bold represent 
rho>0.3 and are considered to represent a substantive correlation (PsO: psoriasis). 
*denotes significance at p<0.05 level. 
4.5 Discussion 
A consensus definition for enthesitis remains undetermined within the published 
literature, with the OMERACT Ultrasound Task Force recently questioning what should 
be classed as an ‘inflammatory’ abnormality (Terslev et al., 2014). The main parameter 
for debate was entheseal thickness, which some experts felt should be included as an 
inflammatory change, while others attributed this to be a structural damage abnormality. 
Both arguments have merit; in the acute phase, increased thickness may be present due 
to inflammation as demonstrated by McGonagle et al, with soft tissue oedema seen at 
the plantar fascia enthesis on MRI (McGonagle et al., 2002b). However, thickening could 
also arise as a result of the disorganised repair process in psoriatic disease as a 
consequence of resolving inflammation. The current published OMERACT definition is 
for enthesopathy and encompasses both inflammatory and chronic damage 
abnormalities, and this was the basis for the ultrasound protocol used in this cohort study 
(Wakefield et al., 2005). In keeping with previous studies, thickness was included as part 
of the inflammation parameters, although the validity of this could be challenged. Further 
research could include improved imaging and histological analysis. This may, in part, 
explain why there are so few published reference values for entheseal thickness, and 
this is the first attempt to provide a means of calculating such measurements to 
standardise what is meant by the term ‘entheseal thickening’.  
The most widely published scoring system for sonographic assessments of the entheses 
is the Glasgow Ultrasound Enthesitis Scoring System (GUESS), but as discussed in the 
previous chapter, GUESS does not include assessments of hypoechogenicity, an 
accepted key inflammatory abnormality, nor calcifications or bony cortical irregularities 
(Balint et al., 2002). GUESS also does not include any assessments of sites outside of 
the lower limb, and as shown in the previous chapter, the distribution of subclinical 
entheseal lesions is diverse. This is the first study to assess all aspects of the OMERACT 
definition of enthesopathy and in a wide variety of upper and lower limb entheses in one 
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ultrasound protocol, for use in patients with psoriasis and subclinical enthesitis and 
healthy volunteers. 
Total enthesopathy scores were calculated in both groups to encapsulate the overall 
burden of chronic and inflammatory abnormalities in all participants, to reflect the 
OMERACT definition in full. However, analyses were also performed on separate 
inflammation and chronic damage scores as it was expected that healthy volunteers may 
have a degree of structural abnormality through age-related degeneration, plus 
understanding the inflammatory burden in psoriasis patients could have future 
implications on therapeutic choice, if it were shown that inflammatory abnormalities were 
responsive to skin-directed treatment with immunosuppressive agents.  
The use of a scoring system to encompass the severity of abnormalities facilitated a 
meaningful comparison with a group of healthy volunteers who were broadly matched 
(as a cohort) in terms of gender, age and BMI. Simply using the presence/absence of 
lesions is not adequate given the frequency of abnormalities among the normal 
population. Quantifying the full spectrum of abnormalities showed the severity of 
subclinical enthesopathy to be generally mild in patients with psoriasis, although the 
variety of abnormalities and the number of entheses involved were significantly greater 
than in healthy volunteers, resulting in higher enthesopathy scores in patients with 
psoriasis. These results are in accordance with those of previous (but more limited) 
studies that have also compared entheseal imaging abnormalities in psoriatic patients 
and healthy controls (Ash et al., 2012b, Bandinelli et al., 2013, de Miguel et al., 2009, De 
Simone et al., 2003, Gisondi et al., 2008, Gutierrez et al., 2011, Naredo et al., 2011, 
Ozcakar et al., 2005).  Gutierrez et al identified grey scale enthesopathy in 8.4% of 
entheses examined in healthy controls, compared with 10.5% in this cohort (Gutierrez et 
al., 2011). Of these, 4.5% of abnormalities were inflammatory, which is similar to the rate 
seen by Naredo and colleagues (5.3%) (Naredo et al., 2011). No power Doppler was 
seen in any controls in these studies, supporting previous observations that a switch to 
a vascular phenotype at tendon insertion sites may be the link to arthritis development 
in genetically predisposed patients with psoriatic disease (Aydin et al., 2013a).  
Entheseal thickening was the most frequent inflammatory abnormality amongst healthy 
volunteers and in similarity to previous studies, predominantly affected the weight-
bearing knee entheses (Gisondi et al., 2008, Gutierrez et al., 2011, Naredo et al., 2011). 
Thickening of the proximal patella enthesis (21.7%) was higher than that reported in 
other studies (2.2-5.6%), but similar rates were observed at the quadriceps (2.2-7.8%) 
and distal patella entheses (3.3-6.5%). Limited thickening was observed at the Achilles 
tendon and plantar fascia as previously shown (Gutierrez et al., 2011) and no 
abnormalities were seen in the smaller, non-weight bearing entheses in the hand. 
Increased BMI was related in both groups to higher inflammation scores, which would 
support the concept of most microtrauma and resultant inflammation occurring at 
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entheseal sites enduring most mechanical strain (Moshrif et al., 2017). It appears that 
the initial insult leading to inflammation is the same regardless of the presence of 
psoriasis, but in genetically-primed individuals, this is sustained and not resolved without 
leaving lasting structural damage. 
Only 6% of entheses in healthy volunteers had any structural damage abnormalities, 
which are thought to occur as a result of age-related degeneration and normal ‘wear and 
tear’. Healthy volunteers were, on average, six years younger than patients with 
psoriasis, potentially influencing the degree of age-related degeneration in this group, 
although the difference in age did not reach statistical significance.  Despite this 
discrepancy, in both groups, increased age was associated with greater chronic damage 
scores, although scores were significantly higher in psoriasis patients suggesting that 
the process of developing structural abnormalities is augmented not only as a 
consequence of age, but also due to a prolonged inflammatory insult at the enthesis. 
Erosions specifically appear to occur as a consequence of this prolonged inflammation, 
with no healthy volunteers in this study, or others, exhibiting osseous destructions 
(Bandinelli et al., 2013, De Simone et al., 2003, Gisondi et al., 2008, Gutierrez et al., 
2011). Data regarding the presence of cortical irregularities and calcifications have not 
been published, and in this cohort, were also rarely observed in healthy volunteers, seen 
in just 1.2% and 2.0% of entheseal insertions respectively. Enthesophytes were the most 
frequent chronic damage abnormality, but still seen at low frequency (2.8%), which is 
comparable to previous findings (Gisondi et al., 2008, Gutierrez et al., 2011). They were 
seen with the greatest frequency at the Achilles tendon and quadriceps insertions, 
presumably as a response to mechanical loading at these sites. Chronic damage 
abnormalities were frequently accompanied by synovitis in healthy volunteers at these 
sites.  
Aside from inflammatory and chronic damage entheseal abnormalities, overall scores 
were also calculated for tenosynovitis and synovitis for all participants in order to assess 
the full burden of inflammation within the synovio-entheseal complex. Scores for burseal 
abnormalities were incorporated into enthesopathy scores. Few previous studies have 
looked beyond the enthesis in patients with psoriasis to surrounding structures to enable 
comparison of findings, particularly with regard to the presence/severity synovitis 
(Naredo et al., 2011) and tenosynovitis (Naredo et al., 2011), with more having included 
bursitis (Ash et al., 2012b, Bandinelli et al., 2013, De Simone et al., 2003, Gisondi et al., 
2008, Gutierrez et al., 2011). However, no previous studies have made a full SEC 
assessment including all of these structures within the same cohort. 
Inflammation within the adjacent bursae has previously been shown to occur with 
variable frequency in patients with psoriasis and concurrent subclinical enthesopathy.  In 
similarity to this cohort, Acquitter and colleagues identified a very low frequency of 
bursitis (1.4% of bursae) although the anatomical sites of positivity are not disclosed 
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(Acquitter et al., 2016). Naredo et al also found low rates of bursitis at the knee 
(suprapatellar bursitis 1.6%, infrapatellar bursitis 0%) but higher rates at the ankle 
(retrocalcaneal bursitis 10.0%) (Naredo et al., 2011). Similar rates were found in studies 
by Gutierrez (retrocalcaneal bursitis 8.9%) and Ash (11%, sites not specified) (Ash et al., 
2012b, Gutierrez et al., 2011). In studies of patients with psoriasis and known PsA or 
musculoskeletal symptoms, rates were much higher in term of retrocalcaneal bursitis 
(33.9%) (De Simone et al., 2011), and infrapatellar bursitis (10.8-15.2%) (Bandinelli et 
al., 2013). Despite this early cohort exhibiting low rates of burseal hypertrophy in patients 
with psoriasis, it does appear from other studies that the frequency and severity of 
bursitis may progress with time, making it a worthwhile inclusion in a comprehensive 
ultrasound protocol. Only one healthy volunteer exhibited one area of grey-scale bursitis 
(out of 230 bursae examined) as a consequence of a sports injury (during marathon 
training), and previous studies support the absence of bursitis in the healthy, non-
psoriatic population (Bandinelli et al., 2013, Gisondi et al., 2008, Naredo et al., 2011). 
Only one previous study has examined the presence of tenosynovitis in patients with 
psoriasis, without PsA (Naredo et al., 2011). Examination was limited to the extensor 
and flexor tendons of the fingers, and identified peritendinous tissue oedema and 
tenosynovitis in 0.4% and 0.3% of tendons respectively. In this cohort of psoriasis 
patients, inflammation of the tendon sheath or peritendinous tissue was also seen with 
very low frequency (1.5%). Given the infrequent finding of tenosynovitis/peritendinitis, no 
significant differences were observed between psoriasis patients and healthy volunteers 
in either cohort, with tenosynovitis/peritendinitis seen in 0.2% of sites in the previous 
study, and 0.5% in this group of healthy volunteers. Due to the small number of patients 
with tenosynovitis/peritendinitis, any interpretation should be considered with caution. 
However, based on these preliminary observations, dissipation of inflammation along the 
tendon away from the insertion site does not appear to be a major association of 
subclinical enthesopathy although further larger scale studies would be needed to 
confirm these findings. However, ‘tendonitis’ has been reported in the Achilles tendon in 
40.7% of a cohort of psoriasis patients with symptoms (11 of whom had a diagnosis of 
PsA), and ‘peritendonitis’ in 7 of 59, suggesting that tenosynovitis and peritendinous 
tissue oedema should be assessed, albeit as a later event, as part of an ultrasound 
protocol for patients with psoriasis. 
The prominence of synovitis in psoriasis patients with subclinical enthesopathy has been 
discussed in Chapter 3. In similarity to the only other study to include assessments of 
the synovial joints in both psoriasis patients and healthy volunteers, grey scale synovial 
hypertrophy was significantly more frequent in psoriatic patients (32.6%, p=0.005) 
(Naredo et al., 2011). Amongst healthy volunteers in both cohorts, synovitis was seen 
most frequently at the wrist (26.1% vs. 9.8%) and knee (6.5% vs. 9.8%) compared to the 
ankle (4.5% vs. 0%), and no synovitis was seen in the proximal interphalangeal, distal 
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interphalangeal or metacarpophalangeal joints of the finger(s). Ultrasound findings 
suggestive of synovial inflammation have been shown to occur frequently in the healthy 
population (Millot et al., 2011, Ellegaard et al., 2007, Terslev et al., 2003), although most 
data are from studies of rheumatoid arthritis and relate to the small joints of the hands.  
The patients with psoriasis in the present cohort were selected as they were known to 
have at least one inflammatory entheseal abnormality on ultrasound, and many had 
inflammatory abnormalities at other sites within the synovio-entheseal complex. 
Interestingly, despite being deemed to be currently asymptomatic and have had no prior 
persistent musculoskeletal complaints consistent with inflammatory arthritis, 11 of 28 
patients had a positive PEST screening questionnaire (score ³3/5) for a diagnosis of 
PsA. At first glance, this appears encouraging, in that screening questionnaires may be 
helpful in detecting patients with subclinical musculoskeletal disease, especially as no 
healthy volunteers had a score ³3. However, on reviewing the questions to which 
patients gave a positive answer, the most frequent question was ‘Have you ever had a 
swollen joint or joints?’ and it was the use of the word ‘ever’ that prompted respondents 
to tick ‘yes’. Many patients, like healthy volunteers, responded ‘yes’ as they had 
sustained an injury following a fall or sporting injury that had resolved within days to 
weeks. Also, patients were aware that they had subclinical enthesitis on their screening 
ultrasound and were taking part in a clinical trial looking for further musculoskeletal 
abnormalities. This may have imposed a positive bias on their decision to report any 
previous minor and self-limiting musculoskeletal problem. No participants in either group 
reported recurrent or sustained symptoms or signs of joint effusion consistent with 
inflammatory arthritis, as would be detected in the real world setting in the dermatology 
clinic. Indeed, PsA screening questionnaires are considered to have resulted in an influx 
of patients without inflammatory arthritis being referred to rheumatology services in the 
UK, and as such a PEST score ³3 in isolation is not used as a solitary trigger for referral 
in many centres. 
While no healthy volunteers had a PEST score ³3, 30.4% of healthy participants gave 
one or two positive responses, again mostly to the question relating to ever having had 
a swollen joint. Most of these participants had no abnormalities on their ultrasound scan, 
but had they had psoriasis and nail involvement, they too would have had a score ³3 
and a falsely positive PEST questionnaire.  
17 of 28 psoriasis patients with subclinical enthesopathy did not screen positive on the 
PEST questionnaire, demonstrating that the use of the PEST questionnaire is 
inadequate to detect patients with the very earliest stages of PsA and cannot be used as 
a guide to target ultrasound screening. It only becomes a sensitive tool once patients 
have sustained symptoms of inflammation (Tinazzi et al., 2012, Haroon et al., 2013), by 
which time patients are likely to have developed irreversible osseous lesions and 
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structural damage. No differences in the burden of enthesitis were seen between those 
with and without a positive PEST score in terms of enthesopathy scores. 
Clinical entheseal examination was also not sufficiently sensitive to reflect the ultrasound 
findings in this cohort of patients with psoriasis and sonographic enthesitis. Of the 392 
entheses assessed both sonographically and clinically, only 5.3% of those with at least 
one inflammatory ultrasound abnormality were also tender. No differences were 
observed in enthesopathy scores between those with and without clinically tender 
entheses to suggest that those with more subclinical disease were more likely to have 
signs on clinical examination. van der Ven and colleagues examined the lateral 
epicondyle of the elbow, quadriceps tendon and Achilles tendon bilaterally both clinically 
and with ultrasound in 111 patients in primary care. In agreement with the findings in this 
cohort, they identified clinical tenderness at 145 of 666 sites, but found corresponding 
sonographic inflammatory abnormalities in only 38 tendons (5.7%) (van der Ven et al., 
2016).  
In this study, 47.8% of clinically tender entheseal points were normal on ultrasound. van 
der Ven et al found an even greater discrepancy, with 63.8% (lateral epicondyle), 76.4% 
(quadriceps tendon) and 87.5% (Achilles tendon) of tender sites having no 
corresponding inflammatory abnormality on ultrasound. These data confirm the need for 
imaging in patients with psoriasis to correctly identify early entheseal pathology, 
especially with the increasing recognition of the need to intervene therapeutically at the 
earliest juncture before significant structural damage occurs. 
The ultrasound protocol described in this chapter took significantly longer than that in the 
previous chapter, averaging around 45-50 minutes per patient. Reasons for this were 
that, despite no longer including the third, fourth and fifth digits of the hand, extended 
time was needed to score each structure, in addition to scanning for signs of burseal 
hypertrophy and tenosynovitis.  This protocol is too long for routine use in the clinical 
setting in every patient with psoriasis, especially in the absence of any clinical or 
demographic ‘biomarkers’ to help target screening. One limitation in this study was the 
small sample size, which prohibited the comparison of enthesopathy scores at different 
anatomical sites (only one or two patients had no disease at a particular anatomical 
location making the group size too small). In a much larger cohort, it would be useful to 
compare scores to see if disease at a particular anatomic location could be predictive for 
a greater burden of subclinical enthesopathy, given that Wilson et al observed that 
patients with disease at the gluteal cleft, nail and scalp had a greater hazard ratio for 
PsA than those without (Wilson et al., 2009). In this cohort, an association was observed 
between mNAPSI score and inflammation score, which warrants further investigation in 
larger studies. 
In terms of reducing scanning time, there are certain abnormalities that were not 
observed at particular sites, such as synovitis at the elbow joint. However, the elbow 
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entheses warrant inclusion as other abnormalities occur not infrequently in psoriasis 
patients, and to view the joint while scanning three tendon insertions adds very little time. 
Similarly, no tenosynovitis was observed in the wrist, but with high rates of synovitis, the 
wrist should not be removed from the protocol. This protocol has however, shown 
significant differences in the burden of subclinical musculoskeletal abnormalities 
between patients with psoriasis and healthy volunteers, and is therefore recommended 
for use in the research setting. It now needs to be tested in a cohort of psoriasis patients 
to observe if it is able to detect subtle changes in abnormalities following 
immunosuppressive therapy.   
4.6 Conclusion 
The development of a scoring system that encompasses the severity of abnormalities in 
an extensive number of entheseal sites and the surrounding synovio-entheseal complex, 
and includes all components of the OMERACT definition of enthesopathy, facilitated a 
meaningful comparison of subclinical musculoskeletal disease between patients with 
psoriasis and healthy volunteers, who were broadly matched in terms of age, body mass 
index and gender. Quantifying the full spectrum of abnormalities demonstrated the 
severity of subclinical enthesitis to be generally mild amongst patients, although the 
range of abnormalities and number of entheseal sites involved were significantly greater 
than in healthy volunteers. Aside from synovitis, few abnormalities were seen outside 
the enthesis in both groups although bursitis and tenosynovitis are commonly reported 
in studies of established PsA and so there may be value in continuing to include these 
parameters for longitudinal assessments.  
As in previous studies, no power Doppler was seen in the control group, supporting the 
concept that a switch to a vascular phenotype at tendon insertion sites may be linked 
with arthritis development and is likely to be a valuable tool in the assessment of disease 
progression. Among patients with psoriasis, entheseal inflammation scores showed 
weak positive correlation with body mass index and nail disease severity, while higher 
chronic damage scores were associated with increasing age and duration of psoriasis. 
High discordance between clinical and ultrasound assessments was observed, with only 
5.3% of clinically accessible, sonographically inflamed entheses being tender on clinical 
examination suggesting that clinical examination is of little value in the dermatology 
setting. No relationship was observed between ultrasound entheseal and synovial 
inflammation scores and PEST score, although the question relating to heel pain 
appeared discriminatory with 8/12 patients reporting symptoms of possible plantar 
fasciitis having sonographic inflammation at that site. 
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Chapter 5  
Response in Ultrasound Appearances of Peripheral Subclinical 
Enthesopathy to Anti-IL-12/23p40 Therapy for Moderate to 
Severe Psoriasis 
5.1 Introduction 
In recent years, the IL-23/17 axis have emerged as a key pathway in the pathogenesis 
of several immune inflammatory diseases including psoriasis and psoriatic arthritis 
(PsA). Murine models have demonstrated the essential role IL-17, IL-22 and IL-23 play 
in bone homeostasis (Quinn et al., 2008, Adamopoulos et al., 2011, Sherlock et al., 
2012). IL-23 regulates bone homeostasis by inducing osteoclastogenesis (Adamopoulos 
et al., 2011) and altering the differentiation of IL-17 and IL-22 secreting innate and 
adaptive immune cells. IL-17, IL-22 and IL-23 also increase bone resorption (Ritchlin et 
al., 2003). Sherlock and colleagues further added credence to the pathogenic role of IL-
23 at the enthesis through the identification of a resident entheseal population of innate-
like T cells in mice with early psoriatic-like spondyloarthropathy (Sherlock et al., 2012). 
This novel population of cells expressed the IL-23 receptor, RORγt and CD3 (but not 
CD4 and CD8), and produced IL-17 and IL-22 in response to stimulation with IL-23. More 
recently, the human enthesis has been shown to harbour a resident population of innate 
lymphoid cells (ILC3s) characterised by the expression of RORγt, which when activated 
by local or systemic IL-1β and IL-23, produce IL-17 and IL-22 (Cuthbert et al., 2017). 
ILC3s have also been shown to be comparatively abundant in synovial fluid (Ciccia et 
al., 2015, Leijten et al., 2015) and psoriatic skin (Villanova et al., 2014) and are likely to 
play a key role in the pathogenesis of psoriatic disease. In addition, genome-wide 
association studies (GWAS) have identified a substantial number of candidate genes of 
significance in both psoriasis and PsA, including those involved in adaptive immune 
responses involving IL-23/IL-17 (HLA-C, IL12B, IL23R, IL23A, TRAF3IP2, ERAP1). 
Given the clear role of IL-23 in the development of spondyloarthropathy-based, 
entheseal-driven pathology, and the acceptance of enthesitis as the primary lesion in 
PsA, a therapeutic strategy aimed at blocking the IL-23/Th17 axis would therefore pose 
a logical option for the treatment subclinical enthesopathy in early PsA. 
To date, only one anti-IL-23 monoclonal antibody, ustekinumab (CNTO 1275, Stelara®; 
Janssen Cilag®) has marketing authority for use in psoriasis and more latterly, PsA. 
Ustekinumab is a potent inhibitor of IL-12 and IL-23 through high affinity binding to their 
shared p40 subunit. Such has been the success of ustekinumab that several other 
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inhibitors of IL-23 are in development for use in psoriasis and other autoinflammatory 
disorders (Guselkumab (CNTO-1959), Janssen-Cilag®; Tildrakizumab (MK-3222; SCH 
900222), Sun Pharmaceutical®; Risankizumab (BI 655066), AbbVie®), although each of 
these specifically target the IL-23 specific p19 subunit, rather than p40. 
In terms of enthesitis, the P-SUMMIT I and II trials examined the response to 
ustekinumab therapy and the results appear promising (Chapter 1.7.3.3.) (McInnes et 
al., 2013, Ritchlin et al., 2014). However, these trials only investigated patients with 
established PsA and enthesitis was included as a secondary outcome measure. 
Assessments of enthesitis were clinical, with no imaging evaluations made of the tendon 
insertion sites. The ECLIPSA trial is the only study to date using clinical enthesitis 
measures (SPARCC) as a primary outcome measure to assess the reponse to therapy 
either with ustekinumab or a TNF inhibitor at six months.  These data showed 
ustekinumab to be superior in resolving the enthesitis component of disease in PsA 
patients with active entheseal disease. The authors conclude by recommending more 
stratified treatment approaches where enthesitis-driven patients are targeted by IL-23/IL-
17 pathway inhibitors (Araujo et al., 2017). 
The sonographic response in subclinical enthesopathy to biologic drugs used in both 
psoriasis and established PsA is not well studied. One small observational study has 
reported a decrease in morphological sonographic abnormalities in a psoriasis patients 
with enthesitis treated with methotrexate with or without a TNF inhibitor for six months, 
although a proportion of these patients fulfilled the CASPAR criteria for PsA (Acquacalda 
et al., 2015). To date, there have been no studies to assess the response to ustekinumab 
in early subclinical disease in patients with psoriasis. Given that in excess of 70% of 
patients who develop PsA will have precedent psoriasis, and ustekinumab provides 
superior PASI responses, it is therefore timely to determine if skin-directed treatment 
with ustekinumab can reduce subclinical enthesopathy and ultimately prevent the 
evolution of PsA in patients with psoriasis.  
The aims and objectives of this chapter were as follows: 
• To assess if any of the ultrasound abnormalities of subclinical enthesopathy (and 
surrounding synovio-entheseal complex changes) alter in response to therapy 
with anti-IL-12-23 p40 (Ustekinumab), a licensed product for the treatment of 
moderate to severe psoriasis, assessed at 12, 24 and 52 weeks. 
• To test the feasibility of a full randomised controlled trial comparing ustekinumab 
with other treatment modalities for the management of subclinical psoriatic joint 
disease in patients with psoriasis.  
• To observe if any change in clinical entheseal assessments relate to the change 
in subclinical enthesopathy seen on ultrasound. 
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• To determine if changes in entheseal scores are related to skin outcomes or 
improvements in nail disease. 
• To establish if there is a relationship between skin outcomes, ultrasound 
responses and the presence of genetic risk alleles (HLA-Cw06 and HLA-B27). 
• To assess whether age, gender, BMI and smoking status impact on sonographic 
enthesopathy scores in response to ustekinumab therapy. 
5.2 Methods 
Ethical approval was obtained from the National Research Ethics Committee (Reference 
YH/12/0483) for a phase IV, prospective, single-centre, open-label feasibility study 
investigating the response of subclinical enthesitis to ustekinumab, an interleukin(IL)-
12/23p40 antagonist. An amendment was subsequently approved to extend the study 
beyond 24 weeks. Relevant approvals were also granted by the Medicines and 
Healthcare Products Regulatory Authority (MHRA) and the Research and Development 
Unit within Leeds Teaching Hospitals NHS Trust. The University of Leeds accepted the 
duties of Sponsor under The Medicines for Human Use (Clinical Trials) Regulations 2004 
and Amendment (No.2) Regulations 2006. 
5.2.1 Sample Size 
This was an exploratory proof-of-concept study and therefore no formal power 
calculations were performed. Published rules of thumb for such studies suggest that 
between 12 and 30 patients should be recruited to provide a good trade-off between 
feasibility and accuracy of effect size estimation (Julious, 2005, Lancaster et al., 2004). 
It was difficult to accurately estimate the recruitment rate to the study given that the 
inclusion criteria include subclinical pathology on which no prior data were available. To 
maximize the accuracy of the effect size estimates, the aim was to recruit 30 patients. 
However, it was decided prior to commencement that should recruitment prove to be 
difficult, a minimum of 12 patients would be deemed acceptable.   
5.2.2 Participant Identification and Recruitment 
The study was conducted in one tertiary centre in the United Kingdom within Leeds 
Teaching Hospitals NHS Trust. Patients were recruited from the Leeds Centre for 
Dermatology, and imaging took place within the Leeds Musculoskeletal Biomedical 
Research Unit (LMBRU), both at Chapel Allerton Hospital.  
Recruitment took place over a two-year period (May 2013 to May 2015), which allowed 
for seasonal variation in psoriasis severity. Recruitment was slower in the summer 
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months due to patients presenting to their new patient appointment with less severe 
psoriasis (PASI score less than 10) and vacations. 
Twenty-three adult patients (aged 18 and over) with moderate to severe chronic plaque 
psoriasis and signs of inflammatory subclinical enthesitis at ultrasound (but without 
clinically diagnosed psoriatic arthritis) were consented for participation.  
These patients were recruited from a cohort of 28 patients who consented to a short 
screening ultrasound (to identify whether they had subclinical enthesitis) followed by a 
more detailed ultrasound scan (to quantify the extent of abnormalities within the synovio-
entheseal complex). They were all new patients who had been referred by their General 
Practitioner (GP) for treatment of moderate to severe chronic plaque psoriasis (defined 
as a Psoriasis Area and Severity Index (PASI) score of 10 or more) and were systemic 
and biologic treatment naïve. They all failed to meet the CASPAR classification for 
psoriatic arthritis on the basis of no definitive symptoms of inflammatory arthritis, defined 
clinically as early morning stiffness (15 minutes or more duration) and/or prolonged and 
non-traumatic joint swelling. Inflammatory subclinical enthesitis was defined as 
entheseal thickening, hypoechogenicity and/or power Doppler signal in at least one 
peripheral tendon insertion site. All participants were rheumatoid factor and anti-
citrullinated peptide (anti-CCP) antibody negative. Chapter 4.2.1.1. provides more detail 
on recruitment into the cohort of 28 patients.  
At the initial new patient consultation, in preparation for starting therapy at the next 
appointment, a series of standard investigations were performed. These form part of 
‘routine’ care for any patient being considered for any form of systemic 
immunosuppressive therapy and feature in the BAD and NICE guidelines for moderate 
to severe psoriasis: 
• Blood tests: Full blood count, urea and electrolytes, liver function tests, C-reactive 
protein, fasting glucose, cholesterol (total, HDL and LDL), triglycerides, anti-
nuclear antibody 
• Hepatitis B and C serology: Hepatitis B surface antigen, hepatitis B core antibody, 
hepatitis C antibody 
• Human immunodeficiency virus (HIV) testing 
• QuantiFERON® Gold serology (to test for tuberculosis) 
• Chest x-ray (to exclude infection, malignancy and latent tuberculosis) 
• Electrocardiogram 
At their initial consultation, patients were provided with impartial information sheets 
written by the British Association of Dermatologists (BAD) for the different treatment 
options that would be potentially available to them (e.g. narrowband phototherapy (with 
or without acitretin), fumaric acid esters and systemic immunosuppressants including 
methotrexate and ciclosporin) if their screening investigations were normal. In addition, 
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those patients with inflammatory subclinical enthesitis on the initial ultrasound scan were 
also given written information about the investigational medicinal product (IMP), 
ustekinumab, an IL-12/23 antagonist and a Patient Information Sheet about the study. 
Patients were asked to contemplate their treatment preferences and consider their 
participation in the trial in the interval between scans, which was between one and three 
weeks depending on sonographer availability. No screening abnormalities or 
contraindications to any therapy were found in the cohort of 28 patients who returned for 
the second, more detailed ultrasound scan.  
Potential participants were made aware that outside of the research setting, biologic 
therapy would not have been available to them at this stage in their therapeutic journey, 
as the National Institute of Health and Care Excellence (NICE) guidelines require 
patients within the NHS to have been treated with at least two non-biologic systemic 
immunosuppressant therapies first. This restriction is based purely on economic 
grounds, and in no way reflects the efficacy or safety of the drug in treatment naïve 
patients.  
At the time of recruitment, ustekinumab was licensed for the treatment of psoriasis, but 
not psoriatic arthritis. Promising musculoskeletal data were emerging and part way 
through the study, ustekinumab was granted marketing authority for the treatment of 
active psoriatic arthritis. Figure 5.1 details the therapeutic indications that ustekinumab 
is licensed for in the United Kingdom: 
Figure 5.1. Licensed therapeutic indications for ustekinumab 
At the second scan appointment, five patients declined participation and chose standard 
therapy (narrowband UVB phototherapy) and 23 chose to enter the study and receive 
ustekinumab. The five who declined participation in the study did consent to undergo the 
second, more detailed ultrasound scan for comparison with the results from volunteers 
in the healthy control group (Chapter 4).  
 
PLAQUE PSORIASIS: Ustekinumab is indicated for the treatment of 
moderate to severe plaque psoriasis in adults who failed to respond to, or 
who have a contraindication to, or are intolerant to other systemic therapies 
including ciclosporin, methotrexate and psoralen ultraviolet A (PUVA). 
PSORIATIC ARTHRITIS: Ustekinumab, either alone or in combination with 
methotrexate is indicated for the treatment of active psoriatic arthritis in adult 
patients when the response to previous non-biological disease-modifying 
anti-rheumatic (DMARD) therapy has been inadequate. 
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5.2.3 Inclusion/Exclusion Criteria 
5.2.3.1 Inclusion Criteria 
• Male and female patients aged 18 years and older 
• Diagnosis of chronic plaque psoriasis, confirmed by a dermatologist (the 
candidate, LS) 
• Duration of psoriasis symptoms greater than twelve months 
• Moderate or severe disease (classified as a PASI score >10) 
• No prior treatment with systemic immunosuppressant or biologic agents 
• Failure to meet the CASPAR classification for psoriatic arthritis on the basis of 
no symptoms of inflammatory arthritis (early morning stiffness lasting 15 minutes 
or more in duration, joint pain and/or prolonged and non-traumatic joint swelling) 
• Evidence of inflammatory subclinical enthesitis on ultrasound in at least one 
peripheral enthesis 
In addition, all male and female subjects biologically capable of having children must 
have agreed to use at least one reliable method of contraception for the duration of the 
study and for 24 weeks after the end of the study. Acceptable methods of contraception 
were surgical sterilization, oral, implantable or injectable hormonal methods, intrauterine 
devices or barrier contraceptives.  
5.2.3.2 Exclusion Criteria 
• Psoriasis of mild to moderate severity (PASI<10) 
• Previous treatment with any systemic immunosuppressant or biologic agent (for 
psoriasis or any other indication) 
• Patients unable or not willing to attend all imaging, serological and clinical 
assessments 
• Any contraindication to magnetic resonance imaging (MRI) scanning (e.g. 
pacemaker, aneurysm coil, history of metal in the eye) (Appendix 10). 
• Patients not willing to use adequate methods of contraception 
• Pregnancy or lactation 
• Any contraindication to systemic or biologic therapy: 
• Active infection, including open leg ulcers, human immunodeficiency virus 
(HIV), hepatitis B or C carriers 
• Active or latent tuberculosis 
• Malignancy – current, or previous within the last ten years (except basal 
cell carcinoma) 
• Severe heart failure (NYHA grade III or more) 
• Demyelinating disorders 
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• Uncontrolled diabetes 
• Chronic lung disease (pulmonary fibrosis or bronchiectasis) 
• Previous PUVA phototherapy (>1000 joules) 
• History of other significant medical conditions, including: 
• Severe pulmonary disease (defined as requiring previous hospital 
admission or supplemental oxygen) 
• Active or severe cardiovascular disorders: uncontrolled hypertension, 
myocardial infarction within the previous twelve months, unstable angina 
within the previous six months) 
• Any immunodeficiency disorder 
• Connective tissue diseases (e.g. primary Sjogrens syndrome, systemic 
sclerosis, systemic lupus erythematosus, polymyositis) 
• Renal impairment (creatinine clearance <45ml/min) 
• Abnormal liver function tests (alanine transferase >3x upper limit of 
normal) 
• Blood disorders, i.e. neutropenia (neutrophils <2.0x109/l), 
thrombocytopenia (platelets <125x109/l) or anaemia (haemoglobin 
<8g/dl). 
• Any forthcoming event that may interrupt participation (e.g. a holiday, elective 
hospital admission) lasting longer than 14 days. 
5.2.4 Drug Therapy 
5.2.4.1 Ustekinumab 
Ustekinumab (experimental name CNTO1275) is a fully human IgG1κ monoclonal 
antibody to interleukin (IL)-12/23p40, produced in a murine myeloma cell line using 
recombinant DNA technology. It is under patent (until 2024) with holders Janssen 
Biotech (the pharmaceutical arm of Johnson & Johnson) with the proprietary commercial 
name Stelara®. It is supplied in a pre-filled syringe, with each vial containing 45mg 
ustekinumab in 0.5ml solution and is available on prescription in the United Kingdom in 
secondary care centres only. Ustekinumab was prescribed by the candidate (LS), a 
dermatologist experienced in the diagnosis and treatment of plaque psoriasis.  
Ustekinumab is administered subcutaneously at a dose dependant on body weight. In 
adults, the standard dose is 45mg, but for patients who weigh in excess of 100kg, 90mg 
is licensed. The recommended posology of ustekinumab is an initial dose followed by a 
second dose four weeks later, and then every 12 weeks thereafter. Every dose was 
administered by the candidate (LS) at a patient’s appointment to ensure compliance and 
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reduce the need for patient training and consumables at home (e.g. burn bins for 
needles). No dose adjustment is needed for elderly patients. 
Known adverse reactions to ustekinumab are listed in Table 5.1. 
 
System Organ Class Frequency Adverse Reaction 
Infections and 
infestations 
Common 
Dental infections, upper respiratory tract 
infections, nasopharyngitis 
Uncommon 
Cellulitis, viral upper respiratory tract 
infections, herpes zoster 
Immune system 
disorders 
Uncommon Hypersensitivity reactions (e.g. rash, urticarial) 
Rare 
Serious hypersensitivity reactions (e.g. 
anaphylaxis, angioedema) 
Psychiatric disorders Uncommon Depression 
Nervous system 
disorders 
Common Dizziness, fatigue 
Uncommon Facial palsy 
Respiratory, thoracic 
and mediastinal 
disorders 
Common Oropharyngeal pain 
Uncommon Nasal congestion 
Gastrointestinal 
disorders 
Common Nausea and diarrhoea 
Skin and 
subcutaneous tissue 
disorders 
Common Pruritus 
Uncommon Pustular psoriasis, skin exfoliation 
Rare Exfoliative dermatitis 
Musculoskeletal and 
connective tissue 
disorders 
Common Back pain, myalgia, arthralgia 
General disorders 
and administration 
site reactions 
Common 
Injection site erythema, injection site pain, 
fatigue 
Uncommon 
Injection site reactions (e.g. haematoma, 
haemorrhage, induration, swelling, pruritus) 
Table 5.1. List of known adverse reactions to ustekinumab 
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Further information on ustekinumab can be found in the Summary of Medical 
Characteristics (www.medicines.org.uk/emc/medicine/32569). 
5.2.4.2 Permitted and Prohibited Concomitant Treatments 
All treatments taken (prescribed or otherwise) by participants in addition to the 
investigational product, on entry to the study or at any time during the study, were 
regarded as concomitant treatments and were documented.  
Concomitant medications were kept to a minimum during the study. However, if they 
were considered necessary for the participants’ welfare, and were unlikely to interfere 
with the investigational products, they were permitted at the discretion of the candidate 
(LS) and recorded. 
Permitted concomitant medications: 
• Topical psoriasis therapies, including: 
• Emollients 
• Vitamin D analogues 
• Topical corticosteroids 
• Coal tar preparations 
• Dithranol 
• Tazarotene 
• Eosin 
• Analgesic medications, including paracetamol, codeine, tramadol and morphine. 
As required use of non-steroidal anti-inflammatory drug (NSAID) medications 
was permitted as long as it was not in excess of two standard doses (e.g. 
ibuprofen 400mg) per week. 
Prohibited concomitant medications: 
• Oral or intravenous steroids 
• Regular NSAIDs 
• Any other systemic, DMARD or biologic agent (regardless of indication, e.g. 
leflunomide for rheumatoid arthritis) 
• Any alkylating agents (e.g. cyclophosphamide) 
• Any experimental drug 
• Vaccination with live vaccines 
Surgical Procedures 
Planned surgery within the study period (which was expected to require omission of any 
study medication for 14 days or more) was an exclusion criterion. However, unplanned 
surgical treatments could be performed; each must have been documented as a 
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separate adverse event. Patients undergoing general anaesthesia were permitted to 
interrupt study medication. In total, a single dosing interruption of 14 days was allowed. 
Patients requiring surgical procedures involving local or regional anaesthesia could 
continue with study medication. 
5.2.5 Participant Visit Schedule 
After their initial new patient consultation, patients consenting to take part in the trial 
attended for a total of six study visits at weeks 0, 4, 12, 16, 24 and 52.  Baseline (week 
0) was taken as the date of first injection, which occurred immediately following written 
consent, the second ultrasound scan and clinical assessment. Ustekinumab was 
administered at week 0, week 4 and week 16 by the candidate (LS). After the primary 
end point of 24 weeks, the administration of therapy was passed to the BUPA™ 
Healthcare at Home team, a free nurse-led service provided by the drug manufacturer 
(Janssen Pharmaceuticals) to the NHS. The drug is delivered to the patient’s home at a 
mutually convenient time, and a nurse then arranges a visit to administer the drug. 
Standardised reporting procedures are in place should the nurse have any concerns 
about the patient or their therapy. Between weeks 24 and 52, patients were asked to 
attend for a brief review in the general psoriasis clinic within the Leeds Centre for 
Dermatology. Patients were reviewed by either the candidate (LS) or the candidate’s 
supervisor, a Consultant Dermatologist (MDG). No research assessments were made 
but any adverse events were recorded. Patients provided written consent a second time 
at the week 52 visit to continue in the study beyond week 24. 
Ultrasound scans were performed at weeks 0, 12, 24 and 52.  The full study schedule 
can be found in Table 5.2. All visits happened within seven days of the scheduled date. 
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5.2.6 Data Collection 
With written consent, three types of data (participant-reported data, clinical examination 
data and imaging data) were collected from participants for research purposes and 
entered into an encrypted, password-protected database by the candidate (LS). 
Participant-reported and clinical examination data collections were carried out solely by 
the candidate (LS) and immediately onto a case report form (CRF). Ultrasounds were 
performed by one of two experienced musculoskeletal sonographers (LH and AJ), who 
recorded the imaging data on a separate CRF (Appendix 9) at the time of the scan.  All 
data was transposed into encrypted password-protected databases on the University of 
Leeds server for analysis within seven days. Care was taken to ensure the check integrity 
of the dataset at upload. Paper record forms are stored in a locked filing cabinet within a 
locked room within LIRMM, in accordance with the University’s Information Security 
Policy.   
Participant-reported data included all elements of the medical history at baseline 
(demographics, skin type, social history (smoking, alcohol and employment), past 
medical and surgical history, history of skin and joint disease, family history, medications 
(current prescribed, over-the-counter, alternative and psoriasis-specific medications, 
and any previous psoriasis therapies), age of psoriasis symptom onset, areas ever 
affected by psoriasis, areas currently affected by psoriasis and current or previous 
musculoskeletal symptoms). Adverse events, medication history, areas of psoriasis 
involvement and musculoskeletal symptoms were recorded at week 4, 12, 24 and 52. 
Patients also self-completed the DLQI at baseline, week 4, week 12, week 24 and week 
52.  
Clinical examination data included assessment of the severity, extent and anatomical 
location of psoriatic plaques, blood pressure and heart rate, height and weight, and 
assessment of any signs of psoriatic arthritis (joint swelling and/or tenderness, entheseal 
tenderness or dactylitis). Clinical examination was performed at baseline, then weeks 4, 
12, 24 and 52. 
5.2.7 Clinical Assessment 
5.2.7.1 Psoriasis Severity and Impact 
At week 0, 4, 12, 24 and 52, patients were fully exposed (to their underwear) and 
unblinded assessments made of their psoriasis (distribution, extent, plaque thickness, 
erythema and scale) and nails (onycholysis, pitting, crumbling, red spots in the lunula, 
leuconychia, oil spot dyschromia, nail bed hyperkeratosis) by the candidate (LS). From 
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these assessments, scores were calculated for the PASI (Appendix X), BSA and 
mNAPSI (Appendix X).  The assessor did not look at previous scores prior to each clinic 
visit. Skin responses to ustekinumab were calculated as the number of patients 
achieving a 75%, 90% and 100% improvement in PASI score from week 0 (termed PASI 
75, PASI 90 and PASI 100, respectively) at week 4, 12, 24 and 52. 
Quality of life was assessed using the patient-completed DLQI questionnaire at weeks 
0, 4 (DLQI only), 12 (DLQI only), 24 and 52. 
5.2.7.2 Psoriatic Arthritis 
All accessible peripheral joints were visually examined for gross evidence of swelling, 
and where a patient reported any discomfort, a closer examination was made to identify 
tenderness. Several entheseal points were also examined for tenderness – direct 
pressure was applied to the following sites, with sufficient force to just blanche the 
thumbnail of the examiner: 
• 1st and 7th costochondral joints 
• Supraspinatus insertion 
• Medial and lateral epicondyles of the humerus 
• Anterior and posterior superior iliac spines 
• Iliac crest 
• 5th lumbar process 
• Greater trochanter 
• Medial condyle of the femur 
• Quadriceps insertion at the patella 
• Inferior pole of the patella 
• Tibial tubercle 
• Proximal Achilles 
• Plantar fascia insertion 
In addition, the fingers and toes were examined for any fusiform swelling (with or without 
tenderness) consistent with dactylitis. Examinations for joint swelling (and tenderness), 
enthesitis and dactylitis were performed at weeks 0, 4, 12, 24 and 52.  
5.2.8 Laboratory Assessment 
Safety monitoring was undertaken in line with standard NHS care procedures for any 
patient taking a biologic therapy. A full blood count, urea and electrolytes, liver function 
tests, C-reactive protein, cholesterol (total, HDL and LDL), triglycerides, fasting glucose 
and anti-nuclear antibody, in addition to urinalysis, were done at the initial new patient 
consultation, then repeated at weeks 4, 12, 24 and 52. Samples were processed in the 
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relevant NHS laboratories within Leeds Teaching Hospitals NHS Trust under the terms 
of their standard operating procedures and patients were informed within 24 hours of 
any abnormalities.   
In terms of study procedures, anti-CCP antibody and rheumatoid factor were sampled at 
week 0 and repeated at week 24 and 52, to ensure that patients did not have, or develop, 
any other rheumatological disorders such as rheumatoid arthritis. All participants were 
negative at baseline. Rheumatoid Factor was measured by nephelometry (IU/ml) and 
anti-CCP antibody was measured by multiplex bead technology (bioplex) (U/ml). 
Patients were also tested at baseline for two genetic risk alleles for psoriatic arthritis in 
patients with psoriasis – HLA-Cw06 and HLA-B27. The former is shown to be associated 
with skin responses to ustekinumab, but any association with subclinical enthesitis is not 
known. HLA-Cw06 and HLA-B27 were both measured by single antigen bead testing 
(median fluorescent intensity, MFI). 
5.2.9 Ultrasonography 
5.2.9.1 Ultrasound Equipment and Protocol 
Ultrasonography was undertaken by two dedicated musculoskeletal research 
sonographers (AJ and LH) in the Leeds Musculoskeletal Biomedical Research Unit 
(LMBRU). Scans were performed at baseline (week 0), week 12, week 24 and week 52. 
Details about the equipment and scanning technique can be found in Chapter 3.1.6. It 
was not possible to blind the sonographers to the study visit due to the same 
sonographers performing the scans and the small number of participants in the trial. 
They were not aware of their response to therapy in the later scans, and participants 
were asked not to disclose any details of their medical consultation to the sonographer. 
Scans were performed in a darkened room reducing the sonographer’s ability to inspect 
the patients’ skin if they wished to do so. 
Tables 4.2., 4.3., 4.4., and 4.5. (Chapter 4) summarise the tendon entheses and 
corresponding bone insertion sites, associated bursa and sites for tenosynovitis and 
synovitis scanned. Chapter 3.1.6. describes the procedure followed by the sonographers 
to incorporate all of these structures in the scan. 
5.2.9.2 Ultrasound Image Interpretation 
Images were evaluated and scored at the time of the scan by the sonographer and when 
possible, the candidate (LS). Enthesopathy, bone erosions, tenosynovitis and synovial 
hypertrophy were identified according to the definitions provided by the Outcome 
Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Special Interest Group for 
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Musculoskeletal Ultrasound in Rheumatology (Figures 4.1., 4.2., 4.3. and 4.4., Chapter 
4) (Wakefield et al., 2005). Bursitis was defined as a well circumscribed, localised 
anechoic or hypoechoic area at the site of an anatomical bursa which was compressible 
by the transducer with bursal wall thickening, with or without periburseal or intraburseal 
power Doppler signal (Schmidt et al., 2004). 
5.2.9.3 Ultrasound Scoring 
Ultrasound parameters were scored either quantitatively or semi-quantitatively: 
Quantitative measurements: 
• Entheseal thickness*: 
0 = Less than threshold 
1 = Greater than threshold but by less than1mm 
2 = ≥1mm above threshold but <2mm 
3 = ≥2mm above threshold 
*Measured at its widest point at the insertion on longitudinal scans. 
Published thresholds used where available. See Chapter 4.2.6.3.1. for 
details of how the other thresholds were determined. 
• Bone erosions**: 
0 = absence of erosions               
1 = present and <2mm in diameter               
2 = present and 2-3mm in diameter             
3 = present and ≥ 3mm in diameter 
**Largest erosion measured at each site. 
Semi-quantitative assessments: 
• Hypoechogenicity* 
• Entheseal power Doppler signal** 
• Calcifications* 
• Enthesophytes* 
• Bone cortex irregularities* 
• Bursal hypertrophy* 
• Bursal power Doppler signal** 
• Tenosynovitis (grey scale* and power Doppler**) 
• Synovitis (grey scale* and power Doppler**) 
*All scored as: 
0 = absence                
1 = mild                
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2 = moderate                 
3 = marked/severe 
**Power Doppler scored as:  
0 = absence 
1 = mild (£3 isolated signals) 
2 = moderate (>3 isolated signals or confluent signal in <50% of the area 
under examination) 
3 = marked (signals in >50% of the area under examination) 
5.2.9.4 Ultrasound Scoring System 
Summative scores were calculated to allow comparisons of the extent of enthesopathy 
over time at a patient level. Based on the Glasgow Ultrasound Enthesitis Score (GUESS) 
score (Appendix 11) (Balint et al., 2002) and Sonographic Enthesitis Index (SEI) (Alcalde 
et al., 2007) (Appendix 12), a more comprehensive enthesopathy score was created 
which encompassed all of the sites and parameters assessed. Like the SEI, this was 
divided into an inflammation score, a chronic damage score and a total overall score (the 
sum of the two). Scores were also calculated for tenosynovitis and synovitis. 
• Enthesopathy Inflammation Score: The sum of scores from the assessment of 
entheseal thickness, hypoechogenicity and power Doppler signal in all tendons, 
plus any bursal hypertrophy and power Doppler signal where appropriate, at all 
entheseal sites. 
Maximum score: 294 
 
• Enthesopathy Chronicity Score: The sum of scores from the assessment of 
entheseal calcification(s), enthesophytes, bone erosions and bone cortex 
irregularity, at all entheseal sites. 
Maximum Score: 312 
 
• Total Enthesopathy Score: The sum of the inflammation and chronicity scores.  
Maximum Score: 606 
 
• Tenosynovitis Score: The sum of scores from the grey scale assessment of 
tendon sheath thickening/hypoechogenicity and power Doppler signal at all 
examined sites. 
Maximum Score: 264 
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• Synovitis score: The sum of the scores from the grey scale assessment of 
synovial hypertrophy/proliferation and power Doppler signal from all examined 
joints. 
Maximum Score: 144 
5.2.9.4.1 Enthesopathy Score 
26 entheses (13 per side) were scanned in each participant, and each parameter scored 
0-3, with a maximum possible score of 606: 
 
• THUMB: Base of distal phalynx - flexor pollicis longus tendon enthesis 
8. Flexor pollicis longus enthesis thickness ≥ 1.0mm 
9. Flexor pollicis longus enthesis hypoechogenicity 
10. Flexor pollicis longus enthesis power Doppler signal 
11. Base of distal phalynx calcification 
12. Base of distal phalynx enthesophyte(s) 
13. Base of distal phalynx bony erosion(s) 
14. Base of distal phalynx bony cortex irregularity 
 
• THUMB: Dorsal base of distal phalynx – extensor pollicis longus tendon 
enthesis 
8. Extensor pollicis longus enthesis thickness ≥ 1.0mm 
9. Extensor pollicis longus enthesis hypoechogenicity 
10. Extensor pollicis longus enthesis power Doppler signal 
11. Dorsal base of distal phalynx calcification 
12. Dorsal base of distal phalynx enthesophyte(s) 
13. Dorsal base of distal phalynx bony erosion(s) 
14. Dorsal base of distal phalynx bony cortex irregularity 
 
• INDEX FINGER: Distal phalynx base - flexor digitorum profundus 
8. Flexor digitorum profundus/superficialis enthesis thickness ≥ 1.0mm 
9. Flexor digitorum profundus/superficialis enthesis hypoechogenicity 
10. Flexor digitorum profundus/superficialis enthesis power Doppler signal 
11. Middle/distal phalynx base calcification 
12. Middle/distal phalynx base enthesophyte(s) 
13. Middle/distal phalynx base bony erosion(s) 
14. Middle/distal phalynx base bony cortex irregularity 
 
• INDEX FINGER: Distal phalynx base - extensor digitorum tendon enthesis 
8. Extensor digitorum enthesis thickness ≥ 0.9mm 
9. Extensor digitorum enthesis hypoechogenicity 
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10. Extensor digitorum enthesis power Doppler signal 
11. Distal phalynx base calcification 
12. Distal phalynx base enthesophyte(s) 
13. Distal phalynx base bony erosion(s) 
14. Distal phalynx base bony cortex irregularity 
 
• ELBOW: Lateral epicondyle of humerus - common extensor tendon enthesis 
8. Elbow common extensor enthesis thickness ≥ 4.9mm 
9. Elbow common extensor enthesis hypoechogenicity 
10. Elbow common extensor enthesis power Doppler signal 
11. Lateral epicondyle of humerus calcification 
12. Lateral epicondyle of humerus enthesophyte(s) 
13. Lateral epicondyle of humerus bony erosion(s) 
14. Lateral epicondyle of humerus bony cortex irregularity 
 
• ELBOW: Medial epicondyle of humerus - common flexor tendon enthesis  
8. Common flexor enthesis thickness ≥ 4.7mm 
9. Common flexor enthesis hypoechogenicity 
10. Common flexor enthesis power Doppler signal 
11. Medial epicondyle of humerus calcification 
12. Medial epicondyle of humerus enthesophyte(s) 
13. Medial epicondyle of humerus bony erosion(s) 
14. Medial epicondyle of humerus bony cortex irregularity 
 
• ELBOW: Olecranon process of the ulna - distal brachial triceps tendon 
enthesis 
10. Elbow distal brachial triceps enthesis thickness ≥ 4.3mm 
11. Elbow distal brachial triceps enthesis hypoechogenicity 
12. Elbow distal brachial triceps enthesis power Doppler signal 
13. Olecranon process of ulna calcification 
14. Olecranon process of ulna enthesophyte(s) 
15. Olecranon process of ulna bony erosion(s) 
16. Olecranon process of ulna bony cortex irregularity 
17. Olecranon bursitis (GS hypertrophy) 
18. Olecranon burseal power Doppler signal 
 
• KNEE: Superior pole of the patella - quadriceps tendon enthesis 
10. Quadriceps enthesis thickness ≥ 6.1mm 
11. Quadriceps enthesis hypoechogenicity 
12. Quadriceps enthesis power Doppler signal 
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13. Superior pole of patella calcification 
14. Superior pole of patella enthesophyte(s) 
15. Superior pole of patella bony erosion(s) 
16. Superior pole of patella bony cortex irregularity 
17. Suprapatellar bursitis (GS hypertrophy) 
18. Suprapatellar burseal power Doppler signal 
 
• KNEE: Inferior pole of the patella - proximal patellar tendon enthesis 
10. Proximal patellar enthesis thickness ≥ 4.0mm 
11. Proximal patellar enthesis hypoechogenicity 
12. Proximal patellar enthesis power Doppler signal 
13. Inferior pole of patella calcification 
14. Inferior pole of patella enthesophyte(s) 
15. Inferior pole of patella bony erosion(s) 
16. Inferior pole of patella bony cortex irregularity 
17. Superficial Infrapatellar bursitis (GS hypertrophy) 
18. Superficial Infrapatellar burseal power Doppler signal 
 
• KNEE: Tibial tuberosity - distal patellar tendon enthesis 
10. Distal patellar enthesis thickness ≥ 4.0mm 
11. Distal patellar enthesis hypoechogenicity 
12. Distal patellar enthesis power Doppler signal 
13. Tibial tuberosity calcification 
14. Tibial tuberosity enthesophyte(s) 
15. Tibial tuberosity bony erosion(s) 
16. Tibial tuberosity bony cortex irregularity 
17. Deep Infrapatellar bursitis (GS hypertrophy)  
18. Deep Infrapatellar burseal power Doppler signal  
 
• FOOT: 5th metatarsal base lateral tuberosity - peroneal brevis tendon 
enthesis 
8. Peroneal brevis enthesis thickness ≥ 1.9mm 
9. Peroneal brevis enthesis hypoechogenicity 
10. Peroneal brevis enthesis power Doppler signal 
11. 5th metatarsal base lateral tuberosity calcification 
12. 5th metatarsal base lateral tuberosity enthesophyte(s) 
13. 5th metatarsal base lateral tuberosity bony erosion(s) 
14. 5th metatarsal base lateral tuberosity bony cortex irregularity 
 
• ANKLE: Superior pole of calcaneus - Achilles tendon enthesis 
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10. Achilles enthesis thickness ≥ 5.29mm 
11. Achilles enthesis hypoechogenicity 
12. Achilles enthesis power Doppler signal 
13. Posterior pole of calcaneus calcification 
14. Posterior pole of calcaneus enthesophyte(s) 
15. Posterior pole of calcaneus bony erosion(s) 
16. Posterior pole of calcaneus bony cortex irregularity 
17. Retrocalcaneal bursitis (GS hypertrophy) 
18. Retrocalcaneal bursae power Doppler signal 
 
• FOOT: Inferior pole of calcaneus - plantar aponeurosis (fascia) enthesis 
8. Plantar aponeurosis thickness ≥ 4.4mm 
9. Plantar aponeurosis hypoechogenicity 
10. Plantar aponeurosis power Doppler signal 
11. Inferior pole of calcaneus calcification 
12. Inferior pole of calcaneus enthesophyte(s) 
13. Inferior pole of calcaneus bony erosion(s) 
14. Inferior pole of calcaneus bony cortex irregularity 
 
5.2.9.4.2 Tenosynovitis Score 
44 tendon sheaths (22 per side) were scanned in each participant, and each parameter 
scored 0-3, with a maximum possible score of 264: 
THUMB: 
• Flexor pollicis longus tendon 
3. Grey scale Tenosynovitis 
4. Power Doppler Tenosynovitis 
• Extensor pollicis longus tendon overlying the interphalangeal joint  
3. Grey scale Tenosynovitis 
4. Power Doppler Tenosynovitis 
• Extensor pollicis longus tendon overlying the carpometacarpal joint  
3. Grey scale Tenosynovitis 
4. Power Doppler Tenosynovitis 
 
INDEX FINGER: 
• Flexor digitorum profundus tendon 
3. Grey scale Tenosynovitis 
4. Power Doppler Tenosynovitis 
• Extensor digitorum tendon 
3. Grey scale Tenosynovitis 
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4. Power Doppler Tenosynovitis 
 
WRIST: 
• Extensor compartment 1 – Abductor pollicis longus and extensor pollicis 
brevis tendons 
3. Grey scale Tenosynovitis 
4. Power Doppler Tenosynovitis 
• Extensor compartment 2 – Extensor carpi radialis, longus and brevis 
tendons 
3. Grey scale Tenosynovitis 
4. Power Doppler Tenosynovitis 
• Extensor compartment 3 – Extensor pollicis longus tendon 
3. Grey scale Tenosynovitis 
4. Power Doppler Tenosynovitis 
• Extensor compartment 4 – Extensor digitorum tendon 
3. Grey scale Tenosynovitis 
4. Power Doppler Tenosynovitis 
• Extensor compartment 5 – Extensor digiti minimi tendon 
3. Grey scale Tenosynovitis 
4. Power Doppler Tenosynovitis 
• Extensor compartment 6 – Extensor carpi ulnaris tendon 
3. Grey scale Tenosynovitis 
4. Power Doppler Tenosynovitis 
 
KNEE: 
• Quadriceps tendon  
3. Grey scale Tenosynovitis 
4. Power Doppler Tenosynovitis 
• Proximal patellar tendon 
3. Grey scale Tenosynovitis 
4. Power Doppler Tenosynovitis 
• Distal patellar tendon 
3. Grey scale Tenosynovitis 
4. Power Doppler Tenosynovitis 
 
FOOT AND ANKLE: 
• Posterior tibialis tendon 
3. Grey scale Tenosynovitis 
4. Power Doppler Tenosynovitis 
• Flexor digitorum longus tendon 
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3. Grey scale Tenosynovitis 
4. Power Doppler Tenosynovitis 
• Flexor hallucis longus tendon 
3. Grey scale Tenosynovitis 
4. Power Doppler Tenosynovitis 
• Anterior tibialis tendon 
3. Grey scale Tenosynovitis 
4. Power Doppler Tenosynovitis 
• Extensor hallucis longus tendon 
3. Grey scale Tenosynovitis 
4. Power Doppler Tenosynovitis 
• Extensor digitorum tendon 
3. Grey scale Tenosynovitis 
4. Power Doppler Tenosynovitis 
• Peroneal longus tendon 
3. Grey scale Tenosynovitis 
4. Power Doppler Tenosynovitis 
• Peroneal brevis tendon 
3. Grey scale Tenosynovitis 
4. Power Doppler Tenosynovitis 
 
5.2.9.4.3 Synovitis Score 
24 joints (12 per side) were scanned in each participant, and each parameter scored 0-
3, with a maximum possible score of 144: 
THUMB: 
• Interphalangeal joint  
3. Grey scale Synovitis 
4. Power Doppler Synovitis 
• Carpometacarpal joint  
3. Grey scale Synovitis 
4. Power Doppler Synovitis 
 
INDEX FINGER: 
• Distal interphalangeal joint  
7. Grey scale Synovitis 
8. Power Doppler Synovitis 
• Proximal interphalangeal joint 
9. Grey scale Synovitis 
10. Power Doppler Synovitis 
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• Metacarpophalangeal joint  
11. Grey scale Synovitis 
12. Power Doppler Synovitis 
 
WRIST: 
• Wrist joint 
3. Grey scale Synovitis 
4. Power Doppler Synovitis 
 
ELBOW: 
• Lateral elbow joint  
3. Grey scale Synovitis 
4. Power Doppler Synovitis 
• Medial elbow joint 
3. Grey scale Synovitis 
4. Power Doppler Synovitis 
• Posterior elbow joint  
3. Grey scale Synovitis 
4. Power Doppler Synovitis 
 
KNEE: 
• Knee joint 
3. Grey scale Synovitis 
4. Power Doppler Synovitis 
 
ANKLE: 
• Midline ankle joint 
3. Grey scale Synovitis 
4. Power Doppler Synovitis 
 
FOOT: 
• Tarsometatarsal joint (between the base of 5th metatarsal and cuboid bone) 
3. Grey scale Synovitis 
4. Power Doppler Synovitis 
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5.2.10 Primary and Secondary Endpoints 
5.2.10.1 Primary Endpoint 
• Change in enthesopathy inflammation score (as assessed by ultrasound of the 
upper and lower limb entheses) from baseline after 24 weeks of treatment with 
ustekinumab (open-label) prescribed to treat moderate to severe psoriasis. 
5.2.10.2 Secondary Endpoints 
• Change in enthesopathy inflammation scores (as assessed by ultrasound of the 
upper and lower limb entheses) to treatment with ustekinumab (open-label) 
prescribed to treat moderate to severe psoriasis, from baseline to week 12 and 
baseline to week 52. 
• Change in enthesopathy chronic damage scores (as assessed by ultrasound of 
the upper and lower limb entheses) to treatment with ustekinumab (open-label) 
prescribed to treat moderate to severe psoriasis, from baseline to week 12, week 
24 and week 52. 
• Change in total enthesopathy scores (as assessed by ultrasound of the upper 
and lower limb entheses) to treatment with ustekinumab (open-label) prescribed 
to treat moderate to severe psoriasis, from baseline to week 12, week 24 and 
week 52. 
• Demonstrable improvement in enthesopathy scores between baseline and week 
24 (and maintenance/improvement through to week 52) to potentially enable an 
accurate power calculation for a larger randomised controlled trial against 
systemic immunosuppressants and/or other biologic molecules. 
• Comparison of new enthesopathy scores with the total modified GUESS score 
(the most widely cited published ultrasound enthesitis score) at all ultrasound 
time points (weeks 0, 12, 24 and 52), to see if the new, more extensive system 
is significantly different (better) in terms of detecting change in subclinical 
enthesitis over time, and can justify the additional time needed to scan more 
entheses in a larger randomised controlled trial.  
• Change in tenosynovitis and synovitis scores (as assessed by ultrasound of the 
upper and lower limb entheses) to treatment with ustekinumab (open-label) 
prescribed to treat moderate to severe psoriasis, from baseline to week 12, week 
24 and week 52. 
• Change in severity of skin psoriasis (as assessed by PASI and BSA) after 
treatment with ustekinumab for 12, 24 and 52 weeks, and correlation with change 
in ultrasound enthesopathy scores and HLA-Cw06 status. 
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• Correlation of anatomical locations of psoriasis (e.g. nail, scalp etc.) and 
response to ustekinumab therapy over time (week 24 and 52). 
• Change in severity of nail psoriasis (as assessed by mNAPSI) after treatment 
with ustekinumab for 12, 24 and 52 weeks and correlation with change in 
ultrasound enthesopathy scores and HLA-Cw06 status. 
• Change in quality of life measure (as assessed by DLQI) after treatment with 
ustekinumab for 12, 24 and 52 weeks and correlation with change in skin disease, 
nail disease and ultrasound enthesopathy scores. 
• Correlation between ultrasound enthesopathy scores and clinical enthesitis 
scores over time, from baseline to weeks 12, 24 and 52. 
5.3 Statistical Analysis 
As appropriate for an unpowered pilot study, primary emphasis is placed on descriptive 
statistics throughout. Results for categorical data are expressed as frequencies, and 
continuous variables are given as means (standard deviation) or medians (inter-quartile 
range), depending on the distribution. Inferential tests are presented for guidance only 
and have not been corrected for multiple comparisons; the results of these tests will be 
considered exploratory rather than confirmatory. Changes from baseline in the primary 
outcome (enthesopathy scores) were assessed using Student’s paired t-tests. 
Correlations between demographic (age, skin type, BMI, smoking history, alcohol 
consumption) and clinical parameters (age of psoriasis onset, duration of psoriasis, 
PASI, BSA, mNAPSI, DLQI) were analysed by Spearman rank correlation; absolute rho 
values >0.3 are considered to indicate weak correlation. For categorical variables 
(gender, family history of psoriasis, anatomical location of psoriasis plaques, 
presence/absence of ultrasound inflammation) associations were evaluated according 
to the extent of descriptive differences between groups. For associations with change in 
enthesopathy score, both unadjusted differences and differences adjusted for baseline 
enthesopathy score have been provided. Effect sizes for within-group changes are 
presented as Cohen’s d, calculated as (mean change/standard deviation of change)*√2. 
For adjusted between group comparisons, partial Eta squared is presented. Statistical 
analysis was performed using IBM© SPSS© version 24.0. 
5.4 Results 
23 patients were recruited to the trial. All patients completed 24 weeks of treatment and 
assessment (primary endpoint). 20 patients completed 52 weeks of treatment and 
assessment, with three lost to follow-up.  
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5.4.1 Participant Characteristics 
23 patients, 12 males and 11 females, with moderate to severe psoriasis and at least 
one lesion consistent with subclinical inflammatory enthesitis on ultrasound consented 
to participation. Three patients did not continue beyond week 24; the first patient in the 
trial was not approached to continue as the decision was only made to extend the study 
beyond the primary endpoint of 24 weeks after he had been discharged, and two were 
lost to follow up. 
Patients were aged between 20 and 74 years, with a median (interquartile range) of 45 
(33-55) years.  All patients were Caucasian (skin types I-III) with the exception of one 
patient with skin type V. Median BMI was 29.6 (27.6-35.3) kg/m2, with 10 patients 
(43.5%) being classed as obese (BMI greater than 30kg/m2). 15 patients (65.2%) were 
current or ex-smokers, with a smoking pack year history ranging from 1-64 years, median 
20 (7-32) years. Four patients did not drink alcohol, with the remainder drinking between 
4 and 76 units of alcohol per week. Average (median) consumption was 10 (10-20) units 
per week, but four patients were drinking excessive amounts at 30 or more units per 
week. 
Psoriasis onset varied from 9 to 54 years of age, with a median duration of disease of 
11 (7-25) years. All had chronic plaque disease. 13 patients had at least one family 
member with psoriasis and two had a family history of psoriatic arthritis. Four had a family 
member with another musculoskeletal diagnosis (all osteoarthritis) and two had a family 
member with autoimmune disease (hypothyroidism, type I diabetes mellitus).  
Patient comorbidities included autoimmune disease (vitiligo, type I diabetes mellitus), 
mild asthma, type II diabetes mellitus (tablet controlled), epilepsy, hypertension, 
gastroesophageal reflux disease, factor V Leiden deficiency (with recent pulmonary 
embolus) and anxiety and depression. At baseline, four patients were taking analgesic 
medications, three of which were taking non-steroidal anti-inflammatory drugs (NSAIDs).  
All three were asked to discontinue their NSAIDs and did so at least one week prior to 
their baseline ultrasound scan. They were permitted to take other forms of analgesia if 
required. 
5.4.2 Laboratory Assessment 
Blood parameters were generally within normal limits, and all patients were deemed safe 
to be prescribed the investigational medicinal product, ustekinumab. At baseline, one 
patient had an elevated CRP at 15.4mg/l (upper limit of normal <10.0mg/l), and coincided 
with coryzal symptoms suggestive of an upper respiratory tract infection. Plasma 
viscosity (PV) was elevated in five patients (upper limit of normal 1.72m.Pa.s, range of 
abnormalities 1.76-1.84mPa.s). Eight patients had an abnormal alanine transferase 
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(ALT) level (upper limit of normal <40iu/l), although none had a level of three times the 
upper limit of normal, a contraindication to ustekinumab (range of abnormalities 41-
72iu/l). Only one of these patients had abnormalities in their other liver function tests, 
and the elevations in bilirubin and alkaline phosphatase were mild. Total cholesterol was 
recorded above 5mmol/l in eight patients, and four had elevated triglycerides (upper limit 
of normal <2.3mmol/l, range of abnormalities 2.4-3.0mmol/l). Such elevations are 
expected in patients with psoriasis, especially in those who are overweight and obese, 
who often have a degree of metabolic syndrome associated with their psoriatic disease. 
These patients were offered lifestyle advice and advised to discuss statin therapy with 
their general practitioner if their levels did not reduce. All remaining blood parameters 
were all within normal limits.  
All patients were negative for rheumatoid factor, anti-CCP antibody and ANA, and 
remained so throughout the study. One patient was positive for the HLA-B27 allele, and 
15 patients (65.2%) were positive for HLA-Cw06. 
CRP was entirely normal in all patients at weeks 24 and 52. Most other blood parameters 
also improved over time, with the exception of ALT in one patient, which rose from 72iu/l 
at baseline to 76iu/l at week 24 and 109iu/l by week 52. Bilirubin remained mildly 
elevated in this patient at 34umol/l, but ALP normalised. This patient was referred for an 
ultrasound scan of the liver, which was reported as normal. Total cholesterol also 
remained elevated above 5.0mmol/l in eight patients (as baseline, maximum level 
7.2mmol/l) and patients were advised again to seek advice from their general practitioner 
if they had not done so already. Triglyceride levels were elevated in six patients, with a 
maximum level of 3.8mmol/l by week 24 and 3.6mmol/l by week 52. Plasma viscosity 
reduced in all but three patients, remaining elevated in these patients at week 52 
(maximum level 1.80mPa.s). 
5.4.3 Adverse Events 
Adverse events were minimal in the study, and most were mild and self-limiting.  
• Three patients developed an upper respiratory tract infection (all around week 
12) for which they consulted with their General Practitioner, for which two 
received a short course of oral antibiotics. 
• Three patients reported tiredness, beginning between week 4 and 12. 
• One patient developed gastroenteritis around week 22. This was self-limiting and 
did not require any treatment other than rest and oral hydration. 
• Two patients reported follicular abnormalities at week 12 – one developed facial 
acne for which a topical retinoid/benzoyl peroxide product was prescribed, and 
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the second developed small areas of folliculitis on the abdominal wall, away from 
the injection site, which resolved without treatment. 
• One patient sustained accidental trauma to the left shoulder at the gymnasium 
around week 2 and chose to wear a sling for a couple of weeks but did not seek 
medical advice. He was symptom free and had a full range of movement at his 
next review at week 4. 
Serious adverse events (SAE) occurred in two patients and were reported to the Sponsor 
(University of Leeds) and the manufacturer (Janssen Pharmaceuticals): 
• One patient was involved in a road traffic accident while riding her scooter just 
before her week 16 visit and sustained a severe fracture of her left femur. She 
underwent surgical pinning and was hospitalised for several weeks. Her 
ustekinumab therapy continued as normal. This SAE was not attributed to the 
investigational medicinal product 
• A different patient developed an abdominal pericolic gutter abscess around week 
37 of treatment. This developed spontaneously, nine weeks after her previous 
dose of ustekinumab. She required hospitalisation and intravenous antibiotics for 
seven days, but made a full recovery. After discussion with the patient and the 
patient’s dermatologist (MDG, the Candidate’s supervisor), ustekinumab was 
continued, at the correct time point. This SAE may have been related to the 
investigational medicinal product and was therefore reported to the MHRA 
through the yellow card scheme. 
5.4.4 Clinical Outcomes 
5.4.4.1 Skin Disease 
All patients at baseline had a diagnosis of moderate to severe chronic plaque psoriasis 
and PASI scores at baseline ranged from 10.4 to 38.4, with a median PASI score of 18.0 
(13.4, 28.4). Body surface area ranged from 10-60%, with a median of 30 (15,40)%. At 
the primary outcome of 24 weeks, median PASI had reduced to 0.6 (0,2.5), and body 
surface area to 1 (0,3)%. Response to ustekinumab therapy was rapid, with every patient 
experiencing a noticeable reduction in PASI score by week 4. Median PASI scores and 
BSA percentages at each time point, and the respective percentage reduction from 
baseline are listed in Table 5.3. 
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 Week 0 Week 4 Week 12 Week 24 Week 52 
Median (IQR) 
PASI score 
18 
(13.4, 28.4) 
7.2 
(4.3, 12.4) 
2.3 
(0.9, 3.9) 
0.6 
(0, 2.5) 
0.1 
(0, 2.93) 
Median (IQR) 
% reduction 
from baseline 
N/A 
61% 
(49%, 77%) 
88% 
(84%, 94%) 
97% 
(87%, 100%) 
99% 
(82%, 100%) 
Median (IQR) 
BSA (%) 
30 
(15, 40) 
15 
(10, 25) 
5 
(1, 10) 
1 
(0, 3) 
0.5 
(0, 2.75) 
Median (IQR) 
% reduction 
from baseline 
N/A 
50% 
(33%, 50%) 
83% 
(67%, 97%) 
98% 
(90%, 100%) 
99% 
(90%, 100%) 
Table 5.3. Median PASI and BSA scores at each time point, and the percentage 
reduction from baseline. PASI: Psoriasis Area and Severity Index, BSA: Body Surface 
Area; IQR: Interquartile Range; N/A: Not applicable. 
At the primary endpoint of week 24, 21 patients (91.3%) achieved a PASI 75 response, 
17 patients (73.9%) achieved a PASI 90 response and 11 patients (47.8%) achieved a 
PASI 100 response. Responses were generally maintained out to week 52.  Two of the 
patients who failed to achieve PASI 90 at week 24 did so by week 52. Two different 
patients who did make PASI 90 at week 24 lost some efficacy but still maintained a 
PASI75 response.  
In terms of distribution of lesions, the frequency at which these were involved at different 
time points is listed in Table 5.4. 
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Location 
Ever 
(n=23) 
Week 0 
(n=23) 
Week 4 
(n=23)  
Week 12 
(n=23) 
Week 24 
(n=23) 
Week 52 
(n=20) 
Nail 
n (%) 
17 
(73.9%) 
17 
(73.9%) 
15 
(65.2%) 
13 
(56.5%) 
10 
(43.5%) 
12 
(60.0%) 
Scalp 
n (%) 
23  
(100%) 
20 
(87.0%) 
14 
(60.9%) 
6 
(26.1%) 
2   
(8.7%) 
3 
(15.0%) 
Retroauricular 
n (%) 
21 
(91.3%) 
17 
(73.9%) 
7 
(30.4%) 
1   
(4.3%) 
0      
(0%) 
3 
(15.0%) 
Gluteal cleft 
n (%) 
19 
(82.6%) 
14 
(60.9%) 
9 
(39.1%) 
5 
(21.7%) 
2   
(8.7%) 
1   
(5.0%) 
Umbilicus 
n (%) 
15 
(65.2%) 
11 
(47.8%) 
8 
(34.8%) 
2   
(8.7%) 
1   
(4.3%) 
1   
(5.0%) 
Face 
n (%) 
16 
(69.6%) 
13 
(56.5%) 
4 
(17.4%) 
2   
(8.7%) 
0      
(0%) 
0      
(0%) 
Upper limb 
n (%) 
23 
(100%) 
23 
(100%) 
23 
(100%) 
16 
(69.6%) 
10 
(43.5%) 
8 
(40.0%) 
Dorsal hand(s) 
n (%) 
15 
(65.2%) 
14 
(60.9%) 
8 
(34.8%) 
3 
(13.0%) 
0      
(0%) 
1   
(5.0%) 
Trunk 
n (%) 
22 
(95.7%) 
21 
(91.3%) 
21 
(91.3%) 
10 
(43.5%) 
7 
(30.4%) 
7 
(35.0%) 
Lower limb 
n (%) 
23 
(100%) 
23 
(100%) 
22 
(95.7%) 
17 
(73.9%) 
8 
(34.8%) 
6 
(30.0%) 
Flexures 
n (%) 
15 
(65.2%) 
11 
(47.8%) 
2   
(8.7%) 
2   
(8.7%) 
0      
(0%) 
1   
(5.0%) 
Genitals 
n (%) 
11 
(47.8%) 
7 
(30.4%) 
1   
(4.3%) 
1   
(4.3%) 
0      
(0%) 
0      
(0%) 
Perianal 
n (%) 
8 
(34.8%) 
6 
(26.1%) 
0      
(0%) 
1   
(4.3%) 
0      
(0%) 
1   
(5.0%) 
Palms 
n (%) 
5 
(21.7%) 
4 
(17.4%) 
1   
(4.3%) 
0      
(0%) 
0      
(0%) 
0      
(0%) 
Soles 
n (%) 
7 
(30.4%) 
3 
(13.0%) 
2   
(8.7%) 
1    
(4.3%) 
0      
(0%) 
1   
(5.0%) 
Table 5.4. Frequency of clinically involved anatomical sites at each time point. 
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The upper and lower limbs had the slowest cutaneous lesions to resolve, followed by the 
trunk. This most probably reflects those areas that have the greatest body surface area 
coverage and are usually the most severe in terms of induration and erythema. These 
data also show a slight worsening or re-emergence of lesions at week 52 compared with 
week 24, but this is likely due to the timing of assessment in relation to the timing of the 
last injection. It is not uncommon for patients to experience a dip in control in the few 
weeks leading up to their next injection. Patients were typically seven or eight weeks 
post their last injection at the week 24 visit and were therefore in the period where their 
therapy was providing maximal disease suppression, compared to the week 52 visit, 
where patients were 12 weeks post their last injection and due their next dose 
imminently.  
5.4.4.2 Nail Disease 
17 patients (73.9%) had nail disease at baseline, with a mNAPSI score between 2 and 
89 (out of a maximum possible score of 140). Pitting was the most frequent abnormality 
in 15 patients (65.2%), closely followed by onycholysis in 13 (56.5%) and crumbling in 
13 (56.5%). 7 of 17 patients (41.2%) with nail disease at baseline had complete 
resolution of their nail psoriasis by week 24, with a further five having at least a 75% 
improvement. Improvement in mNAPSI from baseline to week 24 ranged from 22.2% to 
100%, with a median reduction of 15 points (91.2%), and from baseline to week 52 
ranged from 55.6% to 100%, with a median reduction of 22 points (86.4%). The most 
notable improvements occurred in nail bed psoriasis, leading to a greater reduction in 
onycholysis and nail bed hyperkeratosis than in nail plate changes such as pitting. 
5.4.4.3 Entheseal tenderness and Dactylitis 
Clinically detectable entheseal tenderness in asymptomatic patients was not infrequent 
but of a low level, with 11 of 23 (47.8%) patients having evidence of at least one tender 
enthesis, with a median of 1.5 (1.0-2.5) sites per patient at baseline. With treatment, this 
number reduced, with 7 of 23 (30.4%) patients having clinical entheseal tenderness at 
week 12, 4 of 23 (17.4%) at week 24 and 8 of 23 (34.8%) at week 52. The most common 
clinically tender enthesis was the medial humeral epicondyle, with five entheses (in four 
patients) being tender at baseline. No swollen entheses were found.  
In total, 29 tender entheseal sites were identified from 736 examined in all 23 patients at 
baseline (3.9%). Tenderness resolved in 23 entheseal sites; 17 by week 12, a further 
four by week 24 and a further two by week 52. Tenderness persisted throughout in six 
entheses and new tenderness developed at 12 new entheseal sites (in seven patients) 
over the course of the study to 52 weeks.  
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Dactylitis was evident in four patients at baseline, in one digit in three and in four digits 
in one. These had resolved by week 12. One further patient developed dactylitis later in 
the study (in two digits at week 12), but this resolved by week 24. 
5.4.5 Sonographic Outcomes 
5.4.5.1 Enthesopathy and Bursitis 
26 entheseal sites (13 per side) were scanned in 23 patients at baseline, week 12 and 
week 24, and in 20 patients at week 52. This equates to 598 entheses in all participants 
at week 0, 12 and 24, and 520 entheses in all participants at week 52. 
Frequency of Entheseal and Bursal Abnormalities 
325 entheseal abnormalities were identified at baseline, with the number of abnormalities 
ranging from two to 28 per patient.  The quadriceps tendon was the most frequently 
involved site for both inflammatory and chronic damage lesions at baseline. Inflammatory 
lesions principally involved the large tendon entheses of the knee, elbow and ankle 
(Figure 5.1), whereas there was no correlation with tendon size and the presence of 
structural damage (Figure 5.2)  
 
 
Figure 5.1. Pre-treatment distribution of inflammatory entheseal lesions by enthesis. 
(Common flexor and common flexor tendons at the elbow). 
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Figure 5.2. Pre-treatment distribution of chronic damage entheseal lesions by enthesis. 
(Common flexor and common flexor tendons at the elbow). 
The total number of abnormalities (inflammatory and chronic damage) and the range of 
total number of abnormalities per patient at each time point are displayed in Table 5.5.   
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All abnormalities Week 0 Week 12 Week 24 Week 52 
Number of patients 23 23 23 20 
Maximum number of entheseal 
abnormalities possible per 
patient§ 
182 182 182 182 
Maximum total number of 
entheseal abnormalities possible§ 4186 4186 4186 3640 
Total number of entheseal 
abnormalities found in all patients 324 259 279 222 
Range of total number of 
abnormalities per patient 2-28 0-28 0-34 0-28 
Mean (± s.d.) total number of 
abnormalities per patient 14.1 ± 7.8 11.3 ± 7.5 12.1 ± 8.7 11.1 ± 7.3 
Mean (95% CI) change in total 
number of abnormalities per 
patient 
N/A -2.8  (-4.4, -1.2) 
-2.0  
(-4.2, -0.3) 
-3.1  
(-6.1, -0.11) 
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*Calculated as (|mean change|/SD change)*√2 
Table 5.5. Total number of entheseal abnormalities at each time point (§based on 13 
entheses bilaterally, seven parameters per enthesis)  
Figure 5.3 demonstrates the mean total number of all entheseal abnormalities in all 
patients at each time point. With treatment, the mean number of entheseal abnormalities 
appears to reduce compared to baseline, although such differences failed to reach 
statistical significance at all time points. 
 
 
 
 
 
 
 
 
Figure 5.3. Change in mean total number of all entheseal abnormalities for all patients 
over time.  
However, when separated into inflammatory and chronic damage entheseal 
abnormalities, there are clear differences in way different lesion types appear to respond 
to therapy over time (Figure 5.4). 
Effect size (Cohen’s d*) N/A 1.1 0.5 0.7 
Median (IQR) number of entheses 
involved per patient 9 (4, 12) 6 (3, 9) 7 (4, 9) 6 (5, 9) 
Median (IQR) change in number 
of entheses involved per patient N/A -2 (-4, 0) -1 (-4, 0) -1 (-4, 1) 
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Figure 5.4. Percentage of entheses with inflammatory (blue line) and chronic damage 
(red line) lesions over time in all patients. 
Enthesopathy: Active Inflammation 
At baseline, 145 of 598 (24.2%) entheses scanned in 23 psoriasis patients (median (IQR) 
6 (4, 9) out of 26 per patient) had at least one inflammatory entheseal abnormality 
(thickening, hypoechogenicity and/or power Doppler signal), defined as a grey scale or 
power Doppler signal score in these parameters >0.  
The frequency of inflammatory parameters at the entheseal/bursal and patient level over 
time can be found in Table 5.6. 
In total, 187 inflammatory entheseal abnormalities were identified at baseline, with a 
mean (±s.d.) of 9.8 (±6.7) abnormalities per patient (out of a total possible of 78). The 
number of entheses with an inflammatory abnormality and the total number of 
inflammatory abnormalities per patient declined at each visit (Table 5.7 and Figure 5.5). 
By week 52, the mean number of inflammatory abnormalities per patient had reduced by 
more than half compared to baseline. 
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Table 5.6.  Frequency of active inflam
m
atory param
eters at the entheseal/bursal and patient level over tim
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Inflammatory abnormalities Week 0 Week 12 Week 24 Week 52 
Number of patients 23 23 23 20 
Maximum number of entheseal 
abnormalities possible per patient§ 78 78 78 78 
Maximum total number of 
entheseal abnormalities possible§ 1794 1794 1794 1560 
Total number of entheseal 
abnormalities found in all patients 187 130 109 70 
Range of total number of 
abnormalities per patient 1-17 0-16 0-15 0-15 
Mean (± s.d.) total number of 
abnormalities per patient 8.1 (4.7) 5.7 (3.8) 4.7 (4.2) 3.5 (2.7) 
Mean (95% CI) change in total 
number of abnormalities per patient N/A 
-2.5 
(-3.6, -1.3) 
-3.4  
(-4.9, -1.9) 
-4.7  
(-6.6, -2.7) 
Effect size (Cohen’s d*) N/A 1.3 1.4 1.6 
Total number of entheses involved 145 102 84 54 
Median (IQR) number of entheses 
involved per patient 6 (4, 9) 4 (2, 6) 3 (2, 5) 3 (1, 4) 
Median (IQR) change in number of 
entheses involved per patient N/A -2 (-3, 0) -2 (-5, -1) -3 (-6, -1) 
*Calculated as (|mean change|/SD change)*√2 
Table 5.7. lists the frequency of inflammatory entheseal abnormalities by enthesis at 
each time point  (§based on 13 entheses bilaterally, three parameters per enthesis). 
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Figure 5.5. Change in mean number of inflammatory entheseal abnormalities for all 
patients over time. Statistically significant differences were found at week 12 and 24 
compared with baseline (where p<0.1). 
These data suggest that treatment with ustekinumab may have a positive impact on 
active (inflammatory) subclinical enthesitis within as little as 12 weeks, and the trend in 
this improvement appears to continue with therapy out to a year.  
Enthesopathy: Chronic Damage 
In contrast to active inflammation, structural changes (entheseal calcification, 
enthesophytes, bone erosions and bone cortex irregularities) did not improve with 
ustekinumab therapy over time. The frequency of chronic damage parameters at the 
entheseal/bursal and patient level over time can be found in Table 5.8.  
95 of 598 (15.9%) entheses scanned in 23 patients at baseline (mean ± s.d. 4.1 (3.7) out 
of 26 per patient) had at least one chronic damage abnormality, defined as a grey scale 
or power Doppler signal score in the above parameters >0. In total, 137 chronic damage 
changes were identified at baseline in 23 patients, with a mean ± s.d. of 6.0 ± 4.7 
abnormalities per patient. Over time, the number of entheses with chronic abnormalities 
fluctuated, whilst the total number of chronic abnormalities tended to increase slightly 
(Table 5.9 and Figure 5.6). The majority of abnormalities were entheseal calcifications 
and enthesophytes 
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Chronic abnormalities Week 0 Week 12 Week 24 Week 52 
Number of patients 23 23 23 20 
Maximum number of entheseal 
abnormalities possible per patient§ 104 104 104 104 
Maximum total number of entheseal 
abnormalities possible§ 2392 2392 2392 2080 
Total number of entheseal 
abnormalities found in all patients 137 129 170 152 
Range of total number of 
abnormalities per patient 0 to 17 0 to 18 0 to 24 0 to 19 
Mean ± s.d. total number of 
abnormalities per patient 6.0 ± 4.7 5.6 ± 5.0 7.4 ± 5.7 7.6 ± 6.1 
Mean (95% CI) change in total 
number of abnormalities per patient N/A 
-0.3  
(-1.2, 0.6) 
1.4  
(0.2, 2.7) 
1.6 
(-0.3, 3.4) 
Effect size (Cohen’s d*) N/A 0.2 0.7 0.6 
Total number of entheses involved 95 87 111 104 
Median (IQR) number of entheses 
involved per patient 3 (2, 6) 2 (1, 5) 4 (2, 7) 4 (2, 8) 
Median (IQR) change in number of 
entheses involved per patient N/A 0 (0, 0) 1 (0, 2) 1 (-2, 3) 
*Calculated as (|mean change|/SD change)*√2 
Table 5.9. The frequency of chronic damage/structural entheseal abnormalities by 
enthesis at each time point. (§based on 13 entheses bilaterally, four parameters per 
enthesis). 
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Figure 5.6. Change in mean number of chronic damage entheseal abnormalities for all 
patients over time. 
The trend in these data suggest that treatment with ustekinumab has minimal impact on 
those structural damage lesions associated with enthesopathy and that there may be 
slow progression in damage over time.  However, it may be that progression is slowed 
with ustekinumab, but without a group of patients with psoriasis and subclinical enthesitis 
receiving no treatment, this remains unknown.  
Bursitis 
Bursitis was minimal in this cohort, with only four patients having unilateral grey scale 
synovial hypertrophy throughout the study. One patient had bursitis at two locations at 
baseline (deep infrapatellar bursa and contralateral superficial infrapatellar bursa), both 
of which resolved after 24 weeks of treatment. Bursitis appeared in the deep infrapatellar 
bursa in two patients, one at week 12 and the other at week 24, but both had resolved 
by the next ultrasound scan. A fourth patient developed retrocalcaneal bursitis at week 
24, but this had resolved by week 52. No bursal power Doppler signal was seen 
throughout. 
5.4.5.1.1 Severity of Entheseal/Bursal Abnormalities 
The majority of abnormalities, both inflammatory and structural, were mild (grade 1). The 
overall severity of lesions lessened a little with time. Of the 4186 entheseal inflammatory 
and chronic damage scores at baseline, 60 (1.43%) were of grade 2 or 3. At weeks 12, 
24 and 52, 37/4186 (0.88%), 43/4186 (1.03%) and 33/3640 (0.91%) of the total number 
of abnormality scores were of grade 2 or more, respectively. Bursal synovial hypertrophy, 
where present, was always scored as mild (grade 1). 
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By the primary endpoint of 24 weeks, the severity of inflammatory lesions overall 
improved from baseline, with a reduction from 32/1794 (1.78%) to 16/1794 (0.89%) of all 
inflammatory abnormality scores being of grade 2 or 3. Figure 5.7, Figure 5.8 and Figure 
5.9 provide examples of the reduction in inflammatory abnormalities seen with 
ustekinumab therapy within both small and large entheses of upper and lower limbs. 
 
Figure 5.7. Reduction in entheseal thickness (, grade 2 to 0), hypoechogenicity (Ö, 
grade 1 to 0) and power doppler signal (, grade 3 to 0) within the left proximal patellar 
tendon enthesis between week 0 (a) and week 52 of ustekinumab therapy (b). PT: 
Patellar tendon; Pat: Patella; Tib: Tibia. 
 
Figure 5.8. Reduction in entheseal thickness (, grade 1 to 0), hypoechogenicity (Ö, 
grade 2 to 0) and power doppler signal (, grade 2 to 1) within the right common extensor 
tendon enthesis between week 0 (a) and week 52 of ustekinumab therapy (b). CET: 
Common extensor tendon; LE: Lateral epicondyle. 
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Figure 5.9. Normalisation of entheseal thickness (, grade 2 to 0) and hypoechogenicity 
(Ö, grade 2 to 0) within the left index finger flexor digitorum tendon enthesis between 
week 0 (a) and week 52 of ustekinumab therapy (b). Chronic damage abnormalities () 
(bone cortex irregularities and enthesophytes) remained unchanged. FDP: Flexor 
digitorum profundus; MP: Middle phalynx; DP: Distal phalynx.  
For chronic damage lesions, there was little change, with 28/2392 (1.17%) of all chronic 
abnormality scores being of grade 2 or 3 at baseline compared to 27/2392 (1.13%) at 
week 24. However, these totals mask the fact that at the patient level some lesions 
improved or resolved completely (Figure 5.10 and Figure 5.11), while in others new 
lesions appeared. 
 
Figure 5.10. Reduction in entheseal calcification (, grade 2 to 1), accompanied by a 
reduction in entheseal thickness (, grade 1 to 0) and hypoechogenicity (Ö, grade 2 to 
0) within the right proximal patellar tendon enthesis between week 0 (a) and week 24 of 
ustekinumab therapy (b). PT: Patellar tendon; Pat: Patella; Tib: Tibia.  
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Figure 5.11. Reduction in bone cortex irregularities and enthesophytes (, grade 2 to 1), 
accompanied by a reduction in entheseal thickness (, grade 1 to 0) and 
hypoechogenicity (Ö, grade 2 to 1) within the left quadriceps tendon enthesis between 
week 0 (a) and week 24 of ustekinumab therapy (b). QT: Quadriceps tendon; Pat: 
Patella. 
Table 5.10 shows the changes in entheseal scores between week 0 and week 24.  The 
majority of inflammatory lesions (130/187) scoring 1 or more at baseline either resolved 
or improved, although 2 worsened and 38 inflammatory new inflammatory lesions 
developed while on therapy. 
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Abnormality 
scores 
Score at 
baseline Resolved Improved Unchanged Worse New 
Total 
(Inflammation 
+ Chronic) 
All 151  28  3886  15  106  
0   3756  106 
1 137  113 14  
2 14 22 13 1  
3 0 6 4   
Inflammation All 116  14  1624  2  38 
0   1569  38 
1 106  48 1  
2 10 10 4 1  
3 0 4 3   
Chronic All 35  14  2262  13  68  
0   2187  68 
1 31  65 13  
2 4 12 9 0  
  0 2 1   
Table 5.10. Changes in entheseal abnormality scores between baseline and week 24. 
‘New’ lesions were those that scored 0 at baseline and >0 at follow-up. Conversely those 
that scored >0 at baseline and 0 at follow-up had ‘resolved’. Scores of 1 or 2 could have 
worsened at follow-up, whilst scores of 2 or 3 could have improved. 
Table 5.11 below repeats the same analyses, restricted to patients who were scanned 
by the same sonographer on both occasions. There were still a handful of chronic scores 
that improved or resolved from baseline. 
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Abnormality 
scores 
Score at 
baseline Resolved Improved Unchanged Worse New 
Combined All 90  13  1648 10 59  
 0   1569  59 
 1 83  71 9  
 2 7 13 7 1  
 3 0 0 1   
Inflammatory All 70 4  685  1  20  
 0   649  20 
 1 65  31 0  
 2 5 4 4 1  
 3 0 0 1   
Chronic All 20  9  963  9  39  
 0   920  39 
 1 18  40 9  
 2 2 9 3 0  
 3 - - -   
Table 5.11. Changes in entheseal abnormality scores between baseline and week 24, 
restricted to patients who were scanned by the same sonographer at both time points. 
‘New’ lesions were those that scored 0 at baseline and >0 at follow-up. Conversely those 
that scored >0 at baseline and 0 at follow-up had ‘resolved’. Scores of 1 or 2 could have 
worsened at follow-up, whilst scores of 2 or 3 could have improved. 
5.4.5.1.2 Enthesopathy Scores 
As expected, all enthesopathy scores were low, reflecting the very early stage of disease, 
with only mild abnormalities in a handful of entheses seen in each patient (Table 5.12). 
There was a wide variance in the number of abnormal parameters at each time point 
between patients, with some having only one active inflammatory lesion at baseline, 
compared to others with as many as 17 different abnormalities. Chronic damage lesions 
ranged in frequency from 0 to 24 and were maximal at week 24. 
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Week 0 
n=23 
Week 12 
n=23 
Week 24 
n=23 
Week 52 
n=20 
Inflammation Score     
Range 1-29 0-20 0-19 0-16 
Mean ± s.d. 9.9 ± 6.6 6.8 ± 4.9  5.7 ± 5.3 4.8 ± 4.6 
Mean change ± s.d. N/A -3.1 ± 3.8 -4.2 ± 4.9 -4.7 ± 5.2 
Confidence interval for 
change 
N/A (-4.8, -1.5) (-6.3, -2.1) (-7.1, -2.3) 
Paired Student’s t value, p 
value 
N/A 
t=-4.0, 
p=.001 
t=-4.1, 
p<.001 
t=-4.0, 
p=.001 
Effect size (Cohen’s d*) N/A 1.2 1.2 1.3 
Chronic Damage Score     
Range  0-21 0-20 0-25 0-26 
Mean ± s.d. 7.9 ± 5.7 7.0 ± 5.7 9.1 ± 6.5 8.6 ± 7.0 
Mean change ± s.d. N/A -0.8 ±2.6 1.3 ± 3.3 0.8 ± 5.0 
Confidence interval for 
change 
N/A (-1.9, 0.3) (-0.2, 2.7) (-1.6, 3.1) 
Paired Student’s t value, p 
value 
N/A 
t=-1.5, 
p=.137 
t=1.8, p=.082 t=0.7, p=.512 
Effect size (Cohen’s d*) N/A 0.5 0.5 0.2 
Total Score     
Range 2-42 0-32 0-38 0-42 
Mean ± s.d. 17.8 ± 10.4 13.8 ± 9.1 14.8 ± 10.6 13.6 ± 9.9 
Mean change ± s.d. N/A -4.0 ± 4.7 -3.0 ± 6.3  -4.0 ± 8.3  
Confidence interval for 
change 
N/A (-6.0, -1.9) (-5.7, -0.2) (-7.8, -0.1) 
Paired Student’s t value, p 
value 
N/A 
t=-4.1, 
p=.001 
t=-2.3, 
p=.034 
t=-2.1, 
p=.047 
Effect size (Cohen’s d*) N/A 1.2 0.7 0.7 
*Calculated as (|mean change|/SD change)*√2 
Table 5.12. Range in enthesopathy scores (including bursa) over time.  
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The trends in mean inflammation, chronic damage and total enthesopathy scores with 
treatment over time are shown in Figure 5.12, Figure 5.13 and Figure 5.14. Large 
decreases in inflammation scores were seen between week 0 and weeks 24 and 52; p 
values for these changes were both <0.1 (Table 5.12).  
 
 
 
 
 
 
 
 
 
Figure 5.12. Mean change in total enthesopathy score with treatment over time  
 
 
 
 
 
 
 
 
 
 
Figure 5.13.  Mean change in inflammation score with treatment over time 
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Figure 5.14. Mean change in chronic damage score with treatment over time 
5.4.5.2 Tenosynovitis 
13 of 23 patients (56.5%) had sonographic evidence of grey scale tenosynovitis at some 
stage during the study (Table 5.13).  
At baseline, 14 tendon sheaths in nine patients were abnormal, with a maximum of three 
abnormalities in any one patient. Power Doppler signal was seen in four tendon sheaths 
in three patients - two unilaterally in a single tendon (thumb extensor pollicis longus 
tendon/proximal patellar tendon) and one bilaterally in the proximal patellar tendons. 
Knee and ankle tendons most frequently exhibited tenosynovitis, with very little seen in 
the digits of the hands. Tenosynovitis scores (out of a possible maximum of 264) ranged 
from 0-7. 
With treatment, the majority of abnormalities resolved by the primary endpoint of 24 
weeks with the exception of one lesion in two patients. However, six patients developed 
new areas of tenosynovitis during the study – in four patients at week 24, and in two 
different patients at week 52. Power Doppler signal resolved in all but two tendon sheaths 
(one distal and one proximal patellar tendons) in two patients. Tenosynovitis scores 
ranged from 0-2 at week 12, 0-6 at week 24 and 0-6 at week 52.  
Of the 14 tendons identified at baseline with grey scale tenosynovitis, only eight had 
corresponding entheses included the ultrasound protocol, seven of which had an 
associated inflammatory enthesopathy. The remainder occurred at sites where the 
tendon crosses a bony prominence and acts as an enthesis organ, still subject to the 
same mechanical shearing forces but with no true bone insertion site to visualise with 
ultrasound. Of the twelve sites after baseline with tenosynovitis and corresponding true 
entheses (four at week 12, three at week 24 and five at week 52), six had an associated 
inflammatory enthesopathy and only one had chronic damage (grade 1 bone erosions).  
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S 
1 
2.2 
1 
4.3 
1 
2.2 
1 
4.3 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
PD
 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
Extensor digitorum
 
G
S 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
PD
 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
Wrist 
Extensor C
om
partm
ent 1 
(APL and EPB) 
G
S 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
PD
 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
Extensor C
om
partm
ent 2 
(EC
R
, EC
L, EC
B)  
G
S 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
PD
 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
  
Extensor C
om
partm
ent 3 
(Extensor pollicis longus ) 
G
S 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
PD
 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
Extensor C
om
partm
ent 4    
(Extensor digitorum
)  
G
S 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
PD
 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
Extensor C
om
partm
ent 5    
(Extensor digiti m
inim
i) 
G
S 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
PD
 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
Extensor C
om
partm
ent 6   
(Extensor carpi ulnaris)  
G
S 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
PD
 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
Knee 
Q
uadriceps 
G
S 
1 
2.2 
1 
4.3 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
PD
 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
Proxim
al Patellar  
G
S 
5 
10.9 
3 
13.0 
2 
4.3 
1 
4.3 
1 
2.2 
1 
4.3 
1 
2.5 
1 
5.0 
PD
 
3 
6.5 
2 
8.7 
0 
0.0 
0 
0.0 
1 
2.2 
1 
4.3 
1 
2.5 
1 
5.0 
D
istal Patellar  
G
S 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
1 
2.2 
1 
4.3 
1 
2.5 
1 
5.0 
PD
 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
1 
2.2 
1 
4.3 
1 
2.5 
1 
5.0 
Foot and Ankle 
Posterior Tibialis  
G
S 
2 
4.3 
2 
8.7 
2 
4.3 
2 
8.7 
4 
8.7 
4 
17.4 
2 
2.5 
2 
5.0 
PD
 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
Flexor D
igitorum
 Longus  
G
S 
1 
2.2 
1 
4.3 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
PD
 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
  
Table 5.13. Frequencies of grey scale and pow
er D
oppler tenosynovitis at the patient and tendon level at baseline and after 12, 24 and 52 w
eeks of 
treatm
ent (EPL: Extensor pollicis longus; APL: Abductor pollicis longus; EPB: Extensor pollicis brevis; EC
R
: Extensor carpi radialis; E
C
L: Extensor 
carpi longus; EC
B: Extensor carpi brevis) 
Flexor H
allucis Longus 
G
S 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
PD
 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
Anterior Tibialis  
G
S 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
PD
 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
Extensor H
allucis Longus 
G
S 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
PD
 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
Extensor D
igitorum
 Longus 
G
S 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
PD
 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
Peroneal Longus 
G
S 
2 
4.3 
2 
8.7 
0 
0.0 
0 
0.0 
1 
2.2 
1 
4.3 
0 
0.0 
0 
0.0 
PD
 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
Peroneal Brevis  
G
S 
1 
2.2 
1 
4.3 
1 
2.2 
1 
4.3 
0 
0.0 
0 
0.0 
2 
5.0 
2 
10.0 
PD
 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
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5.4.5.3 Synovitis 
Low grade synovitis was a common finding, with 22 of 23 (95.7%) patients having at 
least one area of grey scale synovitis during the study. At baseline, 18 of 23 (78.3%) 
patients had a total of 79 joints with grey scale synovitis (defined as a score >0), seven 
of which (in four patients) also had power Doppler signal. The number of joints per patient 
with grey scale synovitis ranged from 0-12, with a median (IQR) of 3 (0-6). Median total 
synovitis score was 4 (IQR 0-8) out of a possible 264.  
By week 12, 18 of 23 (78.3%) patients had a total of 68 joints with grey scale synovitis. 
Three of these (in three patients) had persistent power Doppler signal from baseline, with 
the remainder having resolved. Two of the 18 patients with grey scale synovitis were 
different to baseline. The number of joints per patient with grey scale synovitis ranged 
from 0-10, with a median (IQR) of 2 (1-4). Median total synovitis score was 2 (IQR 1-6) 
out of a possible 264.  
By week 24, the number of patients with grey scale synovitis had increased to 21 of 23 
(91.3%), involving a total of 89 joints, three of which (in three patients) also had power 
Doppler signal. These three lesions were new, with the seven from baseline having now 
resolved. The number of joints per patient with grey scale synovitis ranged from 0-11, 
with a median (IQR) of 3 (0-6). Median total synovitis score was 3 (IQR 2-6) out of a 
possible 264. 
By week 52, the number of patients with grey scale synovitis reduced to 14 of 23 (60.9%), 
involving a total of 47 joints, one of which also had power Doppler signal. This was a new 
area of signal, with all previous areas having resolved. The number of joints per patient 
with grey scale synovitis ranged from 0-10, with a median (IQR) of 1 (0-3). Median total 
synovitis score was 1.5 (IQR 1-4) out of a possible 264 (Table 5.14).  
In terms of numbers of joints, by the primary endpoint of week 24 the burden of synovitis 
worsened from baseline in eight patients, and new synovitis appeared in a further seven. 
A reduction of number of joints involved occurred in six and resolved altogether in 
another one patient. One patient remained static with the same number of areas of 
synovitis at baseline and week 24.  
. 
  
Joint 
Mode 
W
eek 0 
W
eek 12 
W
eek 24 
W
eek 52 
Joint    
(m
ax n=46) 
Patient  
(m
ax n=23) 
Joint    
(m
ax n=46) 
Patient  
(m
ax n=23) 
Joint    
(m
ax n=46) 
Patient  
(m
ax n=23) 
Joint    
(m
ax n=40) 
Patient  
(m
ax n=20) 
n 
%
 
n 
%
 
n 
%
 
n 
%
 
n 
%
 
n 
%
 
n 
%
 
n 
%
 
Thumb 
Interphalangeal 
G
S 
6 
13.0 
5 
21.7 
5 
10.9 
4 
17.4 
5 
10.9 
5 
21.7 
3 
7.5 
2 
10.0 
PD
 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
C
arpom
etacarpal 
G
S 
18 
39.1 
12 
52.2 
17 
37.0 
11 
47.8 
28 
60.9 
16 
69.6 
7 
17.5 
4 
20.0 
PD
 
1 
2.2 
1 
4.3 
0 
0.0 
0 
0.0 
1 
2.2 
1 
4.3 
0 
0.0 
0 
0.0 
Index Finger 
D
istal    Interphalangeal 
G
S 
8 
17.4 
8 
34.8 
3 
6.5 
3 
13.0 
4 
8.7 
3 
13.0 
3 
7.5 
3 
15.0 
PD
 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
Proxim
al 
Interphalangeal 
G
S 
8 
17.4 
5 
21.7 
6 
13.0 
4 
17.4 
8 
17.4 
5 
21.7 
5 
12.5 
3 
15.0 
PD
 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
M
etacarpophalangeal 
G
S 
12 
26.1 
8 
34.8 
6 
13.0 
4 
17.4 
5 
10.9 
3 
13.0 
2 
5.0 
1 
5.0 
PD
 
3 
6.5 
2 
8.7 
2 
4.3 
2 
8.7 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
W
rist 
G
S 
17 
37.0 
12 
52.2 
16 
34.8 
12 
52.2 
26 
56.5 
18 
78.2 
15 
37.5 
11 
55.0 
PD
 
3 
6.5 
3 
13.0 
1 
2.2 
1 
4.3 
2 
4.3 
2 
8.7 
1 
2.5 
1 
5.0 
  
Elbow 
Lateral Elbow
 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
 
M
edial Elbow
 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
 
Posterior Elbow
 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
 
Knee 
G
S 
9 
19.6 
7 
30.4 
11 
23.9 
8 
34.8 
8 
17.4 
6 
26.1 
10 
25.0 
6 
30.0 
PD
 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
Ankle 
G
S 
1 
2.2 
1 
4.3 
1 
2.2 
1 
4.3 
2 
4.3 
1 
4.3 
1 
2.5 
1 
5.0 
PD
 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
0 
0.0 
 Table 5.14. Frequencies of grey scale and pow
er D
oppler synovitis at the patient and tendon level at baseline and after 12, 24 and 52 w
eeks of 
treatm
ent. 
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In terms of the grade of synovitis, grey scale synovitis resolved in 42 (79.5%), improved 
in 6 (7.6%), remained unchanged in 28 (35.4%) and worsened in 3 (3.8%) from week 0 
to week 24. New synovial inflammation appeared in 49 joints (Table 5.15). 
Table 5.15. Changes in synovitis scores between baseline and week 24. ‘New’ lesions 
were those that scored 0 at baseline and >0 at follow-up. Conversely those that scored 
>0 at baseline and 0 at follow-up had ‘resolved’. Scores of 1 or 2 could have worsened 
at follow-up, whilst scores of 2 or 3 could have improved. 
Table 5.16 below repeats the same analyses, restricted to patients who were scanned 
by the same sonographer on both occasions.  
Table 5.16. Changes in synovitis scores between baseline and week 24. ‘New’ lesions 
were those that scored 0 at baseline and >0 at follow-up. Conversely those that scored 
>0 at baseline and 0 at follow-up had ‘resolved’. Scores of 1 or 2 could have worsened 
at follow-up, whilst scores of 2 or 3 could have improved 
The carpometacarpal joints of the thumb most frequently exhibited sonographic grey 
scale changes in keeping with synovitis, closely followed by the wrist joints and the index 
finger metacarpophalangeal joints. No synovitis was seen throughout the study in the 
Synovitis 
score 
Score at 
baseline Resolved Improved Unchanged Worse New 
GS 
All 42 6 406 3 49 
0   378  49 
 1 34  28 3  
 2 8 5 0 0  
 3 0 1 0   
PD 
All 7 0 496 0 3 
0   496  3 
1 6  0 0  
 2 1 0 0 0  
 3 - - -   
Synovitis 
score 
Score at 
baseline Resolved Improved Unchanged Worse New 
GS All 20  5  174  2  19  
 0   152  19 
 1 16  22 2  
 2 4 4 0 0  
 3 0 1 0   
PD All 4  0  215  0  1  
 0   215  1 
 1 3  0 0  
 2 1 0 0 0  
 3 - - -   
263 
 
elbow joints or tarsometatarsal joints (between the base of the fifth metatarsal and cuboid 
bone) and was uncommon at the ankle (Figure 5.15). 
Figure 5.15.. Frequency of grey scale joint synovitis with treatment over time (CMC: 
carpometacarpal; MCP: metacarpophalangeal; DIP: distal interphalangeal; PIP: 
proximal interphalangeal: IP; interphalangeal) 
 
Synovitis was usually mild (grade 1). 13 (15.1%) of 86 joints with synovitis at baseline 
had changes that were of grade 2 or 3, in nine patients. At subsequent time points, grade 
2 or 3 changes were seen in 7 (10.3%) of 68 joints with synovitis in six patients at week 
12, 9 (10.1%) of 89 joints with synovitis in nine patients at week 24 and 7 (14.9%) of 47 
joints in four patients at week 52. Severe synovitis (grade 3) was seen in only three joints 
throughout the study – in one joint in one patient at week 0, and in two different joints in 
one patient at different time points (week 12 and week 52). 
5.4.6 Associations between Clinical and Sonographic Outcomes 
5.4.6.1 Correlation between ultrasound and clinical entheseal 
assessments 
The accuracy of clinical examination to detect enthesitis is known to be inferior to 
imaging, although several assessment tools are still advocated for use in patients with 
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PsA, such as the LEI and MASES. It is not known how these assessments perform in 
psoriasis patients with subclinical disease, or if they are able to detect emerging 
pathology. Table 5.17 demonstrates the level agreement prior to treatment between 
clinical examination and ultrasound (inflammatory lesions only) at several anatomical 
sites (where a peripheral enthesis was accessible for both assessments). 
 
 CE<US % 
US<CE 
% 
PEA 
% 
Sp0 
% (n/N) 
Sp1 
% (n/N) 
Kappa 
(95% CI) PABAK 
Site n=46 n=46 n=46     
Medial 
humeral 
epicondyle 
24% - 76% 85% (60/71) 
48% 
(10/21) 
0.37 
(0.12, 0.62) 0.52 
Lateral 
humeral 
epicondyle 
41% 4% 54% 70% (48/69) 
9% 
(2/23) 
-0.03 
(-0.19, 0.13) 0.09 
Quadriceps 41% 4% 54% 70% (48/69) 
9% 
(2/23) 
-0.03 
(-0.19, 0.13) 0.09 
Proximal 
patellar 30% - 70% 
81% 
(60/74) 
22% 
(4/18) 
0.16 
(-0.04, 0.36) 0.39 
Distal 
patellar 54% 7% 39% 
56% 
(36/64) 
- 
(0/28) 
-0.13 
(-0.28, 0.01) -0.22 
Proximal 
Achilles 13% 7% 80% 
89% 
(72/81) 
18% 
(2/11) 
0.08 
(-0.25, 0.41) 0.61 
Plantar 
fascia 17% 2% 80% 
89% 
(70/79) 
31% 
(4/13) 
0.23 
(-0.09, 0.55) 0.61 
Table 5.17. Agreement between clinical examination and ultrasound findings at week 0 
(CE=clinical examination; PABAK=Prevalence-adjusted, bias-adjusted Kappa; 
PEA=percentage exact agreement; Sp0=category-specific proportion of agreement 
(absent); Sp1=category-specific proportion of agreement (present)). 
Given the preclinical stage of enthesitis in the patient cohort, it is not surprising that 
agreement between clinical and sonographic assessments was poor. At worst, 
ultrasound detected an abnormality in 54% of all distal patellar tendon insertions 
scanned where clinical examination was found to be normal (percentage exact 
agreement (PEA) 39%). At best, ultrasound found an abnormality in 13% of proximal 
Achilles tendon entheses when clinical examination was normal (PEA 80%).   
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5.4.6.2 Correlation between enthesopathy scores and cutaneous 
outcomes  
Cutaneous Psoriasis (PASI Score) 
No consensus exists for the best measure of success for a drug therapy in psoriasis. 
The degree of improvement in PASI score is the most widely cited in clinical trials, and 
as therapeutics have advanced, the goal posts have moved – first from PASI 50 (i.e. the 
number of patients achieving at least 50% improvement in their PASI score from baseline 
at the primary endpoint), to PASI 75, and now PASI 90 and PASI 100 (complete 
clearance) are emerging as attainable outcomes. In this cohort, overall clinical response 
was excellent, with 21 of 23 patients achieving at least a 75% improvement by week the 
primary endpoint of week 24, and 17 of 23 achieving PASI 90. The latter was selected 
as the benchmark for skin improvement to permit comparison of change in enthesopathy 
scores between two groups. 
In these analyses, values at each time point were compared according to PASI 90 status, 
controlling for baseline values of the relevant enthesopathy score and baseline PASI 
(Table 5.18). 
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Table 5.18. Difference in enthesopathy scores from baseline according to PASI 90 status 
at each time point (*Adjusted for baseline enthesopathy score and baseline PASI 
**Partial Eta squared) 
There were no substantive differences in inflammation score according to PASI 90 status 
at any of the time-points. Perhaps counterintuitively, patients who achieved PASI 90 
status tended to have higher chronicity scores at 24 and 52 weeks, which was also the 
case in the raw data without adjustment for baseline values. However, effect size was 
small and only a small number of patients (n=6) had not achieved PASI 90 at these visits, 
limiting the accuracy of the data. 
Nail Psoriasis (mNAPSI Score) 
At week 0, the mNAPSI score correlated with inflammation scores for the entheses 
(rho=0.37) and synovial joints (rho=0.44). The link between nail disease and PsA is 
established, but it is unknown if improvements in nail disease with therapy are a marker 
Enthesopathy 
Score 
Unadjusted mean 
(SD) Adjusted mean* 
Difference* 
(95% CI) 
Effect 
size** 
12 weeks 
PASI 90 - 
Yes 
n=10 
PASI 90 
- No 
n=13 
PASI 90 
-Yes 
n=10 
PASI 90 
- No 
n=13 
  
Inflammation 
score 5.7 (4.3) 7.6 (5.3) 6.9 6.7 
0.2 
(-2.5, 2.8) 0.00 
Chronicity 
score 5.6 (6.1) 8.2 (5.4) 6.7 7.3 
-0.6 
(-3.1, 1.8) 0.02 
Total score 11.3 (9.4) 15.8 (8.6) 13.7 13.9 -0.2 (-4.00, 3.67) 0.00 
24 weeks 
PASI 90 - 
Yes 
n=17 
PASI 90 
- No 
n=6 
PASI 90 
- Yes 
n=17 
PASI 90 
- No 
n=6 
  
Inflammation 
score 5.8 (6.0) 5.2 (2.6) 5.6 5.9 
-0.3 
(-4.5, 3.8) 0.00 
Chronicity 
score 9.5 (7.3) 8.2 (4.0) 9.7 7.6 
2.1 
(-1.4, 5.5) 0.08 
Total score 15.3 (12.3) 13.5 (2.6) 15.2 13.9 1.3 (-4.8, 7.3) 0.01 
52 weeks 
PASI 90 - 
Yes 
n=14 
PASI 90 
- No 
n=6 
PASI 90 
- Yes 
n=14 
PASI 90 
- No 
n=6 
  
Inflammation 
score 5.2 (5.2) 3.7 (2.8) 5.0 4.2 
0.8 
(-3.8, 5.5) 0.01 
Chronicity 
score 9.4 (7.7) 6.7 (4.8) 9.4 6.7 
2.7 
(-2.3, 7.8) 0.08 
Total score 14.6 (11.1) 10.3 (5.9) 14.3 11.2 3.0 (-5.2, 11.3) 0.04 
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of underlying improvement in subclinical enthesitis. Table 5.19 compares the change in 
enthesopathy scores with the change in mNAPSI scores with treatment from week 0 at 
each time point in patients with nail disease at baseline (n=17).  
Table 5.19. Association between the change in enthesopathy scores and the change in 
mNAPSI scores from baseline in patients with nail disease at each time point 
In patients with nail involvement at week 0, there were no substantive (|rho|>0.3) 
associations between changes in mNAPSI and changes in inflammatory enthesopathy 
scores. At week 24 there was an inverse association with chronic enthesopathy score 
(the greater the reduction in mNAPSI, the greater the increase in chronic enthesopathy 
score); however, this seemed to be due to one patient with a large reduction (>80) in 
mNAPSI whose chronic enthesopathy score had increased. When this patient was 
excluded, the association disappeared (n=16, rho=-0.05). 
5.4.6.3 Correlation between enthesopathy scores and other patient 
factors 
Assessments were made between the change in enthesopathy scores and gender, age, 
body mass index and smoking status to determine if any of these variables appeared to 
influence the response to ustekinumab therapy.  
Table 5.20 displays the change in enthesopathy scores according to gender at each time 
point.  
 
 
 
 
 
Outcome: Association with change in mNAPSI: Spearman’s rho 
Change in… 12 weeks n=17 
24 weeks 
n=17 
52 weeks 
n=17 
Inflammation score rho=0.26 rho=0.08 rho=-0.01 
Chronicity score rho=-0.13 rho=-0.49 rho=-0.18 
Total score rho=0.11 rho=-0.32 rho=-0.01 
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Enthesopathy 
Score Unadjusted mean (SD) Adjusted mean* 
Difference* 
(95% CI) 
Effect 
size* 
Week 0 Male n=12 
Female 
n=11     
Inflammation 
score 9.3 (8.2) 10.4 (4.8)     
Chronicity 
score 5.4 (4.2) 10.6 (6.0)     
Total score 14.8 (11.0) 21.1 (8.9)     
Week 12 Male n=12 
Female 
n=11 
Male 
n=12 
Female 
n=11   
Inflammation 
score 6.4 (6.2) 7.2 (3.1) 6.8 6.8 
0.0 
(-2.6, 2.5) 0.00 
Chronicity 
score 5.8 (5.1) 8.5 (6.3) 8.2 5.8 
2.5 
(0.2, 4.8) 0.20 
Total score 12.2 (10.5) 15.6 (7.3) 14.6 13.0 1.6 (-2.2, 5.5) 0.04 
Week 24 Male n=12 
Female 
n=11 
Male 
n=12 
Female 
n=11   
Inflammation 
score 6.0 (5.9) 5.4 (4.7) 6.3 5.0 
1.3 
(-2.2, 4.8) 0.03 
Chronicity 
score 8.0 (5.2) 10.4 (7.9) 10.8 7.3 
3.5 
(0.5, 6.5) 0.22 
Total score 14.0 (10.5) 15.7 (11.1) 16.7 12.8 4.0 (-1.5, 9.5) 0.10 
Week 0  
(in those with 
week 52 
data) 
Male 
n=10 
Female 
n=10     
Inflammation 
score 8.2 (5.5) 10.7 (4.9)     
Chronicity 
score 4.7 (3.9) 11.0 (6.1)     
Total score 12.9 (7.3) 21.7 (9.2)     
Week 52 Male n=10 
Female 
n=10 
Male 
n=10 
Female 
n=10   
Inflammation 
score 5.3 (5.1) 4.2 (4.2) 5.8 3.7 
2.2 
(-1.9, 6.3) 0.07 
Chronicity 
score 7.2 (7.4) 10.0 (6.6) 10.3 6.9 
3.5 
(-2.1, 9.0) 0.09 
Total score 12.5 (11.6) 14.2 (8.4) 16.1 10.6 5.5 (-2.9, 13.9) 0.10 
Table 5.20. Comparison of change in enthesopathy scores over time according to gender 
(*Adjusted for baseline enthesopathy score) 
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At baseline, females had higher scores for inflammatory and chronic entheseal lesions 
than males. Consequently, when follow-up values were adjusted for baseline scores, 
males tended to have higher scores at follow-up than females. Adjusted inflammatory 
scores were substantively higher in males at 52 weeks because females had shown 
proportionally greater improvements from baseline. In females, the chronicity scores 
were stable over time, whilst in males the scores at 24 and 52 weeks increased relative 
to baseline. 
Associations between the change in enthesopathy scores with treatment from week 0 at 
each time point and age (Table 5.21), BMI (Table 5.22) and smoking status (Table 5.23) 
were also examined: 
Outcome:  Association with age: Spearman’s rho 
Change in… 12 weeks n=23 
24 weeks 
n=23 
52 weeks 
n=20 
Inflammation score -0.11 -0.03 -0.36 
Chronicity score -0.05 0.25 0.21 
Total score  -0.11 0.22 -0.16 
Table 5.21. Association between age and change in enthesopathy scores from baseline.  
Outcome: Association with BMI: Spearman’s rho 
Change in… 12 weeks n=23 
24 weeks 
n=23 
52 weeks 
n=20 
Inflammation score -0.11 -0.11 -0.09 
Chronicity score -0.32 -0.15 -0.32 
Total score -0.21 -0.21 -0.22 
Table 5.22. Association between BMI and change in enthesopathy scores from baseline 
over time  
There were no consistent associations between age or BMI and any of the entheseal 
scores across the different visits. There was a negative correlation between age and 
inflammation score at 52 weeks but this was not present at week 12 or 24. There was a 
negative correlation between BMI and chronicity score at week 12 and 52 but not at week 
24. These associations were very weak, only just above the pre-specified cut-off (0.3). 
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Enthesopathy 
Score Unadjusted mean (SD) Adjusted mean* 
Difference* 
(95% CI) 
Effect 
size* 
Week 0 Smoker n=15 
Non-
smoker 
n=8 
    
Inflammation 
score 9.7 (5.1) 10.3 (9.3)     
Chronicity 
score 8.9 (5.6) 5.9 (5.6)     
Total score 18.7 (8.1) 16.1 (14.2)     
Week 12 Smoker n=15 
Non-
smoker 
n=8 
Smoker 
n=15 
Non-
smoker 
n=8 
  
Inflammation 
score 6.6 (5.0) 7.1 (5.0) 6.7 6.9 
-0.2 
(-2.8, 2.4) 0.00 
Chronicity 
score 7.8 (5.8) 5.6 (5.7) 6.8 7.5 
-0.6 
(-3.1, 1.8) 0.02 
Total score 14.4 (8.6) 12.8 (10.4) 13.7 14.0 -0.3 (-4.3, 3.6) 0.00 
Week 24 Smoker n=15 
Non-
smoker 
n=8 
Smoker 
n=15 
Non-
smoker 
n=8 
  
Inflammation 
score 5.8 (5.0) 5.5 (6.2) 5.9 5.3 
0.6 
(-3.1, 4.3) 0.01 
Chronicity 
score 10.3 (6.1) 5.9 (7.1) 9.3 8.8 
0.5 
(-2.8, 3.7) 0.00 
Total score 16.1 (9.5) 12.4 (12.7) 15.4 13.7 1.7 (-4.1, 7.4) 0.02 
Week 0  
(in those 
with week 52 
data) 
Smoker 
n=17 
Non-
smoker 
n=7 
    
Inflammation 
score 10.5 (4.9) 7.6 (5.8)     
Chronicity 
score 9.5 (5.9) 4.9 (5.2)     
Total score 19.9 (7.7) 12.4 (10.4)     
Week 52 Smoker n=13 
Non-
smoker 
n=7 
Smoker 
n=13 
Non-
smoker 
n=7 
  
Inflammation 
score 4.5 (4.8) 5.1 (4.5) 4.1 6.0 
-1.9 
(-2.5, 6.2) 0.05 
Chronicity 
score 9.6 (7.3) 6.7 (6.5) 8.2 9.3 
-1.1 
(-6.6, 4.4) 0.01 
Total score 14.2 (10.1) 11.9 (10.1) 12.2 15.4 -3.2 (-11.9, 5.4) 0.04 
Table 5.23. Comparison of change in enthesopathy scores over time according to 
smoking status (*Adjusted for baseline enthesopathy score) 
 
There were no consistent associations between smoking status and enthesopathy score; 
adjusting for baseline scores, at week 24 there were no large differences according to 
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smoking status. Smokers tended to have higher scores than non-smokers because their 
inflammation scores had improved to a lesser degree, and their chronicity scores had 
increased. However, in patients with data at week 52 the opposite was true. The small 
sample size may be limiting the accuracy of these assessments.  
5.4.6.4 Correlation between enthesopathy scores and laboratory 
outcomes 
Median baseline PASI scores were higher in patients positive for HLA-Cw06 in this 
cohort. However, median PASI scores and the median percentage reduction from 
baseline at weeks 12, 24 and 52 did not differ according to HLA-Cw06 status at any of 
the follow-up visits (Table 5.24).  
Table 5.24. Comparison of median PASI score and median percentage reduction in PASI 
score according to HLA-Cw06 status (NB: Due to extreme skew in the PASI scores, only 
unadjusted scores at each visit could be calculated). 
It is not known if the reported phenomenon of enhanced efficacy of ustekinumab in 
patients with the HLA-Cw06 allele extends to the musculoskeletal manifestations of 
psoriatic disease, and in particular, subclinical enthesopathy. Table 5.25 compares the 
change in enthesopathy scores from baseline at each time point according to HLA-Cw06 
status in this cohort.  
 
 
PASI Score Median Score  (IQR) 
Median % reduction 
(IQR) 
 Cw06 - Yes n=15 
Cw06 – No 
n=8 
Cw06 - Yes 
n=15 
Cw06 - No 
n=8 
Week 0 25.7 (14.3, 29.7) 
14.9 
(12.3, 17.4)   
Week 12 2.3 (1.4, 3.9) 
2.3 
(0.9, 4.0) 
88 
(85, 95) 
87 
(72, 93) 
Week 24 0.6 (0.0, 3.9) 
0.4 
(0.0, 2.5) 
97 
(91, 100) 
97 
(84, 100) 
 Cw06 - Yes n=12 
Cw06 - No 
n=8 
Cw06 - Yes 
n=12 
Cw06 – No 
n=8 
Week 0 (in those 
with week 52 data) 
26.5 
(16.9, 32.6) 
14.9 
(12.3, 17.4)   
Week 52 0.3 (0.0, 4.6) 
0.1 
(0.0, 0.4) 
99 
(81, 100) 
99 
(97, 100) 
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Enthesopathy 
Score Unadjusted mean (SD) Adjusted mean* 
Difference* 
(95% CI) 
Effect 
size* 
Week 0 
Cw06 - 
Yes 
n=15 
Cw06 - No 
n=8     
Inflammation 
score 9.5 (7.7) 10.6 (4.2)     
Chronicity 
score 7.7 (6.2) 8.3 (5.0)     
Total score 17.2 (12.0) 18.9 (6.8)     
Week 12 
Cw06 - 
Yes 
n=15 
Cw06 - No 
n=8 
Cw06 - 
Yes 
n=15 
Cw06 - 
No 
n=8 
  
Inflammation 
score 6.5 (5.9) 7.4 (2.3) 6.7 6.9 
-0.2 
(-2.9, 2.4) 0.00 
Chronicity 
score 7.5 (6.4) 6.3 (4.5) 7.7 5.9 
1.8 
(-0.5, 4.0) 0.12 
Total score 13.9 (11.0) 13.6 (4.1) 14.4 12.8 1.6 (-2.2, 5.5) 0.04 
Week 24 
Cw06 - 
Yes 
n=15 
Cw06 - No 
n=8 
Cw06 - 
Yes 
n=15 
Cw06 - 
No 
n=8 
  
Inflammation 
score 6.2 (6.2) 4.8 (3.2) 6.4 4.4 
2.1 
(-1.5, 5.6) 0.07 
Chronicity 
score 9.9 (7.5) 7.6 (4.1) 10.1 7.2 
2.9 
(0.0, 5.8) 0.18 
Total score 16.1 (12.9) 12.4 (2.6) 16.6 11.4 5.2 (-0.1, 10.5) 0.17 
Week 0 (in 
those with 
week 52 
data) 
Cw06 - 
Yes 
n=12 
Cw06 - No 
n=8     
Inflammation 
score 8.7 (5.9) 10.6 (4.2)     
Chronicity 
score 7.6 (6.7) 8.3 (5.0)     
Total score 16.3 (10.7) 18.9 (6.8)     
Week 52 
Cw06 - 
Yes 
n=12 
Cw06 – 
No 
n=8 
Cw06 - 
Yes 
n=12 
Cw06 - 
No 
n=8 
  
Inflammation 
score 4.4 (4.5) 5.3 (5.0) 4.7 4.8 
-0.1 
(-4.3, 4.2) 0.00 
Chronicity 
score 8.8 (8.2) 8.3 (5.1) 9.1 7.9 
1.1 
(-3.8, 6.1) 0.01 
Total score 13.3 (12.2) 13.5 (5.6) 14.0 12.4 1.5 (-6.4, 9.4) 0.01 
Table 5.25. Comparison of change in enthesopathy scores over time according to HLA-
Cw06 status 
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These data show that in this cohort, there appears to be no advantage to possessing the 
HLA-Cw06 allele in terms of response in subclinical enthesopathy.  At 12 and 24 weeks, 
there was preliminary descriptive evidence that patients’ positive for HLA-Cw06 had 
higher chronicity scores, although this effect was not seen in the patients with data 
available at week 52. 
Trends relating to HLA-B27 status could not be assessed in this small cohort as there 
was only one patient in the positive group. 
5.4.7 Feasibility of a large scale, head-to-head comparator, 
randomised controlled trial of anti-IL-12/23p40 in the treatment 
of subclinical enthesitis 
One of the aims of this study was to assess the feasibility of a large, head-to-head 
comparator randomised controlled trial (RCT) of subclinical enthesitis. The data 
generated, while unable to conclusively prove the efficacy of ustekinumab in the 
treatment of subclinical enthesopathy, have highlighted some encouraging trends to 
support the value of a larger, adequately powered study.  
Because there was evidence that inflammatory and chronic entheseal scores change in 
opposite directions with therapy, it would not be appropriate to use the total enthesopathy 
score as an outcome in a future clinical trial. Whilst inflammatory changes showed the 
greatest change with therapy, prevention of chronic structural progression may be the 
ultimate aim clinically.  
Sample sizes have been provided in the following table for future trials using either 
inflammatory enthesopathy score or chronic enthesopathy score at 24 weeks as the 
primary outcome (Table 5.26). Standard deviations for changes from baseline have been 
assumed to be the same as those observed in this study. Two between-group intervals 
have been considered, equivalent to assuming the value observed at week 24 in patients 
treated with ustekinumab would be 80% or 85% as high as that seen in controls, that 
groups would be randomised 1:1 and that they would be compared using an independent 
samples T-test. Alpha has been set at 0.05, 1-Beta at 0.9. 
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Table 5.26. Sample size calculations for a larger head-to-head comparator RCT, using 
the different enthesopathy scores as outcome measures.   
Based on these estimates, a full trial appears feasible, although a multi-centre approach 
should be adopted. In this study, 36 of 73 (49%) patients initially screened had at least 
one inflammatory entheseal lesion in keeping with the OMERACT ultrasound definition 
of enthesopathy. Therefore, not allowing for exclusions for other reasons (e.g. 
contraindications to biologic therapy), approximately 600 patients would need to be 
screened to attain the desired sample size, which is too many for a single centre. 
Consideration should be given to including an internal pilot study in the full trial, to test 
whether or not a control group receiving the chosen active comparator would be likely to 
show progression rates sufficiently high to detect a clinically meaningful difference 
compared to the group receiving ustekinumab. Stop-go criteria would determine whether 
to keep recruiting to the full sample size. 
In addition, given that enthesopathy scores correlated with age and BMI at baseline 
(Chapter 4.4.5.5.), and patients positive for the HLA-Cw06 allele may show greater 
increases in chronicity score, recruitment should be stratified for these variables in any 
future trials, or they should be considered as covariates to include in adjusted analyses. 
However, given that HLA-Cw06 associates with psoriasis, and not necessarily with PsA, 
further considerations around using this genetic marker at all to stratify for arthritis 
prevention merit consideration. 
5.5 Discussion 
The presence of antecedent psoriasis in the majority of patients who are destined to 
develop PsA offers an opportunity to potentially prevent arthritis development if systemic 
therapy is indicated in the dermatology clinic. The recognition of enthesopathy as the 
pivotal early lesion provides a key target for assessment, especially through the use of 
ultrasound during the preclinical phase. The findings in the previous two chapters confirm 
that subclinical enthesopathy in patients with psoriasis is not uncommon, with 49.3% of 
 Week 24 20% improvement  over controls 
15% improvement  
over controls 
Outcome Mean ± SD UST 
Interval to 
detect 
Sample 
size 
Interval 
to detect 
Sample 
size 
Inflammation Score 5.7 ± 5.3 1.43 291 per group 1.01 
579 per 
group 
Chronic Damage Score 9.1 ± 6.5 2.28 171 per group 1.61 
343 per 
group 
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the 73 patients with moderate to severe psoriasis having at least one potentially 
modifiable inflammatory abnormality at first presentation to dermatology, which is in 
broad agreement with other ultrasound studies and recent MRI findings. (Gisondi et al., 
2008, Gutierrez et al., 2011, Naredo et al., 2011, Faustini et al., 2016, Moshrif et al., 
2017).  
Data in this chapter show that targeted treatment of psoriasis with a therapeutic agent 
that has independently been shown to work in PsA, namely anti-IL-12/IL-23, can be 
associated with regression of subclinical inflammatory entheseal abnormalities. A 
statistically significant reduction in overall entheseal inflammation scores were seen after 
just 24 weeks of therapy, and further improvements continued out to week 52, suggesting 
long term therapy is necessary to obtain maximum improvement and prevent the 
progression to symptomatic arthritis. All patients remained free of musculoskeletal 
symptoms with the exception of those who sustained a sports or traumatic injury.  
In contrast to inflammatory lesions, chronic damage abnormalities did not significantly 
change with ustekinumab therapy in this cohort. While some structural lesions worsened, 
some appeared to decrease in severity or resolve, principally bone erosions, which is a 
recognised phenomenon in RA (Ideguchi et al., 2006, Rau et al., 2004). Ultrasound 
studies in SpA have also showed erosion healing over time which likely indicates new 
bone formation and the reparative phenotype of these conditions (McGonagle et al., 
2008).  Rates of progression of structural lesions without therapy are not known; one 
limitation from this study was the failure to include an untreated group of psoriasis 
patients, which may have helped determine if ustekinumab slowed the development of 
damage. However, this limitation is hard to overcome, as it would have been unethical 
to have not treated a group of patients presenting for treatment of psoriasis. One means 
of circumventing this would to have been to include a group of patients treated with a 
comparator drug, ideally the first line systemic agent, methotrexate. However, this was 
designed to be a feasibility study to evaluate the response to ustekinumab, and would 
have necessitated involving at least one other centre to recruit adequate patients and so 
it was decided that a comparator arm would not be included. In addition to including a 
group of patients either not given any systemic therapy or standard treatment with 
methotrexate, it may have been helpful to re-scan the healthy volunteers after 24 and 52 
weeks to indicate the rates of progression the normal population. 
As previously hypothesised by McGonagle and colleagues (McGonagle et al., 2007), 
investigation outside of the enthesis demonstrated dissipation of inflammation 
throughout the synovio-entheseal complex as described in Chapter 4.1. Ustekinumab 
appears to lead to a reduction in inflammatory burden within the entire SEC, and even 
in instances where new areas developed on treatment, these were often transient and 
resolved as therapy continued, providing hope that if treated early, the evolution of 
enthesitis into symptomatic PsA can be attenuated. 
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An interesting observation in this study was the presence of higher entheseal 
inflammation scores in psoriasis patients who did not smoke at week 0, 12 and 52, and 
higher chronic damage scores in smokers at all time points. As discussed in Chapter 3.4, 
tobacco smoking, and specifically nicotine, is demonstrated to have a protective effect 
in the development of PsA (Eder et al., 2012, Pattison et al., 2008) due to the inhibition 
of pro-inflammatory pathways, and may account for the lower mean inflammation scores 
in those who smoked. Compelling experimental evidence also associates nicotine to 
chronic damage changes and degeneration of the intervertebral discs within the spine, 
with downregulation of the proliferation rate and glycosaminoglycan biosynthesis of disc 
cells (Elmasry et al., 2015, Akmal et al., 2004). Moreover, smoking causes the 
constriction of the vascular network, reducing the exchange of nutrients and anabolic 
agents from the blood vessels to bone, and this may explain why more chronic damage 
abnormalities were seen in those who smoked tobacco. 
One limitation of this study was the lack of histological confirmation of the abnormalities 
seen on ultrasound. This would have been particularly helpful for the evaluation of 
synovial changes, which overall were mild and only seen in grey scale. Some of these 
changes may have been physiological, and given the distribution of abnormalities (with 
the most frequent abnormalities seen at the thumb carpometacarpal joint and wrist), 
there is a possibility that these were due to degenerative disease such as osteoarthritis.  
This may account for why some abnormalities were fluctuant and some were not 
modifiable with therapy. 
The relatively small number of patients investigated in this pilot study prevents any 
definite conclusions from being drawn on the effectiveness of ustekinumab in treating 
subclinical enthesitis, bursitis, tenosynovitis and synovitis, although the trends identified 
are encouraging. These data are in keeping with and extended the findings from recently 
published reports of good sonographic responses in entheseal abnormalities after 
treatment with TNF inhibitors in patients with psoriasis (Acquacalda et al., 2015) and 
spondyloarthritis (Naredo et al., 2010, Aydin et al., 2010) which also included only small 
number of patients.  
Unfortunately, no demographic or clinical ‘biomarkers’ were identified in this cohort that 
could be used to predict which patients had the greatest response within the SEC to IL-
12/IL-23 inhibition. In the previous chapters, it was observed that patients with more 
severe nail disease and patients with a higher BMI had greater inflammation scores, and 
age correlated with chronic damage scores. However, with treatment, no consistent 
associations were found between the change in enthesopathy scores and the skin 
response, nor the change in mNAPSI score, age, BMI and smoking status. It is likely that 
the small sample size is limiting the accuracy of these assessments and future testing is 
advocated in a larger, adequately powered clinical trial. 
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HLA-Cw06 is accepted as the psoriasis susceptibility gene with the greatest effect and 
observations have suggested that this genetic polymorphism may serve as a 
pharmacogenetic marker to predict clinical response to immunomodulatory agents 
including ustekinumab (Warren and Griffiths, 2005). Skin responses to ustekinumab 
have been shown to be superior in HLA-Cw06 positive patients (PASI 75 response at 
week 12: 96.4% compared to 65.2% in HLA-Cw06 negative patients) by Talamonti and 
colleagues, and supported by data from a Chinese psoriasis cohort (Chiu et al., 2014, 
Talamonti et al., 2013). However, although median baseline PASI scores were higher in 
patients who were positive for HLA-Cw06, data from this cohort show that there appears 
to be no advantage to possessing the HLA-Cw06 allele in terms of response in 
subclinical enthesopathy. Median PASI scores and the median percentage reduction 
from baseline at weeks 12, 24 and 52 did not differ according to HLA-Cw06 status at any 
of the follow-up visits. This lack of effect is again most probably due to the small sample 
size.  
One of the aims of this chapter was to assess the feasibly of a larger head-to-head 
comparator RCT in subclinical enthesitis, and the data generated has provided 
preliminary support to the value of an adequately powered study. Aiming to demonstrate 
a meaningful difference (i.e. 20% improvement) in inflammation score over a competitor 
drug, a sample size of 582 patients (291 per group) would need to be recruited. Using a 
multi-centre approach with six or more specialist centres, a full trial would be feasible, 
and the larger sample size would hopefully allow a more accurate evaluation of any 
relationship with HLA-Cw06 status or other clinical parameters.  
Despite the small sample size and other limitations in this chapter, these data suggest 
that ustekinumab does appear to be capable of regressing subclinical enthesopathy and 
potentially stem the evolution of PsA in patients who require systemic therapy for 
moderate to severe psoriasis, and support the proposal for a larger multi-centre RCT in 
order to confirm these observations. 
 
5.6 Conclusion 
Data within this chapter support the recognition of enthesitis as a target for assessment 
(using ultrasound) and intervention in the preclinical phase of PsA using skin directed 
biologic therapy. Inhibition of IL-12/IL-23 not only provided an excellent reduction in the 
severity and extent of skin disease, but was accompanied by a statistically significant 
reduction in subclinical entheseal inflammation (42% at week 24, 52% at week 52), while 
chronic damage parameters remained largely static.  No correlations were observed 
between sonographic improvement and any demographic or clinical parameters, 
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although the small sample size is likely to have limited the accuracy of these 
assessments.  
Futher investigation of the natural evolution of subclinical enthesopathy in both patients 
with psoriasis and healthy volunteers is required to acertain if a slowing of disease 
progression and development of PsA occurred as a consequence of ustekinumab 
therapy. However, these data highlight encouraging trends, and sample size estimates 
for a larger prospective longitudinal head-to-head study with a comparator drug would 
be feasibile if a multi-centre approach is adopted. 
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Chapter 6  
Comparison of the MRI Appearances of Axial and Peripheral 
Enthesitis in Patients with Psoriasis in Secondary Care and 
Healthy Controls 
6.1 Introduction 
High-field magnetic resonance imaging (MRI) is widely considered the gold standard 
imaging modality for visualising the soft tissue and bony pathology in PsA, especially 
within the sacroiliac joints and axial skeleton (Ostergaard et al., 2007, van der Heijde et 
al., 2005, McQueen et al., 2007a). Three dimensional image acquisition, high 
reproducibility, ability to detect bone marrow oedema/osteitis and delineation of soft 
tissue pathologies have helped MRI find definite applications in the diagnosis, definition 
of pathogenesis and measurement of therapeutic outcomes in PsA (Poggenborg et al., 
2015c). Conventional MRI permits visualisation of only one anatomical area but has 
been effectively used to demonstrate subclinical enthesopathy in patients with psoriasis 
without PsA at several sites including the hand (Faustini et al., 2016, Offidani et al., 
1998), the foot (Erdem et al., 2008), the knees (Emad et al., 2012, Emad et al., 2010), 
and the lumbosacral spine and sacroiliac (SI) joints (Hamdy et al., 2015).  
The heterogeneity of joint involvement in PsA can be appreciated through the emerging 
technique of whole body MRI (WBMRI), which has permitted comprehensive evaluation 
of the early stages of enthesopathy at both axial and peripheral sites in patients with 
PsA. However, to date, no studies have utilised WBMRI to assess the extent of 
subclinical musculoskeletal disease in patients with psoriasis.  
Only one WBMRI study has evaluated enthesopathy in healthy subjects (without known 
musculoskeletal disease) alongside patients with psoriatic arthritis and axial 
spondyloarthritis (Poggenborg et al., 2015b). Healthy subjects were not free from 
enthesopathy, and although the MRI enthesitis scores were higher in patients with PsA 
or SpA, the entheseal sites with identifiable WBMRI enthesitis were the same in the 
healthy subject group. This supports the findings of Benjamin et al who demonstrated 
microscopic inflammatory changes at sites of high mechanical stress and microtrauma 
in normal aged cadaveric entheses, which were similar to those seen in patients with 
early PsA (McGonagle et al., 2009b, Benjamin and McGonagle, 2007) and thought to be 
part of the normal healing process.  
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This study aims to assess the utilisation of WBMRI to assess the extent, distribution, 
severity and type of inflammatory abnormalities and structural changes in both the 
peripheral and axial skeleton in asymptomatic patients with psoriasis, and compare 
those findings with a cohort of healthy volunteers.  
6.2 Methods 
6.2.1 Participant Recruitment 
This study was conducted in one centre in the United Kingdom – Chapel Allerton Hospital 
(part of Leeds Teaching Hospitals NHS Trust), with imaging performed within the Leeds 
Musculoskeletal Biomedical Research Unit. The study was conducted in accordance 
with the Declaration of Helsinki and approved by the Leeds East Research Ethics 
Committee. 
6.2.1.1 Participant Identification and Recruitment 
Twenty-eight newly referred adult patients with moderate-to-severe chronic plaque 
psoriasis and 23 healthy controls participated in this study. Patients with psoriasis were 
included if they did not have musculoskeletal signs or symptoms consistent with a clinical 
diagnosis of PsA but did have evidence of active subclinical enthesitis in at least one site 
on ultrasound examination of the peripheral entheses, and were systemic (DMARD) and 
biologic treatment naïve. These patients and volunteers were the same as included the 
ultrasound study (Chapter 4) and precise detail on recruitment is described in Chapters 
4.2.1.1. (patients with psoriasis) and 4.2.1.2. (healthy volunteers). Healthy volunteers 
were recruited from staff members and their family and friends in the Leeds Institute of 
Rheumatic and Musculoskeletal Medicine (LIRMM) and Leeds Institute of Cancer and 
Pathology (LICAP) at the University of Leeds. During recruitment, it was ensured that 
there were no contraindications to MRI in any participants. A standard safety patient-
completed questionnaire was filled in and reviewed by the radiographer prior to every 
scan (Appendix 10). 
Written consent was obtained from all participants prior to the collection of any clinical or 
imaging data, which permitted the use of data for research purposes and storage. 
Participants were made aware that the WBMRI scans would only be reported for 
abnormalities within the musculoskeletal system, and that pathology in any other bodily 
systems may not be seen and reported. Conversely, they were made aware that gross 
pathology in other systems may be identified, in which instance they were assured they 
would be informed in a timely manner and referred to the appropriate service/specialist. 
 
 
 
281 
6.2.2 Inclusion/Exclusion Criteria 
6.2.2.1 Patients with psoriasis 
• Age 18 or over 
• First presentation to dermatology secondary care services 
• Diagnosis of chronic plaque psoriasis (confirmed by a dermatologist, the 
candidate LS) with a PASI score ≥10, with symptoms for more than twelve 
months 
• No prior treatment with PUVA phototherapy, systemic immunosuppressants or 
DMARDs, biologic or small molecule therapies or alkylating agent for psoriasis 
or any other condition 
• No symptoms or clinical signs of PsA, or diagnosis of any other rheumatological 
disorder 
• No contraindications to biological therapy (Appendix 6) 
• No contraindications to MRI scanning, including: 
o Implanted electrical/electronic devices including pacemakers, 
implantable defibrillators, neuromodulators, insulin pumps or implanted 
hearing aids 
o Intracranial metal clips 
o Metallic bodies in the eye 
o Severe claustrophobia 
• Presence of at least one inflammatory entheseal abnormality (thickening, 
hypoechogenicity and/or power Doppler signal) in at least one peripheral 
enthesis (identified through an ultrasound screening programme, described in 
Chapter 3). 
6.2.2.2 Healthy Controls 
• Age 18 and over 
• No personal history of psoriasis, psoriatic arthritis or other rheumatological 
condition 
• No prior use of any immunosuppressant, biologic or long term non-steroidal anti-
inflammatory therapy (for any indication) 
• No contraindications to MRI scanning (Appendix 10) 
6.2.3 Data Collection 
The candidate (LS) carried out all data collection.  Magnetic resonance image acquisition 
and storage was undertaken by an experienced MRI/research radiographer (RE) 
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proficient in performing WBMRI, within the Leeds Musculoskeletal Biomedical Research 
Unit (LMBRU) at Chapel Allerton Hospital.  
Clinical data obtained in the consultation was recorded on a paper record and then 
transposed into an encrypted password-protected database on the University of Leeds 
server for analysis. Care was taken to ensure the check integrity of the dataset at upload. 
Paper record forms are stored in a locked filing cabinet within a locked room within 
LIRMM, in accordance with the University’s Information Security Policy.  Magnetic 
resonance images were stored in a password-protected database and analysed using 
OsiriX DICOM viewer. 
6.2.4 Clinical Assessment 
6.2.4.1 Patients with Psoriasis 
Prior to the MRI scan, the candidate (LS) conducted a thorough history and examination 
of each patient. Recorded participant-reported data included:  
• Demographic data (age, gender) 
• Fitzpatrick skin type 
• Social history (smoking (pack years), alcohol consumption (units/week) and 
employment) 
• Past medical and surgical history, including a detailed history of skin and joint 
disease 
• Family history 
• Medications (current prescribed, over-the-counter, alternative and psoriasis-
specific medicines, and any previous psoriasis therapies) 
• Age of psoriasis symptom onset 
• Areas ever affected by psoriasis 
• Areas currently affected by psoriasis 
• Current or previous musculoskeletal symptoms 
Clinical examination data comprised of the following: 
• Baseline observations (height, weight, BMI, blood pressure and heart rate) 
• An assessment of psoriasis severity and extent – BSA and PASI (Appendix 7) 
score (Chapter 4.1.2.4.1.) 
• An assessment of nail psoriasis severity and extent – mNAPSI (Appendix 8) 
score (Chapter 4.1.2.4.1.) 
• The presence of any signs of PsA (joint swelling and/or tenderness, clinical 
enthesitis or dactylitis) 
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• An assessment for clinical enthesitis (defined as tenderness, when the enthesis 
was palpated with a pressure of the thumb sufficient to blanche the nail bed) at 
29 entheseal locations (Chapter 4.2.4.1.2.). 
6.2.4.2 Healthy Volunteers 
Recorded participant-reported data included: 
• Demographic data (age, gender) 
• Fitzpatrick skin type 
• Social history (smoking (pack years), alcohol consumption (units/week) and 
employment) 
• Past medical and surgical history, including a detailed history of skin and joint 
disease 
• Family history 
• Medications (current prescribed, over-the-counter and alternative therapies) 
Baseline observations (blood pressure and heart rate) were recorded in addition to 
height, weight and BMI. 
6.2.5 Whole Body Magnetic Resonance Imaging (WBMRI) 
6.2.5.1 WBMRI Protocol  
WBMRIs were performed on a 3 Tesla (3T) high field MRI unit (Verio, Siemens 
Healthcare, Erlangen, Germany) using multiple coils (4-channel flex coils for shoulders, 
spine array coils for spine, body matrix coil for pelvis and knees, quadrature head coil for 
feet. T1-weighted (turbo spin echo) and short τ inversion recovery (STIR) sequences 
were performed in a total of seven stations, with coronal slice orientation (shoulders, 
costochondral joints, hips and knees), coronal oblique orientation (sacroiliac (SI) joints), 
sagittal orientation (cervicothoracic and thoracolumbar spine), and axial orientation 
(knees and feet). T2 ‘fat sat’ sequences were also performed with coronal oblique 
orientation for the SI joints. Gadolinium was not administered due to the potential to 
cause nephrogenic systemic fibrosis, especially as the patients and volunteers were 
asymptomatic. The technical parameters are shown in Table 6.1. Total scan time was 
55 minutes and was generally well tolerated by participants. 
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Station Sequence Orientation 
TR 
(ms) 
TE 
(ms) 
FOV 
(mm) 
Matrix 
Slice 
thick 
(mm) 
Shoulders and 
Costochondral 
Joints 
STIR Coronal 4500 101.0 500 384x384 4 
Upper Spine 
T1 Saggital 500 11.0 450 512x512 4 
STIR Saggital 4500 94.0 450 512x512 4 
Lower Spine 
T1 Saggital 500 11.0 450 512x512 4 
STIR Saggital 4500 94.0 450 512x512 4 
SIJs 
T1 
Coronal 
oblique 
700 10.0 240 384x384 4 
T2 Fat Sat 
Coronal 
oblique 
4040 71.0 240 256x256 4 
Pelvis/Hips STIR Coronal 4500 98.0 450 384x384 4 
Knees STIR 
Coronal 4500 73.0 400 448x448 4 
Axial 4500 73.0 400 448x448 4 
Feet 
T1 Axial  677 12.0 340 512x512 3 
STIR Axial 6000 85.0 340 512x512 3 
Table 6.1. Technical parameters of the WBMRI scan. 
6.2.5.2 WBMRI Interpretation 
WBMRI were evaluated by a highly experienced rheumatologist (DMcG) experienced 
with WBMRI, who was blinded to all clinical, biochemical and demographic information.  
The images were evaluated in a random order. Readability of the scans was assessed 
for each enthesis as ‘readable’ or ‘not readable’ (e.g. due to artefacts) or ‘not in field of 
view (FOV)’. All images were analysed for active inflammatory lesions and structural 
changes at axial (spine and SIJs) and non-axial (peripheral) sites.  
6.2.5.2.1 Non-axial (peripheral) sites 
Peripheral enthesitis was defined as suggested by Eshed et al (Eshed et al., 2007) as 
the presence of the following on WBMRI: 
• Bone marrow oedema (BMO)/osteitis 
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• Soft tissue inflammation 
• Erosions in adjacent bones 
• Enthesophytes in adjacent bones 
• Additional findings (e.g. synovitis, bursitis) 
At readable peripheral sites, abnormalities were graded from 0-3 depending on severity 
(0=absent, 1=minor, 2=moderate, 3=severe) for bone marrow oedema, soft tissue 
inflammation, synovitis and bursitis, and dichotomously (0=absent, 1=present) for 
erosions and enthesophytes based on the methodology reported by Marzo-Ortega et al 
(Marzo-Ortega et al., 2001) (Table 6.2). Abnormalities must have been visible in at least 
two consecutive slices to be scored. Comparison with the opposite site was made for 
paired entheses.  
 
 Grade 0 Grade 1 Grade 2 Grade 3 
Non-axial (peripheral) sites 
Bone marrow oedema 
(per site)  
Absent Minor Moderate Severe 
Soft tissue inflammation  
(per site) 
Absent Minor Moderate Severe 
Synovitis/effusion  
(per joint) 
Absent 
Slight increase 
in fluid 
Moderate 
increase in fluid 
Large increase 
in fluid 
Bursitis 
(per site) 
Absent Minor Moderate Severe 
Erosions  
(per joint) 
Absent Present - - 
Enthesophytes  
(per joint) 
Absent Present   
Table 6.2. Scores applied to abnormalities at peripheral sites 
The following 45 sites were scored for bone marrow oedema and soft tissue 
inflammation: tendon insertions at the humeral tuberosity (2), acromioclavicular joint (2) 
and coracoid process (2), joint capsule insertion at the sternoclavicular joint (2), 
manubriosternal joint (1), 1st costochondral syndchondrosis (2), 7th costochondral joint 
(2), tendon insertion at the iliac crest (2), anterior superior iliac spine (2) and ischial 
tuberosity (2), pubic symphysis fibrocartilage attachments (2), tendon insertions at the 
greater trochanter of the femur (2), lateral femoral condyle (2), medial femoral condyle 
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(2), lateral tibial plateau (2), intercondylar notch (2) and inferior pole of the patella (2), 
quadriceps tendon insertion (2), tendon insertions at the ankle (2), first tarsometatarsal 
joint of the midfoot (2) and first metatarsophalangeal joint (2) and the insertion sites of 
the Achilles tendon (2) and the plantar fascia at the calcaneus (2).  
The presence of synovitis was assessed at the shoulders (joint capsule, 
acromioclavicular joint and sternoclavicular joint), hips, knees, ankles, 1st 
tarsometatarsal joints and 1st metatarsophalangeal joints. Effusions within the 
subacromial bursae of the shoulders, trochanteric bursae of the hips, pre-patellar bursae 
and pes anserine bursae at the knees and subcutaneous calcaneal bursae and 
retrocalcaneal bursae at the ankles were also assessed. Tenosynovitis was assessed at 
the medial and lateral tendons of the foot. 
Erosions were assessed at the 1st tarsometatarsal joint, 1st metatarsal joint and at the 
insertion sites of the Achilles tendon and plantar fascia into the calcaneus. 
Enthesophytes were also assessed at the Achilles tendon and plantar fascia insertions. 
A high signal on STIR images within the bone marrow or surrounding soft tissue was 
considered as enthesitis. Synovitis/bursitis were categorised by synovial hypertrophy 
and the amount of fluid collected within the joint capsule. Bony erosions were scored as 
cortical defects in T1-weighted sequences.  
6.2.5.3 Axial Sites 
The spine was divided into 23 individual vertebral units (VU) extending from C2/3 to 
L5/S1. Each VU within the spine was evaluated separately in the ventral part (vertebral 
body) and posterior elements (pedicles, facet joints and spinous processes).  The SIJs 
were evaluated at a quadrant level (upper and lower iliac parts, and upper and lower 
sacral parts) as shown in Figure 6.1.  
 
Figure 6.1. Four quadrants of the sacroiliac joints (SIJs) 
Upper sacrum Upper ilium
Lower sacrum Lower ilium
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Images of the axial skeleton were scored for activity using the Berlin modification of the 
AS spine MRI score (Haibel et al., 2006), which has previously been used to score 
WBMRI (Althoff et al., 2013). This scoring system encompasses inflammatory 
abnormalities (BMO) and structural changes (fatty bone marrow infiltration, erosions and 
bone proliferation) and was proposed by MRI experts from the ASAS/OMERACT study 
group (Hermann et al., 2012, Rudwaleit et al., 2009) (Table 6.3). Abnormalities must 
have been visible in at least two consecutive slices to be scored.  
 Grade 0 Grade 1 Grade 2 Grade 3 
Sacroiliac Joints 
Active inflammation  
(BMO of quadrant area) 
Absent 
<33% of 
quadrant 
33-66% of 
quadrant 
>66% of 
quadrant 
Erosions  
(per quadrant) 
Absent 
Minor  
(1-2) 
Moderate (3-5) 
Multiple 
(confluent) 
Fatty bone marrow infiltration  
(per quadrant) 
Absent Present - - 
Sclerosis  
(per joint) 
Absent Present - - 
Ankylosis  
(per joint) 
Absent Present - - 
Spine 
Active inflammation  
(BMO of VU area) 
Absent <25% of VU area 
25-50% of VU 
area 
>50% of 
VU area 
Erosions  
(% of bone surface per VU) 
Absent 
Minor  
(1-2) 
Moderate (3-5) 
Multiple 
(confluent) 
Fatty bone marrow infiltration  
(per VU) 
Absent <25% of VU area 
25-50% of VU 
area 
>50% of 
VU area 
Bone proliferation  
(per VU) 
Absent 
Syndesmophytes 
without bridging 
Bridging 
syndesmophytes 
Transdiscal 
ankylosis 
Active inflammation of 
posterior segments (per VU) 
Absent 
Minor 
inflammation 
Severe 
inflammation 
- 
Table 6.3. Berlin modification of the AS spine MRI activity score for axial sites (VU: 
vertebral unit) 
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In accordance with published scoring techniques (Althoff et al., 2013), each SIJ was 
scored from 0-24 (0-3 for each upper and lower ilium, and each upper and lower sacrum) 
for BMO and erosions, and 0-8 for fatty infiltration, sclerosis and ankylosis. BMO, 
erosions, fatty infiltration and bone proliferation were scored from 0 to 69 (0-3 in each of 
23 VUs), and 0 to 46 (0-2 in each VU) for posterior segment inflammation. 
6.2.5.3.1 Spine 
Active inflammation (BMO) was defined by the ASAS/OMERACT study group as discreet 
areas of increased STIR signal with corresponding T1 signal loss, and were scored when 
located within bone marrow extending out from one or more of the four corners of the 
vertebral bodies or within the posterior elements (Hermann et al., 2012).  
Structural changes were scored within each vertebral body of the spine (not including 
posterior elements) and defined as follows (Hermann et al., 2012): 
• Fatty bone marrow deposition: Replacement of the bone marrow by fatty tissue, 
seen at the vertebral corners and endplates. Decreased STIR signal with 
corresponding high T1 signal intensity. 
• Erosions: Disruption of the cortical line, occurring at the vertebral corners and 
endplates. Hypointense STIR and T1 signal. 
• Syndesmophytes: Bony outgrowths at anterior, posterior or lateral corners of 
vertebral bodies (that do not reach adjacent vertebra). STIR and T1 signal 
isointense to normal bone marrow. 
• Ankylosis: Bony fusion throughout the disc and/or at the attachment site of the 
annulus fibrosus (bridging syndesmophytes). 
6.2.5.3.2 Sacroiliac Joints 
Active inflammation (bone marrow oedema) was defined by the ASAS/OMERACT study 
group as hyperintense signal on STIR images with corresponding hypointense signal on 
T1 images, and were scored when located within subchondral bone marrow at 
periarticular sites (Rudwaleit et al., 2009). 
Structural changes were defined as follows (Rudwaleit et al., 2009): 
• Fatty bone marrow infiltration: Replacement of bone marrow by fatty tissue, 
resulting from the esterification of fatty acids in inflammatory, often periarticular 
bone marrow areas. Increased T1 signal. 
• Erosions: Bony defects at the joint margin (throughout the cartilaginous 
compartment), initially appearing as single lesions and becoming confluent. Low 
signal intensity on T1 weighted images. If active, hyperintense signal on STIR 
and T2-weighted fat saturated images. 
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• Ankylosis: Bony outgrowths appearing along the joint margin, with those directly 
facing one another fusing to form bridges across the joint. Hypointense STIR and 
T1 signal.  
• Sclerosis: Discrete subchondral bands extending at least 5mm from the sacroiliac 
joint space. Low signal intensity on STIR and T1 images.  
6.3 Statistical Analysis 
Primary emphasis is placed on descriptive statistics. Results for categorical data are 
expressed as frequencies and percentages, and continuous variables are given as 
means (standard deviation, s.d.) or medians (interquartile range, IQR), depending on the 
distribution. To explore associations between categorical variables, c2 test was used.  
Differences in the frequencies of each MRI abnormality between groups were assessed 
using independent groups Student’s t-tests. Differences in the median total scores for 
each MRI abnormality were analysed using Mann-Whitney U tests. p values <0.05 were 
regarded as statistically significant, although results were considered exploratory and 
would need to be confirmed in a fully powered study.  
Missing values, were a joint was within the field of view but unreadable, were considered 
to have no abnormality (assumed score of zero) when calculating mean overall scores 
for each MRI abnormality. In a sensitivity analysis, tests were repeated assuming these 
joints all had the maximum possible score for the relevant abnormalities and there was 
no change to the overall trends observed. Multiple imputation analysis was not feasible 
due to the large number of joints relative to the number of participants, which caused 
imputation models to fail to converge.  
Correlations between demographic and clinical parameters and total scores for each 
MRI abnormality were analysed by Spearman rank correlation; absolute rho values >0.3 
are considered to indicate substantive correlation. Statistical analysis was performed 
using IBM© SPSS© version 24.0.  
6.4 Results 
6.4.1 Patient Characteristics 
6.4.1.1 Patients with Psoriasis 
15 male and 13 female patients, aged between 20 and 74 years (mean 46.5 years) were 
consented to participate in the study. No patients had been diagnosed with any 
rheumatological disorder, nor did they report symptoms consistent with inflammatory 
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back pain. Schobers test was negative in all participants. The majority (75%) of patients 
had type I psoriasis, the remainder developing psoriasis after the age of 40. Psoriasis 
severity was variable with PASI scores ranging from 10-60 (median [IQR] 17.1 [12.0, 
26.6]) and duration of psoriasis varied from 1 to 53 years (median 18.0 [7.7, 26.5] years). 
One patient was skin type V, the remainder were Caucasian (skin type I-III). Body mass 
index (BMI) ranged from 19.6kg/m2 to 46.0kg/m2, with a median of 29.6 (28.2, 33.9) 
kg/m2. Chapter 4.4.1.1. provides further detail about family history, past medical history, 
smoking status and alcohol consumption within this cohort. Table 4.8. details the 
anatomical distribution of psoriasis in this group. 15 of 28 patients carried the HLA-Cw06 
allele, and only one patient exhibited HLA-B27 positivity. 
6.4.1.2 Healthy Control Group Volunteers 
12 male and 11 female volunteers, aged between 22 and 59 years (mean 39.3 years) 
were recruited from staff (and their family and friends) within the University of Leeds. No 
volunteers had previously been diagnosed with psoriasis or any rheumatological 
disorder, and none reported any symptoms consistent with inflammatory back pain. 
Schobers test was negative in all volunteers. One volunteer was skin type IV, the 
remainder being Caucasian (skin types I-III). BMI ranged from 19.3kg/m2 to 49.1kg/m2 
(median 26.8 [24.6, 31.5] kg/m2). Chapter 4.4.1.2. provides further detail about family 
history, past medical history, smoking status and alcohol consumption. Table 4.7. shows 
the demographic similarities between the psoriasis patient cohort and healthy volunteer 
group.  3 volunteers carried the HLA-Cw06 allele, and no volunteers were positive for 
HLA-B27. 
6.4.2 Readability of MRI 
6.4.2.1 Non-axial (Peripheral) Sites  
The readability of WBMRI for evaluation of individual entheses is shown in Table 6.4. 
WBMRI allowed evaluation of 1178 of 1260 entheses within the peripheral skeleton of 
patients with psoriasis and 967 of 1035 entheses in healthy volunteers. Overall, 93.5% 
of entheses were within the field of view (FOV) and readable and 6.5% were within the 
FOV but not readable (due to insufficient image quality, movement artefact and off-centre 
artefact) for both groups. No entheseal sites were outside the FOV, principally due to the 
non-inclusion of the upper limb entheses.  
All pelvic, greater trochanter, medial femoral condyle, plantar fascia and Achilles tendon 
entheses could be assessed in ³95% of participants.  In contrast, readability was less 
good (£90%) for the 7th costochondral joint (18% and 13% not readable, for psoriasis 
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and healthy volunteer groups respectively), manubriosternal joint (14%, 13%), lateral 
femoral condyle of the knee (12%, 13%), 1st metatarsophalangeal joint (14%, 11%), 
patella ligament insertion into patella (11%, 13%) and quadriceps tendon insertion (11%, 
13%). Sagittal slices were not available for the knee and ankle/foot which would have 
improved readability at these sites. 
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No. of patients No. of entheses No. of patients No. of entheses 
Supraspinate tendon insertion at humeral tuberosity 
26 (93) 2 (7) 54 (96) 2 (4) 20 (87) 3 (13) 42 (91) 4 (9) 
Acromioclavicular joint 
26 (93) 2 (7) 54 (96) 2 (4) 21 (91) 2 (9) 43 (93) 3 (7) 
Coracoid process 
26 (93) 2 (7) 54 (96) 2 (4) 21 (91) 2 (9) 43 (93) 3 (7) 
Sternoclavicular joint 
25 (89) 3 (11) 50 (89) 6 (11) 21 (91) 2 (9) 42 (91) 4 (9) 
1st costochondral synchondrosis 
24 (86) 4 (14) 49 (88) 7 (13) 21 (91) 2 (9) 42 (91) 4 (9) 
7th costochondral joint 
23 (82) 5 (18) 46 (82) 10 (18) 20 (87) 3 (13) 40 (87) 6 (13) 
Manubriosternal joint* 
24 (86) 4 (14) 24 (86) 4 (14) 20 (87) 3 (13) 20 (87) 3 (13) 
Iliac crest 
28 (100) 0 (0) 56 (100) 0 (0) 23 (100) 0 (0) 46 (100) 0 (0) 
Anterior superior iliac spine 
28 (100) 0 (0) 56 (100) 0 (0) 23 (100) 0 (0) 46 (100) 0 (0) 
Ischial tuberosity 
28 (100) 0 (0) 56 (100) 0 (0) 23 (100) 0 (0) 46 (100) 0 (0) 
Pubic symphysis 
27 (96) 1 (4) 55 (98) 1 (2) 23 (100) 0 (0) 46 (100) 0 (0) 
Greater trochanter 
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No. of patients No. of entheses No. of patients No. of entheses 
28 (100) 0 (0) 56 (100) 0 (0) 22 (96) 1 (4) 44 (96) 2 (4) 
Lateral femoral condyle 
24 (86) 4 (14) 49 (88) 7 (13) 19 (83) 4 (17) 40 (87) 6 (13) 
Medial femoral condyle 
26 (92) 2 (7) 53 (95) 3 (5) 21 (91) 2 (9) 44 (96) 2 (4) 
Lateral tibial plateau 
26 (92) 2 (7) 52 (93) 4 (7) 20 (87) 3 (13) 41 (89) 5 (11) 
Intracondylar notch 
25 (89) 3 (11) 51 (91) 5 (9) 20 (87) 3 (13) 42 (91) 4 (9) 
Patella ligament insertion into patella 
24 (86) 4 (14) 50 (89) 6 (11) 19 (83) 4 (4) 40 (87) 6 (13) 
Quadriceps insertion into patella 
24 (86) 4 (14) 50 (89) 6 (11) 19 (83) 4 (1) 40 (87) 6 (13) 
Ankle joint attachments 
25 (89) 3 (11) 51 (91) 5 (9) 22 (96) 1 (4) 45 (98) 1 (2) 
1st Tarsometatarsal Joint 
26 (92) 2 (7) 53 (95) 3 (5) 21 (91) 2 (9) 43 (93) 3 (7) 
1st Metatarsophalangeal Joint 
24 (86) 4 (14) 48 (86) 8 (14) 20 (87) 3 (13) 41 (89) 5 (11) 
Achilles tendon insertion 
28 (100) 0 (0) 56 (100) 0 (0) 23 (100) 0 (0) 46 (100) 0 (0) 
Plantar Fascia at calcaneus 
27 (96) 1 (4) 55 (98) 1 (2) 22 (96) 1 (4) 45 (98) 1 (2) 
Table 6.4. WBMRI readability at 45 entheseal sites in the peripheral skeleton of patients 
with psoriasis and healthy volunteers.  
The readability of WBMRI for the assessment of individual bursae is shown in Table 6.5. 
WBMRI allowed the evaluation of 329 of 336 bursae within patients with psoriasis and 
268 of 276 bursae in healthy volunteers. Overall, 97.5% of bursae due for inclusion were 
within the FOV and readable. 2.5% of bursae were within the FOV but not readable for 
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all participants and none were outside the FOV. The worst anatomical site for 
visualisation was at the knee, namely the pre-patellar bursa and pes anserine bursa 
(both seen in 91.3% of scans in the healthy volunteer group). The exclusion of sagittal 
slices of the knee may have had a negative impact on readability. 
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No. of Patients  No. of Bursae No. of Patients No. of Bursae 
Subacromial bursae 
26 (92.9) 2 (7.1) 54 (96.4) 2 (3.6) 21 (91.3) 2 (8.7) 43 (93.5) 3 (6.5) 
Greater trochanteric bursae 
28 (100) 0 (0) 56 (100) 0 (0) 22 (95.7) 1 (4.3) 44 (95.7) 2 (4.3) 
Pre-patellar bursae 
26 (92.9) 2 (7.1) 54 (96.4) 2 (3.6) 20 (87.0) 3 (13.0) 42 (91.3) 4 (8.7) 
Pes anserine bursae 
26 (92.9) 2 (7.1) 54 (96.4) 2 (3.6) 21 (91.3) 2 (8.7) 42 (91.3) 4 (8.7) 
Achilles bursae 
28 (100) 0 (0) 56 (100) 0 (0) 23 (100) 0 (0) 46 (100) 0 (0) 
Retrocalcaneal bursae 
27 (96.4) 1 (7.1) 55 (98.2) 1 (1.8) 23 (100) 0 (0) 46 (100) 0 (0) 
Table 6.5. WBMRI readability of 12 bursae in the peripheral skeleton of patients with 
psoriasis and healthy volunteers.  
The readability of WBMRI for evaluation of individual synovial joints is shown in Table 
6.6. At some sites, assessment of synovial fluid was possible where it was not possible 
to see the entheseal insertion. WBMRI allowed evaluation of 438 of 448 synovial joints 
within the peripheral skeleton of patients with psoriasis and 368 of 385 joints in healthy 
volunteers. Overall, 96.7% of synovial joints due for inclusion were within the FOV and 
readable. 3.3% were within the FOV but not readable for all participants. No synovial 
joints were outside the FOV. All sternoclavicular, acromioclavicular, shoulder, hip, knee 
and ankle joints could be assessed in ³95% of participants. Readability was less 
favourable in the feet, with (£90%) for the 1st metatarsophalangeal joints (3.6% and 6.5% 
not readable, for psoriasis and healthy volunteer groups respectively) and 1st 
metatarsophalangeal joints (5.4%, 10.9%). 
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No. of patients No. of entheses No. of patients No. of entheses 
Sternoclavicular joints 
26 (92.9) 2 (7.1) 54 (96.4) 2 (3.6) 21 (91.3) 2 (8.7) 44 (95.7) 2 (4.3) 
Acromioclavicular joints 
26 (92.9) 2 (7.1) 54 (96.4) 2 (3.6) 21 (91.3) 2 (8.7) 44 (95.7) 2 (4.3) 
Shoulder joints 
25 (89.3) 1 (10.7) 55 (98.2) 1 (1.8) 22 (95.7) 1 (4.3) 45 (97.8) 1 (2.2) 
Hip joints 
28 (100) 0 (0) 56 (100) 0 (0) 22 (95.7) 1 (4.3) 45 (97.8) 1 (2.2) 
Knee joints 
28 (100) 0 (0) 56 (100) 0 (0) 22 (95.7) 1 (4.3) 44 (95.7) 2 (4.3) 
Ankle joints 
28 (100) 0 (0) 56 (100) 0 (0) 22 (95.7) 1 (4.3) 45 (97.8) 1 (2.2) 
1st Tarsometatarsal joints 
25 (89.3) 1 (10.7) 54 (96.4) 2 (3.6) 21 (91.3) 2 (8.7) 43 (93.5) 3 (6.5) 
1st Metatarsophalangeal joints 
24 (85.7) 2 (7.1) 53 (94.6) 3 (5.4) 20 (87.0) 3 (13.0) 41 (89.1) 5 (10.9) 
Table 6.6. WBMRI readability of 16 synovial joints in the peripheral skeleton of patients 
with psoriasis and healthy volunteers. 
The readability of WBMRI for the evaluation of erosions and enthesophytes is shown in 
Table 6.7. WBMRI allowed the assessment of 217 of 224 sites (erosions) and 111 of 112 
sites (enthesophytes) in patients with psoriasis, and 175 of 184 sites (erosions) and 91 
of 92 sites (enthesophytes) in healthy volunteers. Visualisation of bone abnormalities 
was better at site of tendon insertions into the calcaneus compared to the insertions in 
the forefoot. 
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No. of Patients No. of Joints No. of Patients No. of Joints 
1st Tarsometatarsal joint (erosions only) 
26 (92.9) 2 (7.1) 53 (94.6) 3 (5.4) 21 (91.3) 2 (8.7) 43 (93.5) 3 (6.6) 
1st Metatarsophalangeal joint (erosions only) 
26 (92.9) 2 (7.1) 53 (94.6) 3 (5.4) 20 (87.0) 3 (13.0) 41 (89.1) 5 (10.9) 
Achilles tendon insertion into calcaneus (erosions and enthesophytes) 
28 (100) 0 (0) 56 (100) 0 (0) 23 (100) 0 (0) 46 (100) 0 (0) 
Plantar fascia insertion into calcaneus (erosions and enthesophytes) 
27 (96.4) 1 (3.6) 55 (98.2) 1 (1.8) 22 (95.7) 1 (4.3) 45 (97.8) 1 (2.2) 
Table 6.7. WBMRI readability of 8 sites of potential erosions and 4 sites of potential 
enthesophytes in the peripheral skeleton of patients with psoriasis and healthy 
volunteers.  
6.4.2.2 Spine and Sacroiliac Joints 
Full evaluation of all 23 vertebral units and 8 sacroiliac joint quadrants was possible in 
all 28 patients and all 23 healthy volunteers.   
6.4.3 MRI Abnormalities 
6.4.3.1 Non-axial (Peripheral) Skeleton 
6.4.3.1.1 Active Inflammation (Bone Marrow Oedema and Soft Tissue 
Inflammation) 
Bone marrow oedema (BMO) and soft tissue inflammation (STI) were assessed at 45 
entheseal sites in each participant. All patients with psoriasis had at least one enthesis 
with inflammatory change (BMO or STI), compared to 14 of 23 (60.9%) healthy 
volunteers. 110 of 1180 (9.3%) visible entheses (i.e. within FOV) exhibited at least one 
inflammatory change in the psoriasis patient group (47/110 BMO, 59/110 STI, 4/110 
BMO and STI), compared to 27 of 968 (2.8%) visible entheses within the healthy 
volunteer group (12/27 BMO, 15/27 STI) (p<0.00001). 
Participants had between 0 and 8 (mean (±s.d.) 1.82 ±1.66) BMO lesions per patient in 
the psoriasis group, and between 0 and 3 (mean 0.52±0.85) BMO lesions per volunteer 
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in the healthy cohort. Patients with psoriasis had between 0 and 6 (mean 2.25±1.46) STI 
lesions per patient and healthy volunteers had between 0 and 3 (mean 0.65±0.94) STI 
lesions per volunteer. Overall, participants with psoriasis had significantly more 
inflammatory lesions (BMO and/or STI) than healthy volunteers (p=0.035), with a mean 
of 4.04±2.37 inflammatory lesions in patients compared to 1.17±1.23 inflammatory 
lesions in healthy volunteers. 
BMO and STI occurred infrequently in the same enthesis. 21 of 28 psoriasis patients had 
both lesions of BMO and STI, of which only four had BMO and STI at the same site (in 
one enthesis each – three at the supraspinatus tendon insertion at the humeral 
tuberosity, and one at the insertion of the plantar aponeurosis). Only 3 of 23 healthy 
volunteers had at least one lesion of both BMO and STI, but no participants in this group 
had concurrent BMO and STI at the same enthesis (Figure 6.2). 
 
Figure 6.2. Coronal short t inversion recovery (STIR) WBMRI sequence showing grade 
1 bone marrow oedema within the right humeral tuberosity at the insertion of the 
supraspinatus tendon, and surrounding grade 1 soft tissue inflammation in a patient with 
moderate to severe psoriasis. 
The frequency of BMO and STI at each enthesis, at both the entheseal level and patient 
level, is shown in Table 6.8.  
 
  Table 6.8. C
om
parison of percentage frequency of readable inflam
m
atory entheseal lesions (BM
O
 and STI) w
ithin FO
V, in patients w
ith psoriasis (n=28) 
and healthy volunteers (n=23). BM
O
: bone m
arrow
 oedem
a; STI: soft tissue inflam
m
ation; FO
V: field of view
. Bold text denotes p<0.05 
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Psoriasis 
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H
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Volunteers 
G
roup 
diff. 
(p=) 
Supraspinate tendon insertion at hum
eral tuberosity 
15 (27.8) 
5 (11.9) 
0.057 
4 (7.4) 
1 (2.4) 
0.272 
14 (53.8) 
3 (15.0) 
0.007 
4 (15.4) 
1 (5.0) 
0.262 
Acrom
ioclavicular joint 
9 (16.7) 
0 (0.0) 
0.005 
0 (0.0) 
0 (0.0) 
N
A 
6 (23.1) 
0 (0.0) 
0.018 
0 (0.0) 
0 (0.0) 
N
A 
C
oracoid process 
1 (1.9) 
0 (0.0) 
0.370 
0 (0.0) 
0 (0.0) 
N
A 
1 (3.8) 
0 (0.0) 
0.364 
0 (0.0) 
0 (0.0) 
N
A 
Sternoclavicular joint 
1 (2.0) 
1 (2.4) 
0.901 
0 (0.0) 
0 (0.0) 
N
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st costochondral process 
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0 (0.0) 
N
A 
7
th costochondral joint 
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0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
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A 
M
anubriosternal joint 
2 (8.3) 
1 (5.0) 
0.662 
0 (0.0) 
0 (0.0) 
N
A 
2 (8.3) 
1 (5.0) 
0.662 
0 (0.0) 
0 (0.0) 
N
A 
Iliac crest 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
Anterior superior iliac spine 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
Ischial tuberosity 
0 (0.0) 
0 (0.0) 
N
A 
3 (5.4) 
0 (0.0) 
0.111 
0 (0.0) 
0 (0.0) 
N
A 
2 (7.1) 
0 (0.0) 
0.191 
Pubic sym
physis 
2 (3.6) 
1 (2.2) 
0.666 
0 (0.0) 
0 (0.0) 
N
A 
2 (7.4) 
1 (4.3) 
0.650 
0 (0.0) 
0 (0.0) 
N
A 
G
reater trochanter 
0 (0.0) 
0 (0.0) 
N
A 
32 (57.1) 
9 (20.5) 
0.000 
0 (0.0) 
0 (0.0) 
N
A 
19 (67.9) 
5 (22.7) 
0.002 
Lateral fem
oral condyle 
0 (0.0) 
1 (2.5) 
0.266 
1 (2.0) 
0 (0.0) 
0.364 
0 (0.0) 
1 (5.3) 
0.255 
1 (4.2) 
0 (0.0) 
0.368 
M
edial fem
oral condyle 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
Lateral tibial plateau 
0 (0.0) 
0 (0.0) 
N
A 
1 (1.9) 
0 (0.0) 
0.372 
0 (0.0) 
0 (0.0) 
N
A 
1 (3.8) 
0 (0.0) 
0.375 
Intracondylar notch 
7 (13.7) 
0 (0.0) 
0.013 
0 (0.0) 
0 (0.0) 
N
A 
5 (20.0) 
0 (0.0) 
0.034 
0 (0.0) 
0 (0.0) 
N
A 
Patella ligam
ent insertion into patella 
4 (8.0) 
0 (0.0) 
0.067 
10 (20.0) 
3 (7.5) 
0.094 
2 (8.3) 
0 (0.0) 
0.198 
8 (33.3) 
3 (15.8) 
0.190 
Q
uadriceps tendon insertion into patella 
1 (2.0) 
0 (0.0) 
0.368 
2 (4.0) 
1 (2.5) 
0.694 
1 (4.2) 
0 (0.0) 
0.368 
2 (8.3) 
1 (5.3) 
0.695 
Ankle joint attachm
ents 
2 (3.8) 
0 (0.0) 
0.184 
0 (0.0) 
0 (0.0) 
N
A 
1 (4.0) 
0 (0.0) 
0.343 
0 (0.0) 
0 (0.0) 
N
A 
1
st Tarsom
etotarsal joint 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
1
st M
etatarsophalangeal joint 
5 (10.4) 
1 (2.4) 
0.135 
0 (0.0) 
0 (0.0) 
N
A 
4 (16.7) 
1 (5.0) 
0.225 
0 (0.0) 
0 (0.0) 
N
A 
Achilles tendon insertion 
0 (0.0) 
2 (4.3) 
0.115 
3 (5.4) 
0 (0.0) 
0.111 
0 (0.0) 
2 (8.7) 
0.111 
2 (7.1) 
0 (0.0) 
0.182 
Plantar fascia insertion at calcaneus 
2 (3.6) 
0 (0.0) 
0.196 
7 (12.7) 
1 (2.2) 
0.054 
2 (7.4) 
0 (0.0) 
0.192 
7 (25.9) 
1 (4.5) 
0.044 
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Large joint enthesitis was not infrequent in patients with psoriasis, particularly at the 
shoulders (supraspinatus insertion 53.8% vs. 5.0% healthy volunteers, p=0.007, 
acromioclavicular joint tendon insertion 23.1% vs. 0% healthy volunteers, p=0.018) 
(Figure 6.3) and knees (intracondylar notch 20.0%, vs. 0% healthy volunteers, p=0.034) 
(Figure 6.4). BMO was observed in patients, but not healthy volunteers, at the patellar 
ligament insertion into distal patella (8.3%) and quadriceps insertion (4.2%) (p>0.05) 
(Figure 6.5).  
 
Figure 6.3. Coronal short t inversion recovery (STIR) WBMRI sequences comparing (a) 
grade 3 bone marrow oedema the right acromioclavicular joint and right humeral head 
in a patient with psoriasis (arrows) with (b) a normal shoulder in a healthy volunteer.  
 
 
 
(a)
(b)
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Figure 6.4. Axial short t inversion recovery (STIR) WBMRI sequences comparing (b) 
normal knees in a healthy volunteer with (a) grade 2 bone marrow oedema within the 
intercondylar notch of the right knee in a patient with psoriasis.  
 
 
 
 
 
 
 
 
 
(a)
(b)
 
 
300 
 
Figure 6.5. Axial short t inversion recovery (STIR) WBMRI sequences comparing (b) 
normal knees in a healthy volunteer with (a) grade 3 bone marrow oedema in the left 
superior patella at the insertion of the quadriceps tendon in a patient with psoriasis. 
Both groups showed high rates of STI in the tissues surrounding the greater trochanter, 
although this was observed with significantly greater frequency in the patients with 
psoriasis than in healthy volunteers (67.9% and 22.7% of participants, respectively, 
p=0.002). A significantly greater number of patients also had STI at the plantar fascia 
insertion than healthy volunteers (25.9% and 4.5% respectively, p=0.044) (Figure 6.6). 
 
 
 
 
(a)
(b)
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Figure 6.6. Long axis short t inversion recovery (STIR) WBMRI sequences showing 
comparing (a) bone marrow oedema and soft tissue inflammation at the plantar fascia 
insertion of the right foot (grade 3) and left foot (grade 1) in a patient with psoriasis with 
(b) normal plantar fascia insertions in a healthy volunteer and (c) grade 1 soft tissue 
inflammation surrounding the left plantar fascia insertion in a healthy volunteer.    
Comparison between the two participant groups of the percentage frequency of 
inflammatory entheseal lesions at each enthesis is shown in Figure 6.7 (BMO) and 
Figure 6.8 (STI). 
(a) (b)
(c)
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Figure 6.7. Comparison of percentage frequency of entheses with bone marrow oedema 
(BMO) between patients with psoriasis and healthy volunteers at each site (p values are 
only shown for entheses where the difference between groups <0.05). 
 
Figure 6.8. Comparison of percentage frequency of entheses with soft tissue 
inflammation (STI) between patients with psoriasis and healthy volunteers at each site 
(p values are only shown for entheses where the difference between groups <0.05). 
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Neither group demonstrated any inflammatory abnormalities at the 1st costochondral 
process, 7th costochondral joint, iliac crest, anterior superior iliac spine, medial femoral 
condyle nor the 1st tarsometatarsal joint. Enthesitis was identified in patients with 
psoriasis only at the coracoid process, lateral tibial plateau and ankle joint attachments, 
although rates were very low (<4%).  
The majority of inflammatory abnormalities were minor in both groups. In healthy 
volunteers, all 27 lesions (BMO and STI) were grade 1, with the exception of one lesion 
at one site in one patient (grade 2 STI at the inferior patella). In patients with psoriasis, 
11 of 114 (9.6%) of abnormalities were of moderate severity (grade 2), and 4/114 (3.5%) 
were severe (grade 3).  
Total scores (calculated from entheses within FOV and readable) ranged from 0-9 for 
BMO and 0-6 for STI in the patient group, compared with 0-3 for BMO and 0-2 for STI in 
the healthy volunteer group. The distribution of total BMO scores and total STI scores 
within each group are compared in Figure 6.9.  
Median [interquartile range, IQR] scores were significantly greater for both BMO and STI 
in the psoriasis patient group (BMO: 2 [1,2.75] psoriasis patients, 0 [0,0] healthy 
volunteers, p=0.000; STI 2.5 [1,4] psoriasis patients, 0 [0,0] healthy volunteers, p=0.000).  
 
(a)                                                                    (b) 
 
Figure 6.9. Comparison of distribution of total (a) BMO and (b) STI scores in patients 
with psoriasis and healthy volunteers. 
6.4.3.1.2 Bursitis 
Bursitis, as defined by a subjective increase in fluid, was assessed at 12 sites in each 
participant. Bursitis was prevalent in both groups, but occurred with greatest frequency 
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in the psoriasis group, affecting 75.0% (21/28) of patients compared to 60.9% (14/23) of 
healthy volunteers. The burden of bursitis was significantly greater in the 28 patients with 
psoriasis, with 57 of 329 (17.3%) visible bursae (i.e. within FOV) exhibiting at least one 
inflammatory change, compared to 25 of 263 (9.5%) visible bursae in the 23 healthy 
volunteers (p=0.006). 
Participants had between 0 and 5 (mean (±s.d.) 2.04±1.60) areas of bursitis per patient 
in the psoriasis group, and between 0 and 4 (mean 1.09±1.24) areas per volunteer in the 
healthy cohort (p=0.257). 
Bursitis was seen in the psoriasis patient group in all six anatomical sites assessed, 
whereas no abnormalities were seen in the subacromial and pes anserine bursae in 
healthy volunteers (Table 6.9). 
 Burseal Level Participant Level 
 No. of lesions (% of lesions within  
readable FOV) 
No. of participants (% of participants 
with bursitis within readable FOV) 
 Psoriasis 
Patients 
Healthy 
Volunteers 
Group diff.  
(p=) 
Psoriasis 
Patients 
Healthy 
Volunteers 
Group diff.  
(p=) 
Subacromial bursae 7 (13.0) 0 (0.0) 0.014 5 (19.2) 0 (0.0) 0.034 
Greater trochanteric bursae 31 (55.4) 19 (43.2) 0.227 18 (64.3) 12 (54.5) 0.485 
Pre-patellar bursae 7 (13.2) 2 (4.8) 0.163 5 (19.2) 1 (5.0) 0.243 
Pes anserine bursae 1 (1.8) 0 (0.0) 0.380 1 (3.7) 0 (0.0) 0.373 
Achilles bursae 2 (3.6) 1 (2.2) 0.678 1 (3.6) 1 (4.3) 0.887 
Retrocalcaneal bursae 9 (16.4) 3 (6.5) 0.128 6 (22.2) 2 (8.7) 0.193 
Table 6.9. Comparison of percentage frequency of readable bursitis lesions within FOV, 
in patients with psoriasis (n=28) and healthy volunteers (n=23). FOV: field of view. Bold 
text denotes p<0.05. 
Bursitis was commonly observed in both patients and volunteers, with only a significant 
difference between the groups seen at the subacromial bursa (19.2% patients vs. 0% 
volunteers, p=0.034). Bursitis frequently occurred at sites of observed STI in all 
participants (Figure 6.10). 
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Figure 6.10. Coronal short t inversion recovery (STIR) WBMRI sequence showing 
bilateral grade 1 subcoracoid bursitis in a patient with psoriasis.  
In both groups, the greater trochanteric bursa was most commonly inflamed, although 
most abnormalities were mild/grade 1 (64.3% and 54.5% in psoriasis patients and 
healthy volunteers, respectively). Differences between groups at the bursal level can be 
seen in Figure 6.11.  
 
Figure 6.11. Comparison of percentage frequency of bursitis lesions between patients 
with psoriasis and healthy volunteers at each site. (p values are only shown for entheses 
where the difference between groups <0.05). 
The majority of abnormalities (>95%) were of minor (grade 1) severity in both groups, 
with one participant in each group exhibiting moderate bursitis in two bursae each. 
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Amongst the healthy volunteers, one participant had ipsilateral grade 2 bursitis in the 
Achilles and retrocalcaneal bursae and on further questioning reported problems with 
Achilles tendonitis secondary to recreational running (Figure 6.12). One psoriasis patient 
had greater trochanteric bursitis bilaterally with no history of trauma. 
 
 
Figure 6.12. Long axis short t inversion recovery (STIR) WBMRI sequences showing 
grade 2 left retrocalcaneal bursitis in a healthy volunteer who was undertaking marathon 
training.  
Total scores (calculated from bursae within FOV and readable) ranged from 0-5 in 
patients with psoriasis, and 0-4 in volunteers. The distribution of total bursitis scores 
within each group are compared in Figure 6.13. Median [IQR] scores were significantly 
greater in the psoriasis patient group (2 [0.25,4] in psoriasis patients, 1 [0,2] healthy 
volunteers, p=0.033). 
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Figure 6.13. Comparison of distribution of total bursitis scores in patients with psoriasis 
and healthy volunteers.  
6.4.3.1.3 Synovitis 
A subjective assessment of synovial joint fluid volume as a surrogate for potential joint 
synovitis was made at 16 joints in each participant to evaluate for the presence of 
synovitis. The presence of synovitis was common amongst all participants, with 92.9% 
(26/28) of patients with psoriasis and 82.6% (19/23) healthy volunteers having at least 
one area of increased synovial fluid suggestive of inflammation. True synovial thickening 
was difficult to determine in the absence of contrast enhancement (Figure 6.14).  
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Figure 6.14. Axial short t inversion recovery (STIR) WBMRI sequences comparing (b) 
normal knees in a healthy volunteer with (a) bilateral grade 1 synovitis (increased fluid 
volume within the joint capsule) in the knees of a patient with psoriasis.  
The overall burden of synovitis was marginally higher in the psoriasis group, affecting 88 
of 438 (20.1%) visible joints (i.e. within FOV) in patients, compared with 58 of 351 
(16.5%) joints in volunteers but did not reach significance (p=0.199). Participants had 
between 0 and 7 (mean (±s.d.) 3.14±1.80) areas of synovitis per patient in the psoriasis 
group, and between 0 and 6 (mean 2.52±1.88) areas per participant amongst healthy 
volunteers (p=0.985). 
Synovitis was seen in patients with psoriasis in all areas except for the tarsometatarsal 
joints. Synovitis was not seen in volunteers in the sternoclavicular, acromioclavicular and 
metatarsophalangeal joints (Table 6.10).  
 
 
 
 
(a)
(b)
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 Joint Level Participant Level 
 No. of lesions (% of lesions within 
readable FOV) 
No. of participants (% of participants 
with synovitis within readable FOV) 
 Psoriasis 
Patients 
Healthy 
Volunteers 
Group 
diff. 
(p=) 
Psoriasis 
Patients 
Healthy 
Volunteers 
Group 
diff. 
(p=) 
Sternoclavicular joints 1 (1.9) 0 (0.0) 0.364 1 (3.8) 0 (0.0) 0.364 
Acromioclavicular joints 4 (7.4) 0 (0.0) 0.065 3 (11.5) 0 (0.0) 0.108 
Shoulder joints 10 (18.2) 6 (13.3) 0.511 6 (22.2) 4 (18.2) 0.727 
Hip joints 10 (17.9) 5 (11.1) 0.343 6 (21.4) 3 (13.6) 0.477 
Knee joints 33 (58.9) 22 (50.0) 0.373 17 (60.7) 11 (50.0) 0.449 
Ankle joints 27 (48.2) 23 (51.1) 0.772 15 (53.6) 13 (59.1) 0.696 
Tarsometatarsal joints 0 (0.0) 2 (4.7) 0.109 0 (0.0) 1 (4.8) 0.252 
Metatarsophalangeal joints 3 (5.7) 0 (0.0) 0.122 2 (7.7) 0 (0.0) 0.205 
Table 6.10. Comparison of percentage frequency of readable bursitis lesions within FOV, 
in patients with psoriasis (n=28) and healthy volunteers (n=23). FOV: field of view.  
In both groups, the greatest burden of synovitis was in the knee (60.8% and 50.0% in 
patients and volunteers respectively) and ankle joints (53.6%, 59.1%), followed by the 
hip (21.4%, 13.6%) and shoulder joints (24.0%, 18.2%) (Figure 6.15).   
 
Figure 6.15. Comparison of percentage frequency of synovitis lesions between patients 
with psoriasis and healthy volunteers at each site.  
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Total scores (calculated from synovial joints within FOV and readable) ranged from 0-7 
in patients with psoriasis, and 0-6 in healthy volunteers. The distribution of total 
synovitis scores within each group are compared in  
Figure 6.16. No statistical difference in median [IQR] score between participant groups 
was observed (3 [2,4] psoriasis patients, 2 [1,4] healthy volunteers, p=0.220). 
 
 
Figure 6.16. Comparison of distribution of total synovitis scores in patients with psoriasis 
and healthy volunteers. 
6.4.3.1.4 Tenosynovitis 
Tenosynovitis was assessed at four sites in each participant (medial and lateral tendons 
of the foot bilaterally). Inflammation of the tendon sheaths was uncommon, and only 
observed in patients with psoriasis, in the lateral tendons (7.1% patients, p=0.191) (Table 
6.11). All abnormalities were mild.  
 Tendon Level Participant Level 
 No. of lesions (% of lesions within 
readable FOV) 
No. of participants (% of participants 
with tenosynovitis within readable FOV) 
 Psoriasis 
Patients 
Healthy 
Volunteers 
Group diff. 
(p=) 
Psoriasis 
Patients 
Healthy 
Volunteers 
Group diff. 
(p=) 
Lateral tendons 4 (7.1) 0 (0.0) 0.064 2 (7.1) 0 (0.0) 0.191 
Medial tendons 0 (0.0) 0 (0.0) N/A 0 (0.0) 0 (0.0) N/A 
Table 6.11. Comparison of percentage frequency of readable tenosynovitis within FOV, 
in patients with psoriasis (n=28) and healthy volunteers (n=23). FOV: field of view.  
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Total scores for tenosynovitis, calculated from foot tendons within FOV and readable, 
ranged from 0-2 in the psoriasis group (26/28 patients had no tenosynovitis, and 2/28 
each scored 2). Median [IQR] scores in both groups were 0 [0,0], with no observed 
statistical difference (p=0.195). 
6.4.3.1.5 Structural Changes 
Osseous destructions/erosions (examined at four sites per participant) and bony 
proliferations (examined at two sites per participant) were not identified at any locality in 
either group. 
6.4.3.2 Axial Skeleton - Spine 
6.4.3.2.1 Active Inflammation 
In total, 18 of 28 (64.3%) psoriasis patients had at least one VU exhibiting active 
inflammation (BMO) within the spine compared with 7 of 23 (30.4%) of healthy volunteers 
on STIR images. Of the 18 psoriasis patients with BMO, 15 showed subchondral BMO 
alone, and 3 showed BMO and structural changes. No individuals had isolated structural 
changes in either group. The majority of abnormalities were found within the bone 
marrow of the vertebral corners, although in some extended across the vertebral 
endplate or superior and inferior corners joined together to cause a ‘white out’ where 
inflammation was most active (Figure 6.17). 
 
Figure 6.17. Saggital short t inversion recovery (STIR) WBMRI sequences showing 
hyperintense signal (osteitis) localised to (a) the anterior superior corner of L1, (b) the 
(a) (b) (c)
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vertebral endplates of C3/4 and C6/7 and (c) the inferior and superior anterior corners of 
T7 causing a white out of 50% of the vertebral unit in a patient with psoriasis. 
In the psoriasis group, participants had between 0 and 6 BMO lesions each, with five 
patients having lesions at three or more sites, which is highly suggestive of axial SpA 
(Hermann et al., 2012).  All healthy volunteers had between 0 and 2 BMO lesions each. 
Only one psoriasis patient had active inflammation within the posterior elements (facet 
joints) at two sites (nil in volunteer group) (Figure 6.18). 
 
Figure 6.18. Saggital short t inversion recovery (STIR) sequence WBMRI of lower spine 
showing hyperintense signal (posterior element inflammation) within the facet joints of 
L4/5 (grade 1) and L5/S1 (grade 2). 
In total, 41 active inflammatory lesions were identified within all vertebral units assessed 
in the psoriasis group, the majority of which were generally low grade (grade 1: 28/41; 
grade 2: 12/41; grade 3: 1/41). In the healthy volunteer group, 10 VUs exhibited BMO, 
which were also mostly low grade (grade 1: 9/10, grade 3: 1/10).  
Overall mean BMO scores per subject were therefore low, although significantly higher 
in the psoriasis patient group (median [IQR] 1 [0,3] out of 69 possible scoring points) 
compared with the healthy volunteer group (0 [0,1], p=0.007) (Table 6.12). The 
distribution of total scores for BMO within each group are compared in Figure 6.19.   
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Table 6.12. Comparison between psoriasis patients and healthy volunteers of scores for 
all abnormalities in the spine. (*) denotes significance at 0.05 level.  
 
Figure 6.19. Comparison of the distribution of total spine BMO scores between patients 
with psoriasis and healthy volunteers. 
The distribution of total scores for posterior segment inflammation were limited (Figure 
6.20). 
 
 
 
Psoriasis Patients Healthy Volunteers 
Range 
Median 
[IQR] 
Range 
Median 
[IQR] 
Bone marrow oedema score 
(0-69) 
0-9 1 [0-3]* 0-4 0 [0,1]* 
Erosion score 
(0-69) 
0 0 [0,0] 0 0 [0,0] 
Fatty bone marrow infiltration score 
(0-69) 
0-5 0 [0,0] 0 0 [0,0] 
Inflammation of posterior segments 
(0-69) 
0-3 0 [0,0] 0 0 [0,0] 
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Figure 6.20. Comparison of distribution of total spine posterior segment inflammation 
scores in patients with psoriasis and healthy volunteers. 
In patients with psoriasis, the most common sites of vertebral body inflammation (BMO) 
were the lumbar and lower thoracic spine - L5/S1 (10/43 lesions), followed by L3/4 (5/43 
lesions), T8/9 (4/43 lesions) and C5/6 (3/43 lesions). Overall however, in both groups, 
all lesions were generally distributed throughout the spine (Table 6.13). 
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Vertebral 
Unit 
BMO Fatty Infiltration 
Posterior Segment 
Inflammation 
Grade 
1 
Grade 
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Grade 
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H
V 
C2/3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
C3/4 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
C4/5 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
C5/6 1 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 
C6/7 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
C7/T1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
T1/2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
T2/3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
T3/4 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
T4/5 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
T5/6 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
T6/7 1 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 
T7/8 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
T8/9 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
T9/10 2 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 
T10/11 2 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 
T11/12 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 
T12/L1 1 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 
L1/2 2 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 
L2/3 2 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 
L3/4 3 1 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
L4/5 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
L5/S1 5 1 4 0 0 0 1 0 1 0 0 0 1 0 1 0 0 0 
TOTAL 28 9 12 0 1 1 7 0 1 0 0 0 1 0 1 0 0 0 
Table 6.13. Comparison of the distribution and grade of BMO, fatty infiltration and 
posterior segment inflammation lesions throughout the spine between psoriasis patients 
(PsO) and healthy volunteers (HV) (C=cervical, T=thoracic, L=lumbar, S=sacral). 
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6.4.3.2.2 Structural Changes 
No structural abnormalities were seen in any healthy volunteers. Within the psoriasis 
patient group, fatty infiltration of the bone marrow was an uncommon finding, with only 
four patients exhibiting low grade changes (grade 1 or 2) which affected less than 50% 
of the vertebral body (Figure 6.21). Three of these patients had fatty infiltration at only 
one site, and the fourth had changes at five sites, only one of which was associated with 
inflammatory change (Figure 6.22). 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.21. Saggital T1w sequence WBMRI images showing five areas of fatty 
infiltration of the bone marrow in two adjacent slices in one patient at T6/7, T7/8, T9/10, 
T11/12 and L3/4. 
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Figure 6.22. Comparison of distribution of total spine bone marrow fatty infiltration (FI) 
scores in patients with psoriasis and healthy volunteers. 
Bone proliferation was identified in four patients (grade 1: 3/4; grade 2: 1/4) at different 
sites (C4/5, T3/4, T8/9 and L4/5), and in only two did this correspond to a site of active 
inflammation. No erosions were identified within the spine. Table 6.13 compares the total 
scores for each abnormality by group.  
 
6.4.3.3 Axial Skeleton - Sacroiliac Joints 
6.4.3.3.1 Active Inflammation 
In total, 4 of 28 patients (14.3%) had at least one area of BMO within the SIJs. 7 areas 
of BMO were identified, all grade 1, located in the upper sacrum (3/7), upper ilium (3/7) 
and lower ilium (1/7). One patient had three involved quadrants, one patient had two, 
and two patients each had one quadrant involved. One healthy volunteer had one area 
of BMO (upper ilium, grade 1) (Table 6.14).  
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Sacroiliac 
Joint 
Quadrant 
BMO Erosions 
Grade 
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Grade 
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Grade 
3 
Grade 
1 
Grade 
2 
Grade 
3 
Ps
O
 
H
V 
Ps
O
 
H
V 
Ps
O
 
H
V 
Ps
O
 
H
V 
Ps
O
 
H
V 
Ps
O
 
H
V 
Upper Ilium 3 1 0 0 0 0 0 0 0 0 0 0 
Lower Ilium 1 0 0 0 0 0 2 0 0 0 0 0 
Upper Sacrum 3 0 0 0 0 0 0 1 0 0 0 0 
Lower Sacrum 0 0 0 0 0 0 0 1 0 0 0 0 
TOTAL 7 0 0 0 0 0 2 2 0 0 0 0 
Table 6.14. Comparison of the distribution and grade of BMO lesions and erosions 
throughout the sacroiliac joints between psoriasis patients (PsO) and healthy volunteers 
(HV). 
The distribution of total SIJ BMO scores is shown in Figure 6.23. 
 
Figure 6.23. Comparison of distribution of total SIJ BMO scores in patients with psoriasis 
and healthy volunteers (SIJ: sacroiliac joint). 
Overall SIJ median [IQR] active inflammation scores were therefore low with no 
difference observed between the groups (0 [0,0] out of a possible 24 scoring points for 
both groups, p=0.226) (Table 6.15). 
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Table 6.15. Comparison between psoriasis patients and healthy volunteers of scores for 
all abnormalities in the SIJs. (*) denotes significance at 0.05 level. 
6.4.3.3.2 Structural Changes 
Structural changes within the SIJs were rare, with no identifiable areas of bone marrow 
infiltration, ankylosis or sclerosis seen in either patients with psoriasis or healthy 
volunteers. Erosions were seen in two psoriasis patients (lower ilium bilaterally in both, 
grade 1), and one volunteer (unilateral upper and lower sacrum, grade 1) (Table 6.14).  
The distribution of total erosion scores is shown in Figure 6.24. Median scores in both 
groups were 0 [0,0], p=0.428  (Table 6.15). 
 
 
Psoriasis patients Healthy Volunteers 
Range 
Median 
[IQR] 
Range 
Median 
[IQR] 
Bone marrow oedema score 
(0-24) 
0-3 0 [0,0] 0-1 0 [0,0] 
Erosion score 
(0-24) 
0-2 0 [0,0] 0-2 0 [0,0] 
Fatty bone marrow infiltration score 
(0-8) 
0 0 [0,0] 0 0 [0,0] 
Ankylosis score 
(0-4) 
0 0 [0,0] 0 0 [0,0] 
Sclerosis score 
(0-2) 
0 0 [0,0] 0 0 [0,0] 
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Figure 6.24. Comparison of distribution of total SIJ erosion scores in patients with 
psoriasis and healthy volunteers (SIJ: sacroiliac joint). 
6.4.4 Correlation between MRI Abnormalities and Clinical 
Characteristics 
6.4.4.1 Peripheral Skeleton 
In psoriasis patients with nail involvement (n=21), there was a weak positive association 
between modified nail psoriasis index (mNAPSI) score and total BMO score 
(Spearman’s rho=0.404) and between mNAPSI score and total STI score (rho=0.369). 
A weak positive association was also seen between total STI score and the presence of 
gluteal cleft psoriasis (rho=0.326). The presence of psoriasis at other sites did not 
correlate with the total score of any MRI abnormality, nor was any association found 
between total scores and PASI score or the body surface area affected with psoriasis. 
The duration of psoriasis did not correlate with any MRI abnormality, although a weak 
correlation was found between the age of onset of psoriasis and total STI score 
(rho=0.327).  
A positive PEST questionnaire (score ³3/5) showed weak association with inflammation 
scores (total BMO score (rho=0.415) and total STI score (rho=0.382)), but not total 
synovitis, bursitis or erosion scores.  
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No associations were found between age, gender, smoking status, alcohol consumption, 
BMI, HLA-Cw06 status or HLA-B27 status and total score for any MRI abnormality in 
either group.  
6.4.4.2 Axial Skeleton 
In patients with psoriasis, a positive correlation was identified between the age of the 
patient and total BMO score in the spine (rho=0.536) and the age of onset of psoriasis 
and the total spine BMO score (rho=0.466). A weak association was also found between 
total spine BMO score and smoking (current or previous) (rho=0.418).  In those patients 
with nail psoriasis (n=21), a weakly positive correlation was identified between mNAPSI 
total and total spine BMO score (rho=0.349) and also total spine fatty infiltration score 
(rho=0.350). The presence of psoriasis at other sites did not correlate with any MRI 
abnormality, nor was any association found between any total MRI scores and the 
duration or severity of psoriasis (PASI score/BSA). No association was found with HLA 
status. 
In the sacroiliac joints, total BMO score showed weak positive correlation with HLA-B27 
status (rho=0.309), in addition to the duration of psoriasis (rho=0.327). In contradiction 
to the spine, there was a negative association between total SIJ BMO score and the age 
of onset of psoriasis (rho=-0.462).  No correlations were identified with total fatty 
infiltration scores, total ankylosis scores nor erosion scores. 
No associations were found between any MRI abnormalities in the spine or SIJs and 
age, gender, alcohol consumption, BMI or PEST score in either patients with psoriasis 
or healthy volunteers. 
6.5 Discussion 
Despite the potential of WBMRI as an emerging tool in identifying widespread 
inflammation in all forms of SpA, only a few studies have used WBMRI in prospective 
studies of patients with psoriatic arthritis, axial spondyloarthritis and healthy volunteers 
to assess enthesitis, synovitis and destructive bony changes (Weckbach et al., 2011, 
Althoff et al., 2013, Poggenborg et al., 2015a, Poggenborg et al., 2015b, Song et al., 
2011a, Karpitschka et al., 2013). This prospective pilot data is the first to demonstrate 
the ability of WBMRI to evaluate early and subclinical peripheral and axial inflammatory 
and structural damage abnormalities in asymptomatic patients with psoriasis.  In this 
chapter, it was demonstrated that psoriasis patients had both higher axial and peripheral 
entheseal related abnormalities compared to healthy controls.    
A small number of authors to date have used conventional MRI in patients with psoriasis 
and without clinical peripheral or axial joint involvement to assess for the presence of 
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enthesitis at a specific anatomical location. There are no published data for comparison 
using WBMRI to identify multiple disease manifestations in both the axial and peripheral 
skeleton in psoriasis patients. However, in SpA, investigation of inflammatory lesions in 
the spine and SIJs by WBMRI have previously been compared with conventional MRI, 
finding a strong correlation and comparable readability between the two methods (Weber 
et al., 2009, Weber et al., 2010). No evaluations of the performance of WBMRI compared 
with conventional MRI in assessing active inflammatory lesions within the peripheral 
skeleton have been published.   
Several WBMRI studies have included healthy volunteers for comparison with disease 
groups, including PsA, SpA and AS, but not subclinical enthesopathy. Comparable with 
this study, Poggenborg et al observed WBMRI enthesitis at several non-axial sites in 
healthy volunteers in two studies (Poggenborg et al., 2015a, Poggenborg et al., 2015b), 
and reported that BMO was markedly more frequent in patients with established PsA 
and SpA. Poggenborg et al identified enthesitis in healthy subjects in similar entheses, 
although often with higher frequency, including the supraspinatus tendon insertion at the 
humerus (13% compared with 15% in this study), quadriceps tendon insertion (13% vs. 
5.3%), greater trochanter (58% vs. 22.7%) and Achilles tendon insertion (28% vs. 8.7%) 
(Poggenborg et al., 2015a).  
The presence of inflammatory abnormalities in healthy volunteers is not a novel concept. 
Imaging abnormalities are widely reported in healthy volunteers, especially in people 
undergoing elite training (Kiuru et al., 2005). At the histological level, Benjamin et al 
identified microscopic inflammatory changes due to the normal healing process at sites 
of microtrauma following mechanical stress, which are similar to, although less 
pronounced than, those seen in patients with early PsA (McGonagle et al., 2011, 
McGonagle et al., 2009b, Benjamin and McGonagle, 2007). However, the detection of 
inflammatory changes in some healthy volunteers indicates a need to define appropriate 
definitions and cut-offs of pathology on WBMRI in future studies, before the method is 
used in clinical practice. Nevertheless, BMO and STI were seen with greater frequency 
in psoriasis patients and it may be difficult to define such definitions when the changes 
amongst asymptomatic patients are subtle.  
Readability of WBMRI in this study was excellent in axial sites and good at peripherally 
located joints. Problems including the fingers, elbows and wrist joints in the imaging 
volume have been previously reported (Althoff et al., 2007, Poggenborg et al., 2015b, 
Poggenborg et al., 2015a) due to restrictions in the maximum width of field of view (FOV) 
and were therefore excluded in this study. Unlike previous studies, all entheses and joints 
were within the FOV, although some were not readable (Poggenborg et al., 2015a). 
Poorer readability had several causes, including movement artefacts, off-centre artefact 
(longer distance from the centre of the MRI unit decreasing field homogeneity) and in 
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smaller joints, insufficient spatial resolution. Areas such as the spine and SI joints were 
favoured by being positioned close to the coil and the centre of the magnetic field, 
providing excellent readability. Image quality was lower if the area scanned was at the 
periphery of the scanner.  
Although image acquisition was not consistently of sufficient quality for robust and 
reliable assessment in absolutely all joints of interest, improvements in hardware, more 
refined techniques of image acquisition and optimal patient positioning have meant that 
more peripheral entheses and joints were within FOV in this study than in previous 
studies.  For example, the first costochondral synchondrosis was visualised in this study 
in 86% of psoriasis patients and 91% of healthy volunteers, compared with just 29% in 
one previously published study (Poggenborg et al., 2015a). Similarly, at the knee, 5% of 
patellar ligament insertions (into the patella) were in FOV and readable in the previous 
study, compared to 86% in psoriasis patients in this study, due to refinements in 
technique, the use of external coils and coil placement.  
Acceptable readability in this study therefore allowed one of the most comprehensive 
assessments of the peripheral and axial skeleton to date. In patients with psoriasis, there 
are no studies using WBMRI for comparison,  but studies using conventional MRI have 
investigated the knee (Emad et al., 2012, Emad et al., 2010), the small entheses of the 
hands (Faustini et al., 2016, Offidani et al., 1998), the feet (Erdem et al., 2008), and the 
lumbosacral spine and sacroiliac joints (SIJs) (Hamdy et al., 2015). In the peripheral 
skeleton, each of these studies demonstrated a high proportion of inflammatory 
abnormalities in patients with psoriasis, with the proportion of participants having at least 
one inflammatory MRI abnormality ranging from 47% and 94.8%. The lowest rates were 
seen in studies of the hands (47% and 68%), which were not included in this WBMRI 
protocol. Given that these data are from individual anatomical sites, it is not therefore 
surprising that all psoriasis patients in this study (which included 23 different anatomical 
sites bilaterally) had at least one inflammatory MRI abnormality in the peripheral 
skeleton.   
In the axial skeleton, the findings in this study are supported by those of Hamdy et al, 
who found comparable but slightly lower rates of active inflammation in the spine (64.3% 
vs. 44%) and SIJs (14.3% vs. 10%) of asymptomatic patients with psoriasis (Hamdy et 
al., 2015). The lower rates may be attributable to the fact that some patients in the study 
by Hamdy and colleagues had received treatment, which although not specified, could 
have been disease modifying therapy, and the authors comment that bone marrow 
oedema can disappear with treatment. In addition, Hamdy and colleagues restricted their 
investigation to the lumbosacral spine, whereas this study included the entire spine. This 
investigation identified lesions in the cervical and thoracic portions in addition to the 
lumbosacral spine, which may account for the greater proportion of patients with 
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inflammatory lesions. Indeed, the most common sites of inflammation in non-
radiographic ax-SpA, as assessed by WBMRI, are reported to be not localised to just the 
lumbosacral spine, but also the lower thoracic spine, which reflects the distribution of 
lesions seen in this cohort of psoriasis patients (Althoff et al., 2013) and reflects earlier 
WBMRI reports in patients with established SpA (Weber et al., 2007). As previously 
described in ax-SpA (Bennett et al., 2009), most BMO lesions affected the corners of the 
vertebral units, but where inflammation was substantial, there were examples of 
vertebral endplate osteitis and of inferior and superior corners within the same vertebral 
unit joining up to create a ‘white out’ appearance. There was, on occasion, difficulty in 
determining if an area of signal change could be due to degenerative disease or 
subclinical ax-SpA, and where any doubt existed, sites were scored as zero. This may 
have led to minimal under-reporting of spine osteitis.   
Although there are no other MRI studies of the SIJs in patients with psoriasis and no joint 
disease, higher rates of have been reported in patients with PsA, psoriasis and 
asymptomatic sacroiliac involvement, with 33.3% of patients having MRI evidence of 
sacroilitis (Ibrahim and El-Shazly, 2011). It has been reported that in patients with non-
radiographic axial spondyloarthritis and without active sacroilitis on MRI, lesions in the 
spine may appear earlier than in the SIJs, thus representing the subclinical or pre-
disease status (Direz et al., 2010), which may account for the higher proportion of spinal 
involvement compared with sacroiliac inflammation seen in this study and that by Hamdy 
et al (Hamdy et al., 2015).  
Regarding the peripheral skeleton, Emad et al identified bone marrow oedema in 20.8% 
of knees scanned in 48 asymptomatic patients with psoriasis (Emad et al., 2012), which 
is comparable to 22.9% of knees in this cohort. Soft tissue inflammation was greater in 
those scanned by Emad and colleagues (60.4% vs. 25.0%) in a comparable population 
(mean age in years 42.2 vs. 46.5, BMI in kg/m2 34.2 vs. 29.6, proportion of males 45.8 
vs. 53.6) (Emad et al., 2012). In a second study including just six psoriasis patients, 
Emad identified less bone marrow oedema (16.7%) and more soft tissue inflammation 
(33.3%), demonstrating the variation that can occur amongst populations, even when 
selected from the same clinic (Emad et al., 2010).  
In this MRI protocol, it was not possible to measure true synovial thickening due to the 
lack of gadolinium contrast enhancement. As a marker of inflammation within the 
synovium, the volume of fluid was analysed. Fluid in the knee and ankle joints, at a low 
level, is common amongst the general population, and so high rates of ‘synovitis’ (or 
effusion) were expected in both groups, although higher rates were anticipated in 
patients with psoriasis. McGonagle and colleagues identified that when compared with 
patients with RA, patients with SpA had much greater rates of perientheseal high signal 
(comparable with fluid or oedema) outside the joint (p=0.01) and suggested that new 
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onset synovitis was a common pathological association of entheseal abnormalities in 
PsA and related spondyloarthropathies (McGonagle et al., 1998b). Subclinical synovitis 
has also been reported to occur frequently in SpA-related diseases alongside subclinical 
enthesitis (identified both by ultrasound and MRI), in the absence of clinical joint 
symptoms (Naredo et al., 2011, Emad et al., 2012).  
In this study, 60.7% of patients had evidence of some degree of subclinical synovial 
inflammation at the knee, all of which was mild (grade 1). While high, this was 
significantly lower than that found by Emad and colleagues, where all patients scanned 
had some degree of knee effusion (97.1% mild, 2.1% moderate). The difference between 
these studies is likely to be attributable to the lack of saggital T1-weighted gadolinium-
enhanced fat-saturated views in this MRI protocol (only coronal and axial views were 
captured), which Emad and colleagues used in their 2012 study and others to quantify 
maximal synovial thickness and fluid volume (Emad et al., 2010, Emad et al., 2012, 
Emad et al., 2009). This may have therefore lead to an under-assessment of synovitis in 
this study.  
Previous microarthroscopy studies compared with histopathological findings have shown 
that joint effusion and synovitis can be differentiated through the use of contrast 
enhanced MR study (Ostendorf et al., 2001) and elimination of contrast enhancement is 
shown to result in low specificity for detecting true synovitis (Stomp et al., 2015). Short t 
inversion recovery (STIR) sequences do not differentiate between synovitis and 
physiological joint fluid, which could also have led to an over-reporting of physiological 
fluid as abnormal in the healthy volunteer group and may explain why no significant 
differences were seen between the groups (Rudwaleit et al., 2009). In this study, 59.1% 
of healthy volunteers were assessed to have mild ankle effusion/synovitis, compared 
with no volunteers in the cohort examined by Erdem and colleagues, who included 
saggital T1-weighted spin echo sequences in their protocol (Erdem et al., 2008).  
Aside from the knee, foot and ankle involvement has been reported to occur in 50-70% 
of patients with PsA (Weishaupt et al., 1999, Gladman, 1998) and often develops early 
in the disease (Gladman, 1998). As described in established PsA, this study found that 
inflammation was not only localised within the joint capsule, but also showed 
extracapsular involvement with oedema of the neighbouring soft tissues and occasional 
tenosynovitis. Assessments of tenosynovitis were only made in the foot as it was thought 
that these weight-bearing sites would be the most susceptible to microtrauma and 
therefore be most likely to exhibit subclinical inflammation.  
The MRI assessment of tenosynovitis in patients with psoriasis has been previously 
reported in both the foot and the hand (Erdem et al., 2008, Faustini et al., 2016). In the 
flexor tendons of the hand, Faustini and colleagues observed similar rates of 
tenosynovitis to this study in both psoriasis patients (4% vs. 7.1%) and healthy volunteers 
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(both 0%) (Faustini et al., 2016). In the foot, higher rates were observed by Erdem (19% 
in psoriasis patients, 0% In healthy volunteers), although as discussed, saggital views 
were obtained of the foot and ankle which may have facilitated more accurate 
assessment of early disease (Erdem et al., 2008). In addition, a greater reduction in 
image quality and more off-centre artefact was observed at the extremities, which may 
have reduced the readability of WBMRI compared to images obtained by Erdem et al 
using conventional MRI of the foot and ankle specifically. Similarly, a reduction in image 
quality and a lack of saggital views may have limited assessment of bursitis. Erdem et al 
identified retrocalcaneal bursitis in 50% and retroachilles bursitis in 4% of patients with 
psoriasis, compared with 16.4% and 3.6% in this cohort, respectively. These data 
confirm the work of McGonagle and colleagues in PsA, which show how entheseal 
inflammation, even at the earliest stage, appears to dissipate to surrounding structures 
within the synovio-entheseal complex in patients with psoriatic disease, principally to the 
joint capsule with resultant synovitis but also to perientheseal tendons and bursa 
(McGonagle et al., 2007).  
In terms of chronic damage lesions, erosive changes and enthesophytes appear not to 
be a significant feature associated with subclinical enthesopathy. Structural 
abnormalities were only assessed in the peripheral skeleton at the feet and ankles and 
as expected (given the primacy of joint disease in psoriasis patients), none were found 
in either group. Erdem and colleagues used conventional MRI to assess the feet and 
ankles of patients with psoriasis and found only one of 26 had one bone erosion, and 
enthesophytes were not seen (Erdem et al., 2008). Similarly, in a study of 75 patients 
with early ax-SpA (symptom duration <5 years) assessed by WBMRI, no erosions were 
detected in any patients in the peripheral joints, including the shoulder, pelvis, hip, knee, 
ankle (Achilles and plantar fascia insertions) and mid-foot (Althoff et al., 2007).  
In the spine, the fatty romanus lesion is defined as a diagnostic imaging feature of axial-
SpA (Bennett et al., 2010) and in keeping with this, no lesions were identified in any 
healthy volunteers. Single areas of fatty infiltration have a low diagnostic utility for SpA, 
but three or more lesions are highly diagnostic (Bennett et al., 2009). Fatty replacement 
of the bone marrow was seen at five sites in one patient, which was a surprise in the 
absence of back pain symptoms. Longitudinal follow up of this patient with repeated MRI 
scanning is desirable. No syndesmophytes were seen in any participant, although this is 
not unexpected as MRI is not ideal for showing such lesions. 
For assessment of the SIJs, T1-weighted sequences with fat saturation and T2-weighted 
gradient echo sequences were included in the WBMRI protocol. The ASAS/OMERACT 
MRI group report that while T1-weighted sequences are usually sufficient to detect 
structural lesions (sclerosis, fat deposition and ankylosis), these other sequences may 
better visualise the cartilage in the SIJs, and may therefore be more useful to detect 
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erosions (Rudwaleit et al., 2009). Despite this comprehensive assessment, erosions 
were seen in just two patients and one healthy volunteer, with no sclerosis or ankylosis. 
This was not unexpected as a very low burden of inflammatory disease was seen in 
patients with psoriasis. In the only published study of patients with psoriasis, only two of 
50 patients (both with inflammatory back pain symptoms) showed erosions and 
periarticular sclerosis, which supports the observations in this study. 
It is clear from the results of this study that the presence of subclinical inflammation and 
structural damage in the peripheral and axial skeleton, as detected by WBMRI, is highly 
variable amongst patients with psoriasis and has no relation to the age of onset of 
psoriasis, PASI score or duration of skin disease. Weak associations were found in 
relation to peripheral inflammation score (BMO and STI) and nail psoriasis, in addition 
to a weak association between gluteal cleft disease and the presence of perientheseal 
STI. This is relevant, as it has been suggested that the pattern of psoriasis could serve 
as a cutaneous biomarker for the subsequent development of PsA. In a recent 
prospective cohort study, 464 psoriasis patients were followed up for eight years, and an 
annual incidence rate of 2.7 PsA cases (95% CI 2.1-3.6) per 100 psoriasis patients was 
observed. In multivariate models, psoriatic nail pitting (relative risk [RR] 2.5, p=0.002) 
and the presence of uveitis (RR 31.5, p=0.0002) were associated with the development 
of PsA (Eder et al., 2016). This study followed that of Wilson et al, who performed a 
larger, retrospective analysis of 1633 subjects with psoriasis and found a cumulative 
incidence of 1.7%, 3.1% and 5.1% at 5, 10 and 20 years following psoriasis incidence. 
Psoriasis features associated with higher risk of PsA included nail dystrophy (hazard 
ratio [HR] 2.93, 95% CI 1.68-5.12) and intergluteal lesions (HR 2.35, 95% CI 1.32-4.19) 
(Wilson et al., 2009). While interesting that the same skin sites were found in this study, 
the associations identified were weak and the numbers too low to formally draw 
conclusions relating to targeted WBMRI screening in patients with nail and gluteal cleft 
psoriasis in the dermatology clinic. 
In summary, in agreement with previous prospective studies of patients with PsA 
(Weckbach et al., 2011) and SpA using WBMRI (Song et al., 2011a, Karpitschka et al., 
2013, Althoff et al., 2013), this technique was able to adequately visualise an extensive 
number of entheses, joints, bursae and tendons and allow the assessment of widespread 
inflammation and structural damage in patients with psoriasis and subclinical 
enthesopathy. Readability overall was very good, and through refinements in technique, 
patient placement and coil position, was better than in previously published studies. The 
WBMRI protocol was not designed to visualise the small joints of the hands, and 
additional conventional MRI images would have been required to provide a more 
complete assessment and allow comparison with ultrasound findings, but this would 
have increased the duration of scanning time significantly.  
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A small number of inflammatory abnormalities were observed in healthy volunteers 
(2.8% of peripheral entheses) which is likely to represent an acute response to recent 
microtrauma, although follow-up examinations would have been helpful to confirm 
resolution. Defining clear cut-offs for pathology in future WBMRI studies could be helpful, 
although it would be difficult to define such definitions when changes amongst 
asymptomatic patients are subtle and are of identical morphology to the temporary 
response seen in healthy individuals to localised injury. 
WBMRI assessments did however detect a greater than threefold increase in the number 
of peripheral entheses with BMO or STI in patients with psoriasis, which compliments 
the overall findings of ultrasound examinations in these patients. Comparison between 
WBMRI ultrasound findings at specific entheses is discussed in Chapter 7.4. WBMRI 
permitted extension of the assessment of subclinical enthesopathy beyond the 
peripheral skeleton and demonstrated low levels of inflammation within the spine and to 
a lesser extent, the SIJs. Compared with healthy volunteers, the number of inflammatory 
lesions observed was four times greater in psoriasis patients in in the spine, and three 
times greater in the SIJs. Low levels of subclinical inflammation were observed within 
the surrounding synovio-entheseal complex in both groups, although omission of 
gadolinium contrast enhancement and absence of saggital views of the knee and ankle 
made the differentiation between physiological and pathological synovial fluid, and 
assessment of joint thickness, difficult. Given the primacy of entheseal abnormalities in 
this cohort, it was not unexpected to find very few structural damage abnormalities in 
either group. Longer-term follow up of a larger cohort of asymptomatic psoriasis patients 
without treatment, and healthy volunteers, would be desirable to understand the natural 
evolution of these abnormalities and assess the rate of progression to symptomatic PsA. 
However, this would have been difficult in this cohort as these patients were presenting 
for treatment of moderate to severe psoriasis. Future studies could include patients 
treated with non-immunomodulatory therapies such as acitretin or fumaric acid esters, 
although they are slower to act and less efficacious than systemic immunosuppressants 
and biologic therapies.  
6.6 Conclusion
This is the first study to demonstrate the ability of WBMRI to evaluate subclinical 
peripheral and axial inflammatory and structural damage abnormalities in asymptomatic 
patients with psoriasis. Readability overall was excellent within the spine and sacroiliac 
joints, and good overall in the peripheral skeleton, suggesting WBMRI is a useful tool for 
the rapid assessment of early and evolving psoriatic arthritis.  
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Abnormalities in healthy volunteers have been demonstrated previously, and relate to 
microscopic inflammatory changes occurring as part of the normal healing process at 
sites of microtrauma following mechanical stress. Psoriasis patients had a significantly 
greater frequency of entheseal-related abnormalities in both the peripheral and axial 
skeleton compared with healthy volunteers, although the distinction between what is 
physiological and what is pathological with regard to subtle abnormalities remains a 
challenge, and the omission of gadolinium contrast further compounded this difficulty. 
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Chapter 7  
Response in MRI Appearances of Axial and Peripheral 
Subclinical Enthesopathy to Anti-IL-12/23p40 Therapy for 
Moderate to Severe Psoriasis 
7.1 Introduction 
Due to its sensitivity and reproducibility, conventional MRI has been widely employed in 
research trials to investigate treatment responses in patients with spondyloarthritis (SpA) 
and psoriatic arthritis (PsA) with several studies having shown improvement in 
enthesopathy using MRI following treatment with TNF-inhibitors (Yanaba et al., 2015, 
Anandarajah et al., 2010, Mancarella et al., 2010, Marzo-Ortega et al., 2007, Marzo-
Ortega et al., 2001). MRI is now used routinely in clinical practice to determine treatment 
outcomes alongside clinical examination, and due to the lack of ionising radiation, is 
suitable for repetitive follow-up examinations.  
The international OMERACT MRI in inflammatory arthritis group has developed the 
OMERACT Psoriatic Arthritis Magnetic Resonance Image Scoring System (PsAMRIS) 
to standardise the evaluation of inflammatory and destructive changes in PsA, but this 
score only applies to the hands (Ostergaard et al., 2009, McQueen et al., 2007a). Other 
authors have described scoring systems for bone marrow oedema (BMO), erosions 
and/or synovitis (Tehranzadeh et al., 2008, Anandarajah et al., 2010) at peripheral sites, 
and for fatty infiltration lesions (Pedersen et al., 2013) in the axial skeleton, but these 
have only been used in a few patients and not outside the introducing centre.  
The diagnostic utility of whole body MRI (WBMRI) has been studied by several research 
groups (Appel et al., 2007, Weber et al., 2009, Weckbach et al., 2011) and has been 
shown to be especially useful for detecting early inflammation and structural damage in 
different locations of both the axial skeleton (Weckbach et al., 2011, Althoff et al., 2013, 
Weber et al., 2012) and peripheral joints and entheses (Weckbach et al., 2011, 
Poggenborg et al., 2015a, Althoff et al., 2007, Eshed et al., 2007). Furthermore, its value 
as a tool for assessing disease activity and monitoring treatment effects has been studied 
in patients with axial spondyloarthropathy (ax-SpA) (Song et al., 2011a, Song et al., 
2011b, Karpitschka et al., 2013, Song et al., 2015, Althoff et al., 2016) using etanercept, 
infliximab and sulfasalazine. WBMRI was found to be effective at detecting changes in 
both active inflammatory lesions (osteitis/BMO, soft tissue inflammation (STI), synovitis 
and bursitis) (Appel et al., 2007, Song et al., 2011a, Karpitschka et al., 2013, Song et al., 
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2015, Althoff et al., 2016) and structural changes (fatty lesions in subchondral bone 
marrow) (Song et al., 2011b) at both axial and peripheral sites.  
To date, virtually all studies investigating the efficacy of ustekinumab in psoriatic arthritis 
have used clinical assessment and ultrasound. Only one small (n=20), open-label, proof-
of-concept study has used conventional MRI to assess the axial skeleton in patients with 
symptomatic ankylosing spondylitis, and identified a significant reduction in osteitis after 
24 weeks of therapy in both the sacroiliac joints (SIJs) and spine (Poddubnyy et al., 2013, 
Poddubnyy et al., 2014a). There are no data for conventional MRI or WBMRI in the 
assessment of the peripheral skeleton of patients with PsA following treatment with 
ustekinumab. As described in Chapter 5.1., given the emergence of IL-23 as a key 
mediator in the development of spondyloarthropathy-based, entheseal driven pathology 
(Quinn et al., 2008, Adamopoulos et al., 2011, Sherlock et al., 2012), and the general 
acceptance of enthesitis as the primary pathology in PsA (Benjamin and McGonagle, 
2001), targeting the IL-23/Th17 pathway would therefore seem a logical therapeutic 
approach to circumvent the progression of inflammation and resultant structural damage. 
Although only a few psoriasis patients without arthritis have been studied using MRI, a 
higher frequency of entheseal abnormalities are reported compared to healthy subjects 
(Chapter 6).  These findings suggest that both conventional and whole-body MRI may 
detect PsA before it becomes clinically apparent, and in patients with psoriasis who are 
destined to develop arthritis, this may offer a window of opportunity to potentially prevent 
arthritis evolution with the early introduction of a skin-directed disease-modifying therapy. 
Currently, there are no data published on the potentially positive effects of early biologic 
therapy in patients with psoriasis and subclinical enthesopathy on outcomes in PsA, 
although increasingly it is assumed that results from rheumatoid arthritis trials (which 
support very early intervention to induce remission and radiographic non-progression) 
may be applicable to patients with PsA (Gremese et al., 2013, Bosello et al., 2011, 
Vermeer et al., 2011). 
The aim of this chapter is to investigate the change in active inflammatory lesions and 
structural abnormalities in the axial and peripheral skeleton seen on WBMRI, following 
skin directed treatment with anti-IL-12/IL-12p40 monoclonal antibody therapy in 
asymptomatic patients with psoriasis and subclinical enthesitis. 
7.2 Methods 
7.2.1 Participant Recruitment 
This single-centre proof-of-concept study was conducted entirely at Chapel Allerton 
Hospital (Leeds Teaching Hospitals NHS Trust), with WBMRI performed within the 
Leeds Musculoskeletal Biomedical Research Unit. The study was conducted in 
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accordance with the Declaration of Helsinki and approved by the National Research 
Ethics Committee – Yorkshire and the Humber (Reference 12/YH/0483). Relevant 
approvals were also granted by the Medicines and Healthcare Products Regulatory 
Authority (MHRA) and the Research and Development Unit within Leeds Teaching 
Hospitals NHS Trust (Reference RR12/10234). The University of Leeds accepted the 
duties of Sponsor under The Medicines for Human Use (Clinical Trials) Regulations 2004 
and Amendment (No.2) Regulations 2006. 
7.2.1.1 Sample Size 
No formal power calculations were performed as this was an exploratory proof-of-
concept study. See Chapter 5.2.1. for further details. 
7.2.1.2 Participant Identification and Recruitment 
Twenty-three patients who were recruited to participate in an ultrasound study 
investigating the response of subclinical enthesitis to anti-IL-12/23 p40 therapy in 
patients with moderate to severe psoriasis were also consented to undergo a whole-
body MRI scan during the same appointment attended for each ultrasound scan. Details 
on recruitment to the ultrasound study are described in Chapter 5.2.2.  A standard safety 
patient-completed MRI questionnaire was filled in and reviewed by the radiographer prior 
to every scan (Appendix 10).  
Written consent was obtained from all participants prior to the collection of any clinical or 
imaging data, which permitted the use of data for research purposes and storage. 
Participants were made aware that the WBMRI scans would only be reported for 
abnormalities within the musculoskeletal system, and that pathology in any other bodily 
systems may not be seen and reported. Conversely, they were made aware that gross 
pathology in other systems may be identified, in which instance they were assured they 
would be informed in a timely manner and referred to the appropriate service/specialist 
as appropriate. 
7.2.2 Inclusion/Exclusion Criteria 
7.2.2.1 Inclusion Criteria 
See Chapter 5.2.3.1. 
7.2.2.2 Exclusion Criteria 
See Chapter 5.2.3.2. 
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7.2.3 Drug Therapy 
Chapter 5.2.4. provides information regarding the qualitative and quantitative 
composition, posology, dosing schedule and known adverse reactions for ustekinumab 
(experimental name CNTO1275) in addition to concomitant therapies permitted and 
prohibited during the study. 
7.2.4 Participant Visit Schedule 
After their initial new patient consultation, patients consenting to participate in the trial 
attended for a total of six further study visits at weeks 0, 4, 12, 16, 24 and 52. 
Ustekinumab was administered at weeks 0, 4 and 16 by the candidate (LS), after which 
time patients continued to received 12-weekly injections given by a dedicated nurse 
through the BUPA™ Healthcare at Home scheme (Chapter 5.2.5). MRI scans were 
carried in the Leeds Musculoskeletal Biomedical Research Unit at Chapel Allerton 
Hospital at weeks 0, 24 and 52 either immediately before or after their ultrasound scan. 
The full study schedule can be found in Table 5.2. All visits took place within seven days 
of the scheduled date. 
7.2.5 Data Collection 
All data collection was carried out by the candidate (LS).  Magnetic resonance image 
acquisition and storage was undertaken by an experienced MRI/research radiographer 
(RE) proficient in performing WBMRI, within the Leeds Musculoskeletal Biomedical 
Research Unit (LMBRU) at Chapel Allerton Hospital.  
Clinical data obtained in the consultation was recorded on a case report form (CRF) and 
then transcribed into an encrypted password-protected database on the University of 
Leeds computer server for analysis. Further information on the type of clinical data 
captured is described in Chapter 5.2.6. Care was taken to ensure the check integrity of 
the dataset at upload. Paper record forms are stored in a locked filing cabinet within a 
locked room within Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM) 
at Chapel Allerton Hospital, in accordance with the University’s Information Security 
Policy.  Magnetic resonance images were stored in a password-protected database and 
analysed using OsiriX DICOM viewer. 
7.2.6 Clinical Assessment 
7.2.6.1 Psoriasis Severity and Impact 
The severity and impact of psoriasis was assessed at weeks 0, 4, 12, 24 and 52. Details 
of the assessments are as described in Chapter 5.2.7.1. 
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7.2.6.2 Psoriatic Arthritis 
All accessible peripheral joints were visually examined for swelling and tenderness at 
weeks 0, 4, 12, 24 and 52. Attempts were also made to elicit tenderness at several 
entheseal points, in addition to assessment for features of dactylitis. Further detail is 
provided in Chapter 5.2.7.2. In addition, Schober’s test was carried out at each clinical 
visit to determine patient spinal flexibility.   
7.2.7 Laboratory Assessment 
Safety monitoring was undertaken in line with standard NHS care procedures and the 
NICE guidelines for any patient taking a biologic therapy. Monitoring blood samples were 
analysed at weeks 0, 4, 12, 24 and 52 in the NHS laboratories within Leeds Teaching 
Hospitals Trust.  In addition, anti-CCP antibody and rheumatoid factor were tested 
alongside two genetic risk alleles for psoriatic arthritis (HLA-Cw06 and HLA-B27). 
Further detail is provided in Chapter 5.2.8. 
7.2.8 Whole Body Magnetic Resonance Imaging (WBMRI) 
7.2.8.1 WBMRI Protocol  
The WBMRI protocol and technical parameters are described in detail in Chapter 6.2.5.1. 
Gadolinium contrast was not given. A combination of T1-weighted (turbo spin echo) and 
short τ inversion recovery (STIR) sequences were performed in a total of 7 stations: 
• Coronal slice orientation (shoulders, costochondral joints, hips and knees) 
• Coronal oblique orientation (SIJs) 
• Sagittal orientation (cervicothoracic and thoracolumbar spine) 
• Axial orientation (knees and feet) 
T2 ‘fat sat’ sequences were also performed with coronal oblique orientation for the SIJs. 
Total scan time was 55 minutes and was generally well tolerated by participants. 
7.2.8.2 WBMRI Interpretation 
WBMRI were evaluated by a highly experienced rheumatologist (DMcG) experienced 
with the analysis of WBMRI, who was blinded to all clinical, biochemical and 
demographic information. The images were evaluated together on a patient basis at the 
end of the trial, but in a random time order. As a safety measure, the images were also 
reviewed by a NHS musculoskeletal radiologist (PO) within 48 hours of each scan to 
ensure no gross abnormalities or concerning features were present that required 
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immediate attention. These analyses did not form part of the WBMRI assessments for 
the trial and were not available to the rheumatologist (DMcG). 
Readability of the scans was assessed for each enthesis as ‘readable’ or ‘not readable’ 
(e.g. due to artefacts) or ‘not in field of view (FOV)’. All images were analysed for active 
inflammatory lesions and structural changes at axial (spine and SIJs) and non-axial 
(peripheral) sites.  
7.2.8.2.1 Non-axial (peripheral) sites 
Images of the peripheral skeleton were assessed for the presence of enthesitis, 
comprising of both active inflammation (BMO and adjacent STI) and structural 
abnormalities (erosions and enthesophytes in adjacent bones). Additional findings within 
the surrounding synovio-entheseal complex were also assessed (synovitis, bursitis, 
tenosynovitis).  
The severity of all abnormalities was scored from 0-3 with the exception of erosions and 
enthesophytes (scored 0 or 1, absent or present). Abnormalities must have been visible 
in at least two consecutive slices to be scored. Comparison with the opposite site was 
made for paired entheses.  In total, 45 sites were scored for BMO and STI, 16 sites for 
synovitis/effusion, 12 sites for bursitis, 8 sites for erosions and 4 sites for enthesophytes 
on each WBMRI at each time point.  Further detail on the assessment of peripheral sites 
and scoring is described in Chapter 6.2.5.2.1. and Table 6.2. 
7.2.8.3 Axial Sites 
The spine was divided into 23 individual vertebral units (VU) extending from C2/3 to 
L5/S1. Each VU within the spine was evaluated separately in the ventral part (vertebral 
body) and posterior elements (pedicles, facet joints and spinous processes).  The SIJs 
were evaluated at a quadrant level (upper and lower iliac parts, and upper and lower 
sacral parts) as shown in Figure 6.1.  
Images of the axial skeleton were scored for activity using the Berlin modification of the 
AS spine MRI score, which encompasses inflammatory abnormalities (BMO) and 
structural changes (fatty bone marrow infiltration, erosions and bone proliferation) (table 
6.3). Abnormalities must have been visible in at least two consecutive slices to be scored. 
In accordance with published scoring techniques (Althoff et al., 2013), each SIJ was 
scored from 0-24 (0-3 for each upper and lower ilium, and each upper and lower sacrum) 
for BMO and erosions, and 0-8 for fatty infiltration, sclerosis and ankylosis. In the spine, 
BMO, erosions, bone marrow fatty infiltration and bone proliferation were scored from 0 
to 69 (0-3 in each of 23 VUs), and 0 to 46 (0-2 in each VU) for posterior segment 
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inflammation.   The definitions of each MRI abnormality within the spine and SIJs are 
given in Chapter 6.2.5.3.1. (spine) and Chapter 6.2.5.3.2. (SIJs).  
7.3 Statistical Analysis 
Descriptive statistics were used primarily throughout, although some exploratory 
analyses were performed. Results for categorical data are expressed as frequencies and 
percentages, and continuous variables are given as means (standard deviation, s.d.) or 
medians (interquartile range, IQR), depending on the distribution. c2 test was used to 
explore associations between categorical variables. Differences in the frequencies of 
each MRI abnormality in each patient at each time point were assessed using Student’s 
paired t-tests. Differences in the median total scores for each MRI abnormality were 
analysed using Wilcoxon signed-rank tests. p values <0.05 were regarded as statistically 
significant, although results were considered exploratory and would require confirmation 
in a fully powered study. Statistical analysis was performed using IBM© SPSS© version 
24.0. 
Missing values, were a joint was within the field of view but unreadable, were considered 
to have no abnormality (assumed score of zero) when calculating mean overall scores 
for each MRI abnormality. In a sensitivity analysis, tests were repeated assuming these 
joints all had the maximum possible score for the relevant abnormalities and there was 
no change to the overall trends observed. Multiple imputation analysis was not feasible 
due to the large number of joints relative to the number of patients, which caused 
imputation models to fail to converge.  
7.4 Results 
23 patients were recruited to participate in the study. 23 patients reached the primary 
endpoint of week 24, and 20 reached the secondary endpoint of week 52.  
7.4.1 Patient Characteristics 
A full description of the distribution of demographic attributes within the cohort of 23 
patients (age, gender, skin type, BMI, smoking status and alcohol consumption) is 
provided in Chapter 5.4.1. Details are also provided about the median age of onset of 
psoriasis symptoms and the duration of disease, in addition to any family history of 
psoriatic, musculoskeletal and autoimmune disease, co-morbidities and concomitant 
medications.  
 
 337 
7.4.2 Laboratory Assessment 
Serological assessment was satisfactory in all participants at baseline to allow 
commencement of the IMP. Fluctuations over time were rarely outside normal 
parameters, those that where are discussed in Chapter 5.4.2. No patients were required 
to withdraw from the study due to serological abnormalities. All patients were negative 
for rheumatoid factor, anti-CCP antibody and ANA, and remained so throughout the 
study. One patient was positive for the HLA-B27 allele, and 15 patients (65.2%) were 
positive for HLA-Cw06. 
7.4.3 Adverse Events 
Two serious adverse events (SAEs) were reported to the Sponsor (University of Leeds) 
and the manufacturer (Janssen Pharmaceutica) during the trial. One was not related to 
the IMP (road traffic accident resulting in hospitalisation) and for the second, causation 
was uncertain but may have been related to the IMP (abdominal abscess requiring 
hospitalisation). The latter was reported to the MHRA through the yellow card scheme. 
Ten mild and self-limiting adverse events were also recorded and included upper 
respiratory tract infections (common expected AE, related to IMP), tiredness (common 
expected AE, related to IMP), follicular abnormalities (unexpected AE, uncertain 
relationship to IMP, reported to MHRA by yellow card scheme) and shoulder trauma 
(unexpected AE, not related to the IMP). Chapter 5.4.3. provided further detail.  
7.4.4 Clinical Outcomes 
7.4.4.1 Skin Disease 
Baseline PASI scores ranged from 10.4 to 38.4 (median 18.0 [13.4, 28.4]), with a median 
BSA of 30% (15%, 40%). By week 24, median PASI had reduced to 0.6 (0, 2.5) and BSA 
to 1% (0%, 3%), and by week 52, median PASI was 0.1 (0, 2.93) and BSA 0.5% (0%, 
2.75%). A further description can be found in Chapter 5.4.4.1., and Table 5.3. shows the 
distribution and frequency of psoriasis lesions for each anatomical site at each time point. 
7.4.4.2 Nail Disease 
17 patients had nail involvement (pitting, onycholysis and/or crumbling) at baseline. 
Changes in modified Nail Psoriasis Severity Index (mNAPSI) scores can be found in 
Chapter 5.4.4.2. 
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7.4.5 Readability of MRI 
7.4.5.1 Non-Axial (Peripheral) Sites  
7.4.5.1.1 Entheses 
The readability for individual entheses at each time point is shown in Table 7.1. WBMRI 
allowed evaluation of 964 of 1035 (93.1%) entheses within the peripheral skeleton of 23 
patients at week 0, 971 of 1035 (93.8%) entheses in 23 patients at week 24 and 844 of 
900 (93.8%) entheses in 20 patients at week 52. The remaining entheses were within 
the field of view (FOV) but not readable (due to insufficient image quality, movement 
artefact and off-centre artefact). Overall, 6.4% of entheses could not be read on all 
WBMRI analysed. No entheseal sites were outside the FOV as the elbows, wrists and 
hands were not included in the protocol, and a specific coil was used to capture images 
of the feet and ankles.  
For the purposes of comparison between time points, 914 of 1035 (88.3%) entheses 
were within FOV and readable at both week 0 and 24, and 790 of 900 (87.8%) at both 
week 0 and 52.  All pelvic, greater trochanter, Achilles tendon and plantar fascia tendon 
entheses could be assessed in ³95% of participants. Readability was poorest in the 
chest (7th costochondral joint, 78-88% and 1st costochondral syndchondrosis, 83-90% 
readability), first metatarsophalangeal joint (75%-91% readability) and at the knee 
(lateral femoral condyle, 80-90%; medial femoral condyle, 80-90%; quadriceps insertion, 
80%-91%; intracondylar notch, 80-93%; patella ligament insertion, 85-95% readability). 
Lack of saggital slices are likely to account for the reduction in readability of the knee 
entheses. 
 W
eek 0 (n=23) 
W
eek 24 (n=23) 
W
eek 52 (n=20) 
In FOV and 
readable 
n/23(%) 
In FOV, but not 
readable n/23(%) 
In FOV and 
readable 
n/46(%) [*n/23(%)] 
In FOV, but not 
readable 
n/46(%) [*n/23(%)] 
In FOV and 
readable 
n/23(%) 
In FOV, but not 
readable n/23(%) 
In FOV and 
readable 
n/46(%) [*n/23(%)] 
In FOV, but not 
readable 
n/46(%) [*n/23(%)] 
In FOV and 
readable 
n/20(%) 
In FOV, but not 
readable n/20(%) 
In FOV and 
readable 
n/40(%) [*n/20(%)] 
In FOV, but not 
readable 
n/40(%) [*n/20(%)] 
N
o. of patients 
N
o. of entheses 
N
o. of patients 
N
o. of entheses 
N
o. of patients 
N
o. of entheses 
Supraspinate tendon insertion at hum
eral tuberosity 
21 (91) 
2 (9) 
44 (96) 
2 (4) 
20 (87) 
3 (13) 
43 (93) 
3 (7) 
19 (95) 
1 (5) 
39 (98) 
1 (2) 
Acrom
ioclavicular joint 
21 (91) 
2 (9) 
44 (96) 
2 (4) 
22 (96) 
1 (4) 
45 (98) 
1 (2) 
18 (90) 
2 (10) 
38 (95) 
2 (5) 
C
oracoid process 
21 (91) 
2 (9) 
44 (96) 
2 (4) 
22 (96) 
1 (4) 
45 (98) 
1 (2) 
19 (95) 
1 (5) 
39 (98) 
1 (2) 
Sternoclavicular joint 
20 (87) 
3 (13) 
40 (87) 
6 (13) 
19 (83) 
4 (17) 
41 (89) 
5 (11) 
18 (90) 
2 (10) 
37 (93) 
3 (7) 
1
st costochondral synchondrosis 
19 (83) 
4 (17) 
39 (85) 
7 (15) 
19 (83) 
4 (17) 
41 (89) 
5 (11) 
17 (85) 
3 (15) 
36 (90) 
2 (5) 
7
th costochondral joint 
18 (78) 
5 (22) 
36 (78) 
10 (22) 
19 (83) 
4 (17) 
38 (83) 
8 (17) 
17 (85) 
3 (15) 
35 (88) 
5 (12) 
M
anubriosternal joint* 
20 (87) 
3 (13) 
20 (87) 
3 (13) 
22 (96) 
1 (4) 
22 (96) 
1 (4) 
19 (95) 
1 (5) 
19 (95) 
1 (5) 
Iliac crest 
23 (100) 
0 (100) 
46 (100) 
0 (0) 
23 (100) 
0 (0) 
46 (100) 
0 (0) 
20 (100) 
0 (0) 
40 (100) 
0 (0) 
Anterior superior iliac spine 
23 (100) 
0 (0) 
46 (100) 
0 (0) 
23 (100) 
0 (0) 
46 (100) 
0 (0) 
20 (100) 
0 (0) 
40 (100) 
0 (0) 
Ischial tuberosity 
23 (100) 
0 (0) 
46 (100) 
0 (0) 
23 (100) 
0 (0) 
46 (100) 
0 (0) 
20 (100) 
0 (0) 
40 (100) 
0 (0) 
 W
eek 0 (n=23) 
W
eek 24 (n=23) 
W
eek 52 (n=20) 
In FOV and 
readable 
n/23(%) 
In FOV, but not 
readable n/23(%) 
In FOV and 
readable 
n/46(%) [*n/23(%)] 
In FOV, but not 
readable 
n/46(%) [*n/23(%)] 
In FOV and 
readable 
n/23(%) 
In FOV, but not 
readable n/23(%) 
In FOV and 
readable 
n/46(%) [*n/23(%)] 
In FOV, but not 
readable 
n/46(%) [*n/23(%)] 
In FOV and 
readable 
n/20(%) 
In FOV, but not 
readable n/20(%) 
In FOV and 
readable 
n/40(%) [*n/20(%)] 
In FOV, but not 
readable 
n/40(%) [*n/20(%)] 
N
o. of patients 
N
o. of entheses 
N
o. of patients 
N
o. of entheses 
N
o. of patients 
N
o. of entheses 
Pubic sym
physis 
22 (96) 
1 (4) 
45 (98) 
1 (2) 
23 (100) 
0 (0) 
46 (100) 
0 (0) 
20 (100) 
0 (0) 
40 (100) 
0 (0) 
G
reater trochanter 
23 (100) 
0 (0) 
46 (100) 
0 (0) 
23 (100) 
0 (0) 
46 (100) 
0 (0) 
20 (100) 
0 (0) 
40 (100) 
0 (0) 
Lateral fem
oral condyle 
20 (87) 
3 (13) 
40 (87) 
6 (13) 
19 (83) 
4 (17) 
39 (85) 
7 (15) 
16 (80) 
4 (20) 
36 (90) 
4 (10) 
M
edial fem
oral condyle 
21 (91) 
2 (9) 
43 (93) 
3 (7) 
20 (87) 
3 (13) 
42 (91) 
4 (9) 
16 (80) 
4 (20) 
36 (90) 
4 (10) 
Lateral tibial plateau 
22 (96) 
1 (4) 
44 (96) 
2 (4) 
20 (87) 
3 (13) 
41 (89) 
5 (11) 
16 (80) 
4 (20) 
36 (90) 
4 (10) 
Intracondylar notch 
21 (91) 
2 (9) 
43 (93) 
3 (7) 
20 (87) 
3 (13) 
41 (89) 
5 (11) 
16 (80) 
4 (20) 
36 (90) 
4 (10) 
Patella ligam
ent insertion into patella 
20 (87) 
3 (13) 
41 (89) 
5 (11) 
20 (87) 
3 (13) 
40 (87) 
6 (13) 
18 (85) 
2 (15) 
38 (95) 
2 (5) 
Q
uadriceps insertion into patella 
20 (87) 
3 (13) 
42 (91) 
4 (9) 
20 (87) 
3 (13) 
42 (91) 
4 (9) 
16 (80) 
4 (20) 
36 (90) 
4 (10) 
Ankle joint attachm
ents 
20 (87) 
3 (13) 
42 (91) 
4 (9) 
21 (91) 
2 (9) 
43 (93) 
3 (7) 
18 (85) 
2 (15) 
36 (90)  
4 (10) 
1
st Tarsom
etatarsal Joint 
21 (91) 
2 (9) 
43 (93) 
3 (7) 
21 (91) 
2 (9) 
44 (96) 
2 (4) 
18 (85) 
2 (15) 
36 (90) 
4 (10) 
 W
eek 0 (n=23) 
W
eek 24 (n=23) 
W
eek 52 (n=20) 
In FOV and 
readable 
n/23(%) 
In FOV, but not 
readable n/23(%) 
In FOV and 
readable 
n/46(%) [*n/23(%)] 
In FOV, but not 
readable 
n/46(%) [*n/23(%)] 
In FOV and 
readable 
n/23(%) 
In FOV, but not 
readable n/23(%) 
In FOV and 
readable 
n/46(%) [*n/23(%)] 
In FOV, but not 
readable 
n/46(%) [*n/23(%)] 
In FOV and 
readable 
n/20(%) 
In FOV, but not 
readable n/20(%) 
In FOV and 
readable 
n/40(%) [*n/20(%)] 
In FOV, but not 
readable 
n/40(%) [*n/20(%)] 
N
o. of patients 
N
o. of entheses 
N
o. of patients 
N
o. of entheses 
N
o. of patients 
N
o. of entheses 
1
st M
etatarsophalangeal Joint  
19 (83) 
4 (17) 
38 (83) 
8 (17) 
21 (91) 
2 (9) 
42 (91) 
4 (9) 
15 (75) 
5 (25) 
34 (85) 
6 (15) 
Achilles tendon insertion 
23 (100) 
0 (0) 
46 (100) 
0 (0) 
23 (100) 
0 (0) 
46 (100) 
0 (0) 
19 (95) 
1 (5) 
38 (95) 
2 (5) 
Plantar Fascia at calcaneus 
23 (100) 
0 (0) 
46 (100) 
0 (0) 
23 (100) 
0 (0) 
46 (100) 
0 (0) 
19 (95) 
1 (5) 
39 (98) 
1 (2) 
Table 7.1. W
BM
R
I readability at 45 entheseal sites in the peripheral skeleton at each tim
e point 
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7.4.5.1.2 Bursae 
The readability of WBMRI for the assessment of individual bursae is shown in Table 7.2. 
WBMRI allowed the evaluation of 273 of 276 (98.9%) bursae in 23 patients at week 0, 
266 of 276 (96.4%) bursae in 23 patients at week 24 and 232 of 240 (96.7%) bursae in 
20 patients at week 52. The remaining bursae were within FOV but nor readable. Overall, 
2.7% of bursae could not be read on all WBMRI analysed. 
For the purposes of comparison between time points, 263 of 276 (95.3%) of bursae were 
within the FOV and readable at both week 0 and 24, and 230 of 240 (95.8%) at both 
week 0 and 52. The most difficult anatomical site to assess for bursitis was the knee, but 
readability was still good, with 94-98% of pre-patellar bursae and 95-98% of pes anserine 
bursae readable. 
7.4.5.1.3 Synovial Joints and Tendons 
The readability of WBMRI for the evaluation of synovial joints is shown in Table 7.3.  At 
some sites, assessment of synovial fluid was possible where it was not possible to see 
the entheseal insertion. WBMRI allowed evaluation of 358 of 368 (97.3%) synovial joints 
in 23 patients at week 0, 355 of 368 (96.5%) joints in 23 patients at week 24 and 309 of 
320 (96.6%) joints in 20 patients at week 52. Overall, 3.2% of synovial joints could not 
be read on all WBMRI analysed. 
For the purposes of comparison between time points, 345 of 368 (93.8%) joints could be 
visualised and read at both week 0 and 24 and 301 of 320 (94.1%) joints at both week 0 
and 52. The most difficult site to analyse was the first metatarsophalangeal joint in the 
foot, although readability was still good with analysis possible in 91% to 94% of joints. 
Readability was best at the hip and ankle, followed by the knee.  
The lateral and medial tendons of the midfoot were within the FOV and readable in all 
patients at each time point. In total, 92 tendons in 23 patients were assessed for 
tenosynovitis at week 0 and 24, and 80 tendons were assessed in 20 patients at week 
52. 
7.4.5.1.4 Enthesophytes and Erosions 
The readability of WBMRI for assessment of structural abnormalities overall was 
excellent, as shown in Table 7.4. For erosions, WBMRI allowed evaluation of 178 of 184 
(96.7%) sites in 23 patients at week 0, 176 of 184 (95.7%) sites in 23 patients at week 
24 and 151 of 160 (94.4%) sites in 20 patients at week 52. For enthesophytes, WBMRI 
allowed assessment of all 92 sites in 23 patients at week 0 and 24, and in 77 of 80 
(96.3%) of sites at week 52.  The remaining sites were within FOV but not readable.
  
W
eek 0 
W
eek 24 
W
eek 52 
In FOV and 
readable n/23 (%) 
In FOV, but not 
readable n/23 (%) 
In FOV and 
readable n/46 (%) 
In FOV, but not 
readable n/46 (%) 
In FOV and 
readable n/23 (%) 
In FOV, but not 
readable n/23 (%) 
In FOV and 
readable n/46 (%) 
In FOV, but not 
readable n/46 (%) 
In FOV and 
readable n/20 (%) 
In FOV, but not 
readable n/20 (%) 
In FOV and 
readable n/40 (%) 
In FOV, but not 
readable n/40 (%) 
N
o. of Patients 
N
o. of B
ursae 
N
o. of Patients 
N
o. of B
ursae 
N
o. of Patients 
N
o. of B
ursae 
Subacrom
ial bursae 
22 (96) 
1 (4) 
44 (96) 
2 (4) 
23 (100) 
0 (0) 
45 (98) 
1 (2) 
19 (95) 
1 (5) 
39 (98) 
1 (2) 
G
reater trochanteric bursae 
23 (100) 
0 (0) 
46 (100) 
0 (0) 
23 (100) 
0 (0) 
46 (100) 
0 (0) 
20 (100) 
0 (0) 
40 (100) 
0 (0) 
Pre-patellar bursae 
22 (96) 
1 (4) 
45 (98) 
1 (2) 
22 (96) 
1 (4) 
43 (94) 
3 (7) 
18 (90) 
2 (10) 
38 (95) 
2 (5) 
Pes anserine bursae 
23 (100) 
0 (0) 
45 (98) 
1 (2) 
22 (96) 
1 (4) 
44 (96) 
2 (4) 
19 (95) 
1 (5) 
38 (95) 
2 (5) 
Achilles bursae 
23 (100) 
0 (0) 
46 (100) 
0 (0) 
22 (96) 
1 (4) 
44 (96) 
2 (4) 
19 (95) 
1 (5) 
38 (95) 
2 (5) 
R
etrocalcaneal bursae 
23 (100) 
0 (0) 
46 (100) 
0 (0) 
22 (96) 
1 (4) 
44 (96) 
2 (4) 
19 (95) 
1 (5) 
39 (98) 
1 (2) 
Table 7.2. W
BM
R
I readability at 12 bursae in the peripheral skeleton at each tim
e point 
 
 W
eek 0 
W
eek 24 
W
eek 52 
In FOV and 
readable n/23(%) 
In FOV, but not 
readable n/23 (%) 
In FOV and 
readable n/46(%) 
In FOV, but not 
readable n/46 (%) 
In FOV and 
readable n/23(%) 
In FOV, but not 
readable n/23 (%) 
In FOV and 
readable n/46(%) 
In FOV, but not 
readable n/46 (%) 
In FOV and 
readable n/20(%) 
In FOV, but not 
readable n/20 (%) 
In FOV and 
readable n/40(%) 
In FOV, but not 
readable n/40 (%) 
N
o. of Patients 
N
o. of Joints 
N
o. of Patients 
N
o. of Joints 
N
o. of Patients 
N
o. of Joints 
Sternoclavicular joints 
21 (91) 
2 (9) 
44 (96) 
2 (4) 
21 (91) 
2 (9) 
43 (94) 
3 (6) 
18 (90) 
2 (10) 
37 (93) 
3 (7) 
Acrom
ioclavicular joints 
21 (91) 
2 (9) 
44 (96) 
2 (4) 
22 (96) 
1 (4) 
45 (98) 
1 (2) 
18 (90) 
2 (10) 
38 (95) 
2 (5) 
Shoulder joints 
22 (96) 
1 (4) 
45 (98) 
1 (2) 
22 (96) 
1 (4) 
45 (98) 
1 (2) 
19 (95) 
1 (5) 
39 (98) 
1 (2) 
H
ip joints 
23 (100) 
0 (0) 
46 (100) 
0 (0) 
23 (100) 
0 (0) 
46 (100) 
0 (0) 
20 (100) 
0 (0) 
40 (100) 
0 (0) 
Knee joints 
23 (100) 
0 (0) 
46 (100) 
0 (0) 
23 (100) 
0 (0) 
46 (100) 
0 (0) 
19 (95) 
1 (5) 
39 (98) 
1 (2) 
Ankle joints 
23 (100) 
0 (0) 
46 (100) 
0 (0) 
23 (100) 
0 (0) 
46 (100) 
0 (0) 
20 (100) 
0 (0) 
40 (100) 
0 (0) 
Tarsom
etatarsal joints 
21 (91) 
2 (9) 
44 (96) 
2 (4) 
21 (91) 
2 (9) 
44 (96) 
2 (4) 
19 (95) 
1 (5) 
39 (98) 
1 (2) 
M
etatarsophalangeal joints 
21 (91) 
2 (9) 
43 (94) 
3 (6) 
20 (87) 
3 (13) 
42 (91) 
4 (9) 
18 (90) 
2 (10) 
37 (93) 
3 (7) 
Table 7.3. W
BM
R
I readability at 16 synovial joints in the peripheral skeleton at each tim
e point 
 W
eek 0 
W
eek 24 
W
eek 52 
In FOV and 
readable n/23 (%) 
In FOV, but not 
readable n/23 (%) 
In FOV and 
readable n/46 (%) 
In FOV, but not 
readable n/46 (%) 
In FOV and 
readable n/23 (%) 
In FOV, but not 
readable n/23 (%) 
In FOV and 
readable n/46 (%) 
In FOV, but not 
readable n/46 (%) 
In FOV and 
readable n/20 (%) 
In FOV, but not 
readable n/20 (%) 
In FOV and 
readable n/40 (%) 
In FOV, but not 
readable n/40 (%) 
N
o. of Patients 
N
o. of Joints 
N
o. of Patients 
N
o. of Joints 
N
o. of Patients 
N
o. of Joints 
1
st Tarsom
etatarsal joint (erosions only) 
21 (91) 
2 (9) 
43 (94) 
3 (6) 
21 (91) 
2 (9) 
44 (96) 
2 (4) 
18 (90) 
2 (10) 
37 (93) 
3 (7) 
1
st M
etatarsophalangeal joint (erosions only) 
21 (91) 
2 (9) 
43 (94) 
3 (6) 
20 (87) 
3 (13) 
40 (87) 
6 (13) 
18 (90) 
2 (10) 
37 (93) 
3 (7) 
Achilles tendon insertion into calcaneus (erosions and enthesophytes) 
23 (100) 
0 (0) 
46 (100) 
0 (0) 
23 (100) 
0 (0) 
46 (100) 
0 (0) 
19 (95) 
1 (5) 
38 (95) 
2 (5) 
Plantar fascia insertion into calcaneus (erosions and enthesophytes) 
23 (100) 
0 (0) 
46 (100) 
0 (0) 
23 (100) 
0 (0) 
46 (100) 
0 (0) 
19 (95) 
1 (5) 
39 (98) 
1 (2) 
Table 7.4. W
BM
R
I readability of 8 sites of potential erosions and 4 sites of potential enthesophytes in the peripheral skeleton at each tim
e point. 
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7.4.5.2 Spine and Sacroiliac Joints 
Full evaluation of all 23 vertebral units and 8 sacroiliac joint quadrants was possible in 
all participants at each time point. 
7.4.6 MRI Abnormalities 
7.4.6.1 Non-axial (Peripheral) Skeleton 
7.4.6.1.1 Active Inflammation (Bone Marrow Oedema and Soft Tissue 
Inflammation) 
Bone marrow oedema (BMO) and soft tissue inflammation (STI) were assessed at 45 
entheseal sites in each participant at each time point. At week 0, 43/964 (4.5%) readable 
entheses demonstrated BMO, and this remained relatively unchanged after 24 weeks 
(44/971, 4.5%), and 52 weeks (40/804, 4.7%) of treatment. STI also did not change 
significantly with ustekinumab therapy, affecting 55/964 (5.7%) of entheses at week 0, 
56/971 (5.8%) at week 24 and 49/804 (6.1%) at week 52.  
Throughout the study, all patients had at least one inflammatory lesion (BMO, STI or 
both) at every time point. 19/23 had at least one BMO lesion at week 0, 18/23 at week 
24 and 14/20 at week 52. 21/23 had at least one STI lesion at weeks 0 and 24, and 18/20 
at week 52.  
As found in the previous chapter, BMO and STI occurred infrequently in the same 
enthesis. 17 of 23 patients at week 0 had both lesions of BMO and STI, of which only 
five had BMO and STI at the same site (supraspinate tendon insertion at the humeral 
tuberosity and plantar fascia). 16 of 23 patients at week 24 and 12 of 20 patients at week 
52 also had lesions of both BMO and STI, of which only 5 and 4 patients respectively 
had simultaneous BMO and STI in the same enthesis. 
The mean number of lesions per patient was static over time for both BMO and STI. 
Patients had between 0 and 8 BMO lesions and 0 and 6 STI lesions at every time point. 
The mean (±s.d.) number of BMO lesions per patient was 1.83 ±1.75 at week 0, 1.91 
±1.86 at week 24 and 1.74 ±2.05 at week 52. The average number of STI lesions per 
patient was 2.30 ±1.40 at week 0, 2.43 ±1.47 at week 24 and 2.13 ±2.05 at week 52. 
The overall burden of inflammation (BMO and STI) remained unchanged with treatment, 
as shown in Figure 7.1.  
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Figure 7.1. Mean (and s.d.) number of inflammatory lesions (BMO and STI) per patient 
at each time point in the peripheral skeleton. 
Comparison of the frequency of BMO and STI at each specific enthesis between weeks 
0 and the primary endpoint (week 24) is shown in Table 7.5. An identical comparison 
between weeks 0 and 52 is shown in Table 7.6. Treatment with ustekinumab for up to 
one year did not significantly reduce the number of inflammatory lesions identified at any 
site. However, subclinical inflammation is expected to advance without treatment, and 
progression does therefore appear to have been limited.   
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W
eek 0 
W
eek 
24 
G
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diff (p=) 
W
eek 0 
W
eek 
24 
G
roup 
diff (p=) 
W
eek 0 
W
eek 
24 
G
roup 
diff (p=) 
W
eek 0 
W
eek 
24 
G
roup 
diff (p=) 
Supraspinate tendon insertion at hum
eral tuberosity 
12 (27.3) 
13 (30.2) 
0.760 
4 (9.1) 
4 (9.3) 
0.973 
11 (52.4) 
12 (60.0) 
0.623 
4 (19.0) 
4 (20.0) 
0.939 
Acrom
ioclavicular joint 
6 (13.6) 
6 (13.3) 
0.967 
0 (0.0) 
0 (0.0) 
N
A 
4 (19.0) 
4 (18.2) 
0.942 
0 (0.0) 
0 (0.0) 
N
A 
C
oracoid process 
1 (2.3) 
0 (0.0) 
0.309 
0 (0.0) 
0 (0.0) 
N
A 
1 (4.8) 
0 (0.0) 
0.300 
0 (0.0) 
0 (0.0) 
N
A 
Sternoclavicular joint 
1 (2.5) 
1 (2.4) 
0.986 
0 (0.0) 
0 (0.0) 
N
A 
1 (5.0) 
1 (5.3) 
0.970 
0 (0.0) 
0 (0.0) 
N
A 
1
st costochondral process 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
7
th costochondral joint 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
M
anubriosternal joint 
2 (10.0) 
1 (4.5) 
0.493 
0 (0.0) 
0 (0.0) 
N
A 
2 (10.0) 
1 (4.5) 
0.493 
0 (0.0) 
0 (0.0) 
N
A 
Iliac crest 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
Anterior superior iliac spine 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
Ischial tuberosity 
0 (0.0) 
0 (0.0) 
N
A 
3 (6.5) 
3 (6.5) 
1.000 
0 (0.0) 
0 (0.0) 
N
A 
2 (8.7) 
2 (8.7) 
1.000 
Pubic sym
physis 
2 (4.4) 
1 (2.2) 
0.544 
0 (0.0) 
0 (0.0) 
N
A 
2 (9.1) 
1 (4.3) 
0.524 
0 (0.0) 
0 (0.0) 
N
A 
G
reater trochanter 
0 (0.0) 
1 (2.2) 
0.315 
26 (56.5) 
27 (58.7) 
0.833 
0 (0.0) 
1 (4.3) 
0.312 
15 (65.2) 
15 (65.2) 
1.000 
Lateral fem
oral condyle 
0 (0.0) 
1 (2.6) 
0.308 
1 (2.5) 
0 (0.0) 
0.320 
0 (0.0) 
1 (5.3) 
0.295 
1 (5.0) 
0 (0.0) 
0.323 
M
edial fem
oral condyle 
0 (0.0) 
2 (4.8) 
0.148 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
1 (5.0) 
0.300 
0 (0.0) 
0 (0.0) 
N
A 
Lateral tibial plateau 
0 (0.0) 
0 (0.0) 
N
A 
1 (2.3) 
1 (2.4) 
0.960 
0 (0.0) 
0 (0.0) 
N
A 
1 (4.5) 
1 (5.0) 
0.945 
Intracondylar notch 
7 (16.3) 
7 (17.1) 
0.922 
0 (0.0) 
0 (0.0) 
N
A 
5 (23.8) 
5 (25.0) 
0.929 
0 (0.0) 
0 (0.0) 
N
A 
Patella ligam
ent insertion into patella 
4 (9.8) 
4 (10.0) 
0.971 
8 (19.5) 
9 (22.5) 
0.741 
2 (10.0) 
2 (10.0) 
1.000 
6 (30.0) 
6 (30.0) 
1.000 
Q
uadriceps tendon insertion into patella 
0 (0.0) 
0 (0.0) 
N
A 
2 (4.8) 
2 (4.8) 
1.000 
0 (0.0) 
0 (0.0) 
N
A 
2 (10.0) 
2 (10.0) 
1.000 
Ankle joint attachm
ents 
2 (4.7) 
2 (4.8) 
0.981 
0 (0.0) 
0 (0.0) 
N
A 
1 (5.0) 
1 (4.8) 
0.972 
0 (0.0) 
0 (0.0) 
N
A 
1
st Tarsom
etotarsal joint 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
1
st M
etatarsophalangeal joint 
4 (10.5) 
3 (7.5) 
0.593 
0 (0.0) 
0 (0.0) 
N
A 
3 (15.8) 
2 (9.5) 
0.550 
0 (0.0) 
0 (0.0) 
N
A 
Achilles tendon insertion 
0 (0.0) 
0 (0.0) 
N
A 
3 (6.5) 
3 (6.5) 
1.000 
0 (0.0) 
0 (0.0) 
N
A 
2 (8.7) 
2 (8.7) 
1.000 
Plantar fascia insertion at calcaneus 
2 (4.3) 
2 (4.3) 
1.000 
7 (15.2) 
7 (15.2) 
1.000 
2 (8.7) 
2 (8.7) 
1.000 
7 (30.4) 
7 (30.4) 
1.000 
Table 7.5. C
om
parison of the frequency of readable BM
O
 and STI lesions w
ithin field of view
 (FO
V) at each enthesis betw
een w
eeks 0 and 24. 
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diff (p=) 
W
eek 0 
W
eek 
52 
G
roup 
diff (p=) 
W
eek 0 
W
eek 
52 
G
roup 
diff (p=) 
Supraspinate tendon insertion at hum
eral tuberosity 
12 (27.3) 
11 (28.2) 
0.925 
4 (9.1) 
5 (12.8) 
0.585 
11 (52.4) 
9 (47.4) 
0.752 
4 (19.0) 
4 (21.1) 
0.874 
Acrom
ioclavicular joint 
6 (13.6) 
6 (15.8) 
0.783 
0 (0.0) 
0 (0.0) 
N
A 
4 (19.0) 
4 (22.2) 
0.807 
0 (0.0) 
0 (0.0) 
N
A 
C
oracoid process 
1 (2.3) 
1 (2.6) 
0.931 
0 (0.0) 
0 (0.0) 
N
A 
1 (4.8) 
1 (5.3) 
0.942 
0 (0.0) 
0 (0.0) 
N
A 
Sternoclavicular joint 
1 (2.5) 
0 (0.0) 
0.333 
0 (0.0) 
0 (0.0) 
N
A 
1 (5.0) 
0 (0.0) 
0.336 
0 (0.0) 
0 (0.0) 
N
A 
1
st costochondral process 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
7
th costochondral joint 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
M
anubriosternal joint 
2 (10.0) 
1 (5.3) 
0.579 
0 (0.0) 
0 (0.0) 
N
A 
2 (10.0) 
1 (5.3) 
0.579 
0 (0.0) 
0 (0.0) 
N
A 
Iliac crest 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
Anterior superior iliac spine 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
Ischial tuberosity 
0 (0.0) 
0 (0.0) 
N
A 
3 (6.5) 
3 (7.5) 
0.859 
0 (0.0) 
0 (0.0) 
N
A 
2 (8.7) 
2 (10.0) 
0.883 
Pubic sym
physis 
2 (4.4) 
0 (0.0) 
0.177 
0 (0.0) 
0 (0.0) 
N
A 
2 (9.1) 
0 (0.0) 
0.167 
0 (0.0) 
0 (0.0) 
N
A 
G
reater trochanter 
0 (0.0) 
2 (5.0) 
0.125 
26 (56.5) 
23 (57.5) 
0.927 
0 (0.0) 
2 (10.0) 
0.120 
15 (65.2) 
13 (65.0) 
0.988 
Lateral fem
oral condyle 
0 (0.0) 
1 (2.8) 
0.289 
1 (2.5) 
1 (2.9) 
0.924 
0 (0.0) 
1 (6.3) 
0.257 
1 (5.0) 
1 (6.7) 
0.833 
M
edial fem
oral condyle 
0 (0.0) 
1 (2.8) 
0.271 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
1 (6.3) 
0.245 
0 (0.0) 
0 (0.0) 
N
A 
Lateral tibial plateau 
0 (0.0) 
0 (0.0) 
N
A 
1 (2.3) 
0 (0.0) 
0.363 
0 (0.0) 
0 (0.0) 
N
A 
1 (4.5) 
0 (0.0) 
0.387 
Intercondylar notch 
7 (16.3) 
7 (19.4) 
0.714 
0 (0.0) 
0 (0.0) 
N
A 
5 (23.8) 
5 (31.3) 
0.614 
0 (0.0) 
0 (0.0) 
N
A 
Patella ligam
ent insertion into patella 
4 (9.8) 
4 (10.5) 
0.910 
8 (19.5) 
7 (18.4) 
0.902 
2 (10.0) 
2 (11.1) 
0.911 
6 (30.0) 
4 (22.2) 
0.587 
Q
uadriceps tendon insertion into patella 
0 (0.0) 
0 (0.0) 
N
A 
2 (4.8) 
2 (5.6) 
0.874 
0 (0.0) 
0 (0.0) 
N
A 
2 (10.0) 
2 (12.5) 
0.813 
Ankle joint attachm
ents 
2 (4.7) 
2 (5.6) 
0.874 
0 (0.0) 
0 (0.0) 
N
A 
1 (5.0) 
1 (5.6) 
0.939 
0 (0.0) 
0 (0.0) 
N
A 
1
st Tarsom
etotarsal joint 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
0 (0.0) 
0 (0.0) 
N
A 
1
st M
etatarsophalangeal joint 
4 (10.5) 
2 (5.9) 
0.477 
0 (0.0) 
0 (0.0) 
N
A 
3 (15.8) 
1 (6.7) 
0.412 
0 (0.0) 
0 (0.0) 
N
A 
Achilles tendon insertion 
0 (0.0) 
0 (0.0) 
N
A 
3 (6.5) 
2 (5.3) 
0.808 
0 (0.0) 
0 (0.0) 
N
A 
2 (8.7) 
1 (5.3) 
0.667 
Plantar fascia insertion at calcaneus 
2 (4.3) 
2 (5.1) 
0.866 
7 (15.2) 
6 (15.4) 
0.983 
2 (8.7) 
1 (5.3) 
0.667 
7 (30.4) 
5 (26.3) 
0.769 
Table 7.6. C
om
parison of the frequency of readable BM
O
 and STI lesions w
ithin field of view
 (FO
V) at each enthesis betw
een w
eeks 0 and 52. 
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At every time point, BMO was most associated with the larger entheses of the shoulders 
(supraspinate tendon insertion at humeral tuberosity and acromioclavicular joint), and 
non-existent in the chest (1st and 7th costochondral joints) and pelvis (ischial tuberosity, 
anterior superior iliac spine and iliac crest) (Figure 7.2). In contrast, STI was associated 
with the largest (and often weight-bearing) joints, especially the greater trochanter of the 
hip, knee (patella ligament insertion, quadriceps insertion), ankle (plantar aponeurosis 
insertion, Achilles tendon insertion) and shoulder (supraspinate tendon insertion) (Figure 
7.3 and Figure 7.4).  
 
Figure 7.2. Comparison of the percentage frequency of entheses with bone marrow 
oedema (BMO) at each site with treatment over time. 
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Figure 7.3. Coronal short t inversion recovery (STIR) sequences showing persistence of 
grade 2 periarticular soft tissue inflammation surrounding the left greater trochanter 
during 52 weeks of ustekinumab therapy.  
 
Figure 7.4. Comparison of the percentage frequency of entheses with bone marrow 
oedema (BMO) at each site with treatment over time. 
WEEK	0 WEEK	24
WEEK	52
 352 
 
The majority of inflammatory abnormalities were minor (grade 1) throughout the study. 
At baseline, 4 BMO lesions were of moderate severity (grade 2) and one was severe 
(grade 3) (Figure 7.5). While the severe lesion improved, three new grade 2 lesions 
appeared by week 24, although these were all associated with trauma (football injury, 
sports training and post-femur fracture following an RTA). These persisted out to week 
52. 
 
 
Figure 7.5. Long axis short t inversion recovery (STIR) sequences showing grade 3 bone 
marrow oedema (solid arrow) and grade 2 soft tissue inflammation (dashed arrow) 
surrounding the insertions of the right and left plantar fascia respectively at baseline, and 
resolution of bone marrow oedema and improvement in soft tissue inflammation (grade 
1) at the same sites after 52 weeks of ustekinumab therapy. 
There were five grade 2 STI lesions at week 0 and three grade 3 lesions. These lessened 
in severity over time, with only five grade 2 STI lesions (and no grade 3 lesions) seen at 
week 24, and only four grade 2 lesions seen at week 52 (Figure 7.6).  
 
 
 
Week 0 Week 52
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Figure 7.6. Long axis short t inversion recovery (STIR) sequences showing grade 3 
inflammation in the soft tissues surrounding the insertion of the left plantar fascia into 
calcaneus at week 0, reducing in severity with ustekinumab therapy (grade 2 at week 24 
and grade 1 at week 52). 
Over time with ustekinumab therapy, new inflammatory lesions did develop, but with low 
frequency. Table 7.7 demonstrates the relatively static nature of BMO and STI lesions 
(in terms of severity) between weeks 0 and 24, and Table 7.8 shows that this trend 
continued out to week 52.  
Abnormality 
scores 
Score at 
baseline 
Resolved Improved Unchanged Worse New 
       
BMO All 5 1 900 2 6 
 0   865  6 
 1 4  32 2  
 2 1 0 3 0  
 3 0 1 0   
STI All 0 3 909 0 2 
 0   858  2 
 1 0  46 0  
 2 0 0 5 0  
 3 0 3 0   
Table 7.7. Changes in the score assigned to individual enthesitis lesions between 
baseline and week 24, where enthesis was in FOV and readable at both time points. 
‘New’ lesions were those that scored 0 at baseline and >0 at follow-up. Conversely those 
that scored >0 at baseline and 0 at follow-up had ‘resolved’. Scores of 1 or 2 could have 
worsened at follow-up, whilst scores of 2 or 3 could have improved. 
 
Week 0 Week 24 Week 52
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Abnormality 
scores 
Score at 
baseline 
Resolved Improved Unchanged Worse New 
       
BMO All 6 1 772 4 7 
 0   744  7 
 1 5  25 4  
 2 1 0 3 0  
 3 0 1 0   
STI All 2 3 781 0 4 
 0   739  4 
 1 2  38 0  
 2 0 0 4 0  
 3 0 3 0   
Table 7.8. Changes in the score assigned to individual enthesitis lesions between 
baseline and week 52, where enthesis was in FOV and readable at both time points. 
‘New’ lesions were those that scored 0 at baseline and >0 at follow-up. Conversely those 
that scored >0 at baseline and 0 at follow-up had ‘resolved’. Scores of 1 or 2 could have 
worsened at follow-up, whilst scores of 2 or 3 could have improved. 
Overall mean total scores for BMO and STI (both out of maximum of 135) were 
understandably low given the subclinical nature of musculoskeletal disease within this 
cohort, and remained low throughout the study. As shown in Figure 7.7, there was no 
significant change with treatment in BMO score between week 0 (mean score 2.13 
±2.12) and week 24 (2.30 ±2.40) (p=0.935), and between week 0 and week 52 (2.55 
±2.80) (p=0.623). Similarly, as shown in Figure 7.8, there was no significant alteration in 
STI score between week 0 (mean score 2.87 ±1.74) and week 24 (2.74 ±1.60) (p=0.257) 
and between week 0 and week 52 (2.70 ±1.56) (p=0.366). 
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Figure 7.7. Mean (s.d.) overall BMO score at week 0 and after 24 and 52 weeks of 
ustekinumab therapy. 
 
 
Figure 7.8. Mean (s.d.) overall STI score at week 0 and after 24 and 52 weeks of 
ustekinumab therapy. 
7.4.6.1.2 Bursitis 
Bursitis was assessed at 12 sites in each patient, at each time point. Bursitis was 
relatively common, with 17 of 23 (73.9%) patients having at least one area of bursitis at 
week 0, 17 of 23 (73.9%) at week 24 and 14 of 20 (70.0%) at week 52. In all patients, 49 
of 272 (18.0%) bursae visualised (i.e. within FOV) exhibited inflammation prior to therapy 
at week 0. Despite ustekinumab therapy, there was little change in the burden of bursitis, 
p=0.935
p=0.623
p=0.257 p=0.366
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with 49 of 266 (18.4%) visible bursae showing features of inflammation at week 24, and 
41 of 232 (17.7%) at week 52. Patients had between 0 and 5 areas of bursitis at each 
time point, with no significant change in the mean (±s.d.) number of lesions per patient 
between week 0 (2.26 ±1.66) and week 24 (2.57 ±1.81) (p=0.365), nor between week 0 
and week 52 (2.45 ±1.79) (p=0.258).  
Bursitis was seen at all anatomical sites assessed, but with greatest frequency (>54%) 
at the greater trochanteric bursae of the hips throughout the study (Figure 7.9). This is 
not an uncommon site for low grade bursitis in healthy individuals without psoriasis 
(Chapter 6), and it is therefore difficult to draw conclusions as to what extent these 
changes are pathological and what is within the accepted boundaries of normal 
physiology and aging.  However, bursitis did frequently occur at sites of STI, which was 
present at a much lesser frequency in healthy individuals, supporting the concept of 
dissipation of inflammation throughout adjacent structures within the synovio-entheseal 
complex. 
 
Figure 7.9. Comparison of percentage frequency of bursitis lesions at each site at each 
time point 
No significant differences were seen in the percentage number of burseal lesions at any 
anatomical site from week 0 after 24 weeks (Table 7.9) and 52 weeks (Table 7.10) of 
ustekinumab treatment (all p>0.05).  
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 Burseal Level Patient Level 
 No. of lesions (% of lesions within  
readable FOV) 
No. of patients (% of patients with 
bursitis within readable FOV) 
 Week 0 Week 24 Group diff (p=) Week 0 Week 24 
Group 
diff (p=) 
Subacromial bursae 6 (13.6) 6 (13.3) 0.967 4 (19.0) 4 (18.2) 0.928 
Greater trochanteric bursae 25 (54.3) 26 (56.5) 0.834 14 (60.9) 14 (60.9) 1.000 
Pre-patellar bursae 6 (13.3) 6 (14.0) 0.932 4 (18.2) 4 (19.0) 0.928 
Pes anserine bursae 1 (2.2) 1 (2.3) 0.975 1 (4.3) 1 (4.5) 0.974 
Achilles bursae 2 (4.3) 2 (4.5) 0.964 1 (4.3) 1 (4.5) 0.974 
Retrocalcaneal bursae 9 (19.6) 8 (18.2) 0.867 6 (26.1) 6 (27.3) 0.897 
Table 7.9. Comparison of the percentage frequency of readable bursitis lesions within 
FOV, in psoriasis patients at week 0 and after 24 weeks of therapy with ustekinumab. 
FOV: field of view.  
 
 Burseal Level Patient Level 
 No. of lesions (% of lesions within  
readable FOV) 
No. of patients (% of patients with 
bursitis within readable FOV) 
 Week 0 Week 52 Group diff (p=) Week 0 Week 52 
Group 
diff (p=) 
Subacromial bursae 6 (13.6) 3 (7.7) 0.385 4 (19.0) 2 (10.5) 0.639 
Greater trochanteric bursae 25 (54.3) 22 (55.0) 0.952 14 (60.9) 12 (60.0) 0.954 
Pre-patellar bursae 6 (13.3) 6 (15.8) 0.751 4 (18.2) 4 (22.2) 0.789 
Pes anserine bursae 1 (2.2) 1 (2.6) 0.891 1 (4.3) 1 (5.3) 0.890 
Achilles bursae 2 (4.3) 2 (5.3) 0.845 1 (4.3) 1 (5.3) 0.890 
Retrocalcaneal bursae 9 (19.6) 7 (17.9) 0.849 6 (26.1) 5 (26.3) 0.983 
Table 7.10. Comparison of the percentage frequency of readable bursitis lesions within 
FOV, in psoriasis patients at week 0 and after 52 weeks of therapy with ustekinumab. 
FOV: field of view.  
Throughout the study, bursitis remained prevalent. The severity of bursitis was generally 
mild (grade 1), with less than 7% of all lesions being grade 2 (moderate), and the severity 
remained relatively unchanged with ustekinumab therapy. Few lesions resolved with 
treatment, but only one new area of bursitis developed by week 24 (Table 7.11) and no 
further new lesions or worsening of severity occurred by week 52 (Table 7.12). This 
suggests that progression of inflammation within the synovio-entheseal complex may 
have been limited, although histological analysis would be required to conclusively prove 
these observations.  
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Abnormality 
scores 
Score at 
baseline 
Resolved Improved Unchanged Worse New 
       
Bursitis All 1 0 258 0 1  
 0   213  1 
 1 1  45 0  
 2 0 0 3 0  
 3 0 0 0   
Table 7.11. Changes in the score assigned to individual bursitis lesions between 
baseline and week 24, where the bursa was in FOV and readable at both time points. 
‘New’ lesions were those that scored 0 at baseline and >0 at follow-up. Conversely those 
that scored >0 at baseline and 0 at follow-up had ‘resolved’. Scores of 1 or 2 could have 
worsened at follow-up, whilst scores of 2 or 3 could have improved. 
 
Abnormality 
scores 
Score at 
baseline 
Resolved Improved Unchanged Worse New 
       
Bursitis All 2 0 228 0 0  
 0   187  0 
 1 2  38 0  
 2 0 0 3 0  
 3 0 0 0   
Table 7.12. Changes in the score assigned to individual bursitis lesions between 
baseline and week 52, where the bursa was in FOV and readable at both time points. 
‘New’ lesions were those that scored 0 at baseline and >0 at follow-up. Conversely those 
that scored >0 at baseline and 0 at follow-up had ‘resolved’. Scores of 1 or 2 could have 
worsened at follow-up, whilst scores of 2 or 3 could have improved. 
 
Overall, mean bursitis scores (out of a possible maximum of 36) were low throughout the 
study, and as shown in Figure 7.10, there was no significant change with treatment in 
bursitis score between week 0 (mean score 2.26 ±1.76) and week 24 (2.26 ±1.71) 
(p=1.000), and between week 0 and week 52 (2.20 ±1.82) (p=0.157). 
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Figure 7.10. Mean (s.d.) overall bursitis score at week 0 and after 24 and 52 weeks of 
ustekinumab therapy. 
7.4.6.1.3 Synovitis 
An assessment of synovial joint fluid volume, as a surrogate marker of potential synovitis, 
was made at 16 joints in each patient at each time point. The presence of increased 
synovial fluid was common amongst all participants, with 21 of 23 (91.3%) patients 
having at least one area of increased fluid suggestive of inflammation at week 0 and at 
week 24, and 18 of 20 (90.0%) patients at week 52. Assessment of true synovial 
thickening was limited by the absence of contrast enhancement. 
In patients with increased synovial fluid, the maximum number of lesions observed in 
any one patient was seven at every time point. No significant changes were observed 
between the mean (±s.d.) number of areas of synovitis per patient at week 0 (3.30 ±1.96) 
and week 24 (3.35 ±1.95) (p=0.982), nor between week 0 and week 52 (2.78 ±2.07) 
(p=0.678). 
Synovitis was observed in all areas except for the tarsometatarsal joints, although the 
observed frequency was low in the metatarsophalangeal joints and in sternoclavicular 
joints at all time points (Figure 7.11).  
p=1.000 p=0.157
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Figure 7.11. Comparison of percentage frequency of increased synovial volume at each 
site at each time point. 
 
There were no significant differences in the percentage frequency of joints or patients 
with increased synovial fluid volumes at any site from week 0 after 24 weeks of treatment 
(Table 7.13) or 52 weeks of treatment (Table 7.14).  
 
 Joint Level Patient Level 
 No. of lesions (% of lesions within  
readable FOV) 
No. of patients (% of patients with 
synovitis within readable FOV) 
 Week 0 Week 24 Group diff (p=) Week 0 Week 24 
Group diff 
(p=) 
Sternoclavicular joints 1 (2.3) 1 (2.3) 1.000 1 (4.8) 1 (4.8) 1.000 
Acromioclavicular joints 4 (9.1) 5 (11.1) 0.752 3 (14.3) 4 (18.2) 0.729 
Shoulder joints 8 (17.8) 8 (17.8) 1.000 5 (22.7) 5 (22.7) 1.000 
Hip joints 10 (21.7) 12 (26.1) 0.625 6 (26.1) 7 (30.4) 0.743 
Knee joints 25 (54.3) 25 (54.3) 1.000 13 (56.5) 13 (56.5) 1.000 
Ankle joints 24 (52.2) 23 (50.0) 0.835 13 (56.5) 13 (56.5) 1.000 
Tarsometatarsal joints 0 (0.0) 0 (0.0) NA 0 (0.0) 0 (0.0) NA 
Metatarsophalangeal joints 3 (7.0) 3 (7.1) 0.976 2 (9.5) 2 (10.0) 0.959 
Table 7.13. Comparison of the percentage frequency of readable synovitis lesions within 
FOV, in psoriasis patients at week 0 and after 24 weeks of therapy with ustekinumab. 
FOV: field of view.  
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 Joint Level Patient Level 
 No. of lesions (% of lesions within  
readable FOV) 
No. of patients (% of patients with 
synovitis within readable FOV) 
 Week 0 Week 52 Group diff (p=) Week 0 Week 52 
Group diff 
(p=) 
Sternoclavicular joints 1 (2.3) 0 (0.0) 0.356 1 (4.8) 0 (0.0) 0.348 
Acromioclavicular joints 4 (9.1) 5 (13.2) 0.557 3 (14.3) 4 (22.2) 0.520 
Shoulder joints 8 (17.8) 7 (17.9) 0.984 5 (22.7) 5 (26.3) 0.790 
Hip joints 10 (21.7) 11 (27.5) 0.535 6 (26.1) 6 (30.0) 0.775 
Knee joints 25 (54.3) 19 (48.7) 0.605 13 (56.5) 10 (52.6) 0.801 
Ankle joints 24 (52.2) 20 (50.0) 0.841 13 (56.5) 11 (55.0) 0.920 
Tarsometatarsal joints 0 (0.0) 0 (0.0) NA 0 (0.0) 0 (0.0) NA 
Metatarsophalangeal joints 3 (7.0) 2 (5.4) 0.772 2 (9.5) 1 (5.6) 0.643 
Table 7.14. Comparison of the percentage frequency of readable synovitis lesions within 
FOV, in psoriasis patients at week 0 and after 52 weeks of therapy with ustekinumab. 
FOV: field of view 
All incidences of ‘synovitis’ documented at week 0 were grade 1, indicating only a mild 
increase in synovial fluid. As shown in Table 7.15 and Table 7.16, there was perceived 
worsening (grade 2) at one site in one patient at both weeks 24 and 52, and seven new 
lesions appeared on treatment (three by week 24 and four by week 52). Very few areas 
resolved throughout the study, which may indicate that the small increase in fluid 
documented was in fact within normal physiological limits, and assessment was inhibited 
by the lack of gadolinium contrast. 
 
Abnormality 
scores 
Score at 
baseline 
Resolved Improved Unchanged Worse New 
       
Synovitis All 1 0 340 1 3 
 0   267  3 
 1 1  73 1  
 2 0 0 0 0  
 3 0 0 0   
Table 7.15. Changes in the score assigned to individual synovitis lesions between 
baseline and week 24, where the joint was in FOV and readable at both time points. 
‘New’ lesions were those that scored 0 at baseline and >0 at follow-up. Conversely those 
that scored >0 at baseline and 0 at follow-up had ‘resolved’. Scores of 1 or 2 could have 
worsened at follow-up, whilst scores of 2 or 3 could have improved. 
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Abnormality 
scores 
Score at 
baseline 
Resolved Improved Unchanged Worse New 
       
Synovitis All 4 0 292 1 4 
 0   233  4 
 1 4  59 1  
 2 0 0 0 0  
 3 0 0 0   
Table 7.16. Changes in the score assigned to individual synovitis lesions between 
baseline and week 52, where the joint was in FOV and readable at both time points. 
‘New’ lesions were those that scored 0 at baseline and >0 at follow-up. Conversely those 
that scored >0 at baseline and 0 at follow-up had ‘resolved’. Scores of 1 or 2 could have 
worsened at follow-up, whilst scores of 2 or 3 could have improved. 
As shown for all other abnormalities (BMO, STI and bursitis), mean synovitis scores (out 
of possible maximum of 48) were low throughout (Figure 7.12) with virtually no change 
with treatment between week 0 (mean score 3.26 ±1.94) and week 24 (3.39 ±1.88) 
(p=0.180), and between week 0 and week 52 (3.30 ±1.92) (p=0.608). 
 
 
Figure 7.12. Mean (s.d.) overall synovitis score at week 0 and after 24 and 52 weeks of 
ustekinumab therapy. 
7.4.6.1.4 Tenosynovitis 
Tenosynovitis was assessed at four sites in each patient at each time point (medial and 
lateral tendons of the foot bilaterally). These serve as functional entheses, whereby 
these tendons run over bony surfaces and fibrocartilage on the under surfaces of the 
p=0.180 p=0.608
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tendons make contact with fibrocartilage on the underlying bone.  It is hypothesised that 
these functional entheses have a similar tendency towards microdamage as true 
entheses in psoriatic arthritis, and in the absence of normal immune regulation, failure 
to repair can lead to persistent inflammation. 
Tenosynovitis was uncommon in this cohort, affecting only 8.7% of lateral tendons and 
no medial tendons. With treatment, there was no change in the prevalence of lateral 
tenosynovitis by week 24 (Table 7.17) and a slight (but not significant) increase in lateral 
tenosynovitis by week 52 (Table 7.18).  
 Tendon Level Patient Level 
 No. of lesions (% of lesions within 
readable FOV) 
No. of patients (% of patients with 
tenosynovitis within readable FOV) 
 Week 0 Week 24 Group diff. (p=) Week 0 Week 24 
Group diff. 
(p=) 
Lateral tendons 4 (8.7) 4 (8.7) 1.000 2 (8.7) 2 (8.7) 1.000 
Medial tendons 0 (0.0) 0 (0.0) NA 0 (0.0) 0 (0.0) NA 
Table 7.17. Comparison of the percentage frequency of readable tenosynovitis lesions 
within FOV, in psoriasis patients at week 0 and after 24 weeks of therapy with 
ustekinumab. FOV: field of view. 
 
 Tendon Level Patient Level 
 No. of lesions (% of lesions within 
readable FOV) 
No. of patients (% of patients with 
tenosynovitis within readable FOV) 
 Week 0 Week 52 Group diff. (p=) Week 0 Week 52 
Group diff. 
(p=) 
Lateral tendons 4 (8.7) 5 (12.5) 0.565 2 (8.7) 3 (15.0) 0.520 
Medial tendons 0 (0.0) 0 (0.0) NA 0 (0.0) 0 (0.0) NA 
Table 7.18. Comparison of the percentage frequency of readable tenosynovitis lesions 
within FOV, in psoriasis patients at week 0 and after 52 weeks of therapy with 
ustekinumab. FOV: field of view. 
As shown in Table 7.19, all lesions were mild (grade 1). Two lesions resolved after 52 
weeks of treatment, although three new areas of mild tenosynovitis developed (Table 
7.20). 
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Abnormality 
scores 
Score at 
baseline 
Resolved Improved Unchanged Worse New 
       
Tenosynovitis All 0 0 92 0 0 
 0   88  0 
 1 0  4 0  
 2 0 0 0 0  
 3 0 0 0   
Table 7.19. Changes in the score assigned to individual tenosynovitis lesions between 
baseline and week 24, where the tendon was in FOV and readable at both time points. 
‘New’ lesions were those that scored 0 at baseline and >0 at follow-up. Conversely those 
that scored >0 at baseline and 0 at follow-up had ‘resolved’. Scores of 1 or 2 could have 
worsened at follow-up, whilst scores of 2 or 3 could have improved. 
 
Abnormality 
scores 
Score at 
baseline 
Resolved Improved Unchanged Worse New 
       
Tenosynovitis All 2 0 75 0 3 
 0   73  3 
 1 2  2 0  
 2 0 0 0 0  
 3 0 0 0   
Table 7.20. Changes in the score assigned to individual tenosynovitis lesions between 
baseline and week 52, where the tendon was in FOV and readable at both time points. 
‘New’ lesions were those that scored 0 at baseline and >0 at follow-up. Conversely those 
that scored >0 at baseline and 0 at follow-up had ‘resolved’. Scores of 1 or 2 could have 
worsened at follow-up, whilst scores of 2 or 3 could have improved. 
Mean tenosynovitis scores (out of possible maximum of 12) were very low throughout 
(Figure 7.13) with no change with treatment between week 0 (mean score 0.17 ±0.58) 
and week 24 (0.17 ±0.58) (p=1.000) and minimal deterioration between week 0 and week 
52 (0.25 ±0.64) (p=0.785).  
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Figure 7.13. Mean (s.d.) overall tenosynovitis score at week 0 and after 24 and 52 weeks 
of ustekinumab therapy. 
7.4.6.1.5 Structural Changes 
Bone erosions (examined at four sites per patient) enthesophytes (examined at two sites 
per patient) were not identified at any locality at any stage throughout the study. 
7.4.6.2 Axial Skeleton - Spine 
7.4.6.2.1 Active Inflammation 
In total, 15 of 23 patients (65.2%) of patients had at least one VU exhibiting active 
inflammation (BMO) within the spine at week 0, 14 of 23 patients (60.8%) after 24 weeks 
of ustekinumab therapy, and 13 of 20 patients (65.0%) after 52 weeks. The majority of 
abnormalities were found within the bone marrow of the vertebral corners, although in 
some more florid cases, BMO could be seen extending across the vertebral endplate 
(Figure 7.14). 
p=1.000 p=0.785
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Figure 7.14. Saggital short t inversion recovery (STIR) sequence showing vertebral 
endplate osteitis/BMO at L5/S1 (pre-treatment). 
Of the 15 patients with spine BMO at week 0, 11 had BMO alone, and four showed BMO 
and structural changes. At week 24, 10 had BMO alone, and four had BMO and structural 
changes, and at week 52, 10 had BMO alone and three had BMO and structural 
changes. No individuals had isolated structural changes at any stage throughout the 
study.  
Patients had between 0 and 6 BMO lesions each at week 0, the same at week 24, and 
between 0 and 5 lesions each at week 52. There were no significant differences in the 
mean number of lesions per patient at week 0 (1.43 ±1.75) and after 24 weeks of 
treatment with ustekinumab (1.39 ±1.88) (p=0.865), nor between week 0 and after 52 
weeks of therapy (1.15 ±1.35) (p=0.270).  Four patients at each time point had BMO 
lesions at three or more sites, which is highly suggestive of axial SpA (Hermann et al., 
2012).   
In terms of the location of BMO lesions, the majority were in the lumbar and lower 
thoracic spine at week 0 – L5/S1 (10/33 lesions), followed by L3/4 (4/33 lesions) and 
T8/9 (3/33 lesions). 
Only one patient had active inflammation within the posterior elements (facet joints) at 
two sites (one area grade 1, one area grade 2), and this remained unchanged in severity 
from week 0 throughout treatment to week 52 (Figure 7.15).   
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Figure 7.15. Saggital short t inversion recovery (STIR) sequences showing grade 1 
posterior element inflammation at L4 and L5, remain unchanged with ustekinumab 
treatment over 52 weeks.  
The majority of abnormalities identified throughout the study were low grade. In total, 33 
active inflammatory lesions were identified within all VUs assessed at baseline (grade 1: 
24/33; grade 2: 8/33; grade 3: 1/33). At week 24, a total of 32 BMO lesions were identified 
(grade 1: 21/32; grade 2: 10/32; grade 3: 1/33) and at week 52, a total of 23 lesions were 
scored (grade 1: 16/23; grade 2: 6/23; grade 3: 1/23).  
As a consequence, total scores for spine BMO were low. Spine BMO scores ranged from 
0-9 (out of a possible maximum of 69) at week 0, with a mean (±s.d.) of 1.87±2.24. There 
was no significant change by week 24, with BMO scores ranging from 0-9 and a mean 
score of 1.91 ±2.64 (p=0.656). Similarly, at week 52, scores ranged from 0-8, with no 
significant change in mean BMO score (1.55 ±2.01) from week 0 (p=0.627) (Figure 7.16).  
 
Week 0 Week 24 Week 52
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Figure 7.16. Mean (s.d.) overall spine BMO scores at week 0 and after 24 and 52 weeks 
of ustekinumab therapy. 
 
The majority of lesions did not change in severity throughout the study, as shown in 
Table 7.21 and Table 7.22. 
Abnormality 
scores 
Score at 
baseline 
Resolved Improved Unchanged Worse New 
       
Bone Marrow 
Oedema  
All 3 1 519 4 2  
0   494  2 
1 2  18 4  
2 1 1 6 0  
3 0 0 1   
Posterior 
Element 
Inflammation 
All 0 0 529 0 0 
0   527  0 
1 0  1 0  
2 0 0 1 0  
3 0 0 0   
Table 7.21. Changes in the score assigned to individual spine vertebral body BMO 
lesions and spine posterior element inflammatory lesions between baseline and week 
24. ‘New’ lesions were those that scored 0 at baseline and >0 at follow-up. Conversely 
those that scored >0 at baseline and 0 at follow-up had ‘resolved’. Scores of 1 or 2 could 
have worsened at follow-up, whilst scores of 2 or 3 could have improved. 
 
p=0.656
p=0.627
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Abnormality 
scores 
Score at 
baseline 
Resolved Improved Unchanged Worse New 
       
Bone Marrow 
Oedema  
All 3 5 446 4 2  
0   432  2 
1 5  12 3  
2 0 2 2 1  
3 0 1 0   
Posterior 
Element 
Inflammation 
All 0 0 460 0 0 
0   458  0 
1 0  1 0  
2 0 0 1 0  
3 0 0 0   
Table 7.22. Changes in the score assigned to individual spine vertebral body BMO 
lesions and spine posterior element inflammatory lesions between baseline and week 
52. ‘New’ lesions were those that scored 0 at baseline and >0 at follow-up. Conversely 
those that scored >0 at baseline and 0 at follow-up had ‘resolved’. Scores of 1 or 2 could 
have worsened at follow-up, whilst scores of 2 or 3 could have improved. 
Despite the overall trend to no therapeutic response, there were cases where spine BMO 
appeared to improve significantly with ustekinumab therapy. These were cases where 
BMO was graded as moderate or severe at week 0, as shown in Figure 7.17. BMO can 
be seen extending from the corners to encompass the C5 inferior end plate (grade 3) 
and C6 superior end plate (grade 2) at week 0 and 24, and has reduced in severity (grade 
1) after 52 weeks of ustekinumab therapy. Where deterioration occurred, it was generally 
subtle, from grade 0 to 1, or grade 1 to 2, as shown in Figure 7.18.  
 
 
 
 
 370 
 
Figure 7.17. Saggital T1w WBMRI sequences of the upper spine showing resolution of 
C5 inferior endplate BMO (grade 3 at weeks 0 and 24) and C6 superior end plate BMO 
(grade 2 weeks 0 and 24) with ustekinumab therapy for 52 weeks. 
 
 
 
Figure 7.18. Saggital T1w WBMRI sequences of the upper spine showing deterioration 
of L1 anterior superior corner BMO from grade 1 (at weeks 0 and 24) to grade 2 (at week 
52) with ustekinumab therapy.  
 
 
Week 0 Week 52Week 24
Week 0 Week 24 Week 52
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7.4.6.2.2 Structural Changes 
Fatty infiltration of the bone marrow was an uncommon finding, with only four of 23 
patients exhibiting low grade non-inflammatory changes at week 0 and 24, and three of 
20 patients at week 52. In each instance, less than 50% of the vertebral body was 
affected, and fatty infiltration was localised to the corners, representative of the ‘fatty 
romanus lesion’ as described by Bennett et al, a diagnostic lesion specific for ax-SpA 
(Bennett et al., 2010). Only one patient had more than one corner lesion at week 0, and 
these five lesions persisted throughout the study, as shown in Figure 7.19. Saggital T1w 
WBMRI sequence of the lower spine showing persistence of vertebral corner fatty 
infiltration (Romanus lesions) in two difference slices at T6/7, T7/8, T9/10, T11/12 and 
L3/4, at weeks 0, 24 and 52.  
 
 
Figure 7.19. Saggital T1w WBMRI sequence of the lower spine showing persistence of 
vertebral corner fatty infiltration (Romanus lesions) in two difference slices at T6/7, T7/8, 
T9/10, T11/12 and L3/4, at weeks 0, 24 and 52. 
Week 0 Week 24 Week 52
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There was no pattern to the distribution of lesions seen in the four patients with fatty 
bone marrow infiltration. In patients with only one fatty vertebral corner lesion, 
inflammation was also present in the form of BMO. In the patient with five lesions, no 
BMO was seen, perhaps suggesting a longer duration of spinal disease resulting in fatty 
replacement of bone marrow and resolution of the inflammatory insult, as is seen in ax-
SpA of more prolonged duration (Bennett et al., 2010). No sclerotic bone formation or 
erosions were seen in any patient throughout the study. 
All fatty infiltration lesions were mild (grade 1), with the exception of one lesion in one 
patient, that persisted as grade 2 throughout, despite ustekinumab therapy. The static 
nature of observed fatty infiltration lesions at each time point is shown in Table 7.23 and 
Table 7.24. 
Abnormality 
scores 
Score at 
baseline 
Resolved Improved Unchanged Worse New 
       
Fatty 
Infiltration  
All 0 0 529 0 0 
0   521  0 
1 0  7 0  
2 0 0 1 0  
3 0 0 0   
Table 7.23. Changes in the score assigned to individual spine fatty infiltration lesions 
between baseline and week 24. ‘New’ lesions were those that scored 0 at baseline and 
>0 at follow-up. Conversely those that scored >0 at baseline and 0 at follow-up had 
‘resolved’. Scores of 1 or 2 could have worsened at follow-up, whilst scores of 2 or 3 
could have improved. 
 
Abnormality 
scores 
Score at 
baseline 
Resolved Improved Unchanged Worse New 
       
Fatty 
Infiltration  
All 0 0 460 0 0 
0   453  0 
1 0  6 0  
2 0 0 1 0  
3 0 0 0   
Table 7.24. Changes in the score assigned to individual spine fatty infiltration lesions 
between baseline and week 24. ‘New’ lesions were those that scored 0 at baseline and 
>0 at follow-up. Conversely those that scored >0 at baseline and 0 at follow-up had 
‘resolved’. Scores of 1 or 2 could have worsened at follow-up, whilst scores of 2 or 3 
could have improved. 
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Overall fatty infiltration scores ranged from 0-5 (out of a possible maximum of 69) at each 
time point. As shown in Figure 7.20, there were no significant changes in mean spine 
bone marrow fatty infiltration scores between week 0 (mean score 0.39 ±1.12) and week 
24 (0.39 ±1.12) (p=1.000), or week 0 and week 52 (0.40 ±1.89) (p= 0.978). 
 
Figure 7.20. Mean (s.d.) overall spine fatty infiltration (FI) scores at week 0 and after 24 
and 52 weeks of ustekinumab therapy. 
 
There were no erosions or syndesmophytes seen in the spine in any patient throughout 
the study. 
 
7.4.6.3 Axial Skeleton - Sacroiliac Joints 
7.4.6.3.1 Active Inflammation 
In total, 3 of 23 patients (17.4%) had at least one area of active inflammation within the 
SIJs at weeks 0 and 24, and 2 of 20 patients (10.0%) at week 52. One new lesion 
appeared in one patient at week 52, and two patients with BMO at weeks and 24 were 
lost to follow up by week 52. Patients had between 0 and 3 lesions each at weeks 0 and 
24, and 0 and 1 lesion at week 52. Lesions were distributed throughout the SIJs (upper 
sacrum, upper ilium and lower ilium).   
Overall, only six areas of BMO were identified in total (out of possible 184) at weeks 0 
and 24, and all were grade 1 with the exception of one area (right upper sacrum) in one 
patient that worsened (grade 2) (Figure 7.21).  
 
 
p=1.000
p=0.978
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Figure 7.21. Coronal oblique T2w fat saturated sequence of the sacroiliac joints showing 
BMO within right sacrum (solid arrow) in one of three patients identified with SIJ BMO at 
week 0. BMO is also seen in the inferior corners of the L5 vertebrae (dashed arrows). 
At week 52, only two areas of BMO (out of a possible 160) were identified. One area 
persisted in one patient from week 0 and one new area appeared in a different patient 
who did not have SIJ BMO at weeks 0 or 24.  Two patients with BMO at weeks 0 and 24 
were lost to follow up by week 52, which accounts for the reduction in lesions rather than 
being due to resolution on treatment.  
Table 7.25 and Table 7.26 demonstrate the static nature of lesions between weeks 0 
and 24, and weeks 0 and 52, respectively.  
Table 7.25. Changes in the score assigned to individual SIJ BMO lesions between 
baseline and week 24. ‘New’ lesions were those that scored 0 at baseline and >0 at 
follow-up. Conversely those that scored >0 at baseline and 0 at follow-up had ‘resolved’. 
Scores of 1 or 2 could have worsened at follow-up, whilst scores of 2 or 3 could have 
improved. 
Abnormality 
scores 
Score at 
baseline 
Resolved Improved Unchanged Worse New 
       
Bone 
Marrow 
Oedema 
All 0 0 183 1 0 
0   178  0 
1 0  5 1  
2 0 0 0 0  
3 0 0 0   
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Abnormality 
scores 
Score at 
baseline 
Resolved Improved Unchanged Worse New 
       
Bone Marrow 
Oedema  
All 2 0 157 0 1 
0   156  1 
1 2  1 0  
2 0 0 0 0  
3 0 0 0   
Table 7.26. Changes in the score assigned to individual SIJ BMO lesions between 
baseline and week 52. ‘New’ lesions were those that scored 0 at baseline and >0 at 
follow-up. Conversely those that scored >0 at baseline and 0 at follow-up had ‘resolved’. 
Scores of 1 or 2 could have worsened at follow-up, whilst scores of 2 or 3 could have 
improved. 
Overall mean SIJ BMO scores were 0.26 ±0.75 at week 0, 0.30 ±0.88 at week 24 and 
0.10 ±0.308. Statistical comparisons are not made as the numbers involved are 
inadequate, and compounded by two of three patients with BMO at week 0 being lost to 
follow up.  
7.4.6.3.2 Structural Changes 
Structural changes within the SIJs were rare, with no identifiable areas of fatty bone 
marrow infiltration, ankyloses or sclerosis seen in any patient throughout the study. 
Erosions were seen in two patients (lower ilium bilaterally in both, grade 1) at week 0, 
and remained unchanged despite treatment. No new erosions developed in any patient 
(Table 7.27). Overall mean erosion scores were 0.09 ±0.42 at each time point. 
Abnormality 
scores 
Score at 
baseline 
Resolved Improved Unchanged Worse New 
       
 All 0 0 2 0 0 
0   0  0 
1 0  2 0  
2 0 0 0 0  
3 0 0 0   
Table 7.27. Changes in the score assigned to individual SIJ erosions between baseline 
and week 24, and also between week 0 and week 52. ‘New’ lesions were those that 
scored 0 at baseline and >0 at follow-up. Conversely those that scored >0 at baseline 
and 0 at follow-up had ‘resolved’. Scores of 1 or 2 could have worsened at follow-up, 
whilst scores of 2 or 3 could have improved. 
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7.5 Discussion 
The results of this prospective, open-label, single-arm, proof-of-concept trial show that 
in asymptomatic patients with moderate to severe psoriasis, with a low burden of osteitis 
in both the peripheral and axial skeleton, no significant change is observed in 
inflammatory or chronic lesions following skin-directed treatment with ustekinumab for 
up to 52 weeks.  
This is the first trial to use WBMRI to investigate the musculoskeletal response of any 
biologic therapy in patients with psoriasis and subclinical enthesopathy. There are no 
published data of the use of WBMRI to assess therapeutic response in established 
psoriatic arthritis (PsA) for comparison. Appel et al first reported the use of WBMRI to 
assess the response of widespread inflammatory lesions to Infliximab in one patient with 
established ankylosing spondylitis (AS) (BASDAI 7.5) after one year, and reported 
‘tremendous improvement’ in both the axial and peripheral skeleton (Appel et al., 2007). 
Following this, three small published studies have used WBMRI to assess the response 
to biologic therapies in symptomatic patients with axial spondyloarthritis (ax-SpA) and 
AS, two using etanercept (Karpitschka et al., 2013, Song et al., 2011a, Song et al., 
2011b, Song et al., 2015, Althoff et al., 2016) and one using ustekinumab (Poddubnyy 
et al., 2013, Poddubnyy et al., 2014a, Poddubnyy et al., 2014b). Change in WBMRI 
osteitis score was the primary endpoint of all studies with the exception of one, which 
reported WBMRI data as a secondary endpoint, with ASAS40 response as the primary 
outcome (Poddubnyy et al., 2014b).  
Reflecting the fact that all published data relates to patients with axial spondyloarthritis, 
WBMRI assessments have focused primarily on the spine and SIJs. However, in two 
studies, peripheral skeleton data has been reported alongside data from the axial 
skeleton (Althoff et al., 2016, Karpitschka et al., 2013).  Althoff and colleagues treated 
41 patients with early ax-SpA with etanercept for up to three years, and WBMRI included 
the assessment of 21 sites bilaterally including the anterior chest wall, pelvis, knee and 
foot. The pre-treatment frequency of peripheral inflammatory lesions was slightly lower 
than in this study (2.6% entheses (in 9 of 41 patients) vs. 4.5% entheses), although this 
is to be expected given that patients had ax-SpA rather than a more predominantly 
peripheral pattern of spondyloarthropathy such as PsA.  With treatment, peripheral 
enthesitis reduced by 31.8%, affecting just five patients with 0.8% of entheses reported 
as showing inflammation after 2 years of continuous treatment (Althoff et al., 2016). 
These data support the ultrasound, but not WBMRI findings from patients in this cohort 
of psoriasis patients, where a 42.1% decrease in the number of peripheral entheses with 
inflammatory abnormalities was observed after 24 weeks of ustekinumab therapy 
(Chapter 5.4.5.1.3.). 
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Further improvement is shown in a small prospective study of ten patients with 
established AS. Karpitschka and colleagues examined the entheses and synovio-
entheseal complex surrounding the pubic symphysis, pelvis and hip (e.g. enthesitis ossis 
ischia, trochanteric bursitis), in addition to the synovium of the knee and upper ankle 
joints (synovitis) using WBMRI. Half of patients exhibited peripheral inflammatory lesions 
(pubic symphysis enthesitis: 3/10; right ischium enthesitis, 1/10; bilateral hip bursitis: 
3/10; unilateral ankle synovitis: 1/10) before treatment. Again, using etanercept, 
peripheral inflammation lesion scores reduced by 60.6% by week 26, and 93.9% by week 
52 (Karpitschka et al., 2013).  
The response of peripheral psoriatic arthritis specifically to biologic therapy has only 
been assessed using conventional MRI and no data are published relating to 
ustekinumab or other non-TNF inhibitors. Most studies have used the PsAMRIS method 
to score images of the hands, which were not included in our MRI protocol, although 
responses at the knee (Anandarajah et al., 2010, Marzo-Ortega et al., 2007, Marzo-
Ortega et al., 2001), foot (Yanaba et al., 2015) and hips (Marzo-Ortega et al., 2001) have 
been reported. 
In contrast to the findings in this study, favourable improvements in inflammatory 
entheseal lesions have been observed in all other published studies and case series 
following biologic therapy, but these studies only included patients with known 
inflammatory arthritis. No data are available for subclinical inflammation. Following six 
months of etanercept, improvement in enthesitis and osteitis was observed at the knee, 
hips and hands of five patients with PsA (mean disease duration 12 years) (Marzo-
Ortega et al., 2001). Yanaba and colleagues describe clearance of BMO and STI in the 
hands and feet of four patients with PsA (mean disease duration 12.0 ±7.7 years) 
following 32 weeks of continuous adalimumab therapy. Tenosynovitis responded less 
well, with complete clearance in two, an improvement in one and no change in the fourth. 
Bone erosions remained unchanged as seen in this study (Yanaba et al., 2015).  
Anandarajah et al reported the effect of adalimumab on BMO, synovitis, joint effusion 
and erosions detected by MRI at the knee and wrist in 11 PsA patients (mean disease 
duration 5.9 years) after 24 weeks of therapy. BMO and effusion scores improved 
markedly (by 65% and 44%, respectively). Tenosynovitis scores, which remained 
unchanged in this study, decreased by 12% with adalimumab. No changes were 
observed in erosion scores, and in further similarity to this study, there was a lack of 
meaningful improvement in mean synovitis score (3% decrease) (Anandarajah et al., 
2010).  
Synovitis also remained problematic in the hands and feet of five patients treated with 
adalimumab for 32 weeks, with an increase in scores in two of five patients, no change 
in one patient and a reduction in two patients (Yanaba et al., 2015). However, 
discrepancy exists with the findings of Marzo-Ortega and colleagues in two studies. In 
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the first, synovitis was observed in the knee joints of three patients and following six 
months of etanercept therapy, a ‘marked improvement ‘was seen in all patients (Marzo-
Ortega et al., 2001). The reduction in synovitis scores was quantified in the second study, 
where a 37.8% to 91.9% decrease was observed in the knees of four patients treated 
with infliximab for 20 weeks. In this cohort, two patients had BMO at the knee, of which 
one resolved and one remained unchanged (Marzo-Ortega et al., 2007). 
Only one longitudinal study has assessed damage progression in patients with PsA 
treated with biologic therapy, using conventional MRI of the hands. MRI signs of 
inflammation were found to decrease, but not disappear during adalimumab therapy, but 
as seen in this study (and the others described above), no overall changes in bone 
erosions or proliferations were observed after 48 weeks of treatment (Poggenborg et al., 
2014c).  
In similar contrast to the findings in this chapter, published data have also shown 
encouraging improvements in active inflammation in the axial skeleton with biologic 
therapy using WBMRI, but again, these data are for patients with established 
inflammatory arthritis. In patients with AS, a significant reduction in osteitis (using the 
Berlin Scoring Method) was observed after 24 weeks of ustekinumab therapy as 
compared with baseline in both the SIJs (BMO change score -2.2 ±3.8, corresponding 
to a 41% reduction from 5.4 ±4.9) and spine (-1.2 ±2.3 corresponding to a 31% reduction 
from 4.1 ±3.6), with even greater improvements seen in those who responded better 
clinically (Poddubnyy et al., 2014b, Poddubnyy et al., 2013). In contrast, in this study, 
increases in spine BMO score (2.1% increase from 1.87 ±2.24) and SIJ BMO score 
(15.4% increase from 0.26 ±0.75) were observed after 24 weeks of ustekinumab therapy, 
although these changes failed to reach statistical significance.  Interestingly, the 
manufacturers of ustekinumab (Janssen Pharmaceuticals) have terminated a phase III, 
multicentre, randomised, double-blind, placebo-controlled study evaluating the efficacy 
and safety of ustekinumab in the treatment of patients with active non-radiographic axial 
spondyloarthritis (ClinicalTrials.gov identifier NCT02407223) because ustekinumab did 
not achieve key endpoints in a related study, although no data is published to clarify if 
patients worsened. The safety profile was reported to be consistent with past 
ustekinumab studies. 
Further explanation for the trends observed in this chapter in the spine and SIJs may be 
that due to the comparatively very low mean osteitis scores in patients with subclinical 
disease (as oppose to patients with symptomatic AS), overall mean scores could be 
disproportionately influenced by any new positive finding or changes, and this is 
compounded by the difficulty in interpreting very subtle abnormalities on WBMRI which 
may or may not be truly pathological. In addition, as shown by Song et al, osteitis can 
fluctuate in severity, with up to 5% of axial BMO lesions resolving intermittently but 
returning in their cohort (Song et al., 2015). This could have a significant influence on 
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low overall mean scores depending on at what stage the WBMRI is performed within a 
study.  
Improvements in spine and SIJ active inflammation scores have been achieved through 
the use of TNF inhibitors, namely etanercept, and reflect those improvements seen in 
the peripheral skeleton (Karpitschka et al., 2013, Song et al., 2011a, Song et al., 2015). 
Karpitschka et al observed a striking improvement from baseline in osteitis scores both 
in the spine and SIJs, with almost complete clearance of inflammation (93.6% (spine) 
and 100% (SIJs) reduction) in ten patients with early AS (mean baseline BASDAI 5.5) 
treated for 52 weeks. Patients were permitted to continue DMARD therapy or 
prednisolone (>7.5mg/day) throughout the study which may have influenced this 
outcome (Karpitschka et al., 2013). In contrast, these concomitant treatments had to be 
discontinued at least four weeks prior to participation in the ESTHER trial (Song et al., 
2011a, Song et al., 2015). This may, in part, explain why the results at the end of week 
48, although impressive, are not as substantial as those from Karpitschka and 
colleagues. At baseline, mean SIJ osteitis scores (assessed using the Berlin Scoring 
Method) were 7.8 ±6.3 (out of a possible maximum of 24) and reduced with treatment by 
69.2% to 2.4 ±3.2, and mean spine osteitis scores (out of a possible maximum of 6) 
reduced by 56.5% from 2.3 ±3.5 to 1.0 ±2.1 (Song et al., 2011a). Of the 76 patients 
reported at week 48, 41 patients remained on treatment and were followed up at the end 
of year two and three. In this cohort, the reduction in mean SIJ osteitis score was 
maintained, with a 71.8% reduction (to 2.0 ±2.2) and 69.0% reduction (to 2.2 ±2.5) from 
baseline after two and three years of therapy respectively. Mean spine osteitis score 
reduction was also maintained, with a 58.8% reduction (to 0.7 ±1.4) at the end of year 
two and 47.1% reduction (0.9 ±1.8) at the end of year three (Song et al., 2015). 
One positive finding from this investigation was the low rates of new BMO appearing 
during treatment. In the peripheral skeleton, only seven new areas of osteitis had 
developed over 52 weeks (0.9%), and two areas worsened (out of a total number of 790 
lesions observed at week 52). In the axial skeleton, two areas of osteitis had developed 
over 52 weeks (0.4%), and four areas worsened (out of a total number of 450 lesions 
observed at week 52). Similarly, very low rates of new-onset osteitis were also observed 
during three years of continuous treatment with etanercept in the ESTHER trial (Song et 
al., 2015). The development of new osteitis in sites that were free of osteitis at baseline 
only occurred in 1.5% SIJ quadrants and in 0.4% of spine VUs in both year two and 
three. In another study, using conventional MRI, patients with very early ax-SpA (disease 
duration <3 years) were treated with infliximab versus placebo for 16 weeks (Barkham 
et al., 2009). Although the duration of treatment was much shorter, the low rate of new 
development of osteitis (3.8%) was similar to that of this study and data from Song et al 
(Song et al., 2015). Interestingly, the spontaneous rate of new BMO development in the 
placebo group was reported at 12%. These observations support the concept that early 
 380 
introduction of biologic therapy in patients with (or destined to develop) spondyloarthritis 
could prevent the development and/or progression of inflammatory arthritis. 
Inflammation in the posterior segment and facet joints of the spine is a recognised feature 
of axial spondyloarthritis, including in patients with psoriatic arthritis. In this cohort, 
posterior element inflammation was minimal, seen in the facet joints of only one patient 
(4.3%) at two sites which persisted, unchanged in severity, despite treatment. This is 
less than the findings reported in other WBMRI studies, but is expected given the primacy 
of enthesitis in this cohort compared to those including patients with early, but 
symptomatic ax-SpA of up to 5 years duration. For example, Karpitschka and colleagues 
found a mean of 2.4 ±1.5 facet joint inflammatory lesions per patient (mean BASADI 5.5) 
at baseline, and like VU osteitis, these decreased significantly after 52 weeks of 
etanercept therapy (0.2 ±0.2) (Karpitschka et al., 2013), In the ESTHER trial (mean 
BASDAI 5.5), 17.1% of patients had at least one site at baseline, compared to just 5% 
after 48 weeks of etanercept (Song et al., 2011a). Given the almost complete absence 
of posterior element inflammation in patients within this cohort, it is not possible to 
determine if the effects of ustekinumab are the same as those seen with etanercept in 
patients with more advance spondyloarthritis, although it is reassuring to not observe the 
development of any new facet joint inflammation during the study, which clearly develop 
as a later phenomenon in ax-SpA. 
A common pathophysiological development in ax-SpA is that the initial osteitis is followed 
by fatty replacement of the bone marrow, and subsequently new bone formation. It is 
therefore thought that ‘fatty corners’ (fatty Romanus lesions) represent the post 
inflammatory phase of SpA, and are a relatively permanent phenomenon once 
developed (Bennett et al., 2010). In a cohort of 174 patients with back pain from which 
the specificity of three or more fatty romanus lesions for ax-SpA was described, those 
with a diagnosis of ax-SpA and fatty romanus lesions on MRI had a disease duration of 
8.3 years (Bennett et al., 2010). Given that patients in this cohort were asymptomatic 
and without a diagnosis of PsA, it is therefore not unexpected that only four patients had 
areas of fatty infiltration. In three patients, this was limited to just one site, and while it 
could be a sign of previous inflammation and evolving ax-SpA, it may also be a sign of 
degenerative arthritis of the spine, especially as the fatty corners were found in the L5/S1 
vertebrae, a common site for degenerative disease, in two patients. However, in one 
patient, five areas of fatty corners were seen. This patient may have had previous bouts 
of now burnt-out inflammation, which can occur without pain. It would have been 
interesting to have observed this patient in the longer term to see if he developed further 
inflammatory lesions or other chronic damage lesions such as syndesmophytes. 
Vertebral corner inflammation followed by fat deposition is shown to be the best 
contributor to the development of new bone at the same vertebral corner (Machado et 
al., 2016).  
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The fatty corners seen at baseline in this cohort remained stable during 52 weeks of 
treatment with ustekinumab, with no deterioration in the severity of lesions and no 
syndesmophyte formation. Ustekinumab could have intervened in the natural 
progression of these lesions, although the differentiation from mechanical or 
degenerative-related arthropathy cannot be confirmed with the data available. For the 
TNF inhibitors at the very least, emerging data support the concept of a ‘window of 
opportunity’ in AS disease modification, whereby intervention when a combination of 
inflammation and fatty changes are detected by MRI can potentially prevent the 
development of future new bone formation (Maksymowych et al., 2009a). Whether this 
is the case for ustekinumab and psoriatic arthritis remains to be confirmed in much larger 
longitudinal studies, and the termination of the phase III study of ustekinumab in non-
radiographic axial spondyloarthritis is discouraging.  
Aside from fatty bone marrow infiltration, other chronic lesions (bone erosions, spine 
syndesmophytes, SIJ ankylosis and SIJ sclerosis) were assessed in the axial skeleton 
in two published studies and one abstract (Song et al., 2011b, Karpitschka et al., 2013, 
Poddubnyy et al., 2014a), and found to be present at baseline in two (Song et al., 2011b, 
Poddubnyy et al., 2014a). In agreement with the findings in this study, both found no 
progression in chronic non-inflammatory lesions with biologic therapy. In 17 patients with 
established AS (mean disease duration 13.3 years), 24 weeks of ustekinumab therapy 
resulted in no change in SIJ erosion, sclerosis, fatty lesion and ankylosis scores, or spine 
erosion, fatty lesion and bone proliferation scores. WBMRI were assessed using the 
same Berlin Scoring Method as used in this study. Given the duration of disease 
symptoms, it is not surprising that many more chronic abnormalities were detected at 
baseline, and scores were higher (e.g. mean SIJ erosion score: 4.0 ±2.4 vs. 0.09 ±0.42 
in this study; mean spine fatty lesion score 5.9 ±4.8 vs. 0.39 ±1.12 in this study) 
(Poddubnyy et al., 2014a). Likewise, in a study of 65 patients with early ax-SpA (mean 
symptomatic disease duration 2.6 years), the frequency of spine and SIJ chronic 
abnormalities at baseline were greater than in this study (spine erosions 0.4% and 
ankylosis 0.7%; SIJ erosions 73.1% and ankylosis 6.9%), but no significant change was 
reported after 48 weeks of etanercept therapy (Song et al., 2011b).  
This study was not without limitations. As a proof-of-concept study, the numbers were 
small, but the aim to provide a ‘snapshot’ of the prevalence of subclinical disease 
principally within the axial skeleton and observe the trends in disease following treatment 
with ustekinumab have been met.  Overall, the number of abnormalities identified were 
generally low prior to treatment, especially in the axial skeleton, which will account for 
why much less dramatic changes following treatment were found in this study compared 
to those described in patients with symptomatic ax-SpA, where it is much easier to 
interpret more pronounced abnormalities as pathological. Further limitations included the 
omission of a second trained musculoskeletal radiologist or rheumatologist with 
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expertise in scoring enthesitis on ultrasound, which prohibited any assessment of 
interobserver agreement. High rates of ‘synovitis’ on WBMRI were found in this study, 
and in part, this could have been a sensitivity issue on behalf of the scorer, although 
there is no means of clarifying this without a second observer.    
In this study, WBMRI has allowed the visualisation of peripheral entheseal sites that are 
not readily accessible by ultrasound, such as the shoulders, costochondral joints, pubic 
symphysis and pelvis, and has shown areas of inflammation at sites not previously 
reported in patients with psoriasis. Only selected tendon entheses, joints and bursa in 
the knee, ankle and foot were visualised with both WBMRI and ultrasound in this study. 
There were contradictory responses to treatment using the two modalities – with 
ultrasound, significant decreases were seen in inflammatory lesions (e.g. patella tendon 
insertion thickening and hypoechogenicity reduced from 30.4% and 43.5% of entheses 
at week 0, respectively, to 17.5% and 15.0% after 52 weeks of therapy). In contrast, 
analysis of WBMRI revealed no significant change in inflammatory lesions (9.8% of 
entheses had BMO and 19.5% had STI at week 0, and 10.5% had BMO and 18.4% had 
STI at week 52). The same discrepancy exists for the quadriceps tendon, Achilles tendon 
and Plantar fascia insertions. There are two potential reasons for this discrepancy: (1) a 
lack of saggital views of the knee, foot and ankle and (2) a lack of gadolinium contrast. 
In addition, poor correlation between MRI and ultrasound findings has also been 
described previously. Aydin et al showed very low (10-26%) positive agreements 
between MRI and ultrasound findings for individual entheseal lesions at the knee, with 
low kappa values (0.06-0.18) and no correlation between MRI and ultrasound scores 
(r2=0.059) (Aydin et al., 2013b).  
Absence of saggital views had an impact on the ability to score the quadriceps and paella 
tendon insertions in the knee, and the Achilles tendon insertion in the ankle, in addition 
to analysis of joint synovitis and enthesophytes. These were excluded to try limit the 
duration of the scan in addition to the number of times a patient had to be repositioned. 
Ultrasound offers the advantage at peripheral sites of being viewed in real-time, with 
greater ease to visualise an entire joint to obtain a comprehensive assessment of any 
abnormalities. It also offers higher spatial resolution and is better suited to looking at the 
architecture of entheses and soft tissues, and is therefore perhaps more suited to the 
assessment of subtle subclinical disease.  
Gadolinium contrast was not administered in this study due to the repeated number of 
investigations required (three WBMRI scans per patient) and the potential for gadolinium 
to cause nephrogenic systemic fibrosis. The lack of gadolinium contrast enhancement 
made visualisation of the entheses difficult and is likely to have resulted in under-
reporting of abnormalities, especially where subtle changes in severity may have 
occurred.  All images were scored by a rheumatologist with expertise in scoring WBMRI, 
but given the subtlety of abnormalities, where any uncertainty existed about the presence 
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of a lesion, the area was scored as zero. This negative bias may have been reduced if 
gadolinium was able to more clearly delineate subtle lesions and a second observed .  
The lack of gadolinium contrast also had an impact on the ability to make a 
comprehensive assessment of synovitis, as synovial thickness could not be measured 
(Chapter 6.5). A surrogate assessment of synovial fluid volume was adopted which may 
not be a true representation of inflammation, nor may this be a sensitive marker to 
change with treatment. The lack of improvement in synovial fluid volumes following 
ustekinumab in this work argues against an inflammatory genesis for the fluid. Prior 
studies have aimed to simplify MRI protocols by eliminating gadolinium administration, 
but found that without contrast, specificity for synovitis and tenosynovitis was low in early 
arthritis (Stomp et al., 2015) 
In summary, this is the first study to use WBMRI to assess the pattern of bone marrow 
oedema, perientheseal soft tissue inflammation and chronic damage abnormalities in 
asymptomatic patients with psoriasis and the response to treatment with ustekinumab. 
No significant change was seen in either inflammatory or structural damage lesions, 
influenced by the low burden of mild disease at the outset, coupled with difficulties in 
image interpretation due to lack of contrast enhancement and a tendency to under-report 
subtle abnormalities. However, in agreement with previous studies in ax-SpA and PsA, 
no progression in either inflammatory lesions or chronic damage abnormalities were 
observed. These findings suggest that early introduction of skin-directed therapy with 
ustekinumab in psoriasis patients that might be destined to develop spondyloarthritis 
(based on US enthesopathy score positivity) could limit the progression to symptomatic 
inflammatory arthritis and hopefully prevent future functional limitation and disability. 
Larger, prospective longitudinal studies, with refinement to the WBMRI protocol, are now 
required to confirm these observations. 
7.6 Conclusion 
This is the first study to use WBMRI to assess the change in active inflammatory lesions 
and structural abnormalities in the axial and peripheral skeleton following skin directed 
treatment with a biologic agent in asymptomatic patients with psoriasis and subclinical 
enthesitis. No significant changes were observed in terms of the severity and extent of 
bone marrow oedema, perientheseal soft tissue inflammation and chronic damage 
abnormalities by the primary endpoint of 24 weeks, or after 52 weeks of therapy. Factors 
influencing the ability to detect any change include a low burden of mild disease at the 
outset and difficulties in image interpretation due to lack of contrast enhancement. 
However, in agreement with previously published studies of patients with psoriatic 
arthritis and axial spondyloarthropathy, no progression of abnormalities occurred, 
suggesting that in those destined to develop PsA, ustekinumab may be able to limit 
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progression to symptomatic arthritis and prevent future disability. Larger scale, 
prospective longitudinal studies with WBMRI protocol refinement are now required to 
confirm these observations.  
  
 
 
385 
Conclusions and Future Directions 
The incidence of psoriatic arthritis (PsA) is increasing, yet many patients remain 
uninformed about the link between musculoskeletal symptoms and psoriasis, and often 
are not adequately screened either in primary or secondary care. Increased recognition 
of the need for early therapeutic intervention has, in recent years, improved the 
collaboration between dermatologists and rheumatologists and lead to the development 
of several screening questionnaires to be used in patients with psoriasis. However, many 
patients with PsA continue to be diagnosed late, after the ‘window of opportunity’ where 
structural damage and functional limitation could potentially have been circumvented.  
In this thesis, 10.1% of psoriasis patients screened in a variety of primary care settings 
had undiagnosed PsA, despite have signs and symptoms consistent with inflammatory 
arthritis. Several patients commented that receipt of the educational leaflet was the first 
time they were aware of the possibility of developing arthritis as part of their psoriatic 
disease, although the provision of an educational leaflet did not improve the response 
rate to the invitation for screening except for in the most deprived areas. Testing of a 
new candidate questionnaire (CONTEST), developed from the most discriminative items 
from the three most widely used PsA screening questionnaires, is shown to be effective 
at detecting PsA for the first time in a primary care setting. However, the CONTEST 
questionnaire did not outperform the Psoriasis Epidemiology Screening Test (PEST), 
which is currently recommended as the screening questionnaire of choice by the National 
Institute of Health and Clinical Excellence (NICE) in their psoriasis guidelines. These 
questionnaires had a reasonable sensitivity and specificity for PsA in this primary care 
cohort, but both had two patients with falsely negative questionnaires, demonstrating the 
need for additional methods of screening and identification of PsA amongst patients with 
psoriasis. 
Within primary and secondary care cohorts of patients with psoriasis, the presence of 
subclinical enthesopathy has been consistently observed using grey scale and power 
Doppler ultrasound, ranging from 33-62.5% of patients examined depending on the 
population studied, the number of entheses scanned and the definition of enthesopathy 
used.  In this thesis, amongst systemic immunosuppressant and biologic naïve patients 
presenting to secondary care with moderate-to-severe psoriasis (PASI³10), 
asymptomatic enthesopathy was identified in 60.3% of patients, of which 49.3% had 
potentially modifiable inflammatory enthesitis.  Ultrasound examinations were, for the 
first time, based on the complete OMERACT definition of enthesopathy and included 
grey scale assessments of entheseal thickening, hypoechogenicity, calcifications, bone 
cortex irregularities, erosions and enthesophytes, in addition to power Doppler (PD) 
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signal. Where reference measurements have not previously been published, objective 
reference values for entheseal thickness were calculated using methods described in the 
literature. Thickening was by far the most common abnormality, but proportionally high 
numbers of entheses also demonstrated hypoechogenicity, calcifications and adjacent 
bone cortex irregularities and enthesophytes. Bone erosions, a later phenomenon of 
sustained entheseal inflammation, were infrequent.   
Whereas earlier assessments have been limited, in this thesis, a broad range of 
entheseal sites were assessed to reflect the heterogeneous nature of PsA, and to test 
the feasibility of a screening ultrasound protocol for use in the research and clinical 
setting. In total,19 sites were scanned bilaterally, and enthesitis was seen in at least one 
patient at all sites. Most enthesitis occurred within the larger enthesis of the knee, elbow 
and ankle, with very few abnormalities seen in those joints that sustain the least 
microtrauma, such as the third, fourth and fifth digits of the hands. It is therefore advised 
that a screening protocol for use in the clinical setting should concentrate on the 
entheses of the knee (quadriceps, proximal patella, distal patella), ankle (Achilles tendon, 
plantar fascia) and elbow (common extensor, common flexor, distal brachial triceps), and 
to provide a more comprehensive assessment in clinical trials, could also include the 
thumb and index extensor and flexor tendons, and the peroneal brevis tendon at the 
ankle. In this thesis, a small number of healthy volunteers were also found to have 
abnormal ultrasound findings in a similar distribution to, but at a significantly lower 
frequency than, patients with psoriasis. Abnormalities were greater in older patients and 
those with a higher BMI. This supports the concept of degeneration occurring as a result 
of repeated microtrauma at weight-bearing sites, but with sustained and aberrant 
inflammation in genetically-primed individuals with psoriasis.  
The ultrasound protocol also included analyses of the entire synovio-entheseal complex 
and identified subclinical abnormalities at sites remote, but in close association to the 
enthesis in patients with psoriasis. Synovitis was a common finding, in contrast with 
tenosynovitis and bursitis which were infrequent. Reflecting the early, pre-clinical stage 
of disease in these patients, power Doppler signal was only observed in just 0.2% of 
entheses. Given the higher rate of PD signal seen in patients with PsA (suggesting a 
later switch to a more vascular phenotype), longitudinal monitoring of PD signal may be 
one method of determine when to instigate therapy in patients with asymptomatic 
enthesopathy.  
As a means of screening, there appears to be limited value in clinical entheseal 
assessments, with 47.8% of patients having clinically tender entheseal points but no 
evidence of inflammation (or any other abnormality on ultrasound). Similarly, in the real 
world setting, there appears to be no value in targeting screening for subclinical 
enthesitis depending on the distribution of psoriatic plaques. In this cohort, no correlation 
was observed between those with disease of the scalp or intergluteal cleft and 
 
 
387 
sonographic inflammation scores, although nail disease did appear to be a marker for 
subclinical enthesitis, and those with more severe nail disease (higher mNAPSI score) 
had more subclinical inflammatory enthesitis and synovitis. Longitudinal assessment of 
patients with nail psoriasis would be useful to determine if this could be a clinical 
biomarker for targeted ultrasound screening in asymptomatic patients.  
Overall, very few data are available regarding the rates of evolution from subclinical 
enthesitis to clinical PsA, and future studies should include a prospective cohort of 
patients followed up over several years to ascertain further predictors of joint disease, 
although this is difficult due to patients requiring therapy for psoriasis. A cohort of patients 
with less severe psoriasis treated with topical medicaments and phototherapy could 
provide these data, although it is likely that a proportion of these patients would transition 
onto immunomodulatory anti-psoriatic therapy, which could influence the progression to 
PsA. 
Aside from ultrasound, this prospective pilot data is the first to demonstrate the ability of 
whole body magnetic resonance imaging (WBMRI) to evaluate subclinical inflammatory 
and structural damage abnormalities in symptomatic patients with psoriasis in both the 
axial and peripheral skeleton. As an adjunct to ultrasound, inaccessible sites could be 
visualised including the shoulders, costochondral joints, pelvis, spine and sacroiliac 
joints (SIJs). Improvements in hardware and refined techniques of image acquisition 
resulted in significantly greater numbers of joints within field of view (FOV) and readable 
compared with the limited data already published (with a minimum of 86% of joints 
readable peripherally and 100% axially).  
Subclinical axial disease is shown here to occur in patients with psoriasis, and WBMRI 
was able to demonstrate, for the first time, a significantly higher rate of osteitis and 
adjacent soft tissue inflammation throughout the entire spine of patients with psoriasis 
compared with healthy volunteers. Several psoriasis patients had bone marrow oedema 
(BMO) affecting the vertebral corners in keeping with changes recognised in 
spondyloarthritis (SpA). However, these abnormalities were generally limited to less than 
three sites and did not therefore fulfil the Assessment of Spondyloarthritis International 
Society (ASAS) diagnostic criteria, although longitudinal review of these patients is 
warranted to determine if they develop further lesions and symptomatic SpA. In keeping 
with the primacy of entheseal disease in this cohort, very few structural damage 
abnormalities were observed in the spine (syndesmophytes) with no erosions. Disease 
within the SIJs overall was limited and confirms the observation that spinal inflammation 
tends to develop first in SpA.  
WBMRI was also able to identify asymptomatic inflammatory abnormalities at peripheral 
sites previously not described in patients with psoriasis, including the manubriosternal 
joint, shoulder entheses and pubic symphysis, complementing the widespread and 
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heterogeneous changes seen in WBMRI studies of patients with PsA.  In similarity to 
ultrasound scores, the most consistent association was mNAPSI score, correlating with 
total WBMRI BMO score in both the peripheral and axial skeleton, suggesting that the 
presence of nail psoriasis should be included as a co-variable in future investigations. 
One of the main objectives of this thesis was to evaluate the effect of biologic therapy on 
subclinical enthesitis in both the peripheral and axial skeleton. This is the first 
comprehensive longitudinal assessment using both ultrasound and WBMRI to evaluate 
the response of imaging abnormalities in treatment naïve patients who require skin-
directed systemic therapy for moderate to severe psoriasis. Ultrasound evaluations of 
the peripheral skeleton demonstrated a significant effect on inflammatory enthesitis, with 
a 31.3% reduction in inflammation score after just 12 weeks, 42.4% reduction after 24 
weeks and a 51.5% reduction after 52 weeks of therapy. No significant alterations were 
observed on ultrasound chronic damage score, prompting interest for future investigation 
to determine if IL-12/23p40 inhibition may have stemmed the progression of existing, 
and the development of new, structural abnormalities. In the axial skeleton, results were 
less impressive, with no significant change in spinal or SIJ lesions, although the 
frequency of inflammatory and chronic damage abnormalities did not increase.  
These data were intended to inform a larger, prospective trial, and sample size 
calculations show this to be feasible. Alongside a group of untreated psoriasis patients 
(to determine the predictive value of subclinical enthesitis in the later development of 
PsA), groups of patients treated with different immunomodulatory therapies should be 
examined to determine whether these observations can be replicated or even 
superseded by other skin-directed immunomodulatory therapies. It is likely that the 
response to ustekinumab is due to suppression of IL-23, and future investigation should 
include patients treated with an IL23p19 inhibitor (which have been shown to have 
superior PASI responses to IL-12/23p40 inhibitors), in addition to molecules that target 
cytokines downstream from IL-23 (e.g. IL-17A inhibitors). Ideally, patients should be 
followed up for several years, and attend for annual screening using the ultrasound 
protocol described in this thesis. Larger numbers per group are necessary to confirm the 
observations seen with BMI, age and nail psoriasis, and therefore a multicentre approach 
would be favourable. Much like RA, early treatment is known to be beneficial in PsA, and 
the data in this thesis suggest, for the first time, that IL-12/23p40 inhibition appears to be 
valuable in subclinical enthesitis. However, the longer-term benefits of biologic therapies 
on the possible progression to PsA and the prevention of disability and functional 
limitation remain to be determined.  
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Appendix 1 
 
Psoriasis Epidemiology Screening Tool (PEST) 
 
 
 
 
 
PSORIASIS EPIDEMIOLOGY SCREENING TOOL (PEST) 
 
 
HOSPITAL NO.   …………………………………………… 
 
PATIENT NAME  …………………………………………… 
 
DATE OF VISIT  …………………………………………… 
 
 
PEST is a validated screening tool for psoriatic arthritis (PsA) and it is recommended that patients 
with psoriasis who do not have a diagnosis of PsA complete an annual PEST questionnaire (NICE 
psoriasis guidelines 2012). A score of 3 or more indicates referral to rheumatology should be 
considered. 
 
In the drawing below, please tick the joints that have caused you discomfort (i.e. stiff, swollen or 
painful joints). 
Elbow
Shoulder
Wrist
Hand /
Fingers
Thumb
Waist level
Hip
Knee
Ankle
Foot / ToesFoot / Toes
Ankle
Knee
Shoulder
Elbow
Wrist
Thumb
HipHand /
Fingers
Upper
Back
Lower
Back
Neck
 
Reproduced with kind permission of Professor Philip Helliwell (University of Leeds) 
 
 
Please answer the questions below and score 1 point for  each  question  answered  ‘Yes’ 
 Yes No 
1. Have you ever had a swollen joint (or joints)?   
2. Has a doctor ever told you that you have arthritis?   
3. Do your finger nails or toenails have holes or pits?   
4. Have you had pain in your heel?   
5. Have you had a finger or toe that was completely swollen and painful 
for no apparent reason?   
Total  
 
 
A total score of 3 or more out of 5 is positive and indicates a referral to rheumatology should be 
considered 
   / 5 
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Appendix 2 
CONTEST Questionnaire (with and without joint mannequin) 
 
 
 
 
(please tick yes or no for each statement) 
 YES NO 
Have you ever had a swollen joint (or joints)?   
Has a doctor ever told you that you have arthritis?    
Do your finger nails or toe nails have holes or pits?   
Have you had pain in your heel?   
Have you had a finger or toe that was completely swollen and painful for no 
apparent reason?    
Have you ever noticed any of these changes in your fingernails:    
  Pits in the nails as shown in PICTURE 1   
 Lifting of the nail from the nail bed as shown in PICTURE 2   
Have you ever had neck pain lasting at least 3 months that was not injury related?   
My back hurts.   
My joints become swollen.   
My joints feel “hot”.   
 
 
       In the drawing below, please tick the joints that have caused you  
                      discomfort (i.e. stiff, swollen or painful joints): 
 
 
LEFT 
 
	RIGHT LEFT 
 
PICTURE 1 
Pits in the nail 
 
 
 
 
 
 
PICTURE 2 
Lifting of the nail 
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Appendix 3 
 
Dermatology Life Quality Index (DLQI) 
 
 
 
 
 
„AY Finlay, GK Khan, April 1992 www.dermatology.org.uk, this must not be copied without the permission of the authors. 
DERMATOLOGY LIFE QUALITY INDEX (DLQI) 
 
Hospital No:                             . Date:                          . 
Name:                                      . Score:                        . 
Address:                                . 
                                                 . 
Diagnosis:                 . 
The aim of this questionnaire is to measure how much your skin problem has affected your life 
OVER THE LAST WEEK. Please tick (¸) one box for each question. 
 
1. Over the last week, how itchy, sore, painful or stinging 
has your skin been? 
 Very much 
A lot 
A little 
Not at all 
r 
r 
r 
r 
  
2. Over the last week, how embarrassed or self conscious 
have you been because of your skin? 
 Very much 
A lot 
A little 
Not at all 
r 
r 
r 
r 
  
3. Over the last week, how much has your skin interfered with 
you going shopping or looking after your home or garden?      
 Very much 
A lot 
A little 
Not at all 
r 
r 
r 
r 
 
 
 
Not relevant 
 
 
 
r 
4. Over the last week, how much has your skin influenced the 
clothes you wear? 
 Very much 
A lot 
A little 
Not at all 
r 
r 
r 
r 
 
 
 
Not relevant 
 
 
 
r 
5. Over the last week, how much has your skin affected any 
social or leisure activities? 
 Very much 
A lot 
A little 
Not at all 
r 
r 
r 
r 
 
 
 
Not relevant 
 
 
 
r 
6. Over the last week, how much has your skin made it difficult 
for you to do any sport?  
 Very much 
A lot 
A little 
Not at all 
r 
r 
r 
r 
 
 
 
Not relevant 
 
 
 
r 
7. Over the last week, has your skin prevented you from 
working or studying? 
 
If "No", over the last week how much has your skin been a 
problem at work or studying? 
 Yes  
No 
 
A lot 
A little 
Not at all 
r 
r 
 
r 
r 
r 
 
Not relevant 
 
r 
 
8. 
 
Over the last week, how much has your skin created 
problems with your partner or any of your close friends or 
relatives?   
 Very much 
A lot 
A little 
Not at all 
r 
r 
r 
r 
 
 
 
Not relevant 
 
 
 
r 
9. Over the last week, how much has your skin caused any 
sexual difficulties? 
 Very much 
A lot 
A little 
Not at all 
r 
r 
r 
r 
 
 
 
Not relevant 
 
 
 
r 
10. Over the last week, how much of a problem has the 
treatment for your skin been, for example by making your 
home messy, or by taking up time?  
 Very much 
A lot 
A little 
Not at all 
r 
r 
r 
r 
 
 
 
Not relevant 
 
 
 
r 
 
Please check you have answered EVERY question. Thank you.  
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Appendix 4 
 
The Psoriatic Arthritis Quality of Life (PsAQoL) Questionnaire 
 
 
• I feel there is no enjoyment in my life 
• I feel I am losing my independence 
• I often get angry with myself 
• I can’t do the things I want to do 
• I feel older than my years 
• I am unable to join in activities with my friends or family 
• It limits the places I can go 
• I have to push myself to do things 
• I am easily irritated by other people 
• I have to keep stopping what I am doing to rest 
• I feel dependent upon others 
• It takes me a long time to get going in the morning 
• I take it out on people close to me 
• I can’t do things on the spur of the moment 
• I feel like a prisoner in my own home 
• I have to limit what I do each day 
• It puts a strain on my personal relationships 
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Health Assessment Questionnaire 
 
 
HEALTH ASSESSMENT
QUESTIONNAIRE (HAQ)
Name PHN Date (yyyy / mm / dd)
Dressing and Grooming
 Dress yourself, including tying shoelaces and doing buttons    
 Shampoo your hair    
Rising
 Stand up from an armless chair    
 Get in and out of bed    
Eating
 Cut your meat    
 Lift a full cup or glass to your mouth    
 Open a new carton of milk    
Walking
 Walk outdoors on flat ground    
 Climb up five stairs    
Hygiene
 Wash and dry your entire body    
 Take a bath    
 Get on and off the toilet    
Reach
 Reach and get down a 5 lb object 
    (for example, a bag of sugar from just above your head)
 Bend down to pick up clothing from the floor    
Grip
 Open car doors    
 Open jars which have been previously opened    
 Turn taps on and off    
Activities
 Run errands and shop    
 Get in and out of a car    
 Do chores such as vacuuming, housework or light gardening    
 NO SOME MUCH UNABLE
 DIFFICULTY DIFFICULTY DIFFICULTY TO DO
1. For each category, please check the one response that best describes your abilities over the past week.
HLTH 5383  2016/11/23 PAGE 1 OF 2
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Appendix 6 
 
Contraindications to biologic therapy (Ustekinumab) 
 
§ Active infection, including open leg ulcers, HIV, hepatitis B or C carriers 
§ Active or latent tuberculosis 
§ Malignancy – current, or previous within the last ten years (except basal cell 
carcinoma) 
§ Severe heart failure (NYHA grade III or more) 
§ Demyelinating disorders 
§ Uncontrolled diabetes 
§ Chronic lung disease (pulmonary fibrosis or bronchiectasis) 
§ Previous PUVA phototherapy (>1000 joules) 
§ History of other significant medical conditions, including: 
• Severe pulmonary disease (defined as requiring previous hospital 
admission or supplemental oxygen) 
• Active or severe cardiovascular disorders: uncontrolled hypertension, 
myocardial infarction within the previous twelve months, unstable angina 
within the previous six months) 
• Any immunodeficiency disorder 
• Connective tissue diseases (e.g. primary Sjogrens syndrome, systemic 
sclerosis, systemic lupus erythematosus, polymyositis) 
• Renal impairment (creatinine clearance <45ml/min) 
• Abnormal liver function tests (alanine transferase >3x upper limit of normal) 
• Blood disorders, i.e. thrombocytopenia (platelets <125x109/l), neutropenia 
(neutrophils <2.0x109/l) or anaemia (Hb <8g/dl). 
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Appendix 7 
 
Psoriasis Area and Severity Index (PASI) 
 
 
 
 
 
 
 
 
 
PSORIASIS AREA AND 
SEVERITY INDEX (PASI) WORKSHEET
HLTH 5379  2009/07/08
PATIENT NAME DATE OF VISIT (YYYY / MM / DD) PERSONAL HEALTH NUMBER
Erythema (E)
Induration (I)  (thickness)
Scaling (S)
SUM: E + I + S
Percentage of Affected Area
Area Score
SUBTOTAL: Sum x Area Score
Body Area: Subtotal X amount indicated
TOTALS
LESION SCORE
Erythema (E)
Induration (I)
Scaling (S)
 No Symptoms Slight Moderate Marked Very Marked
 0 1 2 3 4 SCORE
AREA SCORE
AREA  0 1% - 9% 10% - 29% 30% - 49% 50% - 69% 70% - 89% 90% - 100%
 0 1 2 3 4 5 6 SCORE
      Lower Limbs
 Lesion Score  Head Trunk Upper Limbs (LL)
   (H) (T) (UL) including buttock
 x 0.1 x 0.3 x 0.2 x 0.4
PASI SCORE: H + T + UL + LL
H T UL LL
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Appendix 8 
 
Modified Nail Psoriasis Severity Index (mNAPSI) 
 
 
Features 
Right  Left  
5 4 3 2 1 1 2 3 4 5 
Onycholysis 
0 = none 0 0 0 0 0 0 0 0 0 0 
1 = 1-10% of nail surface 1 1 1 1 1 1 1 1 1 1 
2 = 11-30% of nail surface 2 2 2 2 2 2 2 2 2 2 
3 = >30% of nail surface 3 3 3 3 3 3 3 3 3 3 
Pitting 
0 = none 0 0 0 0 0 0 0 0 0 0 
1 = 1-10 pits 1 1 1 1 1 1 1 1 1 1 
2 = 11-49 pits 2 2 2 2 2 2 2 2 2 2 
3 = >50 pits 3 3 3 3 3 3 3 3 3 3 
Nail plate 
crumbling 
0 = none 0 0 0 0 0 0 0 0 0 0 
1 = 1-25% of nail 1 1 1 1 1 1 1 1 1 1 
2 = 26-50% of nail 2 2 2 2 2 2 2 2 2 2 
3 = >50% of nail 3 3 3 3 3 3 3 3 3 3 
Features (tick if present) Right Left 
Leukonychia           
Splinter haemorrhage           
Nail bed hyperkeratosis           
Red spots in lunula           
Oil spot dyschromia           
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Appendix 10 
 
 
 
The Leeds Teaching Hospitals NHS
NHS Trust
Document: PatientScreeningForm_ver2-4.doc Version: 2.4 Date: 5/6/2015 Authorised By: DD
MAGNETIC RESONANCE IMAGING (MRI) SCREENING FORM
NAME : __________ DOB :
ADDRESS : WEIGHT :
Please answer the following questions (please tick) : YES NO UNSURE
Do you have / have you ever had a cardiac / heart pacemaker?
Do you have / have you ever had an implanted medical device e.g. drug
infusion device, nerve or bone stimulator, cochlear implant etc.
Have you ever had a bleed inside your head?
Have you ever had any operations involving your head, eyes or heart?
Have you had any other operations / surgery in the last six weeks?
Have you ever worked as a machinist, metal worker or welder?
Have you ever had any metallic fragments in your eyes?
Have you ever had any metal in your head or body e.g. shrapnel?
Do you suffer / have you suffered from a heart disorder / fits / blackouts /
epilepsy or diabetes?
Are you under the care of a kidney doctor for kidney failure and/or are
you on dialysis?
Do you have any allergy to any drug?
Do you use an EpiPen or suffer from any of the following: asthma, hay
fever, hives, seafood allergy?
Do you take Beta Blockers?
Do you have any of the following(please tick): YES NO UNSURE
A prosthesis or implant (e.g. breast, eye, ear, hip/knee, penile, artificial limb)
Shunts, lines, catheters, wires, stents, vascular clips
Clips in the brain (e.g. Aneurysm clips)
Dentures or plate, hearing aid
Any medicine patches (e.g. HRT patches, etc.)
As this is a teaching hospital, MR pictures are often used for education and research
purposes. No personal details will accompany the images. Please tick the box if you
DO NOT want your MR pictures being used for these purposes.
Female patients only :
Is there any possibility of pregnancy? YES / NO Are you breastfeeding? YES / NO
IMPORTANT - Please ensure that all removable loose objects e.g. watch, wallet, credit cards,
keys, loose change, jewellery, hair clips, hearing aid, etc are left outside the scanning room in the
lockers provided. If you have any questions feel free to ask.
Patient Signature : Date : ___
Relationship to patient (if applicable) __________________
To be filled in by MRI Staff
3 Point ID Checked : _____ Screening form checked and no contraindications :
 
 
449 
Appendix 11 
The Glasgow Ultrasound Enthesitis Scoring System (GUESS) 
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Appendix 12 
The Sonographic Enthesitis Index (SEI) 
 
PMC full text: Ann Rheum Dis. 2007 Aug; 66(8): 1015–1019.
Published online 2006 Dec 6. doi:  10.1136/ard.2006.062174
Copyright/License ► Request permission to reuse
Table 1 Description of target areas and alterations evaluated in the sonographic scoring of entheses
Entheseal areas Signs of acute injury
Signs of chronic
lesion
Quadriceps tendon enthesis (superior pole  of the patella) Thickening of tendon/aponeurosis Tendon tear
Proximal insertion of the patellar tendon  (inferior pole of
the patella)
Hypoechogenicity of
tendon/aponeurosis
Loss of thickness
Distal insertion of the patellar tendon (anterior  tibial
tuberosity)
Peritendinous/periaponeurotic
oedema
Tendon calcification
Achilles tendon enthesis (superior pole of the  calcaneous) Bursitis* Bone erosion
Plantar aponeurosis enthesis (plantar pole  of the calcaneous)
Total 76 points SEI‐A 0–36 points SEI‐C 0–40 points
SEI‐A, Sonographic Entheseal Index of Acute injury; SEI‐C, Sonographic Entheseal Index of Chronic lesion.
Each variable was scored as 0 (absence) or 1 (presence) and the SEI was the total sum of SEI‐A and SEI‐C.
The maximum SEI scoring was 76 points (36+40).
*Where applicable.
